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vPreface
Within the 20 years after WHO has launched the Global Buruli Ulcer Initiative in 
1998, considerable progress has been made toward the understanding and the con-
trol of this neglected, once mysterious, tropical skin disease. Major practical 
achievements were the evaluation and successful introduction of an antibiotic ther-
apy consisting of oral rifampicin and injected streptomycin administered daily for 
8  weeks, the development of a PCR-based diagnostic test to detect DNA of the 
causative agent Mycobacterium ulcerans in lesion specimens, and the establishment 
of national Buruli ulcer control programs in the most endemic West and Central 
African countries.
Genome research has shown that acquisition of the virulence plasmid pMUM 
has enabled M. ulcerans to produce mycolactone, a highly potent macrolide toxin, 
responsible for much of the chronic, necrotizing pathology of the disease. This evo-
lutionary bottleneck event is considered the key step in the emergence of the species 
M. ulcerans from the environmental M. marinum. Genome reduction and pseudo-
gene accumulation accompanying the further evolutionary history of M. ulcerans 
are indicative for its adaptation to a more stable ecological niche. However, despite 
extensive research efforts, definite reservoirs of M. ulcerans as well as modes of 
transmission to humans have remained unclear. This is in part due to the extremely 
slow growth rate of the pathogen, hampering attempts to obtain isolates from poten-
tial environmental sources. It appears that direct human-to-human transmission is 
very rare, and there may be no single, simple explanation for the acquisition of 
infection from other reservoirs. Proximity to stagnant or slow-flowing water bodies 
seems to be a feature common to all Buruli ulcer endemic regions worldwide, and 
man-made environmental disturbances have been implicated in the emergence of 
the disease in some areas. While possums and mosquitos have been proposed to 
play a role as reservoirs and vectors in the transmission of M. ulcerans in Australia, 
a different scenario is most likely encountered in African settings, where large 
chronic lesions of Buruli ulcer patients may represent a relevant reservoir. Skin 
injuries are considered a potential route of infection, but also contaminated biting 
arthropods may play a role in transmission. The development of local clonal com-
plexes of M. ulcerans in individual Buruli ulcer endemic regions speaks against the 
existence of highly mobile reservoirs. If large, chronic Buruli ulcer lesions are a 
relevant reservoir, early treatment of patients in an endemic area may help to reduce 
transmission locally. During the course of its evolution, M. ulcerans has diverged 
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into different ecovars. The classical lineage, found in Africa and Australia, is respon-
sible for >98% of all reported Buruli ulcer cases worldwide. While the local inci-
dence of Buruli ulcer in Africa and Australia is very high, cases are only sporadically 
observed in Asia and South America, where another ecovar, the ancestral M. ulcer-
ans lineage, prevails and entirely different human contact patterns with the environ-
ment may lead to infection.
As there is no effective vaccine against Buruli ulcer and preventable risks for 
infection are not clearly identified, current disease control measures primarily rely 
on early case detection and rapid initiation of antibiotic treatment. Efficient imple-
mentation of this control strategy is complicated by the fact that most infections 
occur in remote, rural areas of Africa, where access to healthcare is limited. 
Logistics involved in the provision of antibiotic treatment is challenging, and labo-
ratory facilities to perform PCR, which has become the gold standard for the labo-
ratory diagnosis of Buruli ulcer, are centralized. Furthermore, four rounds of 
external quality assessment (EQA) for the molecular detection of M. ulcerans in 
clinical specimens organized since 2009 have shown that reference centers often 
fail to pass the expected performance indicators for PCR-based diagnosis. Daily 
injections, ototoxicity, and other adverse side effects of the current antibiotic treat-
ment are causes for concern. Alternative options for a decentralized diagnosis and 
treatment of Buruli ulcer are urgently needed. Most of the established antibiotics 
used for the treatment of tuberculosis show only limited potency against M. ulcer-
ans. Nevertheless, repurposing of new tuberculosis drug candidates may be the 
most promising avenue to develop potentially faster treatment regimens, associ-
ated with less severe adverse side effects. Whereas no substitute for rifampicin is 
currently available, replacement of the injectable antibiotic streptomycin with oral 
clarithromycin is being evaluated and may support decentralization. Moreover, 
thermotherapy may be considered as an option for community-based treatment. 
Efforts coordinated by FIND to develop a low-cost and simple rapid diagnostic test 
also represent a key element in the strive toward early diagnosis and treatment of 
Buruli ulcer at community level.
In recent years, the number of new Buruli ulcer cases reported to WHO from 
endemic African countries has declined. It has been hypothesized that Buruli ulcer 
control activities may have led to an actual decrease in incidence by early detection 
and treatment of previously unattended lesions, potentially fueling environmental 
reservoirs with the pathogen. However, a significant reduction in Buruli ulcer con-
trol program support by some key NGOs has, on the other hand, decreased active 
case search activities in known endemic areas and diminished efforts to identify 
new endemic sites. Recent focal intensification of control efforts in some endemic 
regions and countries has shown that Buruli ulcer is still an underreported disease. 
In most endemic areas, Buruli ulcer is a disease of the poor that—if untreated—can 
lead to permanent disabilities with very severe psychosocial and socioeconomic 
implications. Limited knowledge on reservoirs and vectors of the pathogen and 
modes of transmission constitute an unpredictable source for new infections. It is 
therefore of uttermost importance to mobilize funding for the maintenance of estab-
lished disease control activities and healthcare infrastructures in the affected 
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countries, for continued research, and for the validation and implementation of 
newly developed diagnostic tests and treatment regimens.
This book provides an overview of the history and current burden of Buruli ulcer, 
contains chapters on the epidemiology and control of the disease, and provides 
insights into current research and development activities. A steady increase in the 
incidence of Buruli ulcer in the past years in Victoria, Australia, shows that this 
neglected disease is not defeated and that its control is even in industrialized settings 
a difficult task.
Basel, Switzerland Gerd Pluschke 
Stanford, CA, USA Katharina Röltgen 
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Buruli Ulcer: History and Disease Burden
Katharina Röltgen and Gerd Pluschke
1  History of a Mysterious Skin Disease
The first description of chronic skin ulcers consistent with the pathology of 
Mycobacterium ulcerans infection dates back to the end of the nineteenth century, 
when the British physician Albert Cook recorded his observations in The Mengo 
Hospital Notes, maintained in the library of the hospital in Kampala, Uganda [1]. In 
1948, characteristics of similar skin ulcers were described by MacCallum and his 
colleagues in six patients from the Bairnsdale District in southeastern Australia [2], 
where the disease is therefore often referred to as Bairnsdale ulcer. The causative 
organism isolated from these ulcers was found to be an acid-fast mycobacterium, 
later named M. ulcerans. Noteworthy, the first isolation of the extremely slow- 
growing mycobacterium in culture was achieved by accidental incubation of culture 
plates in a faulty incubator [3], reflecting the low optimal growth temperature of the 
pathogen at 30–33 °C. This temperature preference is considered a major factor for 
the skin tropism and limited systemic dissemination of M. ulcerans infections. In 
the 1940s and 1950s a larger case series of 170 patients with necrotic skin ulcers, 
caused by an acid-fast mycobacterium, was recorded in the Democratic Republic of 
the Congo [4]. A high prevalence of M. ulcerans infections was noticed in the 1950s 
and 1960s in a geographically very limited area of the then sparsely populated 
Buruli County close to the Nile River in Uganda and as a consequence, the disease 
became more generally known as Buruli ulcer (BU) [5, 6]. In proximity to this ini-
tial infection focus, a second outbreak of the disease in Uganda was reported in 
Rwandans living in a refugee settlement that was opened in 1964 close to the Nile 
2River. Intensive investigation of the 220 BU cases that occurred until 1969, when 
the community moved to a new locality, where case numbers declined, has provided 
much of the basic knowledge about the epidemiology of BU that is still valid today. 
Amongst other insights it became apparent that BU may affect individuals irrespec-
tive of sex and age, although the highest incidence was seen in children aged 
between 5 and 15 years. Furthermore, in contrast to a very low probability of person 
to person transmission, the involvement of an environmental reservoir in the trans-
mission became obvious [7]. While until then clinical attention had been concen-
trated on ulcerative lesions, awareness of the disease in highly endemic regions has 
brought attention to pre-ulcerative forms of the infection including nodules, plaques 
and edema [8].
Until the end of the twentieth century, BU case series were reported mainly from 
West and Central African countries including the Congo [9], Nigeria [10], Gabon 
[11], Ghana [12, 13], Benin [14], and Côte d’Ivoire [15, 16] as well as from Australia 
[17, 18] and Papua New Guinea (PNG) [19]. Moreover, sporadic M. ulcerans infec-
tions occurred in a number of additional countries with tropical, subtropical and 
temperate climates [20], totalling up to 34 countries from which BU has hitherto 
been reported. However, limited awareness of the disease and the fact that it often 
affects poor populations in remote, rural areas has hampered the detection of new 
infection foci and thus the control of BU. In 1998, WHO launched the Global BU 
Initiative, a partnership of Member States, academic and research institutions, 
donors, nongovernmental organizations, WHO, and others with the intention to 
raise awareness and to coordinate global BU control and multidisciplinary research 
efforts. In addition, this Initiative was meant to strengthen BU surveillance systems 
and to assess the disease burden at local, national and global levels. More than 
58,000 BU cases had been reported between 2002 and 2016 from 20 countries in 
Africa (Benin, Cameroon, Central African Republic, Congo, Côte d’Ivoire, 
Democratic Republic of the Congo, Equatorial Guinea, Gabon, Ghana, Guinea, 
Liberia, Nigeria, Sierra Leone, South Sudan, Uganda and Togo), the Americas 
(French Guiana), Asia (Japan), and the Western Pacific (Australia and PNG) 
(Table 1). Since 2008, a steady decline in the number of reported BU patients has 
been noticed (Fig. 1).
While this may in part be due to the establishment of effective national BU con-
trol programs, underreporting is considered likely, as there is lack of data from an 
increasing number of countries that have reported BU cases in the past. Moreover, 
surveillance activities in some of the highly endemic countries may have declined 
due to the decreased availability of specific funding. On the contrary, a steady 
increase in the number of BU patients has been reported from the BU endemic 
region of Victoria in southern Australia, with a peak incidence of 186 new BU infec-
tions in 2016. The geographic distribution of BU recorded by WHO in 2016 is 
illustrated in Fig. 2.
K. Röltgen and G. Pluschke
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42  Evolution, Niche Adaptation, and Transmission 
of Distinct M. ulcerans Lineages
The emergence of M. ulcerans, which has evolved from the fish and opportunistic 
human pathogen M. marinum [21] approximately a million years ago [22], was 
driven by horizontal transfer of genetic material [21]. Most notably, this included a 
virulence plasmid, carrying genes for the synthesis of macrolide toxins, whose cyto-
toxic and immunosuppressive properties account for much of the typical progres-
sive skin necrosis and chronicity of M. ulcerans infections. Several structural 
variants of these mycolactones have hitherto been described [23–25]; for more 
information on the toxin of M. ulcerans the reader is referred to chapter 
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Fig. 1 Number of BU 
cases reported worldwide 
between 2002 and 2016. 
Graph illustrating the 
downward trend of new 
M. ulcerans infections 
reported in the past years. 
Data source: WHO
Fig. 2 Worldwide distribution of BU cases in 2016. Global map illustrating countries that have 
reported cases in 2016 (blue (classical lineage) and green (ancestral lineage)) and in previous years 
(grey). The map was kindly created by Dr. K. Ampah using ‘R’. Data source: WHO
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5“Mycolactone: More than Just a Cytotoxin” of this book. Moreover, acquisition of 
high-copy number insertion sequences (IS2404 and IS2606) and their expansion in 
the M. ulcerans genome has resulted in extensive gene loss, pseudogene formation, 
and modification of gene function, coining the likely adaptation to new, restricted, 
ecological niches [26]. For more detailed information on the population genomics 
and molecular epidemiology of M. ulcerans the reader is referred to chapter 
“Population Genomics and Molecular Epidemiology of Mycobacterium ulcerans” 
of this book. During the process of its genome reduction, M. ulcerans has diverged 
into at least two principal lineages [27], the ancestral and the classical lineage, 
which presumably have been adapting to distinct niche environments within the 
aquatic ecosystem [26]. Both lineages can cause severe tissue destruction if lesions 
are left untreated (Fig. 3).
Until today, the exact source of the infection is not clear, in part because cultiva-
tion of M. ulcerans from potential environmental sources is hindered by the 
extremely slow growth rate of the pathogen. The marked loss of gene function as 
compared to the genome of M. marinum, including genes required for pigment bio-
synthesis and anaerobiosis [26], indicates that M. ulcerans may exist as a commen-
sal associated with a protective organism in the ecosystem [28–30]. Despite 
extensive research, the mode(s) of transmission from environmental reservoirs to 
mammalian hosts is unclear. It is thus likely that M. ulcerans may be transmitted by 
several distinct mechanisms, each enabling the entrance of a sufficient pathogen 
load into the susceptible layers of subcutaneous tissue.
2.1  Ancestral M. ulcerans Lineage
Strains of the ancestral lineage, which are closely related to M. marinum, mainly 
cause disease in ectotherms such as fish and frogs [25, 31–33], but certain sub- 
groups sporadically infect humans. Due to their distinct host range, some 
mycolactone- producing ancestral strains were initially given different species 
designations such as M. marinum for globally detected fish pathogens [25], M. 
pseudoshottsii for mycobacteria isolated from diseased Chesapeake Bay striped 
bass [32], or M. liflandii for strains isolated during a mycobacteriosis outbreak in 
a laboratory colony of Xenopus tropicalis [31]. Furthermore, ancestral strains iso-
lated from the lesions of BU patients from Japan are often referred to as M. ulcer-
ans subspecies shinshuense [34]. Indeed, comparative genome analysis has shown 
that based on the sequences of fish and frog isolates on the one hand and human 
disease isolates from Japan on the other hand the ancestral lineage may be subdi-
vided into two major sub- lineages [26]. The common feature of all of these iso-
lated pathogens is the production of mycolactone and thus it was no surprise when 
comparative genome analysis of ancestral and classical M. ulcerans strains has 
revealed that all mycolactone- producing mycobacteria have evolved from a com-
mon M. marinum-like progenitor and should therefore be considered as ecovars of 
a single M. ulcerans species [26, 35]. Ecovars of the ancestral lineage appear to 
Buruli Ulcer: History and Disease Burden
6Fig. 3 Ulcerative BU lesions in patients from West Africa (upper panel) and Japan (lower panel). 
Photographs from Japanese patients were kindly provided by Dr. M. Ohtsuka, Fukushima Medical 
University
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7be adapting to an ecological niche environment, from which they infect humans 
only occasionally. Environmental studies in regions where the ancestral lineage of 
M. ulcerans prevails are still in their infancy. However, in French Guiana, M. 
ulcerans-specific DNA sequences (IS2404 and the ketoreductase-B domain of the 
M. ulcerans mycolactone polyketide synthase genes (KR)) were found in differ-
ent freshwater bodies [36]. In Japan, an outbreak of BU among several family 
members was linked to a stagnant water channel in the backyard of the family’s 
house, in which a sample of a crayfish contained an IS2404 sequence identical to 
that of M. ulcerans [37].
Sporadic human infections caused by ancestral strains were reported from the 
Americas (French Guiana [36], Suriname [38], Peru [39], Brazil [40] and Mexico 
[41]) and from Asia (Japan [42] and China [43]). Between 2002 and 2016, French 
Guiana and Japan reported to WHO 80 and 59 BU cases, respectively. No official 
records are available for the other South-American and Asian countries. For more 
detailed information on BU in French Guiana and Japan the reader is referred to 
chapters “Mycobacterium ulcerans Infection in French Guiana; Current State of 
Knowledge” and “Buruli Ulcer in Japan” of this book.
2.2  Classical M. ulcerans Lineage
Strains of the classical lineage are responsible for the vast majority of human M. 
ulcerans infections, reported mainly from Africa [20], Australia [17, 18, 44], and 
PNG [19, 45, 46]. Considering the often very high local prevalence of BU in African 
and Australian endemic regions, the classical lineage may be present in an environ-
mental reservoir that—compared to ecovars of the ancestral lineage—is associated 
with a higher risk for humans to contract an infection. Some environmental investi-
gations in African BU endemic areas have shown that M. ulcerans-specific DNA 
sequences can be detected in many biotic components of aquatic ecosystems, such 
as plants, snails, fish, or insects pointing towards the ubiquitous presence of the 
pathogen in these ecosystems [47]. For reasons that are currently not clear, the 
detection rate was much smaller in other environmental studies in African BU 
endemic areas [48, 49]. Studies in southeastern Australia have revealed that pos-
sums are highly susceptible to M. ulcerans infection. Sporadic infections have also 
been found in other native wildlife and domestic mammals [50, 51]. For more 
detailed information on BU in animals the reader is referred to chapter “Buruli 
Ulcer in Animals and Experimental Infection Models” of this book. Infected pos-
sums were shown to harbour high loads of M. ulcerans DNA in their gastrointestinal 
tracts. However, M. ulcerans cultivation from faeces failed, while being successful 
from skin lesions of infected possums [50, 51]. Genome comparison of classical 
lineage M. ulcerans isolates from possums and humans revealed an extremely close 
Buruli Ulcer: History and Disease Burden
8genetic relationship, supporting a role for these animals in the ecology of infection 
as a reservoir of the pathogen [26]. In Far North Queensland (FNQ), another BU 
endemic area of Australia, M. ulcerans DNA was detected in excreta of bandicoots 
[52]. These findings suggest that certain Australian marsupials may be highly sus-
ceptible to M. ulcerans infection. In contrast, until today, surveys of small mammals 
in African BU endemic areas have not led to the detection of an M. ulcerans animal 
reservoir [48, 53]. It has been suspected that in highly endemic areas of Africa, large 
chronic lesions of BU patients may contribute significantly to the dissemination of 
M. ulcerans in the environment.
Between 2002 and 2016, a total of 57,591 BU cases were reported from 16 
African countries, 1081 from Australia and 163 from PNG. No official records are 
available for other countries, in which the presence of classical M. ulcerans infec-
tions was suspected, such as Kiribati [54] or Malaysia [55]. For more detailed infor-
mation on BU in Africa and Australia the reader is referred to chapters “Buruli 
Ulcer in Africa” and “Buruli Ulcer in Australia” of this book.
3  Characteristics of BU Disease in Humans
In the following paragraphs, relevant data for BU disease in different BU endemic 
areas are compiled to enable a comparison of epidemiological and clinical fea-
tures as well as environmental characteristics. For that purpose, PubMed was 
searched using the query “Buruli ulcer” OR “Mycobacterium ulcerans”. All titles 
(N = ∼1180) and available abstracts were screened for relevant content. Studies 
including more than 30 BU cases were used to extract information on demo-
graphic and geographic features of BU in these areas. In view of the multitude of 
publications on African BU endemic settings, representative studies conducted in 
eight different countries were selected. We included at least one and not more than 
three studies from the seven countries that have reported the vast majority of BU 
cases in the past decade, namely Côte d’Ivoire [56], Ghana [57–59], Benin [60–
62, 76], Cameroon [63, 64], Democratic Republic of the Congo [65], Togo [66] 
and Republic of the Congo [67] as well as a case series from Nigeria [68], one of 
the few countries, which has recorded an increase in the number of reported cases 
over the past years. Studies were selected based on a preference for (1) quantity 
of BU cases (large case series), (2) quality (preferentially studies including labo-
ratory-confirmed patients), (3) content (data on many epidemiological aspects), 
and (4) “up-to-datedness” (recent publications, if available and complying with 
other preferences). Furthermore, a very detailed study of 220 BU cases that were 
identified within a community of Rwandan refugees between 1964 and 1969 near 
the river Nile in Central Uganda was included [7] (Tables 2 and 3). BU endemic 
regions outside of Africa included in this comparative analysis are French Guiana 
(chapter “Mycobacterium ulcerans Infection in French Guiana; Current State of 
Knowledge” of this book) [69], Japan [42] (chapter “Buruli Ulcer in Japan” of this 
book), PNG [19, 46], FNQ, Australia [44, 70] and Victoria, Australia [71, 72] 
(chapter “Buruli Ulcer in Australia” of this book).
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3.1  Demographic and Clinical Characteristics of M. ulcerans 
Infection
3.1.1  Age Distribution of BU Patients
BU has long been considered as a disease that mainly affects children under the 
age of 15 years living in rural areas of Africa. A comparison of the age distribu-
tion reported for various BU case series (Table 2) shows that this assumption still 
holds true for African BU endemic areas and for endemic sites in PNG. However, 
this generalized view lapsed when larger case series were reported from Victoria 
in southeastern Australia, where a high average age of BU patients was observed 
(Table 2). The peak incidence of BU among children in Africa and the elderly in 
Victoria may be partly related to the average age of the respective general popu-
lations in the affected areas. While the population in BU endemic areas in Africa 
is very young [64, 73, 74], the affected communities in Victoria are popular sea-
side holiday resorts, where many retired people have their homes. But even if 
taking the skewed age distribution of the study populations into account, the 
elderly were most affected in Australia [75] and a bi-modal distribution of the 
age-related risk of developing BU was observed in Africa with young teenagers 
and the elderly being overrepresented among cases [64, 74, 76]. Increasing risk 
of developing BU with age may be due to the gradual deterioration of the immune 
system in the elderly. Interestingly, a marked underrepresentation of BU patients 
among children below 4 years of age was found [64]. This observation was in 
line with subsequent sero- epidemiological studies in Ghana and Cameroon, indi-
cating that young children are considerably less exposed to M. ulcerans than 
older children [77, 78].
In Japan, where BU disease is caused by strains of the ancestral M. ulcerans 
lineage, a tendency towards middle-aged adults was found [42]. In French Guiana, 
a marked transition of the most affected age groups was observed: over a period of 
45 years the median age of patients increased significantly from 9 years of age in the 
study period between 1969 and 1983 to 36 years of age between 1999 and 2013 
[69]. Taken together the age-related risk of developing BU appears to be determined 
both by differential exposure to M. ulcerans and by higher susceptibility of certain 
age groups.
3.1.2  Gender Distribution of BU Patients
A comparison of various BU case series (Table  2) reveals an overall balanced 
male:female ratio among patients, although in some studies the proportion of one of 
the sexes was higher than that of the other. While more female than male patients 
were recorded in Japan, more men than women tended to be affected in FNQ, 
Australia. Several studies conducted with large numbers of African BU cases 
revealed significant differences in the male:female ratio, when the study population 
was stratified by age. All of these studies have consistently reported that in children 
below the age of 15 years, M. ulcerans infection is more common in boys than in 
girls and conversely that in individuals above the age of 15 years the infection is 
more frequent in females than in males [7, 56, 61, 62] (Table 2). It appears likely 
Buruli Ulcer: History and Disease Burden
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that observed differences are due to different environmental contact patterns associ-
ated with the movement radius of children or different occupational exposure to 
environmental reservoirs.
3.1.3  Distribution of BU Lesions on the Human Body
While the mode of transmission of M. ulcerans remains unclear, it is commonly 
assumed that infection takes places via inoculation of the bacteria into the skin 
through direct trauma or bites of insects such as water bugs or mosquitoes [47, 51]. 
The site of inoculation is thought to be also the site of infection, not least because 
about 95% of BU patients present with a single lesion. A disseminated disease pro-
gression may only be found in those 5% of the patients presenting with multiple 
lesions (Table 2). Therefore, the location of BU lesions on the body of patients has 
been extensively studied, with the hope of detecting specific distribution patterns, 
such as a clustering of lesions at preferred feeding sites of biting arthropods vs. 
common sites for mechanical skin injuries, favouring any of the discussed mecha-
nisms of infection. BU lesions, irrespective of whether they are caused by strains of 
the ancestral or the classical M. ulcerans lineage, occur mostly on parts of the body, 
which are not commonly protected by clothing (Table 2). The vast majority of stud-
ies found that lesions occurred in 90% or more of the cases on the limbs. Around 
two-thirds of the lesions occurred on the lower limbs, followed by the upper limbs, 
and less frequently the trunk, and sites on the neck/head (Table 2). While overall 
patterns observed in different regions, such as for example in Cameroon and 
Victoria, Australia appear to be surprisingly similar [64, 72], several studies have 
reported that the anatomical site of the lesions may vary with both gender and age. 
Interestingly, in studies conducted in French Guiana and Victoria upper limb lesions 
were more common in men than in women, who were more frequently affected on 
the lower limbs than were men [69, 71, 72]. Conversely, in African BU endemic 
areas lower limb lesions were more common and upper limb lesions were less com-
mon in men than in women [7, 76]. The most likely explanation for this differential 
pattern of lesion distribution is that women in Africa more commonly protect their 
lower limbs with clothing as compared to women in South America or Australia. 
Along the same line, men tend to be more often affected on the chest than women 
[64, 69]. Similarly, differential exposure to M. ulcerans may serve as an explanation 
for differences between age groups. It was reported that in children below 5 years of 
age any part of the body may be affected, while with increasing age the head and the 
trunk seem to be less commonly affected and limb lesions become more dominant 
[7, 57, 62, 76]. Failure to wear protective clothing has been identified as a risk factor 
for BU in several case-control studies [79–81]. In summary, the distribution of BU 
lesions appears to be strongly correlated with exposure of body parts to M. ulcerans, 
which may in turn be related to insect bites, skin injuries, or both.
3.1.4  WHO Categories and Clinical Manifestations of BU
M. ulcerans infections have been classified by WHO into three categories: category 
I is defined as a single, small lesion <5 cm in diameter, category II includes single 
lesions between 5 and 15  cm in diameter, plaque and edematous forms, and 
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category III is comprised of single extensive lesions >15 cm in diameter, multiple 
lesions, lesions at critical sites (e.g. eye, genitalia, joints), and osteomyelitis [82]. 
There are marked differences in the proportion of BU patients presenting at health 
facilities with lesions of one of these categories for different geographical regions 
(Table  2). In Japan and Australia, where healthcare is readily available, the vast 
majority of BU patients present with category I lesions, for which standard national 
antibiotic regimens are highly effective. On the contrary, a significant proportion of 
BU patients in Africa and in particular those detected by active case search, present 
with more advanced stages of the disease, for which time required for healing is 
prolonged and healing is often accompanied by permanent disability. The percent-
age of patients with category II and III lesions is strongly dependent on the degree 
of remoteness of a population and consequently access to healthcare as well as with 
awareness of the disease among populations at risk. A high degree of awareness 
among the Rwandan population in the Kinyara refugee settlement as well as the 
establishment of a BU treatment center, has for example led to reporting at early 
stages of the disease [7]. On the contrary, due to a lack of adequate health infrastruc-
ture for the diagnosis and treatment of BU, a large cohort of patients from south-
western Nigeria presented to a health center in Benin with 58% category III and 
only 8% category I lesions [68]. Osteomyelitis is mainly observed in African popu-
lations [61, 63, 68] and only occasionally in Australia [71]. The fact that ulcers are 
the most common form of BU lesions in all of the affected geographical areas is 
related to the relatively unspecific, nodular onset and the often reported painlessness 
[84] of M. ulcerans disease.
3.2  Geographical Features of M. ulcerans Infection Foci
3.2.1  Environmental and Climatic Characteristics of BU Endemic 
Areas
Environmental and climatic factors are highly diverse in different M. ulcerans infec-
tion foci, not only if areas are compared where either the ancestral or the classical 
lineage prevails, but also among areas affected by the same lineage (Table 3).
French Guiana is located at the Atlantic Ocean in northern South America 
between Suriname and northern Brazil. Most of the inhabitants reside along a 50 km 
wide coastline, which is mainly composed of marshy savannah and mangroves, 
whereas the rest of the country consists of dense, barely accessible rainforest. 
Located between latitudes 2° and 6° N and rising only to modest elevations, the 
climate in French Guiana is tropical (hot and humid) all year round. While rainfall 
may be heavy from January to June/July, the period between August and December 
is considered the main dry season [85]. The highest mean incidence of BU was 
detected in the western coastal area around the towns of Sinnamary and Mana adja-
cent to the Sinnamary and La Mana rivers, respectively [69]. On the contrary, Japan 
extends through a wide latitude from 30° to 45° N, with climate conditions ranging 
from humid subtropical to humid continental. BU cases are sporadically distributed 
throughout the large, mountainous Honshu Island, which separates the Sea of Japan 
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from the North Pacific Ocean. Much of Honshu belongs to the temperate zone with 
humid, subtropical climate characterized by four distinct seasons including a period 
with higher rainfall between mid of June and end of July. Humid, continental cli-
mate may be encountered in northern Honshu, with cold winters commonly experi-
encing snowfall [86]. The 60 sporadic BU cases reported between 2003 and 2016 in 
Japan were distributed over 17 of the 47 prefectures of the country (chapter “Buruli 
Ulcer in Japan” of this book). Interestingly, in some of the northern regions report-
ing BU cases, the temperature can be below zero degrees Celsius during the coldest 
season of the year. In Australia, M. ulcerans infections mainly occur in two geo-
graphically distinct areas in a temperate climatic zone in the south-eastern state of 
Victoria, and in tropical FNQ. In Victoria, M. ulcerans infections are consistently 
associated with low-lying coastal areas, where rainfall is spread throughout the year 
[75]. After first BU cases were described in the Bairnsdale region [2], the pathogen 
appeared to migrate westwards [87] causing larger outbreaks in the 1990s in Phillip 
Island [18] and Frankston/Langwarrin [17]. Since 1998 new foci have continuously 
appeared on the Bellarine and Mornington Peninsulas [71, 80, 88]. The second sig-
nificant BU endemic area of Australia in FNQ comprises a rim of coastal valleys 
and lowlands surrounding the Dagmar Range, and extending from Daintree in the 
North to Mossman in the South [44]. The climate in FNQ is characterized by two 
distinct seasons with a warm, dry season during the winter period in May–October/
November and a warm, wet season during the summer period in November/
December–April [52]. Information on the distribution of BU in PNG is sparse, 
although infections have sporadically occurred in different parts of the country. One 
main BU focus was seen in the coastal Oro province in villages along the Kumusi 
River, where the climate is hot and humid and rainfall is high throughout the year 
with a relatively drier period from May to November [46]. BU endemic areas of 
West and Central Africa are mainly located in remote, rural areas and are character-
ized by a focal distribution with often high local prevalence rates. Affected regions 
have a tropical climate, typically with distinct dry and rainy seasons and are often 
associated with slow flowing and stagnant water bodies in proximity to large rivers. 
In West Africa the dry period lasts generally from November to February and is fol-
lowed by region-specific rainy seasons. The southern areas of West Africa in the 
Guinea Coast region, where most of the BU cases occur, commonly experience two 
rainy seasons, one from April to July and a shorter one in September/October. In 
contrast, only one rainy period between July and September is observed in the North 
[89]. Distinct, region-specific dry and rainy seasons are also observed in Central 
African regions reporting BU cases [90].
Taken together M. ulcerans infection foci may be located in tropical or temperate 
climatic zones with or without distinct seasons, are connected with coastal lowlands 
in French Guiana, Australia and PNG, and with water bodies in remote, rural inland 
or coastal areas of Africa (Table 3).
3.2.2  Seasonality of BU Transmission
The detection and interpretation of seasonal fluctuations in the incidence of M. 
ulcerans disease is complicated by a combination of different factors, including 
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the extremely long incubation period of the infection and the lack of knowledge 
on the mode of transmission and accordingly the timing of the infection, unless 
the patient has visited an endemic area only once and for a short time. Furthermore, 
features of early lesions are relatively uncharacteristic, causing delays in detec-
tion of the disease and reporting to health facilities. Well-documented records of 
BU cases among short-term visitors to BU endemic sites represent a unique source 
for the estimation of the time from exposure to disease onset. This approach was 
applied in south- eastern Australia by systematic identification of BU patients with 
a single visit exposure to one of the well-known focal BU endemic areas. The 
mean incubation period determined for patients infected in Victoria was 4.5 months 
with a wide variation from 32 to 264 days [91, 92]. In the Daintree region of FNQ, 
a large spike of BU cases was observed in September and October 2011, 7–8 month 
after an exceptionally long and very wet rainy season with peak rainfall in 
February 2011 that was suspected to be connected with the occurrence of the 
infections [44]. While this may speak for a longer average incubation period in 
FNQ as compared to Victoria, in the Kinyara refugee camp in Uganda, the period 
between short stays of visitors and the development of BU was estimated to be 
between 1 and 3 months [7]. These apparent differences in the mean incubation 
period may be due to mode of transmission-related differences in the inoculation 
dose of M. ulcerans. All of these studies have shown that the time interval between 
exposure and onset of symptoms and finally to the diagnosis of BU can vary sub-
stantially on an individual basis, which may obscure potentially distinct seasonal 
variations in transmission intensity. Nevertheless, seasonal patterns of BU inci-
dence have been reported for infection foci caused by both ancestral and classical 
M. ulcerans strains (Table  3). In French Guiana, M. ulcerans was found to be 
correlated with short-term (6 months) and long-term (a decade) rainfall patterns 
and the El Niño-Southern oscillation [85], (chapter “Mycobacterium ulcerans 
Infection in French Guiana; Current State of Knowledge” of this book). In Japan, 
approximately 80% of the reported BU cases were diagnosed during autumn and 
winter [42] (chapter “Buruli Ulcer in Japan” of this book), indicating contraction 
of the infection during or shortly after the hot and rainy season in summer. 
Between 2009 and 2015, most BU cases in FNQ were diagnosed during the dry 
season from July to November, which is likely explained by a surge in transmis-
sion during the wet season [44]. For the BU endemic focus in villages along the 
Kumusi River in PNG, a consistently higher incidence of cases in the drier months 
(May–November) was recorded [46].
Analyses of seasonal patterns of M. ulcerans infection are particularly dif-
ficult for remote BU endemic regions in Africa, where very long delays in 
reporting of patients to the public health system have to be taken into account. 
In addition, several studies assessing seasonal patterns of the disease in Africa 
have used country- wide data, ignoring local differences in rainfall patterns. In 
a study assessing seasonal patterns of BU in an endemic area of Cameroon, 
case incidences between 2002 and 2012 peaked in March. Assuming a delay 
between infection and diagnosis of 5–6 months, this suggested that the risk of 
infection is highest during the high rainy season from August to October [93]. 
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Similarly, transmission in the Kinyara refugee camp, was estimated to be great-
est from July to September [7].
Seasonal patterns of BU incidence may result from differences in the environ-
mental presence of the pathogen or potential vectors, as well as from behaviour- 
associated variations in exposure of populations to M. ulcerans. These variations 
may be triggered by climatic conditions and connected landscape dynamics as 
well as by seasonal changes in agricultural and other activities intensifying envi-
ronmental exposure. Considering the general association of BU endemicity with 
aquatic ecosystems, one of the main drivers of increased transmission may be 
flooding and the seasonal appearance of stagnant temporary water bodies and 
swamps, providing a breeding ground for potential reservoirs/vectors and/or the 
pathogen itself.
3.2.3  Linkage of the Emergence of BU Foci to Environmental 
Changes
Altered environmental conditions may be favourable for the growth and dissemina-
tion of pathogens and may lead to increased contact of populations to pathogens, i.e. 
their vector(s) and/or environmental reservoir(s) [94, 95]. Therefore changes in land 
use including intensification and changes in the nature of agricultural activities, 
water management projects, deforestation and urbanization as well as natural phe-
nomena, such as cyclones, flooding, or volcanic eruption can lead to ecological edge 
effects that promote disease emergence. It is suspected, that the emergence of some 
of the M. ulcerans infection foci was related to different types of ecological and 
environmental disturbances (Table 3).
In French Guiana, an increase in the incidence of BU in Mana between 1984 and 
1988 was observed just after the creation of rice fields [69]. On the other hand, con-
struction of the hydroelectric Petit-Saut Dam on the Sinnamary River in 1994 
upstream of an adjacent BU endemic area has been associated with a significant 
decline in case numbers, possibly due to a better regulation of water flows. In Japan, 
a BU outbreak affecting several members of a family was linked to a stagnant agri-
cultural water channel [37] and in Victoria an outbreak in Phillip Island in the 1990s 
was suspected to be triggered by a newly formed lake and/or a golf course irrigation 
system [96]. The population in BU endemic areas along the Kumusi River in PNG 
has claimed that infections had only occurred after a great flood following the erup-
tion of the nearby volcano Mount Lamington. In FNQ, a spike of cases seen in 2011 
was connected with the aforementioned exceptionally long and very wet rainy sea-
son. The subsequent decrease in the number of cases since 2011, may be due to 
much drier conditions in the following years [44]. In African BU endemic areas 
associations have been suspected between BU incidence and damming of rivers or 
streams leading to the creation of artificial lakes; e.g. a small stream on the University 
campus in Ibadan, Nigeria [97], the Mapé River in Cameroon [98], the Densu River 
in Ghana, or the Bandama River in Côte d’Ivoire [99]. High risk zones for the con-
traction of BU were also connected with land cover changes; e.g. establishment of 
irrigated rice and banana fields in Côte d’Ivoire [100] or areas of mining and agri-
cultural activity in Ghana [101].
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4  Risk/Protective Factors for BU
In order to identify risk factors for BU, a number of case-control studies were con-
ducted in areas endemic for the classical lineage of M. ulcerans. In view of a limited 
reliability of the clinical diagnosis, laboratory confirmation of patients enrolled in 
these studies is a crucial prerequisite for the quality of obtained results. Due to the 
multitude of studies conducted on behavioural risk factors for BU, only those with 
laboratory-confirmed patients were included here. On the other hand, considering 
that only very limited information is available to date on potential host genetic fac-
tors and on the impact of BCG vaccination and HIV co-infection, also studies with 
only partly reconfirmed cases are discussed in the corresponding paragraphs. The 
BU case confirmation status of all of these studies is listed in Table 4.
Table 4 Assessment of risk factors for the contraction of BU caused by classical M. ulcerans 
strains identified by comparative case-control studies
Country/
site
Time 
span of 
study 
(Ref.)
No of 
confirmeda 
BU cases
No of 
controls 
(matching 
factors)
Assessed risk 
factors
Risk factors 
identified
Protective 
factors 
identified
Behavioural risk factors
Australia 
(Victoria)
1998–
2005 
[80]
49 609 
(community- 
based)
Lifestyle and 
insect 
exposure
Mosquito 
bites on 
lower legs 
and lower 
arms
Use of 
insect 
repellent, 
wearing 
protective 
clothing, 
washing 
of wounds
Benin 2006–
2008 
[105]
104 312 
(community- 
based; 
matched by 
age, sex and 
village of 
residence)
Water 
sources, 
family 
relationships
BU history 
in the 
family, 
contact with 
natural 
water 
sources
Côte 
d’Ivoire
2012 
[102]
51 102 (hospital/
health 
center- based; 
matched by 
age 
(±5 years), 
sex, and type 
of residency)
Socio-
sanitary, 
environment, 
and behaviour
Regular 
contact with 
unprotected
surface 
water and 
absence of 
protective 
equipment 
during 
agricultural 
activities
Good 
knowledge 
about the 
risks that 
may result 
in BU and 
perception 
about the 
disease 
causes
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Table 4 (continued)
Country/
site
Time 
span of 
study 
(Ref.)
No of 
confirmeda 
BU cases
No of 
controls 
(matching 
factors)
Assessed risk 
factors
Risk factors 
identified
Protective 
factors 
identified
Ghana 1999 
[104]
51 51 (hospital- 
based; 
matched by 
age group, 
sex, BCG)
Water-related Swimming 
in rivers on 
a habitual 
basis
2000 
[79]
116 116 
(community- 
based; 
matched by 
age and 
village)
Environment 
and behavior
Wading in a 
river or 
stream
Wearing a 
shirt while 
farming, 
sharing 
indoor 
living 
space with 
livestock, 
bathing 
with toilet 
soap
2010–
2011 
[81]
113 113 
(community- 
based; 
matched by 
age, sex and 
village)
Demography, 
socio-
economy, 
health and 
hygiene as 
well as 
environment
Presence of 
wetland, 
insect bites 
in water, use 
of adhesive 
when 
injured, and 
washing in 
river
Use of 
alcohol 
for 
injuries, 
covering 
limbs 
during 
farming
2013–
2015 
[103]
176 176 
(community- 
based; 
matched by 
age 
(±5 years), 
sex, and place 
of residence)
Demography, 
environment, 
and behaviour
Farming in 
swampy 
areas,
farming 
while 
wearing 
short 
clothing, 
insect bites, 
and 
application 
of leaves on 
wounds
Farming in 
long 
clothing, 
washing 
wounds 
with water, 
and 
application 
of adhesive 
bandage on 
wounds
(continued)
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Table 4 (continued)
Country/
site
Time 
span of 
study 
(Ref.)
No of 
confirmeda 
BU cases
No of 
controls 
(matching 
factors)
Assessed risk 
factors
Risk factors 
identified
Protective 
factors 
identified
Togo 2014–
2015 
[106]
83 128 
(community- 
based; 
matched by 
sex and place 
of residence)
Socio- 
demography, 
environment 
and behaviour
Bathing with 
water from 
open 
borehole, 
frequently 
crossing or 
swimming 
in a river, 
and 
receiving 
cuts, 
scratches or 
insect bites 
near a river
Using 
detergents 
for 
washing 
clothes or 
dishes
Host genetic factors
Benin 2005–
2013 
[111]
208 300 
(community- 
based; 
matched by 
age, sex, 
water contact 
habits, and 
ethnic 
background)
Autophagy- 
related genes
rs1333955 
SNP in 
PARK2
rs2241880 
SNP in 
ATG16L1
Ghana 2006 
[110]
102 of 182 191 
(community- 
based; 
matched by 
age)
Polymorphisms 
in the natural 
resistance- 
associated 
macrophage 
protein gene 
(SLC11A1)
D543N in 
SLC11A1
2011 
[109]
96 384 
(community- 
based; 
matched by 
age, sex, 
ethnicity and 
home village)
Polymorphisms 
in genes known 
to be associated 
with 
susceptibility to 
Tuberculosis 
and Leprosy
rs9282799 
SNP in iNOS 
and 
rs2069705 in 
IFNG
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4.1  Behavioural Risk Factors
Failure to wear protective clothing [102, 103] and activities close to or in certain 
unprotected water sources [79, 81, 102–106] have repeatedly been connected with 
an increased risk of contracting BU. Conversely, wearing protective clothing [79–
81, 103], wound care [80, 81, 103] and good hygiene [79, 106] have been identified 
Table 4 (continued)
Country/
site
Time 
span of 
study 
(Ref.)
No of 
confirmeda 
BU cases
No of 
controls 
(matching 
factors)
Assessed risk 
factors
Risk factors 
identified
Protective 
factors 
identified
BCG vaccination
Benin 2002–
2003 
[117]
134 of 279 988 
(community- 
based; 
matched by 
age and sex)
BCG 
vaccination
None None
Côte 
d’Ivoire
2001 
[119]
56 of 116 116 
(community- 
based; 
matched by 
age, sex, and 
village)
BCG 
vaccination 
(and other 
risk factors 
not discussed 
here)
No history 
of BCG 
vaccination
DRC, 
Ghana 
and Togo
2010–
2013 
[118]
401 826 (mostly 
family 
members and 
neighbours)
BCG 
vaccination
None None
Ghana 2000 
[79]
116 116 
(community- 
based; 
matched by 
age and 
village)
BCG 
vaccination 
(and other 
risk factors 
discussed 
above)
None None
HIV co-infection
Benin 2002–
2003 
[120]
258 of 426 613 
(community)
HIV infection HIV 
infection
Ghana 2000 
[79]
116 116 
(community- 
based; 
matched by 
age and 
village)
HIV infection 
(and other 
risk factors 
discussed 
above)
None None
aLaboratory confirmation of clinically diagnosed patients by at least one diagnostic test
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as factors conferring some degree of protection (Table 4). In southeastern Australia, 
where an involvement of mosquitoes in the transmission of M. ulcerans infections 
as either biological or purely mechanical vectors of the pathogen has been sug-
gested, mosquito bites were identified as a risk factor. In addition to using insect 
repellent, immediate cleansing of wounds has also been associated with a decreased 
risk of contracting an M. ulcerans infection [80]. In African settings, insect bites, 
but also cuts and scratches near or in water bodies have been linked with an increased 
risk of infection [106]. One of the case-control studies came to the conclusion that 
good knowledge about BU and the risk factors involved in infection had a protective 
effect [102].
4.2  Host Genetic Factors
With the availability of a large number of human genome sequences, millions of 
polymorphic markers have been identified [107]. For case-control studies aiming at 
uncovering genetic factors that influence disease susceptibility, there are two main 
principal approaches; one based on testing candidate genes and the other based on 
genome-wide association studies. While candidate gene studies have higher statisti-
cal power, they cannot discover new markers or marker combinations. Even with 
several thousands of samples, genome-wide association studies can on the other 
hand be underpowered [108] and in the case of infectious diseases the element of 
exposure adds complexity and can contribute to statistical noise.
In view of the limited number of BU patients that can be enrolled for geographi-
cally restricted case-control studies, it is not surprising that only candidate gene 
studies have so far been conducted for BU.  To date, single nucleotide polymor-
phisms (SNPs) in the inducible nitric oxide synthase gene iNOS and in the inter-
feron gamma gene IFNG [109], the natural resistance-associated macrophage 
protein gene SLC11A1 (NRAMP1) [110], and the autophagy-related E3 ubiquitin- 
protein ligase gene PARK2 [111] have been linked to susceptibility to BU (Table 4). 
However, these initial findings should be reconfirmed in future studies enrolling 
larger BU patient cohorts.
The fact that SNPs, which reduce the promoter activity of iNOS and IFNG impli-
cated in macrophage activation, were found to increase susceptibility to BU, sup-
port the hypothesis that macrophages may be of crucial importance for the 
containment of M. ulcerans infections. Also, the influence of polymorphisms in 
SLC11A1 implicated in the transport of divalent cations to late endosomes/lyso-
somes [112] and in the ubiquitin ligase PARK2 implicated in resistance to intracel-
lular pathogens [113], hint to a key role of macrophages in the early stage of an M. 
ulcerans infection, when low mycolactone levels may still permit elimination of the 
inoculated mycobacteria. For more detailed information on the immunology of BU 
the reader is referred to chapter “The Immunology of Buruli Ulcer” of this book. It 
should be noted however, that selection of candidate genes investigated so far was 
strongly biased towards host polymorphisms that have previously shown significant 
associations with susceptibility to intracellular mycobacteria, such as M. 
K. Röltgen and G. Pluschke
29
tuberculosis and M. leprae. Genome-wide association studies for susceptibility to 
BU could thus potentially reveal even more robust gene-disease association data for 
genes that are relevant for other immune effector mechanisms.
4.3  BCG Vaccination
No specific vaccine is currently available to prevent M. ulcerans disease, but the 
protective effectiveness of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) 
vaccination has been controversially discussed [114]. Two randomized controlled 
trials, one at the settlement of Rwandan refugees in Kinyara between 1967 and 1969 
[115] and a second in another BU endemic area of Uganda in the 1970s [116] indi-
cated a certain protective effect of BCG vaccination, although protection appeared 
to be short-lived [116]. Results of three case-control studies showed no evidence of 
a protective effect of BCG vaccination on the risk of developing BU [79, 117, 118], 
whereas no history of BCG vaccination appeared to be associated with BU in 
another study [119] (Table 4). Uncertainty about the BCG vaccination status among 
study populations with missing vaccination records should be considered as a 
potential confounder in these investigations.
4.4  BU-HIV Co-infection
BU-HIV co-infection is not uncommon due to the high HIV prevalence in many BU 
endemic areas. But until today, there is paucity of information on epidemiological 
and clinical relationships of the two infections. A case-control study conducted in 
Benin found that the prevalence of HIV in BU patients (2.6%) was significantly 
higher (P = 0.003) than that of the local control population (0.3%) [120], indicating 
that HIV increases the risk of BU. Similar percentages were reported in another 
case-control study performed in Ghana, with 5% of the BU patients and 0.9% of the 
control individuals testing positive for HIV, although—probably due to the small 
number of study participants—this association was not statistically significant [79] 
(Table 4). Furthermore, the prevalence of HIV among BU patients was significantly 
higher than that of the regional estimated prevalence [121] or that of other patients 
or pregnant women attending the same health facilities [122]. HIV infection weak-
ens the immune system and seems to also affect the clinical presentation of BU, as 
co-infected patients tend to have more severe and more often multifocal lesions than 
HIV-negative patients [121, 122]. This is also indicated by a number of BU-HIV 
case reports describing aggressive, multifocal BU disease progression [123–128]. 
Management of BU-HIV co-infection is challenging [129]. It is recommended that 
all BU patients should be tested for HIV co-infection and that HIV-positive indi-
viduals should receive early antiretroviral treatment to reduce mortality (for more 
information on the management of BU-HIV co-infection see chapter “Management 
of BU-HIV Co-infection” of this book), which seems to be higher in BU-HIV co- 
infected than in HIV-negative patients [121, 122, 126, 128].
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5  Diagnosis and Treatment of BU in Different 
Geographical Settings
The diagnosis of M. ulcerans infections is not trivial. The disease has a wide spec-
trum of clinical manifestations including ulcerative lesions as well as non-ulcer-
ative forms such as nodules, plaques, and edema. As a consequence, the differential 
diagnosis of BU is broad, particularly in tropical endemic areas, where the preva-
lence of skin conditions with similar presentations is high [130]. Findings from a 
recent retrospective assessment of the diagnosis of BU in Ghana between 2008 and 
2016 has revealed that in over 50% of all cases, a clinical suspicion of BU could 
not be confirmed by laboratory testing [59]. While surgical excision of lesions had 
long been the only treatment option for BU, pre-treatment laboratory confirmation 
of M. ulcerans infections has gained further in importance after the introduction of 
antibiotic therapy in 2004. In recent years, PCR targeting the IS2404 element of M. 
ulcerans has become a gold standard for the diagnosis of BU in reference labora-
tories of the endemic countries. PCR-based laboratory confirmation of suspected 
BU cases is routinely performed in countries with resource rich healthcare systems 
and good laboratory infrastructure such as Japan [131] and Australia [132]. In 
French Guiana, the proportion of laboratory-confirmed BU cases increased from 
52% before PCR became available in 2000 to 92% after 2000 [69]. However, the 
main drawback of PCR-based diagnosis for rural African endemic areas is its lim-
ited accessibility. To date, the only laboratory test locally available is microscopy 
of Ziehl-Neelsen stained smears from lesion specimens, a method with low sensi-
tivity. In-country PCR reconfirmation in Africa can only be performed at a few 
reference laboratories. Samples are often stored for bulk shipments to these labo-
ratories, leading to delayed delivery of results. Initiation of antibiotic therapy is 
thus often based on clinical diagnosis only, bearing the risk that some of the BU 
patients (and also misdiagnosed non-BU patients) do not receive appropriate treat-
ment. A low-tech, accurate, rapid diagnostic test for the diagnosis of BU is of 
urgent need. For more information on the laboratory diagnosis of BU see chapter 
“Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives” of 
this book.
WHO treatment recommendations include an eight-week course of a rifampicin- 
based combination of antibiotics, and—if needed—adjunct debridement and skin 
grafting. Until recently, rifampicin—the most effective drug against M. ulcerans—
was prescribed in combination with intramuscular doses of streptomycin. However, 
administration of streptomycin through injections has a major impact on patient 
acceptance and adherence, and is often not practical in rural BU endemic areas. 
Moreover, prolonged use of streptomycin has been shown to cause permanent oto-
toxicity and transient nephrotoxicity in BU patients [133]. Therefore, the WHO 
Technical Advisory Group on Buruli ulcer recommended in 2017 to replace strep-
tomycin with oral clarithromycin for BU treatment. Current first-line eight-week 
treatment regimens include rifampicin combined with clarithromycin, moxifloxacin 
or ciprofloxacin in Australia [134], a triple combination of rifampicin, levofloxacin, 
and clarithromycin in Japan (chapter “Buruli Ulcer in Japan” of this book) and 
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rifampicin combined with amikacin or clarithromycin in French Guiana (chapter 
“Mycobacterium ulcerans Infection in French Guiana; Current State of Knowledge” 
of this book). WHO has developed a policy of free supplies of antibiotics to the 
affected countries on request from national BU control programs, which should in 
turn ensure that BU treatment facilities have an uninterrupted supply of the antibiot-
ics [82]. However, the logistics involved in the provision of medication to remote, 
rural health facilities is challenging and hence antibiotics are not always available to 
patients in these areas. Alternative options for the treatment of BU, in particular the 
potential of new tuberculosis drug candidates are currently being investigated. 
Furthermore, local thermotherapy at the site of the lesions with simple phase change 
material devices showed promising results in a phase II clinical trial [135] and may 
be suitable for treatment at community level. For more information on the treatment 
of BU see chapters “Antimicrobial Treatment of Mycobacterium ulcerans Infection” 
and “Thermotherapy of Buruli Ulcer” of this book. Another important component 
to improve the healing process of lesions and to prevent secondary infections is 
adequate wound management. Interested readers are referred to chapter “Secondary 
Infection of Buruli Ulcer Lesions” of this book dealing with secondary infection 
and management of BU lesions.
6  Socio-Economic Burden of BU for Patients and their 
Families
The diagnosis and treatment of BU patients in Australia, Japan, and French Guiana 
is secured by well-resourced universal healthcare systems. In contrast, health ser-
vices in remote BU endemic communities of Africa and PNG are often very limited. 
Although in many BU endemic countries, antibiotic treatment of BU is free of 
charge, other expenditures and required efforts may prevent patients from seeking 
care at the formal health system. The economic burden arising from transport, 
accommodation and food for patients and caregivers, lost earnings and work force 
may be too high for the affected families [136, 137], in particular if long hospital 
stays are required. Cultural beliefs, perceptions regarding the effectiveness of BU 
treatment, and stigma derived from the perceived mystical origin of the disease 
further aggravate the situation [138, 139] (see chapter “Social Science Contributions 
to BU Focused Health Service Research in West-Africa” of this book for more 
information on social science aspects of BU). In many BU endemic areas, patients 
prefer to first consult traditional healers and only refer to hospitals as a last resort 
[137]. Although BU is a slowly progressing disease, delays in receiving adequate 
medical care is detrimental to the treatment outcome. Chemotherapy is highly 
 effective for early stages of BU, whereas the management of advanced stages is 
often complicated by delayed wound healing requiring prolonged hospitaliza-
tion. Moreover, treatment of advanced BU may not prevent permanent functional 
disabilities.
Neglected tropical diseases (NTDs) have a substantial, cumulative effect on the 
economy and the health of affected populations, imposing a devastating social and 
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economic burden on affected individuals, households and communities. A number 
of studies in BU endemic African countries have revealed that BU can push house-
holds into poverty, whether patients were hospitalized or not. For instance, the 
median cost burden of hospitalization of BU patients in Central Cameroon was 
reported to correspond to 25% of the annual earnings of a household due to high 
non-medical costs and productivity loss. More than half of the families were forced 
to withdraw financial and hence social support to the patient, resulting in the 
patient’s isolation at the hospital. Indeed, social isolation of in-patients has been 
mentioned as the principal cause for abandonment of biomedical treatment [140]. 
On the other hand, for non-hospitalized BU patients in Ghana, transportation and 
other costs added up to 45% of the annual income of households. For these out- 
patients, social isolation was also an issue, particularly for children, who were often 
not accompanied for treatment [141]. In a study conducted in Nigeria it was revealed 
that costs before a definite diagnosis of BU was established (including costs for 
medications, drugs, wound care, hospitalization, transportation, food, and others), 
accounted for the brunt of the total costs for the treatment of BU. Costs were cata-
strophic for 50% of all affected households [142].
Taken together, new, socially more compatible intervention strategies, such as a 
more decentralized system of diagnosis and care as well as improved community 
mobilization and education of populations concerning BU to reduce care-seeking 
delays are of urgent need. Results of a recent pilot BU outreach campaign and 
decentralized care program in one of the most endemic districts of Benin demon-
strated the great value of such interventions, reflected by a strong community sup-
port and a dramatic increase in the detection of BU cases that was associated with 
immediate, free, and accessible care [143]. However, a major challenge will be the 
mobilization of both financial and human (organization, training, health staff etc.) 
resources to implement and sustain decentralized care at a larger scale and on a 
long-term basis.
7  Outlook
Launching of the Global BU Initiative in 1998 and adding BU to the WHO list of 
NTDs, has helped to increase awareness of the disease among affected popula-
tions, health staff, potential donors, and researchers. As a result, national BU con-
trol programs were established in the affected countries, healthcare provision to 
BU patients was improved, and new diagnostic tools and treatment modalities have 
been developed. The decline in the number of new infections reported to WHO in 
the past years might on the one hand be a result of the progress made in the fight 
against the disease. Active case finding and treatment of patients with chronic 
ulcerative BU lesions, which may represent significant reservoirs of the pathogen, 
may be an important corner stone for the control of the disease. But on the other 
hand, the declining number of reported BU patients has also led to a decrease in 
awareness of and interest in the disease. The reduction in the number of reported 
cases may therefore be in part related to a decline in active case search activities in 
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known BU endemic regions and also to a lack of efforts to identify new BU endemic 
areas. The large BU burden in Nigeria only became apparent when Nigerian 
patients presented to established BU health facilities in Benin [68, 144], indicating 
that the true number of BU cases in regions where no fully functional BU control 
programs are in place, may be vastly underestimated. While the detection and 
treatment of BU in Australia, Japan, and French Guiana will continue to be covered 
by their universal healthcare systems, a major task for the next years will be the 
sustained control of BU in Africa. For that purpose, funding for control activities 
and research has to be mobilized to maintain established healthcare infrastructure 
in the affected countries and to implement newly developed diagnostic tests and 
treatment regimens. Support by NGOs has played in many settings an important 
role in the development of BU control activities and treatment centers and was 
crucial for BU research funding (an example for funding of a BU research consor-
tium by an NGO is provided in Chapter “Transdisciplinary Research and Action to 
Stop Buruli Ulcer: A Case Study from Philanthropy”). This has major implications 
for sustainability as reductions in program support by major partners may lead to 
severe drops in performance of BU control activities [145] and a loss in research 
output and capacity development.
Fragmentation of health interventions and services is a widely discussed issue, 
since narrowly targeted interventions can generate in particular in low resource set-
tings inequity and substantial extra costs. Therefore, it has been suggested to inte-
grate BU control into the broader context of care for skin NTDs [146]. The 
co-endemicity of several of these diseases, such as BU, yaws, scabies, mycetoma, 
and leprosy may allow maximizing financial and human resources by the imple-
mentation of integrated approaches, including training of health workers in differ-
ential diagnosis of skin NTDs, basic dermatology and wound management [147].
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1  Introduction
The first description of skin lesions resembling those caused by Mycobacterium ulcer-
ans, dates back to the late nineteenth century, when the missionary physician Albert 
Cook [1] recorded a range of chronic, necrotizing skin ulcers in patients in Uganda. In 
the 1950s and 1960s a larger case series of patients with similar ulcers was detected in 
today’s Nakasongola district in Uganda [2, 3], formerly known as Buruli County. 
Since then, cases of the disease, henceforth designated “Buruli ulcer” (BU), were 
reported from 20 additional African countries, where the major burden commonly 
falls on children aged five to 15 years. BU in Africa is characterized by a patchy geo-
graphical distribution, affecting mainly rural communities with often very high local 
prevalence rates. Access to the formal health sector in these regions is limited and as 
a result knowledge on the actual distribution and frequency of infections is scanty [4]. 
The occurrence of M. ulcerans infections in Africa is closely linked to areas of land 
drained by rivers and their tributaries. While the probability of person-to-person trans-
mission is thought to be very low, the nature of relevant environmental reservoirs is 
highly controversial and the mode by which the pathogen is transmitted from 
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environmental sources to humans is not clarified [5, 6]. Several routes for the intro-
duction of M. ulcerans into the susceptible layers of the skin are discussed.
Causes of BU disease are commonly perceived by the local population as some-
what mysterious and are often associated with witchcraft or sorcery [7–9]. Also 
insect bites, contamination of skin lesions, and contact with swamps and water bod-
ies often connected with changes in ecology are considered risk factors for contract-
ing BU and a concept of dual causality is frequently encountered, particularly among 
affected populations in West African countries [9]. As a consequence, patients may 
first consult traditional healers or prayer camps to deal with witchcraft before seek-
ing biomedical treatment at hospitals or health centers. Other patients may consider 
care seeking at the formal health sector only as a last resort [8, 10, 11]. Findings from 
a biosocial analysis of BU among fishermen in northwestern Uganda revealed that 
late presentation for biomedical treatment resulted from a perceived lack of its effi-
cacy and a perceived efficacy of herbalists’ treatment, which was sought promptly 
after first signs of lesions appeared [12]. These insights explain why in many BU 
endemic regions a high proportion of patients present to formal health facilities with 
large lesions, which require extended periods for healing and often result in perma-
nent disabilities. According to the WHO classification system, BU lesions fall into 
one of three categories. Category I includes single, small lesions (nodules or ulcers) 
below five cm in diameter, Category II comprises single lesions between five and 
15 cm in diameter as well as plaque and edematous forms, and Category III includes 
single lesions above 15 cm in diameter, multiple lesions, lesions at critical sites such 
as eyes, genitalia, and joints, as well as osteomyelitis [13]. Category II and III lesions 
are particularly prevalent in remote areas, where access to healthcare is limited and 
awareness of the disease is low. Surveillance and reporting of cases supported by 
community health workers, teachers, and other community volunteers are important 
elements for the control of BU. As long as preventable risks are not clearly identified 
and no vaccine is available, the main goal is to diagnose and treat patients in an early 
disease stage, when most lesions heal fast and without adjunct surgical treatment so 
that long-term sequelae and other complications can be avoided.
A momentum for the establishment of organized National BU Control Programs 
(NBUCPs) in the most affected countries was created by the Yamoussoukro Declaration 
and the global BU Initiative, launched by WHO in 1998 [14]. The three main pillars of 
global and national BU control strategies included (1) the strengthening of health sys-
tems by the development of infrastructure and provision of training for health workers, 
(2) sensitization and involvement of communities by information and education cam-
paigns to facilitate early case detection and reporting, and (3) standardized case man-
agement in terms of diagnosis, treatment, and prevention of disability.
BU has been reported from five of the six WHO regions except the European 
region [4]. However, Africa bears the brunt of the disease burden with around 
57,500 cases reported to WHO from 16 African countries between 2002 and 2016, 
representing 98% of all BU cases recorded worldwide during that time. The decreas-
ing numbers of cases reported to WHO in the past couple of years play their part in 
further neglect of BU. Major efforts are required in the coming years to mobilize 
resources for the establishment, maintenance, and expansion of BU control 
activities.
E. N. Tabah et al.
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2  Management of BU in Africa
2.1  Structure of Health Systems in Africa and Implications 
for the Management of BU
Health systems are organized in many African countries in three levels, each com-
posed of administrative structures and care facilities [15, 16]. The central (ter-
tiary) level constituted by the technical departments of the Ministry of Public 
Health is in charge of the development of national health strategies, national hos-
pitals as well as reference laboratories. In the case of BU, control activities at this 
level are organized by NBUCPs, which define control strategies, plan the imple-
mentation of interventions, supervise and evaluate these interventions. National 
hospitals are usually not directly involved in the management of BU patients, 
whereas laboratory confirmation of suspected BU patients by PCR analysis is 
performed by national reference laboratories. The intermediate (secondary) level 
is composed of regional delegations of public health and regional hospitals, super-
vising control activities for BU. The peripheral (primary) level, where the imple-
mentation of BU control activities is based, is the health district, comprising the 
district health service, district hospitals, primary health centers, and communities. 
While the district health service organizes community sensitization and BU case-
finding in collaboration with the primary health centers and community stake-
holders, the district hospitals act as BU diagnostic and treatment centers 
(BU-DTCs), supervise BU care in primary health centers, and assist the district 
health service in community-based activities.
BU-DTC facilities have in the past often been built or rehabilitated and equipped 
by support partners to provide adequate infrastructure for BU diagnosis and treat-
ment, including surgical theatres, wound dressing rooms, laboratories, physiother-
apy units, and admission wards. Within the framework of national BU surveillance, 
all BU-DTCs are provided with BU case-definition, diagnostic and treatment guide-
lines and other documentation on the disease for use by health workers. Standard 
WHO BU case record files and registers referred to as BU01 and BU02 forms, 
respectively, are used at the BU-DTCs to document information on each patient. 
The BU-DTC health staff receives specific training through workshops organized 
by the NBUCPs and facilitated by BU experts, using the WHO training modules 
and guidelines on BU care. The data recording and reporting process at BU-DTCs 
is regularly monitored and supervised by the NBUCPs to ensure correctness and 
completeness [17, 18].
Main activities of the BU-DTCs include early case detection at the community 
level, training of village health workers and strengthening of the community-
based surveillance system, information, education, and communication cam-
paigns in communities and schools, strengthening of the health system and 
infrastructure, management of equipment, transport and logistics, standardized 
recording and reporting using WHO BU01 and BU02 forms, standardized case 
management (diagnosis and treatment), prevention of disability/rehabilitation, 
supportive activities, advocacy, social mobilization, partnerships, and operational 
research.
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Box 1: Benin
The first case of BU in Benin was registered in 1977 at the Saint Camille 
Hospital in Dogbo (Couffo Department). A first focus of the disease was 
detected in the Ouinhi district (Zou Department) in 1988 [19], cases of which 
were reported by Muelder and Nourou in 1990 [20]. The NBUCP in Benin 
was created in 1997 and surveillance using the WHO BU01 and BU02 forms 
started in 2003. In Benin, there are four peripheral BU-DTCs, which are 
locally referred to as ‘Centre de Dépistage et de Traitement de l’Ulcère de 
Buruli (CDTUB)’. These centers, which are responsible for the implementa-
tion of BU control activities, are distributed across the main endemic regions 
and located in Allada, Lalo, Pobe, and Zangnanado (Fig. 1). Health workers 
at these facilities have considerable experience in diagnosing and treating BU 
patients. Early case detection and referral of patients to the CDTUBs is super-
vised by health workers of the nearest health post, but relies strongly on 
community- based surveillance teams, comprising village volunteers (‘relais 
communautaires’) and teachers (‘focal points’). These teams are also respon-
sible for the follow-up of patients after treatment. In order to facilitate report-
ing at each CDTUB, BU cases are registered on a BU02 form, which is sent 
out each quarter to regional authorities and the NBUCP, where data are ana-
lyzed and mapped. Feedback is provided annually by the NBUCP at a review 
meeting attended by the heads of all CDTUBs and other partners involved in 
BU activities in Benin. The CDTUBs perform quarterly data analyses, which 
they feed back to the teams in each center. Refresher workshops for the teams 
are conducted and new team members are trained [17]. This system allows to 
(1) conduct permanent active surveys for BU, (2) determine the burden of the 
disease, (3) provide the most adapted care for each patient. With this system 
in place, the number of reported BU cases increased steadily from 2003, 
reached a peak of 1203 cases in 2007 and decreased continuously thereafter, 
to 312 in 2016. The geographical distribution of BU cases in 2016 is shown in 
Fig. 1.
In contrast to the decrease in the number of new BU cases reported in 
recent years in Benin, the percentage of patients diagnosed with WHO 
Category III lesions has increased (Fig. 2). Between 2007 and 2011 the num-
ber of new BU cases with Category I and II lesions detected was much higher 
than those with Category III lesions, whereas almost half of the newly detected 
BU cases between 2012 and 2016 were diagnosed with Category III lesions.
Therefore, the current challenge for the Ministry of Health through the 
NBUCP is to effectively address the issue of severe, chronic BU lesions. 
According to national health statistics, 267 new BU cases were detected in 
2017. Of these, 46% presented with ulcers, 30% with mixed forms, 13% with 
plaques, and only a minority with nodules and edema. For a significant pro-
portion of cases (23%) in 2017 BU-related disability was registered at entry.
E. N. Tabah et al.
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Fig. 1 Geographical distribution of BU in Southern Benin. The map illustrates the number of 
reported BU cases in 2016 as well as the location of the CDTUBs in the main BU endemic region 
of Benin
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Box 2 Cameroon
BU was first reported in Cameroon in 1969 [21]. Organized BU control in the 
country began 33 years later with the creation of two BU-DTCs in Ayos and 
Akonolinga in 2002 with the support of FAIRMED (formerly known as ALES 
(Aide Aux Lépreux Emmaüs-Suisse)) and MSF (Médecins Sans Frontières) 
Suisse, respectively. Effectiveness of BU management in these initial centers 
prompted the Ministry of Health in Cameroon to establish an NBUCP in 2004. 
Following a national BU survey in 2004, three additional BU-DTCs were created 
in 2006  in the three newly identified highly endemic health districts, namely 
Bankim, Mbonge, and Ngoantet-Mbalmayo. The initial strategy of medical teams 
from these BU-DTCs was to perform mass screening for BU, sensitization and 
awareness campaigns in communities and schools, and management of the BU 
cases detected. Gradually, health committees were activated in the intervention 
areas, and became responsible for community sensitization and awareness cam-
paigns for BU, case-finding, and referral. Community participation in referral of 
suspected cases to the BU-DTCs for confirmation and treatment increased after 
many volunteers were trained to recognize BU in their communities. As commu-
nities became more aware of BU, active case-finding gradually gave way to pas-
sive case-finding with cases coming on their own or being referred to BU-DTCs.
In Cameroon, the WHO BU02 forms together with activity reports are sent by 
BU-DTCs to the NBUCP on a monthly basis. Between 2002 and 2016, 3850 BU 
cases were reported in the country, with a peak of 914 cases seen in 2004, 
explained by the national survey for BU in that year. Considerably lower numbers 
of cases were reported in recent years with a trough of 85 cases in 2016. Between 
2002 and 2014 the number of health districts identified to be endemic for BU rose 
from 2 to 64 (Fig. 3). While endemic regions were mainly detected in the South 
and Central part of Cameroon, a national survey is required to confirm the sus-
pected presence of BU in the northern part of the country. However, it has been 
shown that a reduction in program resources and activities by the major support 
partners over the past years has led to decreased surveillance activities, which has 
negatively impacted performance indicators in Cameroon [18].
Fig. 2 Evolution of new 
BU cases detected in Benin 
according to the WHO 
classification system. The 
percentage of patients 
diagnosed with Category 
III (red) and Category I 
and II (blue) lesions is 
shown
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In many African BU endemic areas, government expenditure on health care is 
extremely low. Low per capita income and limited potential for domestic revenue 
mobilization hamper the ability of governments to respond effectively to national 
health problems, such as BU. Many NBUCPs depend strongly on external partner 
funding, which has decreased considerably in the past few years in some of the BU 
endemic countries, leading to a decrease in BU surveillance and laboratory confir-
mation of cases. This may in turn lead to a rise in the proportion of patients report-
ing with WHO Category III lesions [18]. Therefore, financing remains a key 
challenge for the establishment and sustainability of effective BU control 
programs.
2.2  Diagnosis and Treatment of BU
In addition to relatively typical ulcerative disease stages, BU may present in the 
form of rather unspecific, non-ulcerative nodules, edema, or plaque lesions. The 
clinical diagnosis of BU in Africa is complicated by many skin conditions with 
similar presentation ranging from cysts, lipoma, psoriasis, skin lymphomas, tropical 
ulcers, ulcerated skin malignancies, and venous or vascular ulcers, over bacterial 
skin infections such as actinomycosis, boils, cellulitis, ecthyma, folliculitis, furun-
cle, impetigo, noma, treponematosis, parasitic infections including cutaneous leish-
maniasis and myiasis, to cutaneous tuberculosis, leprosy, and atypical 
mycobacteriosis [17, 22, 23]. At the level of district health facilities, microscopic 
detection of acid-fast bacilli (AFBs) is usually the only available laboratory diag-
nostic test for BU. As this method has limited sensitivity and specificity, specimens 
from suspected lesions are commonly collected and shipped in bulk to diagnostic 
reference laboratories for the detection of M. ulcerans DNA by PCR analysis, the 
current gold standard for the diagnosis of BU. To avoid further delay and dropout of 
patients, treatment of clinically suspected BU cases is often started before PCR 
results are reported back to the health centers.
Since 2004, WHO recommends treatment of BU with an 8-week course of daily 
combination antibiotic therapy consisting of oral rifampicin and injectable strepto-
mycin [13]. However, prolonged duration of streptomycin therapy can cause persis-
tent hearing loss and nephrotoxicity in BU patients [24]. In 2017 the WHO Technical 
Advisory Group on BU decided that the recommendation for treatment should be 
changed to oral clarithromycin and rifampicin, pending the full results of a clinical 
trial for the new regimen. At national level, this combination has already been intro-
duced in several African BU endemic countries. Free provision of antibiotics to BU 
treatment centers is managed by the NBUCPs. However, logistics involved in the 
supply of the drugs to remote, rural health facilities is complicated and access to the 
required antibiotics is not always secured. Other direct and indirect treatment costs, 
such as for transport and stay at health facilities, wound management, and loss of 
labor of patients and caretakers have to be covered by patients and their families. 
The main source of funding for these costs is direct household spending, mostly 
through out-of-pocket payments, which may prevent patients from seeking care or 
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may have catastrophic consequences for the household economies [25, 26]. The 
situation is further aggravated by the fact that many patients report with advanced 
stages of the disease, for which treatment is both much more demanding and more 
expensive. Although antibiotic treatment is effective, extensive destruction of tissue 
complicates healing and often leads to contractures and deformities. For such 
lesions, surgical debridement, skin grafting, and physical re-education may be 
required after antibiotic therapy. Lifelong functional limitations are a common out-
come of large ulcers and are associated with loss of workforce, school abandonment 
[27], stigma, and social exclusion [28].
Early detection of BU, the development of an inexpensive, sensitive and specific 
point-of-care diagnostic test suitable for pre-treatment diagnosis, as well as the 
development of shorter treatment regimens suitable for decentralized care in rural 
endemic areas are key priorities for future efforts to improve the control of BU in 
Africa. For the diagnosis at field sites, the application of M. ulcerans antigen 
capture- based approaches are currently being evaluated [29]. Local thermotherapy 
of BU lesions using heat packs filled with phase change material [30] may be devel-
oped into an alternative treatment option if antibiotic treatment is not indicated, not 
tolerated or not readily available. Considering the continued preference of many 
patients to first seek care from traditional healers, sustained collaborations between 
community health workers, BU-DTC health staff, and traditional healers is essential 
for the implementation of BU control activities [10].
3  Geographical Distribution of BU: Reporting of Cases 
Versus Actual Situation in Africa
The geographical distribution of BU cases in Africa by country reported to WHO 
between 2002 and 2016 is illustrated in Fig.  4, with Côte d’Ivoire, Ghana, and 
Benin being the most affected.
These three countries were among the first with well-established BU surveil-
lance systems [31–34], after their governments have signed the Yamoussoukro dec-
laration on BU in 1998, an agreement to mobilize resources for the establishment of 
NBUCPs with technical support from WHO. In Cameroon, which is ranked fourth 
among the most affected countries, a wide-spread distribution of endemic regions 
was detected upon increased case-finding activities (Fig. 3) [18], strongly suggest-
ing that the number of BU cases is vastly underestimated in some other BU endemic 
countries, where organized BU control programs have only more recently been set 
in place. This is for example illustrated by large series of BU patients from Nigeria, 
who presented to established health facilities in Benin over the past few years 
[35, 36], demonstrating an urgent need for the improvement of BU control activities 
in Nigeria [37].
Reasons for a marked reduction of new infections reported from Africa in the 
past few years are not entirely understood, but may at least in part be related to a 
decline in international support for BU control programs [18]. In Ghana, the annual 
BU case confirmation rates gradually decreased over the past years, from a high 
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proportion of 76% in 2009 to a trough of only 15% in 2016. High confirmation rates 
in earlier years may be attributed to prior training activities on case detection and 
proper specimen collection provided by the NBUCP to healthcare givers within the 
facilities of the Ghana Health Service as well as to quarterly early case search activi-
ties conducted within the framework of the Stop BU project by researchers of the 
Noguchi Memorial Institute for Medical Research. The downward trend in confir-
mation rates may be a reflection of both an actual reduction in BU incidence and 
ceasing outreach activities by the NBUCP in recent years [38]. On the other hand, 
initiation of surveillance activities in the endemic countries may have led to the 
detection of many patients with long-standing infections and the current number of 
reported cases may reflect more the true incidence of BU. As the shedding of the 
bacteria from chronic BU lesions is hypothesized to fuel potential reservoirs of the 
pathogen, early identification and treatment of BU patients may lead to a reduction 
Fig. 4 Geographical distribution of BU in Africa by country. The map shows an accumulated 
number of cases reported to WHO between 2002 and 2016. Data source: WHO
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of the bacterial burden in the environment, which may in turn reduce transmission. 
This view is supported by the fact that no major animal reservoir has been detected 
to date in Africa, as opposed to BU endemic areas of southern Australia, where large 
numbers of possums in BU endemic settings were shown to be infected with M. 
ulcerans [39]. Another aspect to be considered is the potential cyclical occurrence 
of the disease associated with environmental or climatic factors. Also, a number of 
African countries, where BU cases had been detected in the past, do no longer 
report cases to WHO. These include countries where political instability or overbur-
dened health systems may prevent efforts to control BU. On the other hand, also the 
possibility of over-reporting in areas where access to reliable laboratory confirma-
tion is limited has to be taken into consideration, when estimating the actual burden 
of BU in Africa.
4  Distribution of BU Among Affected Populations 
in Africa
The distribution of BU within endemic countries is highly focal and local preva-
lence rates may vary from one village to another. Affected populations commonly 
live in remote, rural areas, which are sometimes largely isolated from the world 
around. Families typically live on subsistence-level agriculture and small-scale hus-
bandry and obtain their water from nearby rivers or tributaries. Stagnant water bod-
ies, which are used for washing clothes or bathing, appear to be strongly associated 
with the occurrence of BU [40] (Fig. 5).
In many areas the emergence of BU or an increase in the incidence of BU have 
been ascribed to environmental disturbances such as damming of rivers, establish-
ment of permanent wet agricultural areas like rice fields, deforestation, sand digging 
or mining activities with remaining water holes and seasonal ponds. For example, 
on the campus of the University of Ibadan, Nigeria, damming of a small stream 
flowing through the campus was associated with the emergence of BU among 
Fig. 5 Typical BU endemic settings in Africa. Left photograph: Health post in Cameroon. Right 
photograph: Water site in Cameroon used for doing the laundry or bathing
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Caucasians living on site [41]. In northern Liberia, BU cases emerged when the 
Manor River was dammed and wetlands extended for swamp rice farming [42]. 
Other examples include the damming of the Mapé River in Cameroon [43], the 
Densu River in Ghana [44], and the Bandama River in Côte d’Ivoire [45]. Apart 
from man-made environmental changes, heavy rainfall may also lead to an upsurge 
of BU; in Uganda, an outbreak in the Busoga District was for example related to 
unprecedented flooding of the lakes of Uganda between 1962 and 1964 [46].
All age groups may be affected with an often equal gender distribution. However, 
children between five and 15 years of age are vastly overrepresented among cases in 
Africa, even if the age distribution of the typically very young general population is 
taken into account [47, 48]. In contrast, very young children seem to be underrepre-
sented [47], and sero-epidemiological studies of populations living in BU endemic 
areas of Ghana and Cameroon have shown that children below the age of four years 
are also less exposed to M. ulcerans than older individuals [49, 50]. This suggests 
that exposure to M. ulcerans intensifies at an age, when children start to have more 
intense contact with the environment, outside their hitherto confined movement 
range. While the risk of developing BU seems to drop in young adults, the popula-
tion age adjusted cumulative incidence of BU in the elderly was reported to be simi-
lar to that in older children [47, 48]. This may be related to immunosenescence, the 
gradual deterioration of the immune system associated with natural age advance-
ment. The fact that in Japan and Australia middle-aged or elderly individuals are 
most commonly affected may at least in part reflect the much higher average age of 
the population living in the BU endemic areas.
Mounting evidence exists that infection with HIV increases the risk of BU [51]. 
Moreover, a number of case studies report a more aggressive progression of BU in 
HIV-positive individuals [52–54]. Although helminth infections elicit an immune 
response potentially enhancing susceptibility to mycobacterial diseases, no associa-
tion between BU and schistosomiasis was found in one study [55]. Potential asso-
ciations of BU with other co-infections prevalent in African BU endemic areas or 
with malnutrition have not been systematically investigated so far. Studies on a 
potential link between susceptibility to BU and host genetic factors are in their 
infancy [56, 57] and are hampered by the limited number of BU cases that can be 
enrolled in the studies.
5  The Etiology of BU in Africa
M. ulcerans is an acid-fast mycobacterium that has evolved from an M. marinum- 
like progenitor through an evolutionary bottleneck event; the acquisition of a viru-
lence plasmid, encoding the enzymatic machinery for the synthesis of the unique 
macrolide toxin mycolactone [58]. Subsequent genome reduction and pseudogene 
development is indicative of an adaptation of M. ulcerans to a more stable ecologi-
cal niche [58]. Definite identification of an environmental niche is complicated by 
the extraordinarily long generation time of M. ulcerans. This hampers the isolation 
of the bacterium from potential environmental sources, as M. ulcerans is readily 
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overgrown by other, less fastidious organisms, including other environmental myco-
bacteria that are also resistant to decontamination methods developed for primary 
isolation [59, 60]. Considering that the occurrence of BU is commonly associated 
with stagnant water bodies in river basins, a habitat in aquatic ecosystems seems 
likely. Indeed, M. ulcerans-specific DNA sequences were detected by PCR analyses 
in environmental samples, such as biofilms, water, soil and plants, as well as in vari-
ous aquatic animals [5]. For unclear reasons, vastly different PCR positivity rates 
have been reported in various studies conducted in BU endemic regions of Africa 
[40, 61, 62]. In contrast to endemic sites in Australia, where terrestrial mammals 
may be implicated as reservoirs in the disease ecology of M. ulcerans [39, 63], no 
similar reservoir has so far been detected in Africa [6, 64]. Therefore, it has been 
hypothesized that shedding bacilli from large chronic lesions of BU patients into the 
environment may play a role in M. ulcerans transmission in African BU endemic 
areas [4]. While mosquitoes have been proposed as vectors of M. ulcerans in 
Australia, several modes of transmission including vector-mediated, but also skin 
trauma-induced may be involved in African settings [5]. Direct person-to-person 
transmission is considered unlikely.
All M. ulcerans isolates derived from lesions of BU patients from Africa have 
been found to belong to the classical M. ulcerans lineage. Genetic diversity of these 
isolates is very low and only comparative whole genome sequencing allowed resolv-
ing the population structure and evolutionary history of African M. ulcerans disease 
isolates. These genome analyses have identified in many BU endemic areas, local 
clonal complexes of M. ulcerans that show limited diversification by the accumula-
tion of point mutations and are associated with particular hydrological drainage 
areas [44, 65–67]. After introduction of M. ulcerans in a particular area, the local 
clone seems to remain isolated, which allows some point mutations to become fixed 
in that population. Spread of these locally confined clonal complexes between 
endemic areas seems to occur only rarely [68, 69], speaking against the existence of 
a highly mobile animal reservoir. While the dominating African M. ulcerans sublin-
eage MU_A1 has been endemic in Africa for several hundred years, another less 
common and geographically more restricted African sublineage (MU_A2) has been 
recently identified, which seems to have been introduced into the African continent 
in the late nineteenth and early twentieth century [66]. Sequence analyses of the 
virulence plasmid pMUM encoding genes for the biosynthesis of mycolactones 
have shown that all mycolactone producing mycobacteria have evolved from the 
same progenitor which has acquired the plasmid [70]. Different M. ulcerans lin-
eages produce different species of mycolactone; the M. ulcerans disease isolates 
from Africa mainly produce mycolactone A/B, the most potent form of the toxin 
[71, 72]. There is no doubt that the ability to produce mycolactone is critical for the 
evolution and persistence of M. ulcerans as a human pathogen. While the combina-
tion of cytotoxic and immunosuppressive properties of mycolactone is thought to 
confer a fitness advantage for M. ulcerans in mammalian hosts by preventing an 
immune system-mediated elimination of the bacteria, it is not yet clear how the 
bacteria might benefit from mycolactone production in aquatic niche 
environments.
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6  Future Perspectives
If human BU lesions prove to be a relevant maintenance reservoir for M. ulcerans 
transmission, active case-finding programs, improved disease surveillance, early 
diagnosis, and adequate treatment may lead to a reduction in disease transmission. 
This hypothesis is supported by the recent decline in the number of new infections 
reported to WHO from many African countries and particularly from areas, where 
effective BU control programs have been implemented. A major challenge for the 
coming years will be the maintenance of established control strategies and the 
implementation of improved diagnostic tools and treatment approaches.
In many regions of Africa a number of tropical skin diseases, such as cutaneous 
leishmaniasis, leprosy, lymphatic filariasis, mycetoma, onchocerciasis, and yaws 
are co-endemic with BU. Screening of individuals for the presence of skin condi-
tions in communities or schools offers the opportunity to detect these neglected 
diseases using a common rather than a disease-specific approach. Development of 
locally adapted triage criteria and diagnostic algorithms for the recognition of 
changes in the appearance of the skin can furthermore allow health workers at the 
primary health care level making appropriate decisions on either treatment or refer-
ral of patients. After specific treatment, repair of tissue damage often requires simi-
lar wound management approaches. Therefore, integrated strategies for the control 
and management of these diseases are now strongly promoted by the WHO 
Department of control of neglected tropical diseases (WHO/NTD) [73].
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1  Bairnsdale Ulcer and the Discovery of Mycobacterium 
ulcerans
“Bairnsdale ulcer” (synonymous with Buruli ulcer (BU)) was first recognised and 
named as a distinct clinical entity in the late 1930s by General Practitioners working 
in Bairnsdale—a regional town in east Gippsland, Victoria, Australia [1, 2] (Fig. 1). 
They suspected their patients were suffering from a new type of infection caused by 
an acid-fast bacillus, but with clinical features distinct from tuberculosis and lep-
rosy. Pathology specimens forwarded to the University of Melbourne and the trans-
fer of patients from Bairnsdale to the Alfred Hospital in Melbourne provided 
researchers with clinical samples from which the microbiology and pathology of 
Mycobacterium ulcerans infection were first definitively described [3]. Although 
not listed as authors on the original 1948 publication “A New Mycobacterial 
Infection in Man” the contribution of these doctors was pivotal in the discovery of 
M. ulcerans. Glen Buckle, who with Jean Tolhurst first isolated M. ulcerans in pure 
culture, later drew special attention to the important contribution of Drs D. S. Alsop, 
L. E. Clay and J. R. Searls of Bairnsdale, and Dr. K. E. Torode of Colac [1].
In their initial research, Buckle and Tolhurst showed that M. ulcerans was able to 
grow on media that supported other pathogenic mycobacteria provided the incuba-
tion temperature was kept at 30–33 °C. They noted that growth slowed above 35 °C 
and that cells started to slowly die above 37 °C. They went on to establish experi-
mental infections in mice, rats and rabbits and observed that while local lesions 
were produced at the site of subcutaneous inoculations, when inoculated into the 
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peritoneal cavity, peripheral lesions developed on distant extremities in cooler body 
areas (scrota, tails). Sir Frank Fenner, a renowned Australian scientist who later 
worked on the eradication of smallpox, studied M. ulcerans in the 1950s. Fenner 
demonstrated that an inoculum of only 5–10 cells would reliably produce lesions in 
mice that appeared after at least 150 days (5 months) and that BCG was protective 
in an animal model at low but not higher inoculums [2]. Interestingly, the very low 
inoculum required to produce an experimental infection has recently been con-
firmed in new research that demonstrated a mosquito could initiate an M. ulcerans 
infection in a mouse-tail coated with M. ulcerans cells. In these experiments, the 
calculated effective inoculum size was in the range of just 2–3 cells [4].
Between 1948 and 1975 Radford reported 39 human cases of BU in Australia: 12 
from Victoria including those in the original report, 4 from the Northern Territory 
(three from Croker Island and one from the coastal mainland near Darwin) and at 
least 20 from near Rockhampton and near Cairns in Queensland. A single case 
report from New South Wales (NSW) was published in 1954 but was thought likely 
to be an imported infection as the patient had epidemiological links to Papua New 
Guinea [2].
The Bairnsdale region in Victoria (latitude 38°S) is approximately 2000 km by 
road from Rockhampton in Queensland (latitude 23°S) and almost 3000 km from 
Cairns (latitude 17°S) (Fig. 1). There are large continuous human populations along 
the NSW Coast between the Victorian and Queensland endemic regions, yet locally 
acquired BU remains almost unknown there with the exception of one published 
confirmed case [5] and a small number of others from southern coastal NSW very 
close to the Victorian border. There has also been only one confirmed case from the 
Fig. 1 Australia with locations of confirmed BU acquisition since 1937 shown in red
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northern tropical coast of Western Australia but no local transmission in the more 
populated temperate areas further south [6]. BU does not occur in South Australia 
or Tasmania, western Victoria or anywhere in the dry Australian interior. The reason 
for this patchwork focal distribution within and between states is unknown, but the 
geographic pattern has remained stable from the 1950s, except in Victoria.
All Australian isolates of M. ulcerans belong to the virulent so called “Classical 
Lineage” that also causes BU in Africa [7, 8], but there are small differences at the 
genomic level that allow location of Australian clinical isolates to specific geographic 
regions. Variable number of tandem repeat (VNTR) typing has been used to success-
fully attribute region of acquisition when newly diagnosed patients report multiple 
potential exposures [9]. More recently a detailed investigation using whole genome 
sequencing of 178 M. ulcerans isolates from different regions of Australia spanning 
70  years has been conducted [10]. The results strongly support single introduction 
events into each of the major Australian endemic areas with subsequent local evolution. 
It also appears that M. ulcerans first reached Australia in the north, possibly from Papua 
New Guinea and has moved in large skip-steps down the east coast of Australia and 
along the Southern coast of Victoria as far as Melbourne. These introductions are his-
torically recent and may have been assisted by coastal shipping activities down the east 
coast since European settlement. In Victoria movement from east to west along the 
southern mainland coast is continuing with the most recent recognised introduction 
event occurring in about 2003 to Rye on the Mornington peninsula [10] (Figs. 1 and 2).
Fig. 2 Sketch map showing of southern approaches to the city of Melbourne including Port Phillip 
Bay, Western Port, the Mornington and Bellarine Peninsulas and towns mentioned in the text
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2  Buruli Ulcer in Queensland
Buruli ulcer was recognised in Queensland from the early 1950s and possibly even 
earlier [3, 11]. In Queensland, the local names Daintree ulcer or Mossman ulcer 
have been used in preference to Bairnsdale ulcer [12]. To avoid confusion in this 
chapter, the term “Buruli ulcer” refers to all cases of M. ulcerans infection acquired 
in Australia, past and present.
Two separate endemic areas were recognised in Queensland from the early 
1950s, one in the Douglas Shire just north of Cairns, particularly between Mossman 
and the Daintree River [13, 14], and a second on the Capricorn Coast near 
Rockhampton and Yeppoon [2, 11]. There have also been single cases or small 
clusters linked to Nambour near Brisbane, the Glass House Mountains (Sunshine 
Coast), Maryborough (Fraser Coast), Townsville [15, 16], and Port Douglas near 
Cairns and Mossman [2, 11, 16, 17]. However, due to the long incubation period of 
BU [18] it is difficult to confirm that any one location is endemic based on a single 
case unless a detailed travel history is obtained that excludes contact with all other 
regions or there is other evidence such as strain typing of the isolate to support 
geographic attribution. For most historical cases, these details are no longer 
available.
The most active recent Queensland focus of M. ulcerans transmission is in the far 
north of the state, from Mossman to the Daintree River in the Douglas Shire. The 
great majority of infections associated with this region have occurred in permanent 
residents rather than visitors [12]. In her Master of Science thesis published in 1996, 
May Smith, for many years Director of Nursing at Mossman Hospital, reported 41 
cases of BU acquired in this small geographic region [13]. The first likely case 
occurred in 1952 and the first confirmed case in 1964. However, local aboriginal 
people had been aware of a disease resembling BU in this region for several genera-
tions. Subsequently, Steffen et  al. reviewed five decades of BU in the far North 
Queensland endemic area and reported a gradual increase from approximately one 
case every 2 years in the 1960s and 1970s to approximately two cases per year in the 
1980s rising to approximately four cases per year in the 2000s [12]. Subsequently 
the incidence reduced again to an average of two cases per year with the notable 
exception of 2011 and 2012 when there were 61 and 11 confirmed cases respec-
tively [17]. Since then, the usual pattern has resumed with only 6, 2 and 1 new 
diagnoses in 2013, 2014 and 2015. In the 2011 Australian census, the permanent 
population of the Douglas Shire was just over 11,000. From this a crude annual 
incidence of BU for the Douglas Shire can be estimated to range from 9 to 550 per 
100,000 population.
Steffen and Freeborn proposed that the exceptional year of 2011 followed an 
unusually long and unusually wet 2010/2011 rainy season that may have led to an 
abrupt temporary expansion of an unknown reservoir or vector. Interestingly, most 
cases in the exceptional year of 2011 were diagnosed in the dry season (winter) 
which is likely explained by a surge in transmission during their unusual wet season 
(summer) followed by a delay of several months attributable to the long incubation 
period of BU and an additional pre-diagnostic interval [18]. Despite the very 
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different climate and geography, exactly the same temporal pattern is observed in 
temperate Victoria with peak transmission likely occurring in summer but most new 
diagnoses made in winter and early spring [19, 20].
3  Buruli Ulcer in Victoria
In the original definitive description of Mycobacterium ulcerans published by 
MacCallum et al. in 1948, 6 patients were described, 5 from “in and around” the 
town of Bairnsdale and a sixth case from Colac over 400 km to the west of Bairnsdale 
by road (Fig. 2). It was noted that the Bairnsdale cases were from separate house-
holds unknown to each other, suggesting from the outset chance exposure to a dis-
persed environmental pathogen rather than exposure to single point source or person 
to person transmission [3]. Also noted at the time was the wide age distribution with 
the disease affecting children and adults and both genders equally which has 
remained a consistent pattern in Victoria since then [21–23]. John Hayman, a 
pathologist with a long-standing interest in BU, reported 42 cases in Victoria, all 
from the general Bairnsdale region, including the original 5 from the 1930s to 1990. 
Notably only 14 of these were directly linked to the town of Bairnsdale itself, 8 were 
from the nearby lakeside hamlet of Loch Sport but others were from up to 50 km to 
the east of Bairnsdale. In seeking to understand the distribution he observed, 
Professor Hayman proposed proximity of cases to relict rain forest and suggested 
this was intermittently disturbed through fire or flooding leading to temporary seed-
ing of lower lying areas near human habitation with M. ulcerans. He also proposed 
that M. ulcerans may be distributed through aerosols generated by wind action over 
water bodies that were supporting temporary blooms of M. ulcerans recently dis-
lodged from its usual rainforest habitat upstream [24].
From 1990 there was a notable change in the epidemiology of BU in Victoria as 
M. ulcerans appeared to switch its behaviour from low level endemicity in a fixed 
geographic region to high-level transmission in completely new regions not previ-
ously endemic. Initially, a handful of new cases were identified by John Hayman 
around Tooradin and Warneet on the shores of Western Port, 240 km to the west of 
Bairnsdale [25] (Fig. 2). Next, at East Cowes (known as “Silverleaves”) on Phillip 
Island a local General Practitioner, Dr. Paul Flood, recognised a cluster of unusual 
ulcers in patients in his practice from late 1992 which were subsequently confirmed 
by histology and culture to be caused by M. ulcerans [26]. From 1992–1995 there 
were at least 25 new cases, almost all within a very small region surrounding a golf 
course and a newly formed shallow lake that had developed following the construc-
tion of a fire access track [27]. The golf course was irrigated with treated recycled 
water purchased from the Phillip Island sewerage facility which was delivered to a 
permanent dam on the golf course and allowed to mix there with natural ground 
water before the dam contents were pumped to sprinklers on the greens and fair-
ways. Victorian public health authorities arranged for improved drainage of the 
newly formed lake behind the access track in 1993 and altered the way recycled 
water was used on the golf course from 1995. This was followed by a sustained 
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reduction in new cases linked to Phillip Island in subsequent years [21] and east 
Cowes/Silverleaves is currently disease free.
We attempted to support the hypothesis that the golf course irrigation system 
and/or shallow lake that formed behind the fire access track close to houses where 
people had acquired BU had become contaminated with M. ulcerans initially with 
direct culture of environmental samples and later by direct detection with PCR in 
water samples collected from the outbreak region. In a pilot study aimed at develop-
ing a PCR method to detect M. ulcerans in environmental samples we discovered 
the insertion sequence (IS) 2404 and developed an IS2404-based PCR assay in 1995 
[28, 29]. We then investigated whether M. ulcerans was present in stored samples 
obtained from the dam and golf course irrigation system. In the first ever example 
of environmental detection of M. ulcerans, we identified PCR-positive water sam-
ples from the Cowes golf course pumping system and ground water that had col-
lected behind the fire access track the previous year [28, 29]. Our attempts to directly 
culture M. ulcerans from environmental samples were unsuccessful.1
Clinical samples supplied by Professor John Hayman were crucial in the initial 
validation of the new PCR assay and it was quickly appreciated that IS2404 PCR 
would be an excellent rapid diagnostic test for BU and soon become the diagnostic 
test of choice in Australia, due to its quick turn around and exceptional sensitivity 
and specificity. PCR based on the IS2404 target is now also the gold standard for 
BU diagnosis in reference laboratories worldwide [16, 28, 30, 31].
The sudden appearance of a new focus of transmission at Cowes, Phillip Island, 
the high attack rate (up to 6% of the permanent population of east Cowes were 
affected) [21] and the recognition of infection in visitors who may have spent only 
brief periods in the outbreak area has become a hallmark of the new epidemiology of 
BU in Victoria since 1990. At the same time as the Phillip Island outbreak, there was 
a similar less intense outbreak over a slightly longer period (1990–1996) at Frankston/
Langwarrin on the Mornington peninsula [25]. Dr. Mark Veitch, an epidemiological 
intelligence officer with the Department of Human Services in Victoria described the 
detailed epidemiology of the Cowes outbreak, and made an interesting link between 
the two outbreaks (Frankston/Langwarrin from 1990, East Cowes from 1992) noting 
that sand mined near Langwarrin had been used in the construction of a new road 
system in East Cowes (Silverleaves) just prior to the outbreak there [21].
Between 1995 and early 2000s there were very few cases of BU in humans in 
Victoria and the disease returned to its former obscurity. However, the situation 
changed again abruptly with large new outbreaks on the Bellarine Peninsula and most 
recently on the Mornington Peninsula (Fig. 2). At the time of writing (late 2017) there 
has been an exponential increase in cases in Victoria for the past 4 years (Fig. 3), and 
several new endemic areas have become established. The re-emergence began in 1998 
when cases of BU were linked to St Leonards. St Leonards is a small town on the 
Bellarine Peninsula with a permanent population of 2480 (2016 Census) and like 
Cowes on Phillip Island also a popular summer holiday destination. The outbreak at 
1 This work was performed by scientists at the Mycobacterium Reference Laboratory, then located 
at Fairfield Infectious Diseases Hospital.
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St. Leonards was investigated by the Victorian Department of Human Services 
Communicable Diseases Branch. There were two cases in 1998, one more in 2000 
and then 11 diagnosed in 2001. Environmental PCR was attempted following the suc-
cess at Phillip Island but no positive results were obtained from low-lying water 
sources or from the local golf course irrigation system (recycled water not used).
Cases have continued to occur at St Leonards since 1998 albeit at low intensity 
after 2001. Possible explanations to explain the outbreak at the time included much 
higher than usual rainfall and local reports of high mosquito numbers. A small pro-
portion of mosquitoes trapped in CO2 traps at St. Leonards were subsequently 
shown to harbour M. ulcerans DNA [32].
In 2002 new cases of BU abruptly appeared at Point Lonsdale, 20 km around the 
coast to the south of St Leonards (Fig. 2) heralding the onset of an intense, sustained 
outbreak that peaked in 2011 and is slowly abating now, but has been an important 
local public health issue at Point Lonsdale for 15 years [23]. Point Lonsdale is a 
small seaside resort town with a permanent population of around 2684 (2016 cen-
sus) which increases significantly during the summer. The crude incidence in 2011 
was estimated as 770/100,000 of the permanent population (C. Lavender personal 
communication). Many of the local population are retirees and a feature of the Point 
Lonsdale outbreak was the high attack rate in older people with up to 3.7% of all 
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residents aged over 75 requiring treatment for BU [22]. A second notable feature at 
Point Lonsdale and elsewhere in Victoria since 1990 has been the high proportion 
of visitors who developed BU [22]. At Point Lonsdale in the first 2 years of the 
outbreak only local residents were affected but after 2004 this changed with both an 
increase in outbreak intensity and the appearance of disease in visitors and residents 
in almost equal proportions [22].
The changing epidemiology of BU in Victoria and concern from local councils and 
influential residents prompted the creation of a series of Victorian Government Public 
Health Grants to investigate the new epidemiological patterns of disease. From 2001 
diagnostic PCR for BU became a standard diagnostic test performed at the Victorian 
Infectious Diseases Reference Laboratory, and from January 2004  in response to 
increased local concern BU became a legally notifiable infection in Victoria which has 
greatly aided mapping of cases and new endemic areas. In 2005 a new BU focus 
appeared at Barwon Heads (and the adjacent town of Ocean Grove) a further 10 km 
around the coast from Point Lonsdale (Fig. 2). From 2012 onwards new endemic foci 
have appeared along the Mornington Peninsula affecting towns including Sorrento, 
Blairgowrie, Rye Tootgarook, Mornington, Frankston and surrounding suburbs, and 
further north at Seaford and Beaumaris, just 24 km from the centre of Melbourne.
In 2007 two important studies from the Bellarine Peninsula were published which 
have changed our understanding of likely modes of transmission of BU in Victoria. 
Quek et al. conducted a case control study that examined risk factors in 49 cases and 
609 controls. The key new finding of this research was a statistically significant asso-
ciation between mosquito bites and risk of BU.  In their final multivariate model 
being bitten by mosquitoes was found to increase risk (odds ratio 2.60 [95% c.i. 
1.22–5.53]) and use of insect repellent to reduce risk (odds ratio 0.37 [95% c.i. 0.19–
0.69]) [33]. In the second study conducted at Point Lonsdale between 2004 and 2007, 
11,500 mosquitoes were trapped of which approximately 4/1000 were PCR-positive 
for IS2404 and in a subset of samples there was molecular evidence that we were 
detecting the human outbreak strain of M. ulcerans [22, 30]. At the time of writing 
the detection of M. ulcerans in several species of mosquitoes has been repeatedly 
confirmed in Victoria [32] but similar studies have so far been negative in Africa [34].
4  Buruli Ulcer in Animals in Victoria
During the 1980s, in the Bairnsdale region of Victoria, M. ulcerans infection was 
identified in 11 Koalas (arboreal marsupials) from a population of about 200 ani-
mals on Raymond Island, just a few km southeast of Bairnsdale [35–38]. This was 
the first recognition of naturally occurring BU in any species other than humans 
anywhere. The affected animals were mature, usually male and it was suggested that 
lesion distribution was consistent with wounds acquired during social behaviour 
such as fighting.
In the late 1990s after the decline in human cases at Phillip Island, several sick 
adult possums (also native arboreal marsupials) were detected at Phillip Island with 
ulcerative disease, at least three of which were confirmed to have M. ulcerans 
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infection by histology and PCR [35]. Although brushtail possums had previously 
been shown to be susceptible under experimental conditions to M. ulcerans infec-
tion and to transmit the infection to other co-housed individuals [39], this was the 
first recognition of natural infection in possums. There is a koala reserve at Phillip 
Island just 2 km from the endemic area in east Cowes, yet no cases of BU in this 
koala population were observed despite notification to local wild life officers of the 
presence of the disease in local humans and possums.
Subsequently, while seeking possible environmental sources of mosquito exposure 
to M. ulcerans we identified positive PCR signals in environmental samples at Point 
Lonsdale, with by far the strongest signals arising from possum excreta. This led to a 
systematic investigation of the possible role that possums may play as a reservoir and 
environmental amplifier of M. ulcerans in Victoria. We performed environmental sur-
veys and trapped and screened 63 possums (42 ringtail, 21 brushtail). During the sur-
veys, we discovered that 42% of possum excreta samples collected at Point Lonsdale 
were strongly PCR-positive for M. ulcerans compared with <1% in non-endemic areas. 
Further, 9/42 trapped ringtail possums had clinical BU lesions confirmed by PCR as 
did 1/21 brushtail possums. Additional trapped animals without clinical lesions were 
found to be excreting high levels of M. ulcerans DNA in their faeces. This research 
confirmed the validity of using possum excreta surveys as a proxy for mapping the 
occurrence of BU in possum populations, and for the first time suggested that BU may 
be a zoonosis with humans acting as spill- over hosts connected directly or indirectly to 
possums via mosquitoes [40]. In 2011, just prior to the surge in new cases in Victoria 
on the Mornington Peninsula, Carson et al. validated this model in a new endemic area 
by showing that possum excreta at Sorrento and Blairgowrie on the Mornington penin-
sula was strongly PCR-positive close to the location of new human cases of BU [41]. 
Interestingly, no analogous small animal reservoir has yet been identified in Africa [42] 
but there is recent evidence that bandicoots2 in the far north Queensland endemic focus 
of BU also excrete M. ulcerans in their faeces [43].
In Victoria, but not elsewhere in Australia several other naturally acquired BU 
infections have been reported in animals including at least three species of possums 
[44]. On the Bellarine Peninsula four domestic dogs have been diagnosed with BU 
[45], there has been a confirmed case in a cat from eastern Victoria [46], a long 
footed potoroo (small terrestrial marsupial) from eastern Victoria [46], two horses 
from eastern Victoria and at least three alpacas (Bellarine Peninsula and eastern 
Victoria) [35, 44–47]. Notably these animal infections have occurred across the 
same geographical region that is endemic for humans in Victoria (Fig. 1). Given the 
relatively wide experimental host range of M. ulcerans (lizards, amphibians, chick 
embryos, possums, armadillos, rats, mice, rabbits, guinea pigs, pigs and cattle [35, 
48, 49]) it is surprising that naturally acquired disease in animals appears to be rela-
tively rare and restricted. The failure (so far) to identify natural infections in animals 
outside Victoria is also surprising and remains unexplained. Possible explanations 
include the particular susceptibility of humans (and possums), something specific 
about Victorian strains of M. ulcerans compared with Queensland and Northern 
2 Bandicoots are small to medium sized native terrestrial marsupials.
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Territory strains [6], or that the concentration of M. ulcerans that accumulates in the 
environment in Victoria is higher than elsewhere. It is also possible that the disease 
does occasionally occur in animals outside Victoria but is not recognised or not 
brought to the attention of veterinarians familiar with the disease (Fig. 4).
5  Recent Epidemiology of Buruli Ulcer in Victoria
The rapid expansion of BU endemic areas and recent exponential increase in num-
bers of cases in humans is unprecedented and a significant cause of local concern. 
There is published and unpublished evidence that possums carry and excrete M. 
ulcerans DNA in high concentration in faeces at Point Lonsdale, Barwon Heads, 
Sorrento, Blairgowrie, Beaumaris and near Rosebud - all places where human BU 
has become endemic since 2002 (Fig. 2). Similar surveys outside endemic areas 
yield negative results [40]. The frequent acquisition of BU by visitors to endemic 
areas in Victoria as well as local people in almost equal proportion suggests that 
transmission of M. ulcerans is a chance event  and that  risk may not be pres-
ent throughout the year. Possums are likely to carry M. ulcerans disease over pro-
longed periods yet from what we understand so far, the risk of acquiring infection 
appears to occur mainly in summer for both residents and visitors as cases in both 
groups present to doctors at similar times (winter and spring). This may be explained 
by an increase in vector activity in warmer weather [22] combined with greater 
exposure to the outdoor environment and/or less use of protective clothing. 
Interviews with visitors have identified very short exposure periods in some cases 
which have allowed us to estimate a median incubation period of 4.5 months but a 
range up to 9 months. A recent study of 649 BU lesions in 579 patients identified a 
highly non-random distribution with BU lesions in Victoria preferentially occurring 
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on ankles, back of calves, forearms and elbows but rarely on the soles of feet, palms 
of hands or parts of the body that usually remain covered [19] (Fig. 5). One explana-
tion for this distribution is targeting behaviour by biting insects although it is pos-
sible that there is more than one mode of transmission. A recent study of family 
clusters of BU in Victoria has suggested that exposure risk per household lasts only 
a short time and provides molecular typing evidence to support the long-standing 
epidemiological observation that M. ulcerans is not transmitted between individuals 
within a household [50].
6  Clinical Management of Buruli Ulcer in Australia
The large number of recent cases in Australia, particularly in Victoria and the rela-
tive complexity of treating BU has meant that a small group of Infectious Diseases 
Physicians and Surgeons have greatly increased their clinical experience and 
Front (n = 369) Back (n = 280)
Fig. 5 Lesion distribution from 649 BU lesions occurring in 579 patients, Victoria, Australia. 
PLOS Neglected Tropical Diseases 2017: doi: https://doi.org/10.1371/journal.pntd.0005800.g002
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understanding of the management of BU. Much of this experience has been cap-
tured in a number of recent publications. We are fortunate to have universal health-
care coverage and rapid access to doctors and diagnostic tests. Many recently 
diagnosed cases are WHO category I (<5 cm), nevertheless from time to time we 
also see severe cases, sometimes due to delayed diagnosis or acute oedematous 
disease which appears in every respect to be similar to severe cases in Africa [19, 
51]. National treatment guidelines have been developed [52, 53] and there is now 
general agreement that all-oral antibiotic regimens based on rifampicin with a 
companion drug (generally clarithromycin) are highly active against M. ulcerans 
[14, 54, 55], and that medical therapy alone is frequently curative without surgical 
intervention. However, drug therapy is not straightforward particularly in the 
elderly [51, 56] and patients with larger lesions often appear to deteriorate during 
treatment due to paradoxical inflammatory reactions [57, 58]. Short courses of oral 
steroids may help these reactions to settle [59, 60]. The optimal role and timing of 
surgery has still to be established but clearly surgery has an important role in assist-
ing with healing through removing extensively necrotic tissue and to repair large 
skin defects. For small lesions the decision to treat with primarily surgical or medi-
cal therapy is partly determined by patient and clinician preference as both 
approaches are curative in the majority of cases. Relapse is more common if anti-
biotics are not used [17, 61, 62].
7  Buruli Ulcer: The Australian Paradox
BU is classified by WHO as a neglected tropical disease with most cases occurring 
in poor subsistence farming families in tropical river land regions in West and 
Central Africa. For unknown reasons rates of BU in Africa are now static or may 
even be in decline after significant epidemics during the past 20–30 years. In con-
trast, the south-eastern Australian state of Victoria is temperate and economically 
developed, yet case numbers are exponentially increasing. Most people affected live 
in or visit affluent coastal resort towns that have become newly endemic. Despite 
the contrast in epidemiology between Africa and Victoria the disease is quite similar 
in its clinical appearance, the suffering it causes and the complexity of treatment of 
severe forms of BU [63, 64].
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1  Introduction
M. ulcerans infections (Buruli ulcer; BU) have been reported in French Guiana 
since the 1960s [1]. It is striking to see that French Guiana concentrates most of the 
cases of BU in America with only a few cases reported in Suriname, Peru, Mexico 
and Bolivia in the past [2, 3]. Either BU is underdiagnosed and underreported in 
most of the continent; or the specific environmental conditions in French Guiana 
represent a unique niche for the disease to appear; or a sublineage of M. ulcerans 
has established in French Guiana that has a higher virulence than other members of 
the ancestral lineage found in the Americas.
French Guiana is a tropical country located in South America on the Atlantic 
coast between Suriname and northern Brazil. It is mostly covered by Amazonian 
rainforest with the exception of the coastal strip, which is mainly composed of 
marshy savannah and mangroves. Most inhabitants reside along the coastal strip. 
There are several communities living in French Guiana, including Creoles, Maroons, 
Amerindians, mainland French people, Asians and many immigrants from South 
America and the Caribbean Islands. Since the early 1970s, French Guiana has seen 
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very rapid demographic and socioeconomic changes, with a population that 
increased from 45,000 in 1969 to 260,000 in 2017 and a gross domestic product 
(GDP) that grew by 7.2% per year between 1960 and 2002. Although the territory 
has developed rapidly, with improving living conditions such as better hygiene, 
gradual elimination of intestinal nematodes and easier access to health care, several 
migration waves from poor regions of Southern and Central America have led to 
pockets of poverty.
Here, we review current knowledge of BU in French Guiana with specific empha-
sis on links of M. ulcerans to the human host and the natural environment.
2  Links Between the Human Host and the Bacteria
2.1  Risk Factors of BU in French Guiana
A case-control study was conducted between 2002 and 2004 to determine relation-
ships between the presence of M. ulcerans in the environment and human activi-
ties associated with the occurrence of BU in French Guiana [4]. The study involved 
30 laboratory confirmed BU cases and 60 controls matched for age, gender and 
town of residence. Increased risk of contracting the disease was strongly associated 
with environmental factors and human behavioural factors. The environmental fac-
tors implicated in the transmission of M. ulcerans were proximity of the home or 
workplace of patients to natural freshwater habitats (e.g. marshes, rivers, and flood-
able areas). In addition, some behavioural factors such as hunting, fishing, recre-
ational activity, and contact with river banks were associated with BU cases. These 
results are consistent with previous studies performed in Africa and Australia that 
have shown that people who are in close proximity to water sources or take part in 
outdoor activities are at higher risk of contracting BU. These findings suggest that 
informal professional or recreational activities like hunting or fishing and contact 
with those water sources are risk factors for contracting BU in French Guiana 
(Fig. 1).
2.2  Epidemiology and Clinical Aspects of BU in French Guiana
The epidemiology of BU in French Guiana since the first diagnosed case in 1969 
was recently studied with the aim of characterising the incidence of the disease in 
the past 45 years, the temporal demographic trends of patients, and the associated 
clinical aspects of the disease [1]. Data were collected at Cayenne Hospital’s derma-
tology department where 245 BU patients were reported between 1969 and 2013. 
Most cases occurred in coastal areas surrounded by marshy savannah. The highest 
number of cases was reported in Cayenne (47% of diagnosed cases), followed by 
Mana (20%), Sinnamary (16%), Kourou (11%), and forest areas (6%). The annual 
number of cases varied widely, with no cases in some years and up to 27 in others. 
Over the 45 years, the mean annual number of new cases was 5.4 per year and the 
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mean annual incidence rate was 4.3 per 100,000. However, the annual incidence of 
BU significantly decreased over time across all districts, from 6.1 infections per 
100,000 persons in 1969–83 to 3.5 infections per 100,000 persons in 1999–2013. 
The highest mean annual incidence rate over the 45 years was found in the western 
coastal area around Sinnamary (21.1 per 100,000 persons) and Mana (21.2 per 
100,000 persons). Annual incidence peaks were observed in the Sinnamary area 
between 1974 and 1978 (71.8 cases per 100,000 persons) and another in the Mana 
area between 1984 and 1988 (101.4 cases per 100,000 persons). Over  time, the 
mean age of patients with BU increased significantly in French Guiana between 
1969 and 2013. The proportion of children diagnosed with BU before 1984 was 
similar to that in Africa (more than 70%), but decreased with time, reaching around 
21% in 1999–2013, which is closer to the proportion observed in Australia. Men 
and women were similarly affected in French Guiana, as observed in other countries 
and lesions were usually ulcerated (92%) mainly with single ulcers with under-
mined edges. Nodules and plaques were less frequent, sometimes ulcerated. Only 
8% of the patients had multiple lesions. Lesions mainly affected limbs (lower limbs 
in 66% of patients; upper limbs in 24% of patients), which is similar to settings in 
Africa and Australia. Adults were significantly more often affected on the ankles 
than were children (14% vs 4%). No bone infections were diagnosed in French 
Fig. 1 Location of BU cases in French Guiana identified between 1969 and 2016. Precise geo-
graphic coordinates were available for 94 cases only. BU cases were sorted by periods of 10 years 
that are represented by different colors in the map. Top: location of the 94 BU cases along the 
coastline. Bottom: zoom on the Mana and Sinnamary region, Kourou and Cayenne city. The map 
was created online with BatchGeo
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Guiana whereas some studies in Africa reported osteomyelitis in up to 10% of cases. 
With the use of antibiotic therapy as first-line treatment of the infection since the 
2000s in French Guiana (rifampicin combined with amikacin or clarithromycin), 
we described some cases of patients with a paradoxical reaction, an apparent wors-
ening of the lesions during treatment [5]. These reactions are also described in 
Australia and Africa.
The global change of the epidemiology of BU in French Guiana over the past 
45 years, (i.e. decrease in the incidence of BU and a decrease in the proportion of 
children with infections) might have been mostly driven by better living conditions 
(higher GDP per person, changes in clothing, improved hygiene, wound care with 
soap), prophylactic recommendations (improvement of BCG immunisation cover-
age), reduction of children coming into contact with freshwater habitats because of 
education and protection of water sites as well as access to health care (access to the 
French universal healthcare system with faster access to care). These data indicate 
an epidemiological transition from the African-like epidemiology, with mostly chil-
dren infected, to the Australian-like epidemiology, with mostly adults infected. The 
absence of bone lesions in this patient series also raises the hypothesis of specific 
genetic variants of M. ulcerans in French Guiana.
Finally, some environmental changes induced by human activities, such as 
increased deforestation, building of dams (Sinnamary) and irrigation systems 
(Mana) that deeply modified the floodplain structure as well as modifications in 
rainfall patterns due to global climate change could also have influenced the change 
of BU incidence in French Guiana.
2.3  A Link Between Rainfall and BU Cases
Links between changes in rainfall and outbreaks of BU in French Guiana were stud-
ied from 1969–2012 [6]. During the study period, four inter-annual peaks in rain-
fall, each followed by three inter-annual periods of rainfall recessions were observed, 
with three corresponding peaks and recessions of BU cases. Intra-annual analysis 
showed bi-annual peaks in the number of new BU cases; after a peak in rainfall, the 
number of BU cases increased during a dry period. This was observed over several 
years but also annually, when BU cases are most likely to spike in the annual sea-
sons. It has also been shown that climatic anomalies such as peaks in sea surface 
temperature (El Niño) create a decline in the oscillation of BU cases. This shows 
that outbreaks of BU in French Guiana can be triggered by combinations of rainfall 
patterns occurring on a long (i.e., several years) and short (i.e., seasonal) temporal 
scale, in addition to stochastic events driven by the El Niño-Southern Oscillation 
that may modulate these patterns.
Two hypotheses may explain the observed peaks and recessions of cases of 
BU. Firstly, the long periods of wet weather characterised by floods, during which 
the bacteria could be dispersed across the floodplain, are followed by a decrease in 
rainfall that leads the flooded areas to recede into a series of disconnected stagnant 
pools prone to bacterial development [7]. These rapid changes in aquatic habitat 
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from flowing, well oxygenated habitats with rich animal communities to eutrophic, 
diversity poor communities have been shown to favour the development of M. ulcer-
ans in the environment. Secondly, during the dry period these newly created fresh-
water pools become more easily accessible by foot for hunting or fishing or simply 
for recreational bathing. The combination of emergence of favourable habitats for 
M. ulcerans and increased contact of the local population with these habitats during 
dry periods could explain the observed link between rainfall and increased numbers 
of BU cases in French Guiana.
2.4  Genetic Diversity of M. ulcerans Among Local BU Cases
Only two clinical strains of M. ulcerans (ITM7922 and Mu_1G897) from French 
Guiana were genotyped prior to 2014 [8–10]. Comparative whole genome sequenc-
ing showed that the isolate Mu_1G897 belongs to the ancestral lineage of M. ulcer-
ans. In the phylogenomic analysis it clustered with fish pathogens belonging to the 
sublineage 1 of the ancestral lineage, as defined by Doig et al. [8]. A recent study 
based on Multilocus Variable Number Tandem Repeat Analysis (MLVA) looked at 
the genetic diversity of M. ulcerans strains isolated from BU patients from French 
Guiana between 1994 and 2013 [11]. A total of 23 DNA samples obtained from 23 
patients were purified from ulcer biopsies or derived from cultures. Three allelic 
combinations were characterised in this study: genotype I, which has been described 
previously (ITM7922 and Mu_1G897), genotype III, which is very similar to geno-
type I and genotype II which has distinctly different characteristics in comparison 
with the other two genotypes. In the MLVA based phylogenetic tree the classical 
lineage strains from Africa and Australia formed a separate cluster, indicating that 
all three genotypes from French Guiana belong to the ancestral lineage. This study 
revealed for the first time genetic variability between clinical isolates of M. ulcerans 
in French Guiana, a diversity that appears to be more pronounced than in Africa, 
where closely related local clonal complexes are observed. In addition, no correla-
tions were observed between the MLVA-based phylogenetic clustering of the strains 
from French Guiana and the age of patients, date of infection or geographic 
location.
3  Environment and the Bacteria
3.1  First Detection of Mycobacterium ulcerans DNA 
in Environmental Samples from French Guiana
In French Guiana in 2014 a study identified for the first time the presence of M. 
ulcerans DNA in environmental samples from South America [12]. A total of 163 
environmental samples, taken from 23 freshwater bodies were tested for the pres-
ence of the M. ulcerans-specific markers IS2404 and KR by real-time (q)
PCR. Sampling sites were selected by looking for (1) water-bodies near the homes 
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of BU cases with habitats representing a high probability of human contact 
(including paths near or through the water site, presence of fishing or boating 
activities or other recreational uses and close proximity to human settlements) and 
(2) similar habitats in areas where there were no BU cases and with little human 
contact. Samples taken included water (from various sampling sites including 
bank-side, centre of the water body, water from within aquatic vegetation, shaded 
areas and sun exposed areas), soil (underwater sediment), detritus, dominant 
aquatic and semi- aquatic plant species, algae and biofilms. In addition, abiotic 
data such as dissolved oxygen, pH, conductivity and water temperature were 
measured.
Only five samples out of 163 were found positive for both IS2404 and KR in 
three different water bodies from the Sinnamary and Tonate districts. All three 
positive sites were typologically similar, with areas that were highly stagnant, 
forming shallow water bodies. There was no statistical significance for differ-
ences in abiotic data between positive and negative sites. These three freshwater 
bodies with qPCR positive samples were on floodplains, suggesting that in French 
Guiana, this type of environment constitutes a source for environmentally-persis-
tent mycobacteria or a “receptacle” concentrating these bacilli from further 
upstream (Fig. 2).
Fig. 2 Diversity of environmental sites positive for M. ulcerans DNA in French Guiana. For each 
site sediment, water and invertebrates samples were tested for M. ulcerans DNA by targeting the 
genetic markers IS2404 and KR [6]
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3.2  Biodiversity Drivers of M. ulcerans Distribution Across 
Freshwater Habitats
A study on a larger number of environmental samples was conducted to study the 
links between the drivers of freshwater foodwebs in French Guiana and the emer-
gence of M. ulcerans in the environment. A collection of 3600 invertebrates and fish 
were sampled and catalogued from 17 freshwater sites across French Guiana [7, 13]. 
Landscape data as a measure of land use along a gradient from urban through agri-
cultural to pristine rain forest were extracted from two maps including the CORINE 
2006 European land cover map using satellite-derived data and the Hansen defores-
tation map. Each site was surveyed twice in the rainy season, during February and 
June 2013. Each insect taxon was positioned in the foodweb using a measure of 
stable isotopes (nitrogen δ15N and carbon δ13C).
For each site, the M. ulcerans load was calculated for each taxon from the qPCR 
data for both IS2404 and KR molecular markers. Each taxon’s regional mean tro-
phic niche width (metric of total available trophic niche space within a site), vulner-
ability (number of potential predator species for each prey taxon), connectance (a 
standard measure of foodweb complexity) and generality (number of potential prey 
species each predator taxon can consume) were calculated and weighted by the 
abundance at each site. The relationships between land cover data and trophic niche 
width were identified at the local site level using general additive models (GAMs) 
of the level of deforestation within each buffer zone in addition to urban and agri-
cultural cover.
A total of 78 different freshwater taxa were identified, of which 383 specimens 
representing 44 taxa tested positive for both IS2404 and KR. The highest concentra-
tions of M. ulcerans were in species lower in the food chain, suggesting a diet high 
in aquatic algae, detritus, diatoms and similar food sources. These taxa were pre-
dominantly invertebrates in both adult and larval form.
Deforestation and either agricultural or urban intrusion were associated with a 
decline in local trophic niche width, resulting in decreased regional means of vul-
nerability and generality of taxa. This had an important effect on the potential local 
M. ulcerans load. Host taxa, which on average carried a high level of M. ulcerans, 
were most abundant at sites where there was a very low level of vulnerability and a 
mid-level of generality.
4  Conclusion
The epidemiology of BU in French Guiana has changed in the past 45 years, mainly 
with respect to a decrease in incidence, an increase in the average age of patients 
and peak incidences in geographical areas that have undergone environmental 
changes. Improved socioeconomic conditions may explain this transition from 
an African-type epidemiology to an Australian-type epidemiology. In addition, a 
link between the occurrence of human cases and climatic patterns has clearly been 
established. The influence of rainfall has been evidenced on an intra-annual 
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(6 months) and inter-annual (8 years) scale to which climatic anomalies such as El 
Niño are randomly added. Overall, episodes of high rainfall followed by relative 
drought are significantly associated with the increase in BU cases.
From a genetic perspective, the fairly large genetic diversity of M. ulcerans 
within French Guiana is rather unusual. The strains causing disease in French 
Guiana belong to the ancestral lineage and are markedly different from classical 
lineage strains from Africa and Australia. This seems to eliminate the possibility 
of an introduction of M. ulcerans into French Guiana with the arrival of popula-
tions from endemic areas of Africa. However, the diversity of strains present in 
the environment remains unknown and needs to be better understood in order to 
highlight potential selective processes shaping the genome of disease causing 
strains.
Current environmental data show a relatively high abundance of M. ulcerans 
DNA across freshwater habitats along the coastline of French Guiana. Human- 
induced environmental modifications (e.g. deforestation, agriculture, urbanization) 
have been found to be significant drivers of foodweb changes towards an increase in 
taxa with higher M. ulcerans loads.
Ongoing studies are looking to further our understanding of transmission path-
ways from the environment to the local human population. There may be multiple 
pathways, which may act as strong selective filters for M. ulcerans strains found in 
the environment.
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Buruli Ulcer in Japan
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1  Epidemiology and Bacteriological and Genomic 
Features of M. ulcerans subsp. shinshuense
1.1  Epidemiology
Japan is one of the few countries located in a temperate zone that reports cases of 
Buruli ulcer (BU). The first case, a 19-year-old female who presented with a chronic 
and necrotic ulcer on her left elbow, was reported by Mikoshiba et al. in 1982 [1]. 
This was considered to be an endemic infection due to the lack of a travel history 
outside the country. A taxonomic study using DNA hybridization assays was later 
performed on a mycobacterial strain (ATCC 33788) isolated from the skin ulcer 
lesion of this patient, revealing that this Japanese strain was highly similar to the 
classical Mycobacterium ulcerans strain ATCC 19423. However, the Japanese strain 
differed from the previously described M. ulcerans strain in mycolic acid 
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composition and some biological and biochemical characteristics; therefore, it was 
deemed to belong to a new subspecies of M. ulcerans named M. ulcerans subsp. 
shinshuense [2]. The disease was not noticed again in Japan until the second case of 
BU was identified and reported in 2003 [3]. Since then, the number of cases has 
increased gradually, summing to a total of 60 cases reported from 17 of the coun-
try’s 47 prefectures till the end of 2016. M. ulcerans subsp. shinshuense has been 
isolated from 41 of the cases [4–7].
BU cases are rather sporadically distributed throughout the main and largest 
island of Japan, Honshu Island, with no particular focus [6, 8]. The  Okayama 
Prefecture, which is localized in the central western regions of Japan facing the Seto 
Sea, has so far reported most of the cases (ten [17%] cases), followed by the Tottori 
Prefecture (six [10%] cases) and the Shiga Prefecture (seven [12%] cases). The Akita 
Prefecture is the most northern prefecture reporting BU cases, where the tempera-
ture can be below zero degrees Celsius during the coldest season of the year. All 
reported  cases in Japan are considered to be domestic infections as none of the 
patients had a history of oversea travel to BU endemic countries before symptom 
onset. The acquisition of the pathogen from a suspicious aquatic environment 
remains undetermined in most cases. However, it is interesting to note that most BU 
cases in Japan were diagnosed in autumn and winter (48 cases), which may indicate 
a higher incidence of infection during summer considering the expected time lag 
between infection and symptom onset [9].
1.2  Genome
M. ulcerans and related mycobacterial strains (such as M. liflandii) share a charac-
teristic genome structure consisting of a chromosome and a giant plasmid. This 
genome structure caused  some difficulty when analyzing the whole genome 
sequences. Recently, with the help of next-generation sequencing (NGS), the com-
plete genome sequences of two representative isolates, M. ulcerans Agy99 and M. 
liflandii 128FXT, were unraveled [10–12]. The complete genome sequence of M. 
ulcerans subsp. shinshuense (ATCC 33728) was also reported by a Japanese group 
[13]. Comparison of the whole genome of M. ulcerans subsp. shinshuense with 
those of the related strains revealed that it bears more similarity with M. liflandii 
128FXT than with M. ulcerans Agy99 (Table 1). M. ulcerans subsp. shinshuense 
has a 5,899,681 bp chromosome with 65.64% GC content and a 166,617 bp giant 
plasmid with 62.76% GC content. The average nucleotide identities were 98.36% to 
M. ulcerans Agy99 and 99.10% to M. liflandii 128FXT [13]. The total number of 
coding DNA sequences (CDSs) in both M. ulcerans subsp. shinshuense and M. 
liflandii 128FXT were found to be roughly around 5000, approximately 800 CDSs 
more than in the M. ulcerans Agy99 chromosome (Table 1) [10–13]. With respect 
to insertion sequences (IS), IS2606 was much more abundant in M. ulcerans Agy99 
than in M. ulcerans subsp. shinshuense and M. liflandii 128FXT (Table 1) [10–13]. 
In contrast, more than 200 copies of IS2404 were observed in M. ulcerans subsp. 
shinshuense, which share approximately 99% identity with the classical M. 
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ulcerans strains and M. liflandii [4, 7, 13]. Due to the abundance of IS2404, PCR 
amplification of a partial IS2404 sequence is currently used for sensitive detection 
of M. ulcerans subsp. shinshuense, although differentiation from other closely-
related IS2404-harboring species requires further investigation. The 16S rRNA 
sequences in M. ulcerans subsp. shinshuense were almost identical to those in M. 
ulcerans Agy99 (Table 2), except for two characteristic nucleotide substitutions at 
base positions 492 and 1288 found exclusively in M. ulcerans subsp. shinshuense 
(Table 2) [4, 7]. Including the listed representative isolate ATCC 33728 (Table 2), 
the same nucleotide substitutions have been found in ten clinical isolates of M. 
ulcerans subsp. shinshuense [7].
Table 1 Genomic characteristics of M. ulcerans subsp. shinshuense and related mycobacteria
Characteristics
M. ulcerans subsp. shinshuense ATCC 
33728
M. ulcerans 
Agy99
M. liflandii
128FXT
Chromosome
 Size (bp) 5,899,681 5,631,606 6,208,955
 G + C (%) 65.64 65.47 65.62
 No. of CDSs 5015 4160 4994
 No. of 
pseudogenes
451 771 436
 No. of IS2404 206 209 224
 No. of IS2606 1 83 1
Plasmid
 Size (bp) 166,617 174,155 190,588
 G + C (%) 62.76 62.5 62.9
 No. of CDSs 72 72 95
 No. of 
pseudogenes
7 7 22
 No. of IS2404 4 4 15
 No. of IS2606 1 8 3
References [7], Yoshida et al. (unpublished) [8] [9, 10]
GenBank accession 
no.
AP017624
AP017625
CP000325
BX649209
NC_020133
NC_011355
CDS coding DNA sequence, IS insertion sequence
Table 2 Nuclotide substitutions observed in 16S rRNA sequences from M. ulcerans subsp. shin-
shuense and related mycobacteria
Species
Differentiating sequence position 
(underline) GenBank 
accession no.492 1288
M. ulcerans subsp. shinshuense 
ATCC 33728
TGGGGAA TAAGGCC AB548733
M. ulcerans Agy99 TGGAGAA TAACGCC AB548729
M. liflandii 128FXT TGGAGAA TAAAGCC CP003899
M. marinum ATCC 927 TGGAGAA TAAAGCC AB548717
M. pseudoshottsii JCM 15466 TGGAGAA TAAAGCC AB548713
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Comparison of eight pMUM001 gene sequences encoding lipid toxin mycolactone- 
producing enzymes (including repA, parA, serine/threonine protein kinase [STPK] 
gene, loading domain of mls, acyltransferase domain of mls, rep type II thioesterase 
gene, rep type III ketosynthase gene, and rep P450 hydroxylase gene) in the giant 
plasmid of M. ulcerans subsp. shinshuense and the African M. ulcerans strain by 
PCR amplification revealed the presence of seven pMUM001 gene sequences and 
the loss of the STPK gene in Japanese isolates [4, 7]. The elucidation of the complete 
genome sequence of M. ulcerans subsp. shinshuense further verified the above find-
ing by showing that the STPK gene in M. ulcerans subsp. shinshuense is truncated, 
with low similarity to STPK in M. ulcerans Agy99 [13]. Despite the deficiency of a 
functional STPK gene in Japanese clinical isolates, no apparent bacteriological dif-
ferences were observed, indicating the possibility that some signaling pathways 
compensate for STPK function in M. ulcerans subsp. shinshuense [14]. Intriguingly, 
a Chinese M. ulcerans strain has a 16S rRNA gene identical in sequence to that in M. 
ulcerans subsp. shinshuense, and also lacks the STPK gene in its giant plasmid like 
M. ulcerans subsp. shinshuense [4, 7]. This finding supports the suggestion that the 
Chinese strain is phylogenetically closest to M. ulcerans subsp. shinshuense among 
other M. ulcerans strains [15]. However, further characterization of the whole 
genome sequence of the Chinese strain is required for its classification.
The close resemblance, in addition to distinctive genomic features, between the 
classical M. ulcerans strains and the Japanese strain M. ulcerans subsp. shinshuense 
has evoked great interest in the intra-species evolutionary scenario for M. ulcerans. 
Phylogenetic analysis of irreversible genomic changes focusing on insertion- deletion 
polymorphisms in 12 regions of difference among M. ulcerans strains has unambigu-
ously resolved a phylogenetic tree showing that M. ulcerans has evolved into at least 
two distinct lineages since divergence from the M. marinum progenitor [15]. In addi-
tion to M. ulcerans subsp. shinshuense, strains from China, South America, and 
Mexico were shown to belong to a lineage that is more closely related to M. mari-
num, namely the ‘ancestral’ lineage; while strains from Africa and Australia belong 
to the ‘classical’ lineage that has undergone major genomic rearrangement [15]. In 
agreement with this evolutionary scenario, 26,564 single nucleotide polymorphisms 
(SNPs) were found in a Japanese strain by a comparison with the reference genome 
of the classical lineage isolate Agy99 using a high-resolution phylogeny analysis 
based on genome-wide SNPs [16]. Moreover, calculation of time scales of the evolu-
tionary process by the minimum evolution tree-based approach estimated that the 
divergence of Ghanaian subtypes (including Agy99) from the M. marinum progeni-
tor occurred about 1000–3000 years ago, whereas M. ulcerans subsp. shinshuense 
diverged much earlier (about 394,000–529,000 years ago) [16].
1.3  Biochemical Properties
Mycolactone, secreted by M. ulcerans in the process of chronic infection, is an essen-
tial molecule for the virulence of BU [17]. Mycolactone is also secreted by strains 
originally designated M. pseudoshottsii, M. liflandii, and a subset of M. marinum 
strains [18–20]. M. ulcerans subsp. shinshuense produces mycolactone A/B, among 
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five analogs of mycolactone, which was originally found in African M. ulcerans 
strains [12, 17, 18] (Fig. 1). In contrast, the Chinese strain of M. ulcerans produces a 
unique mycolactone D that is not observed in other M. ulcerans strains [21]. 
Mycolactone D possesses an additional methyl group in its acyl side chain, whereas 
the mycolactone A/B conserves an intact form (Fig. 1) [12, 17, 18, 21]. In the Chinese 
strain, nonsynonymous substitutions that could cause drastic functional changes have 
been found in the mlsB gene involved in synthesis of acyl side chains, while corre-
sponding mutations were not observed in Japanese M. ulcerans subsp. shinshuense or 
the African strains, suggesting that the Chinese strain might have uniquely acquired 
the ability to modify mycolactone A/B to D through genetic alternations [12].
A variety of glycolipids are present in the mycobacterial cell wall that likely 
functions as a protective barrier from host immune attack [22, 23]. Mycolate is a 
type of long chain fatty acid covalently linked to various glycolipids as a major 
component in the mycobacterial cell wall [22, 23]. Mycobacteria produce three 
main types of mycolate: alpha-, keto- (which contains additional ketone groups), 
and methoxy-mycolate (which contains additional methoxy groups) [22, 23]. 
Tsukamura et al. reported that both M. ulcerans subsp. shinshuense and other M. 
ulcerans strains share the three types of mycolate, while the average number of 
carbons in mycolate in M. ulcerans subsp. shinshuense is higher than that in an 
Australian M. ulcerans strain (ATCC 19423) [2]. However, comprehensive com-
parison is needed to determine whether the distribution of the three mycolate types 
differs between M. ulcerans subsp. shinshuense and other M. ulcerans strains, 
and to unravel their implications in mycobacterial virulence.
M. ulcerans subsp. shinshuense
M. ulcerans (African strains) 
M. ulcerans (Chinese strain) 
OH OH
OH
OH
OHOH
OH
O
O
O
O
O
O
O
O
OH
OH OH
Mutation in mlsB gene
Mycolactone A/B
Mycolactone D
Fig. 1 Structural variation in mycolactones caused by a mlsB mutation uniquely found in a 
Chinese M. ulcerans strain. The dashed circle in mycolactone D represents the methyl group that 
distinctively differentiates it from mycolactone A/B produced by M. ulcerans subsp. shinshuense 
and African strains of M. ulcerans
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As one major glycolipid component in the mycobacterial cell wall, phenolic gly-
colipids (PGLs) were found in M. leprae, M. tuberculosis, M. marinum, and M. 
ulcerans [24–26]. PGLs vary in their compositions of sugar moieties (including 
rhamnose, fucose, and glucose), which are highly species-specific [24–26]. Daffe 
et al. found that 10% of M. ulcerans strains produced PGL consisting of monosac-
charide (3-O-methyl-rhamnose), supporting a close phylogenetic link between M. 
ulcerans and M. marinum [27]. However, the rest of the tested strains, including M. 
ulcerans subsp. shinshuense, did not produce PGL [27]. In M. leprae, PGL is known 
to induce a strong antibody response and to play a role in invasion into Schwann 
cells [28, 29]. In M. tuberculosis, clinical isolates have been divided into PGL- 
producing and non-producing groups, and the former is regarded as more virulent, 
suggesting that PGL plays a role in the pathogenicity of mycobacteria [30]. This 
suggests that PGL-producing M. ulcerans subsp. shinshuense strains may be found, 
albeit less frequently. Analysis of PGL in M. ulcerans subsp. shinshuense as well as 
in other M. ulcerans strains with reference to the clinical symptoms in each case 
might offer a new approach to understand the causes of invasive BU cases.
Drug susceptibility tests showed that M. ulcerans subsp. shinshuense strains 
were more sensitive to streptomycin (SM), kanamycin (KM), and clarithromycin 
(CAM) than reference M. ulcerans strains (ATCC 19423 and Agy99) [7]. Differing 
from other antimicrobial drugs, such as rifampicin (RFP) and levofloxacin (LVFX), 
in the mechanism of action, binding to ribosomal RNA is exclusively required for 
SM, KM, and CAM to exert their actions to inhibit mycobacterial protein synthesis. 
The specific nucleotide substitutions found in the 16S rRNA of M. ulcerans subsp. 
shinshuense might have affected the conformation of its transcribed ribosomal 
structure, rendering it more accessible to the drugs [4, 7].
M. ulcerans subsp. shinshuense strains and the Chinese strain were all positive for 
urease activity, whereas the M. ulcerans strains from Africa and Australia were nega-
tive [7]. This feature may allow scientists to distinguish M. ulcerans subsp. shins-
huense from M. ulcerans strains by a simple urease activity test. It has been shown in 
some mycobacterial species that urease plays a key role in metabolizing urea as a 
sole nitrogen source under nutrition-limited conditions and in neutralizing the sur-
rounding milieu to inhibit phagolysosomal maturation [31, 32], indicating that ure-
ase-positive strains may be more adapted to harsh environments and more capable of 
achieving intracellular survival. Further comparisons between urease-positive strains 
with urease-deficient mutants might clarify whether urease activity contributes to the 
persistence of M. ulcerans subsp. shinshuense in the host.
2  Clinical Features and Treatment of BU in Japan
2.1  Antimicrobial Treatment
In the BU cases diagnosed in Japan, skin lesions mostly developed on exposed body 
parts including upper and lower limbs, face, ear, jaw, and clavicle. Although multi-
ple lesions were present in 14 cases, no single lesion larger than 5 cm in diameter 
K. Suzuki et al.
93
was reported. Therefore, all cases fall into World Health Organization (WHO) cat-
egory I or II. Advanced BU infection has not been seen in Japan. In contrast to the 
general impression that BU lesions are typically painless, approximately half of the 
cases confirmed to be infected by M. ulcerans subsp. shinshuense have  reported 
pain [5, 8].
In Japan, a variety of antimicrobial drugs have been used to treat BU; e.g., RFP, 
minocycline (MINO), CAM, LVFX, gatifloxacin (GFXN), norfloxacin (NFX), eth-
ambutol (EB), isoniazid (INH), ethionamide (ETH), and tosufloxacin (TFLX). 
However, surgical intervention was often unavoidable. Nakanaga et al. tested the 
drug susceptibilities of M. ulcerans subsp. shinshuense to major antimicrobial 
agents and found that it is most susceptible to RFP and CAM, while resistant to EB, 
ETH, and INH (Table 3) [7]. LVFX, a broad-spectrum fluoroquinolone antibiotic, 
which also showed satisfactory activity against M. ulcerans and M. ulcerans subsp. 
shinshuense (Table 3) [7], has been preferentially used for treating skin infections in 
Japan due to its better transferability to soft tissue and skin. Based on these reasons 
and in reference to WHO BU guidelines, a triple antimicrobial therapy with RFP 
(450 mg/day), LVFX (500 mg/day), and CAM (800 mg/day), called RLC therapy, 
has been recommended and has increased cure rates of BU without surgery (Table 4).
In our latest investigation on the efficacy of BU treatment in Japan, 50 cases (83% of 
the total reported cases) consisting of 19 male and 31 female patients, aged from 2 to 
88 years (average: 45.8 ± 27.63 years) were included. Ten cases were excluded because 
of the absence of detailed information for treatment. These 50 BU cases were divided in 
two groups based on their antimicrobial regimens. One group (21 cases) received high-
dose RLC (CAM at 800 mg/day). The other 29 cases received other treatments includ-
ing low-dose RLC (CAM at 400 mg/day) or monotherapy of RFP, CAM or MINO; this 
group also included cases with interrupted RLC due to side effects and subsequent alter-
native chemotherapies. Five children received TFLX (12 mg/kg/day) substituted for 
LVFX, as TFLX (but not LVFX) is covered by medical insurance for children in Japan. 
Table 3 Susceptibility 
testing results of M. ulcerans 
subsp. shinshuense
Antimicrobial agent
MIC (μg/mL)
M. ulcerans subsp. shinshuense
ATCC33728 501
SM 0.125 0.25
EB 16 8
KM 0.25 0.25
INH 8 8
RFP 0.06 0.06
LVFX 0.25 0.5
CAM 0.03 0.06
ETH 16 8
AMK 0.5 0.5
AMK amoxicillin, CAM clarithromycin, EB ethambutol, ETH 
ethionamide, INH isoniazid, LVFX levofloxacin, KM kanamy-
cin, MIC minimal inhibitory concentration, RFP rifampicin, SM 
streptomycin
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Fifteen/twenty-one (71.4%) high-dose RLC-treated patients compared to 4/29 (13.7%) 
of the other patients had avoided surgery (P < 0.0001, Fisher’s exact test). The distribu-
tion of age, sex, size of skin ulcer, or WHO category did not significantly differ 
for patients treated with high-dose RLC therapy and the others. Together, these results 
suggest that high- dose RLC therapy has been most effective among all chemotherapies 
(Table 4), which is in agreement with a previous investigation that included 40 BU cases 
in Japan by June 2013 [8]. The duration of high-dose RLC therapy ranged from 8 to 
48 weeks (24 weeks in most cases), which was compared to the standard 8-week antibi-
otic treatment. The failure to determine a significant correlation between the duration of 
high-dose RLC therapy and the size of skin ulcers (r = −0.2, with Pearson correlation 
coefficient) indicates a tendency of overtreatment for BU in Japan.
The ineffectiveness of low-dose RLC may be attributed to a complex pharmaco-
kinetic interaction between CAM and RFP. It has been reported that RFP induces 
production of cytochrome P450 3A4, an enzyme involved in the metabolism of 
CAM [33, 34], which would hasten the elimination of CAM from serum when used 
together [35, 36]. These reports indicate the need for a higher dose of CAM when 
used in combination with RFP. With reference to the WHO BU meeting in 2015, we 
currently recommend a high-dose RLC triple therapy consisting of RFP (10 mg/kg/
day), LVFX (500 mg/day), and CAM (800 mg/day) in Japan [37].
2.2  Alternative Treatments of BU
Surgical excision and skin grafting were the only options for BU treatment until 2004 
[38]. Since then, apart from chemotherapy also other  therapeutic options, such as 
negative-pressure wound therapy (NPWT), ozone therapy, and hyperbaric oxygen 
therapy (HBOT) have been used or considered in the treatment of BU. Particularly 
for patients who have received surgical excision and still present large non- granulating 
wound areas, NPWT or ozone therapy could be a good choice for the next stage.
Since larger lesions or multiple ulcerative lesions often took a longer time to heal 
or failed to be cured by chemotherapy alone, surgical excision of the necrotic, ulcer-
ated tissues had been performed in Japan. Among 31 cases that received surgical exci-
sion, 21 (67.7%) also received skin grafts (Table 5). Among the 21 patients, NPWT 
was tentatively performed in one patient for the purpose of wound bed preparation 
before skin grafting [39]. This patient had an ulcer on the right ankle with a necrotic 
Table 4 Efficacy analysis of treatment for BU in Japan
Treatment No. Age
Sex 
(M/F)
Category 
(I/II)
Ulcer size 
(mm)
Cured completely 
without surgery
RLC (high 
dose)
21 42.1 ± 30.2 11/10 18/3 25.6 ± 23.8 15
Others 29 48.4 ± 26.3 8/21 24/5 27.3 ± 15.7 4
P value 0.43 0.087 1.0 0.79 6.95 × 10−5
BU Buruli ulcer, RLC triple therapy with rifampicin (450 mg/day), levofloxacin (500 mg/day), and 
clarithromycin (800 mg/day)
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bed, and the Achilles tendon and the calcaneal bone were exposed. NPWT with the 
Vacuum-Assisted Closure (V.A.C.) Therapy System (Kinetics Concepts Inc.; KCI) 
was started as a pretreatment for a skin graft to be performed 22 days after surgical 
excision of the necrotic tissue. The vacuum suction was maintained at 125 mmHg. 
The wound dressings were changed every third day for 24 days. At the end of NPWT, 
acceptable granulation tissue had covered the ulcer bed and the skin graft was conse-
quently successfully engrafted. The patient was cured without disability.
NPWT has been widely used in Japan for many kinds of ulcerative lesions or for 
wound treatment after skin grafting, as it can reduce exudate, improve local edema, 
and activate granulation. It is not to be used for wounds with active infection. 
Therefore, for BU treatment, NPWT is preferable for use after surgical debridement 
combined with appropriate antimicrobial chemotherapy. Dressings must be changed 
every 48–72 h. The absence of active wound infection should be checked each time 
at dressing. The exact frequency of dressing changes depends on the individual 
patient’s circumstance, but it should not be less than three times a week. There are 
rental and purchasable NPWT (portable and disposable) models. Rental models 
include RENASYS by Smith & Nephew and V.A.C. by KCI, and purchasable mod-
els include PICO by Smith & Nephew. Otherwise healthy patients often must 
remain hospitalized for the sole purpose of receiving NPWT because the rental 
devices are only for hospital use. Thus, an affordable and purchasable NPWT device 
like PICO may be more cost-effective for an otherwise healthy patient. Nevertheless, 
its high cost is a large problem for patients in many countries (Table 6).
2.3  Other Suggested Therapies
Ozone therapy has been reported to shorten the course of wound healing and to pro-
mote lipid peroxidation and antioxidant protection indices [40]. Briefly, O3 is topi-
cally administered by positioning a bag around the lesion and insufflating an O2-O3 
mixture at a concentration of 25–30 μg/mL. To avoid gas leakage, the inflated bag 
is sealed just above the lesion. The bag is positioned and closed with an elastic band 
to give the gas mixture contact with the wound for about 20 min. When the bag is 
removed, the wound is covered with a sterile gauze. A case with a skin ulcer in 
Benin was reported to be healed after the ozone applications in 2 weeks [41].
Table 5 Treatment for BU in Japan
Treatment
RLC (high dose) 
(n = 21)
Others 
(n = 29)
Total 
(n = 50)
Antimicrobial treatments only 15 4 19
Surgical excision 2 8 10
Surgical excision + skin graft 3 17 20
Surgical excision + NPWT + skin 
graft
1 0 1
BU Buruli ulcer, NPWT negative-pressure wound therapy, RLC triple therapy with rifampicin 
(450 mg/day), levofloxacin (500 mg/day), and clarithromycin (800 mg/day)
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Compared to surgical treatment, NPWT and ozone therapy are easy to use pro-
cedures. NPWT requires only the NPWT device, dressings, and canisters, though 
the disposable dressings and canisters are expensive. In contrast, ozone therapy 
does not require such expensive disposable materials. It requires an oxygen tank, an 
ozone generator, sterile water, and plastic bags, together with a system to drive the 
gas into contact with the lesions. The oxygen generator is expensive (4000–8000 
Euros), but the cost of the disposable items for ozone therapy is much lower than 
that for NPWT. This simpler and more affordable therapy may offer an effective 
option for managing BU as an alternative treatment in endemic areas.
HBOT has long been established to treat skin ulcers and wounds such as diabetic 
foot ulcers, burns, and serious soft tissue infections including gas gangrene and 
necrotizing fasciitis [42]. HBOT is the application of 100% oxygen at a pressure 
two or three times of the atmospheric pressure at sea level. This pressure increases 
arterial and tissue oxygen tension to exert multiple physiological and therapeutic 
effects [43]. HBOT has been experimentally used to treat mice with M. ulcerans- 
infected footpads [44, 45]. In human patients, Pszolla et al. reported that supportive 
therapy with HBOT promoted healing after surgical excision of the deep ulcers with 
osteomyelitis caused by M. ulcerans [45]. HBOT requires hyperbaric chambers, 
which may limit its application in endemic areas. However, if used in conjunction 
with other therapeutic procedures, HBOT may be an effective therapeutic adjunct in 
treating BU, and it may contribute to reduce large surgical interventions like ampu-
tations and to prevent permanent disabilities [46].
3  M. ulcerans subsp. shinshuense in the Environment 
of Japan
3.1  Detection of Environmental M. ulcerans subsp. 
shinshuense in Japan
So far, M. ulcerans has been detected in the backyard of a family house in a rare 
case of concurrent familial clustering in Japan [47, 48]. In November, three mem-
bers of a family living in a rural town in Japan, developed BU symptoms almost 
Table 6 Approximate costs for NPWT per week
Company and device
Smith and Nephew KCI
Country RENASYS (US$/week) PICO (US$/week) V.A.C. (US$/week)
Japan 620 420 700
South Africa (private) N/A N/A 600
South Africa (public) 450 175–300 450
Egypt (private) 290–340 220 N/A
Egypt (public) 145–155 N/A N/A
Costs shown are approximate costs per week as of January 2017. The weekly costs include the 
costs for three sets of dressings and canisters and rental fee for the NPWT device (RENASYS and 
V.A.C.). The costs vary due to the size of lesions. KCI Kinetics Concepts Inc., N/A not available, 
NPWT negative-pressure wound therapy, V.A.C. vacuum-assisted closure therapy system
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simultaneously. At first, the 2-year-old daughter had a gradually enlarging eruption 
on her right cheek. Soon after her symptom onset, an asymptomatic indurated erup-
tion appeared on the right forearm of her 5-year-old brother, and a gradually enlarg-
ing eruption developed on the right wrist of her 37-year-old mother, both of which 
showed acid-fast bacilli-positive histopathological features similar to  the lesions 
found in the little girl. The patients were tentatively given oral anti-mycobacterial 
multi-drug therapy combined with surgical treatment and cured without recurrence. 
PCR amplification and gene sequencing afterwards determined the strains isolated 
from the patients’ skin biopsy cultures to be M. ulcerans subsp. shinshuense, thus 
giving an indubitable diagnosis of BU. The concurrent familial cases strongly sug-
gested the presence of the pathogen in their common living environment, although 
person-to-person transmission of M. ulcerans cannot be excluded. A  field study 
involving environmental sampling was therefore carried out in summer (July and 
August) and autumn (October) of the following year in an attempt to determine the 
presence of M. ulcerans in the environment around the family’s house.
The family was living in an old house surrounded by rich farmland and exten-
sive irrigation channels. Immediate suspicions centered on a one-meter-wide agri-
cultural water channel of stagnant water slowly flowing through the family’s 
backyard, to which  the family had routine access and where  the children enter-
tained themselves by catching small water creatures. Environmental samples, 
including water, mud, crayfish, earthworms, a freshwater snail, a hoverfly, a moth, 
and several kinds of aquatic or semi-aquatic insects, were collected from or near 
the water channel in the patients’ backyard in summer and autumn. Genomic DNA 
was purified from each sample and subjected to whole genome amplification 
(WGA) to achieve higher sensitivity in PCR to detect trace amounts of mycobacte-
rial DNA. PCR amplifications and DNA sequencing results showed that the M. 
ulcerans IS2404 was detected in WGA-amplified DNA from a crayfish that was 
collected in summer (but not in the crayfish collected in autumn or in any other 
sample), presenting so far the only piece of evidence that links a contaminated 
aquatic environment to BU occurrence in Japan.
Intriguingly, M. ulcerans IS2404 was detected in a crayfish but not in the water 
samples collected from the same channel at the same time [47], indicating that 
despite the presence of the pathogen in the contaminated aquatic environment, its 
potential presence in the water was nevertheless below the detection sensitivity of 
PCR amplification. In an aquatic community, due to biotic interactions between 
various habitants such as filter feeders, herbivorous, scavengers, and predators, M. 
ulcerans may be widespread across the whole community. In agreement with this 
point of view, in endemic areas M. ulcerans DNA has been detected in a wide vari-
ety of environment samples, such as aquatic insects, biofilms, soil, mosquitoes, 
crustaceans, detritus, fish, frogs, snails, worms, and various small mammals [49]. 
The transmission of pathogens within an aquatic environment, depending on biodi-
versity and the number of habitants, can drive the environmental load of the patho-
gens to be enriched or diluted in certain hosts, carriers, or biofilms. Additionally, 
certain keystone organisms could play an overwhelming role in the transmission 
and overall prevalence of M. ulcerans in a specific environment [50]. The crayfish 
(Procambarus clarkii) is known to have a wide food range, including plants, small 
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fish, shrimp, plankton, benthos, and algae, and especially prefers mud and deceased 
aquatic organisms. Such an omnivorous eating habit may explain an enrichment of 
M. ulcerans in crayfish.
3.2  Seasonal Variation of BU in Japan
In addition to establishing the presence of M. ulcerans subsp. shinshuense in an aquatic 
environment in Japan for the first time, the findings of the field work were in line with 
a noticeable feature of seasonal variation of BU occurrence in Japan. Eighty percent of 
BU cases in Japan were diagnosed in autumn and winter (from September to February), 
but only a few in summer (July and August) [6, 8]. Under the assumption that the diag-
nosis is preceded for several months by M. ulcerans infection due to a long incubation 
period [9] and due to the delay in seeking medical care, it was speculated that the 
exposure to the pathogen occurred during summer. Such dynamics in M. ulcerans 
infection are putatively driven by a complex interplay of human activities and the prev-
alence of the pathogen in the environment. Japan has four distinct seasons with a rainy 
season throughout early summer (typically from early June to mid-July), and there are 
naturally more chances for bare skin to be exposed to an aquatic environment during 
the hot and humid summer time, especially in the water-rich countryside.
On the other hand, there was no direct information regarding the prevalence of 
M. ulcerans in the environment throughout the year in Japan before the field work. 
The results that M. ulcerans subsp. shinshuense was detected only in July, but not in 
any of the samples collected from the same water channel in October, hints at poten-
tial seasonally changing prevalence of environmental M. ulcerans subsp. shins-
huense with a high peak in summer, which may have contributed to the observed 
seasonal variation of BU incidence in Japan. However, the scale of this fieldwork 
alone was far too small to make a solid prediction. Seasonal dynamics in environ-
mental M. ulcerans prevalence can be driven by an extremely complex interplay 
between multiple biotic and abiotic factors, such as topographic factors (distribution 
and latitude of land cover of watersheds), climatic factors (temperature, precipita-
tion), physical-chemical conditions (pH, dissolved oxygen, salinity) in stagnant and 
slow flowing ecosystems, and networks of aquatic taxa, as suggested by large-scale 
field studies conducted in BU endemic countries [51, 52]. In this respect, the sea-
sonal dynamics of the prevalence of M. ulcerans in Japan (especially in a high lati-
tude area as the site in the field work) may differ substantially from that reported in 
tropical/subtropical areas.
3.3  PCR Detection of M. ulcerans subsp. shinshuense DNA 
in the Environment
Field studies to detect environmental M. ulcerans subsp. shinshuense in Japan are 
still in their infancy compared to studies in BU endemic countries. Presently, the 
detection of M. ulcerans in the environment is mostly based on demonstrating by 
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PCR the presence of IS2404, an insertion sequence with over 200 copies in the 
whole genome of M. ulcerans [10]. IS2404-PCR is highly specific and sensitive for 
testing clinical specimens from human BU lesions; however, its application in the 
detection of environmental M. ulcerans is less straightforward, and the IS2404- 
PCR- based results should be interpreted with caution. IS2404-PCR detects the pres-
ence of IS2404 regardless of the pathogenicity of the detected mycobacteria, which 
alone has little power in predicting endemicity of BU. M. ulcerans DNA was 
detected by IS2404-PCR extensively across southern Louisiana, U.S., leading to the 
conclusion that the distribution of environmental M. ulcerans is not restricted to 
areas where BU is endemic [53].
In a large-scale field study conducted in Benin, IS2404-positive samples were 
detected with similar prevalence in environmental samples in both non-endemic 
(9/10) and endemic (12/12) villages [49]. However, when IS2404-positive samples 
were further analyzed for a second PCR target, the enoyl reductase (ER) that is 
required for the synthesis of mycolactone, only 2/10 non-endemic villages had 
ER-positive samples, whereas 9/12 endemic villages had ER-positive samples. 
Thus, the PCR for IS2404 alone falsely predicted 9/10 non-endemic villages to be 
endemic, and the additional use of the PCR for ER accurately predicted 8/10 non- 
endemic villages [49]. In a field study, the use of a single PCR target for detection 
of environmental M. ulcerans may easily signal a false alarm  to public health 
authorities. Secondly, the results of  conventional IS2404 PCR analyses  are  only 
qualitative and do not reveal the abundance of the pathogen. They are thus inade-
quate to describe potential seasonal dynamics in the overall environmental load of 
M. ulcerans. Lastly, analysis of many IS2404-positive samples in Ghana have 
revealed the presence of mycolactone-producing mycobacterial species other 
than  the ones commonly associated with BU disease  in humans [54]. 
Mycobacterial strains closely related to the human pathogenic M. ulcerans, includ-
ing ecovars originally designated M. liflandii, M. pseudoshottsii, and mycolactone- 
producing M. marinum, have been found to harbor IS2404 [55, 56].
Thus, the analyses of M. ulcerans that rely solely upon the conventional PCR 
assay for IS2404 are flawed. TaqMan Multiplex real-time PCR assays that target two 
insertion sequences of M. ulcerans (IS2404, IS2606) and a multicopy sequence 
encoding the ketoreductase B domain [55, 57], in which samples are considered 
positive only if the detected cycle threshold values are strictly lower than a default 
value based on external standard curves with serial dilutions of Mycobacterial DNA, 
can quantify the copy number of the targets to allow the differentiation of classi-
cal M. ulcerans from other IS2404-harboring strains in the environment [55, 57].
Moreover, a novel category of variable tandem repeats (VNTRs) called myco-
bacterial interspersed repetitive units (MIRUs) have been identified in the genomes 
of M. ulcerans and M. marinum. Analysis of strain-specific polymorphisms of 
MIRU loci has been used to tentatively genotype M. ulcerans, M. marinum, and an 
M. marinum-like organism that is considered a possible missing link between M. 
ulcerans and M. marinum [56, 58]. Ideas inspired by many studies conducted in the 
BU endemic countries, such as the use of multiple targets in quantitative PCR assays 
and MIRU-VNTR typing, will better equip us to evaluate the environmental 
Buruli Ulcer in Japan
100
distribution of M. ulcerans in future field studies in Japan. Distribution maps of 
Asian strains will play a key role in understanding the transmission mode of M. 
ulcerans and support control of BU.
4  BU in Asia and Future Perspectives
4.1  BU in China
In addition to BU cases reported from Japan, M. ulcerans subsp. shinshuense has 
also been identified as the causative agent of BU in a patient from China [59]. In 
1997, a 40-year-old women, who had grown up in China and had been living in 
Europe, traveled to Shandong Province, China in the summer (July and August). 
According to the patient’s narrative, she received many mosquito bites after walking 
barelegged in the field. Three months later, the patient noticed a swelling at the front 
of her left lower leg that afterwards developed a slightly depressed center with no 
other systemic symptoms. Four months after that, a surgeon excised her lesion. 
Reportedly, there was no noticeable bleeding during the procedure, and the excised 
tissue was pale and firm. The lesion did not heal after excision but further developed 
ulceration. After the patient went back to Europe, a doctor specializing in infectious 
diseases examined the lesion and suggested that it might be skin tuberculosis. 
Consequently, a smear of the ulcer base was made by the patient’s general practitio-
ner, and Ziehl-Neelsen staining revealed acid-fast bacteria scattered and in clumps. 
The patient was therefore referred to the Department of Dermatology, Section of 
Tropical Dermatology of the Academic Medical Center, Amsterdam, where diag-
nostic procedures showed BU-characteristic clinical, histopathological, and molec-
ular findings [59].
At first examination, it was a single painless lesion (3 × 3.5 cm in diameter) on 
the lower leg with necrotic ulcer bed and undermined border. Histopathological 
examination of the biopsy specimens showed thickening and broadening of the epi-
dermis, extensive eosinophilic necrosis in the deeper dermis and the subcutaneous 
tissue without granulomatous inflammatory reactions. Cultivation tests using a 
biopsy sample yielded pale-cream to yellow colonies after 40-day incubation on 
Coletsos medium only at 30°C. PCR analyses using DNA extracts both from ulcer 
biopsies and culture isolates confirmed the presence of the M. ulcerans-specific 
IS2404 sequence. Using classical identification schemes the isolate was identified 
as M. ulcerans subsp. shinshuense. Treatment began with RFP + CAM and was later 
switched to ciprofloxacin (CPFX) + rifabutin (RFB) based on the results from drug 
susceptibility test of the original culture isolate. The patient was cured with an 
8-months antibiotic treatment without reported recurrence [59].
The putative infection site of Shandong Province, China is above latitude 
30°N. BU occurrence at such a high latitude is rare, and had only been reported in 
Japan, suggesting that M. ulcerans subsp. shinshuense is more adapted to environ-
ments at higher latitudes than the classical M. ulcerans that is observed to be con-
fined to tropical/subtropical regions and temperate climatic areas. Moreover, the 
infection by M. ulcerans subsp. shinshuense in the patient from China was highly 
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suspected to have occurred during her travel in summer, 3–4 months prior to symp-
tom onset, which is in line with the proposed seasonal variation of BU occurrence 
in Japan. Thus, in contrast to the majority of BU cases that are caused by classical 
M. ulcerans, BU infections by M. ulcerans subsp. shinshuense have so far been only 
infrequently found in Japan and China, as apparent from the clinical reports [6, 8].
As stated before, it is possible that extensive reductive genomic changes have 
enabled the classical lineage to habituate in a more confined environment, resulting 
in clonal populations within Africa and Australia with genomic rearrangements ren-
dering them  more pathogenic and strengthening their ability to infect mammals 
[15]. In contrast, the ancestral lineage, closer to the M. marinum progenitor, may 
have  remained as  a largely environmental mycobacterium that only occasionally 
affects humans. From this point of view, it is reasonable to predict that large-scale 
field studies in Japan or China may reveal an unexpectedly extensive presence of M. 
ulcerans subsp. shinshuense in the environment that does not necessarily lead to an 
outbreak of BU.
4.2  Toward Detection of BU in Other Asian Countries
It appears that the stably increased number of reported BU cases from Japan is due 
to increased awareness of the disease among health workers rather than to an actual 
rise in the number of infections. On the other hand, the extremely low disease report-
ing rate in China and the absence of BU reporting from the neighboring Asian coun-
tries may be indicative of hidden cases. In non-endemic and less resourced Asian 
countries, awareness and knowledge of BU disease among health workers and the 
community are lacking, so there is the possibility of misdiagnosis. Moreover, insuf-
ficient health infrastructure and geographical challenges can also contribute to the 
underreporting of cases. Despite little evidence supporting a predictable future out-
break of BU in Asia, the importance of an early diagnosis cannot be overemphasized 
because of the potential life-long disfigurement and disabilities this disease can cause 
if left undiagnosed and untreated. Residents of Asian countries should be aware that 
BU is a mycobacterial infection that is not limited to tropical or subtropical regions.
Education of health workers, in particular dermatologists, in Asian countries is 
essential for early diagnosis of BU. Also, it is important to provide public health 
education to familiarize people, especially those living near rural aquatic environ-
ments, with BU symptoms. Since international travel has become more popular, the 
so-called imported tropical diseases may be seen more frequently than before. In 
addition to early diagnosis, the establishment of a standard treatment guideline opti-
mized for BU infections in Asian countries is also needed to ensure efficacy without 
unnecessary surgery and overtreatment. Furthermore, a comprehensive comparison 
of the proteomes of M. ulcerans subsp. shinshuense with classical M. ulcerans may 
shed new light on the differences in their adaptive biology and response to antibiotic 
treatment.
For investigating the phylogenetics of M. ulcerans subsp. shinshuense, various 
approaches including genomic and biochemical analyses have been carried out 
[2,  4, 7, 12, 13, 15]. Only one strain of M. ulcerans subsp. shinshuense has 
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undergone whole genome sequencing so far [13]. Genomic differences among the 
sequenced strain of M. ulcerans subsp. shinshuense and other ecovars of M. ulcer-
ans have been found. Further comparative genomic analyses with multiple M. ulcer-
ans subsp. shinshuense strains, including the Chinese strain, would enable a more 
precise phylogenetic characterization of M. ulcerans subsp. shinshuense, which 
could give information on the spread of these bacteria in Japan as well as in China. 
However, at the moment, only one Chinese strain has been recognized, so discovery 
of multiple Chinese strains might further contribute to the above-mentioned phylo-
genetic  resolution. Additionally, it is still unclear whether the clinical features 
caused by M. ulcerans subsp. shinshuense differ from those of other M. ulcerans 
strains. Future attempts involving generation of recombinant and mutant strains of 
M. ulcerans subsp. shinshuense might clarify the unique characteristics of this M. 
ulcerans subspecies and could provide important clues into the pathogenic mecha-
nisms of BU.
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1  First Insights from the Complete Genome 
of Mycobacterium ulcerans
The first genome sequence of a M. ulcerans isolate was published in 2007 [1]. This 
finished and completely annotated genome represented an African clinical isolate 
(strain name Agy99), which was obtained in 1999 from a BU patient living in the 
Amansie West District of Ghana. An unexpected feature of the genome was the 
presence of a circular 174 kpb megaplasmid (named pMUM001) [1, 2]. The plas-
mid harboured three unusually large genes encoding the polyketide synthases (PKS) 
required for the biosynthesis of the major virulence factor, mycolactone [2, 3]. The 
5.6 Mbp circular chromosome of the Agy99 genome also held some surprises, with 
the architecture of a bacterium undergoing reductive evolution. There was an abun-
dance of pseudogenes (15% of the predicted ancestral protein-coding genes had 
been inactivated by accumulated mutations), evidence of large chromosome dele-
tions and rearrangements, and extensive proliferation of two insertion sequences 
(IS2404 and IS2606) [1]. Collectively, these features pointed to a bacterial popula-
tion that had ‘recently’ passed through an evolutionary bottleneck and was adapting 
to a changed environment. Scrutiny of the types of genes lost by mutation or DNA 
deletion in the Agy99 genome, suggested a mycobacterium adapting to an environ-
ment where the proteins and pathways required to both survive in diverse aquatic 
environments and persist intracellularly are no longer required. This assessment 
also showed that M. ulcerans has lost many of the proteins and cell-wall associated 
molecules known to be potent antigens in other notable mycobacterial pathogens 
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such as Mycobacterium tuberculosis, Mycobacterium kansasii and Mycobacterium 
marinum. These observations, combined with the presence of pMUM001 and the 
specific ability of M. ulcerans to make the immunosuppressive small molecule 
mycolactone, suggested a mycobacterium adapting to a protected niche environ-
ment where extracellular persistence and an immune evasion phenotype provide a 
survival advantage [4, 5].
2  An Aquatic Origin and Two Bottlenecks for a Recently 
Emerged, and Globally Distributed Pathogen
The initial M. ulcerans genome assessment was based on a comparison with the 
complete genome sequence of a single strain of the fish and human pathogen, M. 
marinum. From the mid-2000s onwards, scientists began reporting the presence of 
mycolactone-producing mycobacteria (MPMs) infecting fish, frogs and other ecto-
therms worldwide [6–11]. Subsequent comparative genetic and then comparative 
genomic studies of these mycobacteria with strains of M. marinum and M. ulcerans 
confirmed that all MPMs likely emerged during a single evolutionary event when a 
population of M. marinum-like bacteria acquired a pMUM plasmid and the specific 
ability to make mycolactones and then spread worldwide (Fig. 1) [12, 13]. The key 
genetic signatures of extensive pseudogene accumulation, expansion of IS2404 and 
pMUM plasmid acquisition were present in the ancestor of all MPMs before they 
radiated around the world, represented by three main lineages, called lineages 1–3 
(Fig. 1) [12]. The MPMs have been given a variety of species names including M. 
pseudoshottsii, M. liflandii, M. shinshuense and (confusingly) M. marinum. Based 
on their extensive shared genomic features and recent common heritage, it has been 
proposed that all MPMs should be considered under the single species banner of M. 
ulcerans [14]. The collective term M. ulcerans–M. marinum complex (abbreviated 
as MuMC) has also been proposed for all M. marinum and M. ulcerans as they share 
>97% nucleotide identity across a substantial 4.3 Mbp conserved core genome [12].
This first major evolutionary bottleneck that saw the emergence of M. ulcerans 
has been followed by at least one further population constriction that gave rise to 
lineage 3. This lineage, also designated the ‘classical’ lineage in the literature [15], 
represents the M. ulcerans isolates causing Buruli ulcer in Australia, Papua New 
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Fig. 1 A recently emerged and globally distributed pathogen
K. Vandelannoote et al.
109
Guinea (PNG), and Africa, and is thus the lineage that accounts for most of the 
human cases of Buruli ulcer. This lineage is characterized by additional reductive 
evolution and expansion of IS 2606 to high copy numbers [12]. Interestingly, the 
‘success’ of this lineage as the major human pathogen among all the MPMs is not 
due to the acquisition of additional genes. Lineage 3 contains no additional DNA 
sequences compared to isolates in lineages 1 and 2, thus more subtle genetic changes 
might underlie lineage 3 dominance. One potential genomic region for such changes 
is the mycolactone PKS gene locus on the pMUM plasmid. The different lineages 
of M. ulcerans produce different mycolactone sidechain structural variants with 
varying biological potencies (discussed in more detail in chapter “Mycolactone: 
More than Just a Cytotoxin” of this book). The genetic basis for some of these vari-
ants has been determined. Changes in acyltransferase domain substrate specificity 
within a particular PKS extension module or loss of an extension module within 
mlsB, the gene required for synthesis of the mycolactone sidechain, lead to biosyn-
thesis of different mycolactones [16–18].
Given the ancestor of all M. ulcerans was an aquatic mycobacterium (M. mari-
num) and many of the MPMs are recovered from fish, frogs, and turtles, it seems 
likely that the origin of all MPM (including those lineages associated with Buruli 
ulcer) had an aquatic animal association. These ideas and inferences should be used 
to frame thinking around potential reservoirs of M. ulcerans in BU endemic areas. 
Of note too, the phylogeny of M. ulcerans from Australia and Papua New Guinea is 
ancestral to that of M. ulcerans from African countries, indicating that the spread of 
M. ulcerans throughout Australasia likely predates the spread of M. ulcerans across 
Africa [33].
3  New Understandings from Genomics on the Spread 
of M. ulcerans Across Africa
African countries carry the highest burden of BU, but until recently, knowledge on 
the spread of M. ulcerans across the continent has been sparse. Early studies of M. 
ulcerans populations using traditional genotyping techniques readily identified a 
highly clonal population structure, showing that M. ulcerans isolates had very con-
served genomes that associated strongly with their geographic origin [19–24]. 
However, these techniques sampled only a small proportion of the mycobacterial 
genome, and thus lacked sufficient discriminatory power to crack the clonal popula-
tion structure of this species at even the scale of a country, let alone at the scale of a 
BU endemic village. The advent of low cost, high throughput DNA sequencing has 
given researchers access to all the potential genetic variation arising within a M. 
ulcerans population and several studies have capitalised on this advance. Most 
recently, the genomes of an extraordinary collection of 165 M. ulcerans clinical 
isolates spanning 48  years and representing 11 endemic countries across Africa 
were sequenced and compared. Assessment of these genomes has produced the first 
detailed understanding of the introduction and continental spread of this pathogen. 
Key findings included the establishment of a molecular clock signal in the sequence 
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data, suggesting that M. ulcerans is accumulating mutations at a rate of 0.33 SNPs 
per chromosome per year (approx. 6 × 10−8 substitutions/site/year). This rate of 
genetic change is comparable to M. tuberculosis, but 10–100 times slower than that 
of other pathogens such as Staphylococcus aureus [25]. Combining these temporal 
data with the high- resolution phylogeny inferred from genome comparisons and the 
geographic origins of the 165 isolates has permitted a reconstruction of the spread 
of M. ulcerans across Africa. The data suggest that there have been two distinct 
introductions of the bacteria to the African continent; the first occurring around 
68 BC, with a likely origin in the area around current day Cameroon and Gabon, and 
then spreading outwards from these regions [26] (Fig. 2). This has been followed by 
a second, far more recent introduction during the 1800s. For both the early and 
recent sub-lineage (called Mu_A1 and Mu_A2 respectively; both representing sub-
lineages of lineage 3), there were geographically localized but substantial clonal 
expansions of M. ulcerans populations in four particular hydrological basins 
(Congo, Kouffo, Oueme, and Nyong). These expansions occurred contemporane-
ously from the late 1800s onwards and in waves that mimicked interference in those 
specific regions by colonial powers during the ‘scramble for Africa’ [26].
Interestingly, the Mu_A2 genotype was also found in PNG, and phylogenetic 
inference suggests PNG may have been the origin of the Mu_A2 genotype. How the 
bacteria were transported across oceans and continents from south east Asia to Africa 
in the mid 1800s is not clear, although again, several European colonial powers were 
active in both these regions of the world at that time.
The presence of the Mu_A2 genotype in Africa indicates M. ulcerans can be 
mobilised and displaced across large distances, but the dominant characteristic of 
M. ulcerans populations is their strong, geographically restricted genotypes. In 
Africa, these constrained genotypes align with different hydrogeological basins 
Mu_A2 Lineage:
Introduced to Africa in
1800 A.D.
Mu_A1 Lineage:
Present in Africa
since 68 B.C.
Fig. 2 Spread of two distinct M. ulcerans lineage 3 genotypes across Africa
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[26]. This observation is consistent with the well-described epidemiology of BU, 
where human disease is strongly associated with lentic and lacustrine environments, 
and also supports the notion of an aquatic reservoir for the bacterium (or at least a 
reservoir species restrained somewhat by these basins), with the hydrogeography 
likely providing a major barrier to reservoir (and therefore pathogen) movement 
[26, 27].
In South Eastern Australia, the native possum is a wildlife reservoir of M. ulcer-
ans and there is a strong association between possums harbouring the bacteria and 
human Buruli ulcer [28, 29]. Genomics has shown that possum and patient M. 
ulcerans isolates have identical genotypes [29] indicating that humans and possums 
are part of the same transmission network.
4  Genomic Approaches to Micro-Molecular 
Epidemiological Investigations of BU
There were expectations at the dawn of the genomic revolution that comparisons 
of M. ulcerans genomes collected from BU patients in endemic areas would reveal 
striking patterns of bacterial spread that in turn would lead to a substantially 
deeper understanding of how this enigmatic disease is transmitted [15]. Several 
M. ulcerans population genomic studies have now been conducted in Africa and 
Australia at the descending scales of country, region and village. Important new 
insights have been made, whilst also raising new questions about how M. ulcerans 
is spreading.
Several teams have explored genomic variation of M. ulcerans populations in 
West Africa and they have all reported and confirmed the strong association between 
genotype and region as described above. This relationship has a fractal quality, 
where genotypes continue to associate with region across large spatial scales; from 
continental, to country, to regional levels. However, somewhat unexpectedly, micro-
epidemiological observations powered by the extreme resolution offered by whole 
genome sequence comparisons have shown that this association breaks down at 
very local scales (buffer size <50 km2), where the distribution of M. ulcerans geno-
types appears to become random. This finding is illustrated in several independent 
studies from Ghana and Cameroon that report clonal complexes aligned with spe-
cific river systems as predicted from earlier pre-genomic studies, but there is also 
mixing of genotypes at district and village levels [30–32]. Conclusions from these 
observations include the possibility that (1) the disease is being vectored by a some-
what mobile entity, perhaps an insect or (2) people are moving to different local 
areas and acquiring the infection. While the data are not conclusive for any specific 
hypothesis, there are examples of very young infants with no history of any travel 
developing BU and becoming infected with genotypes present in more distant vil-
lages, thus suggesting something(s) is vectoring M. ulcerans to susceptible human 
hosts [32].
In addition to the genotypic mixing at local scales, there are also several exam-
ples now of very distinctly different genotypes co-circulating with a ‘local’ endemic 
M. ulcerans clone. This was first described in the Asante Akim North district of 
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Ghana, where a genotype reminiscent of strains originating from Nigeria was 
detected alongside strains representing a local endemic clone [32]. The same phe-
nomenon was recently described in south east Australia, with a distinct M. ulcerans 
clone from the far east of the country detected in a highly BU endemic area, co- 
circulating with a local clone [33]. These studies demonstrate the potential for M. 
ulcerans to be not recent at all mobilized and spread over large distances. The mech-
anisms of pathogen dispersal remain to be discovered, but perhaps it could be linked 
to the movement of human or other mammalian reservoirs [30, 31, 33].
M. ulcerans population genomic studies of highly active BU endemic areas in 
south east Australia have revealed some interesting features of the pathogen and the 
disease [33]. A study of 178 M. ulcerans genomes, collected over 70-years has pro-
vided a compelling reconstruction of the temporal and spatial spread of the patho-
gen in that region. The disease appears to have emerged in the early 1800s in the 
east of the country and then spread suddenly westward, moving into areas around 
the major population centre of Melbourne in the 1980s. Comparison of the temporal 
phylogeny with epidemiological data indicates that arrival of the bacteria in a spe-
cific region predates the appearance of human disease by 7–10 years. Similar to the 
African genomic studies, these observations and inferences suggest strongly that M. 
ulcerans is spreading, rather than awakening a reservoir of quiescent bacteria, per-
haps following environmental disturbance. This information could help inform con-
trol strategies for BU, where environmental surveillance of the pathogen might help 
predict the occurrence of disease in humans.
5  Distinguishing Relapse from Reinfection and Familial 
Studies
An application of genomics has been to try and establish if a patient presenting 
twice with BU might have suffered a relapse of the previous infection or has been 
unlucky enough to be reinfected with a different population of bacteria. 
Distinguishing between these two scenarios is important for informing treatment 
options. Work in this area is just beginning, but in a study of four patients with 
recurrent BU episodes three were concluded to have relapsed, with 0–1 SNP differ-
ences between first and last obtained isolates from each patient, while the fourth 
patient was a possible example of re-infection with 20 SNPs different between first 
and last isolates [34]. This was the first study to deploy genomics in this way for 
informing BU treatment. The correct interpretation of these comparisons is obvi-
ously dependent on the availability of isolates from the patient over time, but equally 
important is a detailed understanding of the local population structure of M. ulcer-
ans in that region. This understanding is necessary to give the proper context and 
therefore interpretation to any SNP differences discovered over time within a single 
patient. Another focused genomics study with similar aims was reported from 
Australia, where the research team sequenced and compared six M. ulcerans 
genomes recovered from three familial clusters [35]. The sequence data, combined 
with epidemiological information argued against person-to-person transmission and 
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suggested that there was a relatively short time window of 1–2 months when family 
members were exposed to the pathogen [35].
6  Summary and Future Perspectives
M. ulcerans is likely a niche adapted mycobacterium. Its ability to make mycolac-
tone is almost certainly critical to the persistence of the bacterium in that niche. 
The bacterium’s primary host and reservoir is likely aquatic. This reservoir is 
probably restrained within lentic systems. BU spreads when the bacterium moves 
from one region to another. Pathogen spread can occur rapidly. These are some of 
the useful insights that genomic approaches have yielded. From glimpses into the 
unusual biology of the pathogen when the genome was first revealed, to the large, 
population- based studies that reconstruct pathogen spread, genomics has been the 
key tool to drive these new understandings. Future research should capitalize on 
the advent of cost-effective long-read sequencing to focus on establishing and 
comparing complete M. ulcerans genomes. The additional DNA sequence varia-
tion that potentially lies within complex regions of the M. ulcerans genome could 
prove very informative for efforts to track pathogen spread. More effort should be 
made too, to interrogate and predict metabolic pathways from genome sequence 
data that can then be exploited to improve efforts to detect and isolate M. ulcerans 
in pure culture from environmental sources. The pMUM plasmid in particular 
should be a focus for complete sequence assembly, as assessment of the mycolac-
tone PKS genes will inform on the basis for the biosynthesis of mycolactone 
structural variants and differential pathogenesis.
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Mycolactone: More than Just a Cytotoxin
Laure Guenin-Macé, Marie-Thérèse Ruf, Gerd Pluschke, 
and Caroline Demangel
From their observation of necrotic areas around bacterial foci in Buruli ulcers 
(BUs), Connor and co-workers were the first, back in 1965, to suggest that M. ulcer-
ans may produce a diffusible cytotoxin [1]. This hypothesis was later confirmed by 
injecting mycobacterial culture filtrates into the skin of guinea pigs, showing that 
this causes focal necrosis resembling that of naturally occurring human infections 
[1–3]. In 1999, George et al. succeeded in isolating a cytotoxic factor from M. ulcer-
ans lipid extracts, and deciphered its chemical nature [4]. The M. ulcerans toxin was 
named mycolactone, based on its mycobacterial origin and macrolactone structure: 
a 12-membered lactone ring, to which a C5-O-linked polyunsaturated acyl side 
chain and a C-linked upper side chain comprising C12–C20 are appended (Fig. 1). 
Follow-up studies showed that M. ulcerans-derived mycolactone was in reality a 
mixture of two stereoisomers called A and B [6, 7] (Fig. 1). Since the initial discov-
ery of mycolactone A/B, eight additional mycolactone congeners have been identi-
fied that are either produced by M. ulcerans strains of different geographical origins 
or genetically related fish and frog pathogens, which were initially given different 
species designations such as M. pseudoshottsii and M. liflandii. Comparative 
genome analysis later revealed that all mycolactone-producing mycobacteria 
evolved from a common M. marinum-like progenitor, and are therefore ecovars of a 
single M. ulcerans species [8]. While the macrolide core structure and upper side 
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chain are conserved, mycolactone populations from different M. ulcerans sub- 
lineages vary in the length, number and localization of hydroxyl groups and number 
of double bonds of the lower side chain. These modifications of the lower polyun-
saturated acyl side chain cause pronounced changes in cytotoxicity [9–11]. The 
origin and chemistry of natural mycolactones, structure-activity relationships and 
the various approaches that were developed to generate synthetic mycolactones 
have been reviewed recently [12, 13]. These aspects will therefore not be further 
discussed here. Instead, this chapter provides an update on our understanding of 
mycolactone (A/B) biology, and discusses its proposed mechanisms of action in 
relation with BU pathogenesis.
1  Mycolactone and BU Disease
1.1  Pharmacodistribution
Mycolactone’s diffusion in infected hosts was initially believed to coincide with its 
cytocidal action. However, in mice experimentally infected with M. ulcerans in 
footpads, the distinctive mass spectrometric signature of the toxin was detected in 
peripheral blood cells, spleen, liver and kidneys [14], showing that bacterially-
produced mycolactone distributes far beyond infected tissues. The presence of 
mycolactone was assessed by extracting total lipids from homogenized organs 
with organic solvents, and analyzing the resulting acetone-soluble fractions by liq-
uid chromatography tandem-mass spectrometry (LC-MS/MS). The body-wide dis-
tribution of mycolactone was further supported by animal studies using a 
radiolabeled form of the toxin, generated by feeding M. ulcerans cultures with 
[1–14C] propionic acid and [1,2–14C] acetic acid. In mice injected with 
O
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Fig. 1 Structure of mycolactone A/B. The red line indicates the region where stereoisomers differ 
(from [5])
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14C-mycolactone via the subcutaneous, intravenous or intraperitoneal routes, radio-
activity was indeed detected in peripheral blood, spleen, liver and kidneys after 
24 h [14]. Using the LC-MS/MS approach, structurally-intact mycolactone was 
detected in human skin biopsies harvested from the center of pre-ulcerative BU 
lesions or the edge of viable skin around ulcers [15], in ulcer exudates and in serum 
samples from newly diagnosed patients and patients undergoing antibiotic treat-
ment [16]. While toxin concentrations within lesions declined upon M. ulcerans 
killing by antibiotic treatment, mycolactone’s presence was still detected several 
weeks after completion of therapy [15, 16], indicating a slow elimination rate. By 
spiking cell pellets or serum samples with purified toxin, we noted the poor yield 
of mycolactone extraction with organic solvents (around 10%). Assuming that 
90% of mycolactone is lost during the process, serum concentrations of mycolac-
tone would thus be estimated to fall within the 0–20 nM range at the start of anti-
biotic therapy [16]. These numbers should nevertheless be considered with caution, 
as they are based on a limited number of measurements. How mycolactone traffics 
from bacteria infecting the skin to peripheral blood and distant organs, and whether 
it accumulates preferentially in certain cell populations or tissues during the course 
of BU disease remains largely unknown.
At the cellular level, mycolactone is currently believed to diffuse passively 
through the plasma membrane. In support of this model, fluorescently labeled 
mycolactones were shown to penetrate fibroblasts in a non-saturable and non-
competitive manner within minutes [17] and to accumulate in the cytoplasmic 
compartment [9, 18]. Two studies using molecular dynamics simulations on the 
one hand, and Langmuir monolayers as membrane models on the other hand, 
recently suggested that the passage of mycolactone across cellular membranes 
may nevertheless alter their dynamic properties, and cause mechanical and phys-
ical perturbations [19, 20].
1.2  Mycolactone Contribution to BU Disease Manifestations
1.2.1  Pathogenesis and Histopathology of BU Lesions
BU is a chronic necrotizing skin disease affecting primarily subcutaneous adipose 
tissue. Lesions usually start as single, painless, subcutaneous nodule or papule. The 
dermis and epidermis overlying the lesion eventually degenerates and sloughs off, 
leading to the development of ulcers with undermined edges and a necrotic slough 
at the base. Contiguous coagulation necrosis of the deep dermis and subcutaneous 
fat tissue with destruction of blood vessels and interstitial edema, epidermal hyper-
plasia and the presence of fat cell ghosts and extracellular clusters of acid fast bacilli 
(AFB) constitute hallmarks of BU disease. In advanced lesions the necrotic process 
may extend through deep fascia and expose deeper structures like muscle or bone. 
In early lesions, necrosis of dermal collagen is leading to a fibrillary appearance, but 
gradually all cellular and structural details are disappearing and an amorphous 
coagulum is developing in the center of the lesion [21]. Clusters of extracellular 
acid-fast bacilli are primarily found in the deep layers of the necrotic adipose tissue 
[22], but tissue destruction extends far beyond (Fig. 2), which is ascribed to the 
Mycolactone: More than Just a Cytotoxin
120
diffusion of mycolactone. In the center of active lesions, inflammatory cells are 
rarely found (Fig. 2) and cellular responses are defective at both the local and the 
systemic levels. There is multiple evidence, summarized below, that mycolactone 
contributes directly to these disease manifestations.
The most commonly used experimental infection models for BU is the mouse 
model, in which inoculation of M. ulcerans into the footpads, ears or the tail causes 
lesions that develop over several weeks. Evaluation of antibiotic treatment modali-
ties in this model has been shown to be predictive for treatment efficacy in humans. 
However the mouse model has some limitations for the investigation of the patho-
genesis of BU in humans, since the composition of the tissue at the injection sites 
differs markedly from human skin. Therefore the pig has been recently evaluated as 
a model to study the early pathogenesis of BU [24]. Pig and human skin share many 
similarities like thickness, general structure of the epidermis, dermis and the subcu-
taneous tissue [25], making porcine skin a preferred model for burn and wound 
healing studies [26]. Also guinea pigs have been used to study early host-pathogen 
interaction and in particular the effect of mycolactone [27]. However both in pigs 
and guinea pigs no chronic infections are establishing [28].
The key role of mycolactone in the pathogenesis of M. ulcerans infection has 
been first demonstrated by injection of this molecule into the skin of experimental 
a b
Fig. 2 Histopathological features of a tissue punch biopsy from an untreated human BU plaque 
lesion. Histological sections were stained with Haematoxylin-Eosin (HE) or Ziehl-Neelsen (ZN). 
(a) The subcutaneous tissue presents with the typical signs of BU histopathology: massive necro-
sis, fat cell ghosts and edema. The epidermis presents with epidermal hyperplasia. (b) A band of 
extracellular ZN positive AFB is present focally in the deep layer of the necrotic subcutis (adapted 
from [23])
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animals. In guinea pigs injection reproduced cell death and lack of acute inflam-
matory response observed after challenge with viable bacteria [27]. In pigs a 
necrotic lesion is developing that is surrounded by an infiltration belt after myco-
lactone injection (Fig. 3b), resembling closely the histopathological picture found 
in early human lesions (Fig. 3a). The key role of mycolactone in BU pathogenesis 
a
b
Fig. 3 Formation of a necrotic lesion core surrounded by an infiltration belt. Histological sections 
were stained with Ziehl-Neelsen (ZN)/Methyleneblue (A1) or Methyleneblue alone (B1), the “In 
situ cell death detection kit” (A2) or by immunohistochemistry for the macrophage marker CD68 
(B2). (a) Early human BU lesion presenting with a necrotic core containing extracellular clusters 
of AFB (location indicated by red stars) surrounded by a belt of infiltrating leukocytes demon-
strated by the blue staining of nuclei (A1). Strong TUNEL staining inside the necrotic core and in 
some of the infiltrating cells of the infiltration belt (B1). (b) Lesions in the skin of a pig (Sus scrofa) 
induced by a single subcutaneous injection of 50 μg of synthetic mycolactone A/B. The toxin 
caused formation of a lesion with a necrotic core (B1 and B2) surrounded by a dense belt of infil-
trating cells consisting primarily of CD68 positive macrophages (B2) (adapted from [29])
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has been further demonstrated by infection of experimental animals with myco-
lactone negative M. ulcerans mutants. While wild-type bacteria cause an extracel-
lular infection, the mycolactone negative mutants produce an intracellular 
inflammatory infection [30, 31] similar to that of M. marinum, the progenitor of 
M. ulcerans [8].
M. ulcerans is multiplying in the sanctuary of the central necrotic core of the 
lesion, which is usually free of living infiltrating leukocytes, although large num-
bers of macrophages and lymphocytes are collecting already in early lesions at the 
margin of the necrotic center of the lesions [29]. These infiltrates form a belt, 
which separates the highly confined necrotic core from the still intact tissue sur-
rounding the lesion (Fig. 3a). Infiltration of leukocytes may be reduced by sub-
lethal concentrations of mycolactone affecting chemokine production by skin 
dendritic cells (DCs) [32] (see Sect. 1.2.3), while cells entering the necrotic core 
may undergo apoptosis caused by mycolactone’s diffusion from bacterial foci in 
the center of the lesions (see below). Some of the leukocytes in the infiltration belt 
are TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) stain-
ing positive [29], which is regarded as a sign for double-strand DNA breaks gener-
ated during apoptosis. The necrotic core of BU lesions shows a very strong, but 
diffuse TUNEL staining (Fig. 3a). At the periphery of BU lesions, interaction of 
phagocytes with AFBs and intracellular M. ulcerans can be observed and in par-
ticular in resolving BU lesions, granulomatous inflammation can be found. During 
antibiotic treatment of BU, intra-lesional concentrations of mycolactone decline 
[15]. This allows leukocytes to reach the extracellular mycobacteria located in the 
necrotic core of the lesion, leading to their phagocytosis and destruction [33]. In 
turn, chronic leukocyte infiltration cumulates in the development of ectopic lym-
phoid structures [34]. Gathering of DCs and development of defined granuloma 
structures indicate that antigen recognition and processing is leading to active M. 
ulcerans specific immune responses. Three main types of mixed infiltrates have 
been identified in antibiotic treated lesions, highly organized epithelioid granulo-
mas, diffuse infiltrates and dense lymphocyte clusters in proximity to vessels. AFB 
already start to be internalized by phagocytes after 2 weeks of treatment, when M. 
ulcerans can still be cultured from tissue homogenates. Antibiotic treatment may 
act rapidly on the bacterial production of mycolactone, whereas complete killing 
of bacteria may take longer.
The cellular mechanism(s) of mycolactone-induced ulceration of the skin were 
investigated by exposing fibroblasts, epithelial cells and endothelial cells to purified 
mycolactone in  vitro and monitoring dose-response effects on cell viability. 
Prolonged exposure (>48 h) to nanomolar concentrations (>10 nM) of mycolactone 
A/B induced the detachment and death of all skin cells studied. This included mouse 
(L929) and human (HDF) fibroblast cell lines, human epithelial (HeLa) and kerati-
nocyte (HaCaT) cell lines [17, 18, 27, 35–37], and human dermal microvascular 
endothelial cells [38]. Primary human keratinocytes were relatively more suscepti-
ble to mycolactone-mediated cytotoxicity, with cell mortality being detected after 
only 24 h of treatment [39, 40]. Notably, cell detachment was preceded by altera-
tions of the actin cytoskeleton [17, 18, 35]. In HeLa cells exposed to mycolactone, 
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production of spike-like protrusions was activated after 30 min, while actin polym-
erization abnormally localized in the perinuclear area after 4 h, coinciding with a 
near-complete incapacity of the cells to adhere to plastic wells [18]. Longer treat-
ments (16–24  h) induced defects in epithelial cell capacity to establish cell-cell 
contacts and close wounds in vitro [18, 41]. In the mouse ear model, intradermal 
injection of mycolactone caused a dramatic loss of E-cadherin–adhesive contacts in 
the stratum spinosum, coupled to thinning of the external stratum granulosum and 
lucidum, resulting in a significant decrease in epidermis width after 54 h [18]. In 
accordance with the coagulative necrosis in BU lesions, exposing human dermal 
microvascular endothelial cells to mycolactone depleted thrombomodulin from the 
cell surface [38]. Mycolactone also decreased the production of collagen biosynthe-
sis enzymes by L929 fibroblasts [35]. Together, these studies suggest that mycolac-
tone provokes BU formation by concomitantly reducing the viability and the healing 
potential of skin cells, altering the strength of cell-cell and cell-extracellular matrix 
adhesion, and affecting coagulation control.
1.2.2  Local Analgesia
Early reports favored the hypothesis that BU-associated analgesia was primarily 
due to nerve destruction. Indeed, the histopathological examination of BU biopsies 
showed local axonal damages, with loss of myelin in 24% of the patients [42]. 
Consistently, mouse footpad infection with M. ulcerans induced nerve fiber degen-
eration in advanced ulcers [43], and injection of purified mycolactone in mouse 
footpads triggered neurological damages associated with hyposensitivity [44]. The 
possibility that mycolactone causes analgesia by directly killing sensory neurons 
and Schwann cells, the peripheral nervous system (PNS) cells generating and trans-
mitting pain signals, was investigated in vitro. Anand and co-workers observed sig-
nificant neurite degeneration in rat and human primary dorsal root ganglion (DRG) 
sensory neurons after 24 h of exposure to a 100 nM concentration of toxin [45]. 
Consistently, we found that exposing mouse DRG to 25 nM mycolactone for 16 h 
downregulated the production of multiple proteins mediating interactions between 
neurons and the extracellular matrix [46]. Longer treatments (>48 h) induced mas-
sive mortality of primary DRGs in both studies [45, 47], although a third study 
reported a minimal loss of viability following exposure to mycolactone doses of up 
to 70 μM [48]. Schwann cells, the principal glia of the PNS, are important in many 
aspects of peripheral nerve biology including the conduction of nervous impulses 
along axons, nerve regeneration upon injury and production of the nerve extracel-
lular matrix. Prolonged (>48 h) exposure to mycolactone also caused significant 
mortality in the mouse Schwann cell line SW10 [49], and primary rat Schwann cells 
(IC50 of 1 nM) [47]. Of note, microglia showed comparable susceptibility to myco-
lactone-induced toxicity, with decreased viability manifesting after 48 h of treat-
ment with mycolactone concentrations varying between 3 and 10 nM [47]. Whether 
mycolactone diffuses into peripheral nerves and reaches the central nervous system 
(CNS) in vivo is unknown. However, these cellular studies fully support the view 
that BU-associated analgesia may be due, at least partially, to cytopathic effects at 
the lesion level.
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Notably, Marsollier, Brodin and co-workers showed that infection with M. ulcer-
ans can induce local hypoesthesia at early stages of disease, in the absence of appar-
ent nerve destruction [50]. Here, pain was generated by applying a focused radiant 
heat source onto infected footpads, and pain perception was monitored by an adap-
tation of the tail-flick procedure, in mice that had been previously anesthetized. 
Injection of 5 μg mycolactone in mouse footpads produced the same effects after 
2  h and during 2  days, with normal nociceptive abilities being recovered after 
8 days. Parallel to this, we showed that systemic delivery of mycolactone (2 μg) 
limits the development of distantly generated inflammatory pain [10]. Mycolactone 
was administered intraperitoneally 1 h before formalin injection into the hind paws, 
and stereotypical licking and biting behaviors were monitored after 10 min, the time 
that it takes for inflammatory processes to develop. In addition to demonstrating the 
intrinsic analgesic properties of mycolactone, these animal studies indicated that 
bacterially-derived mycolactone reduces pain perception in infected hosts by other 
mechanisms than cytotoxicity. Section 2 reviews the molecular targets that have 
been proposed to explain these observations.
1.2.3  Local and Systemic Immunomodulation
Transient defects in the systemic production of IFN-γ have been repeatedly reported 
in BU patients with progressive ulcers [51–55]. The relative lack of IFN-γ in 
ex vivo-stimulated blood samples from BU patients reversed at late stages of dis-
ease, which may explain why it was not observed in two studies [56, 57]. Of note, 
IFN-γ production defects resolved after surgical excision of the lesions, indicating 
their association with M. ulcerans bacteria [54]. These defects were observed with 
antigen-specific [51, 52] and non-specific [53–55] activation stimuli (such as the 
T-cell mitogen PHA), suggesting that M. ulcerans infection induces T cell anergy. 
In line with this hypothesis, multi-analyte profiling of PHA-stimulated whole blood 
culture supernatants revealed that most T cell-derived cytokines were suppressed 
during BU progression [55]. Moreover, patients with BU displayed a distinctive 
immunosuppressive signature in their serum, marked by a downregulation of mul-
tiple mediators of inflammation [55, 58]. In all, these studies revealed that M. ulcer-
ans impairs the normal development of inflammatory and cellular immune responses 
to infection.
Downregulation of cytokines and chemokines in patient sera was still observed 
1  month after the end of antibiotic therapy [55, 58]. Since mycolactone was 
detected in lesions and serum of patients several weeks after they had completed 
antibiotic treatment [15, 16], the concept emerged that mycolactone may be the 
bacterial factor causing immunological defects in infected individuals. This 
hypothesis was supported by mouse studies showing that infection with wild-type 
M. ulcerans, but not with a mycolactone-deficient mutant, causes systemic defects 
in IL-2 production [14]. Pioneering work conducted by Foxwell and co-workers 
showed that mycolactone prevents the LPS-induced release of TNF and IL-10 by 
human monocytes, and production of IL-2 by activated T lymphocytes, under con-
ditions not altering cell viability [59]. Subsequent studies by our group and others 
examined in detail the cell-type specific effects of mycolactone on immune func-
tions, with the following conclusions. Comparably to skin cells and cells of the 
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nervous system, human primary macrophages and DCs were susceptible to pro-
longed (>48 h) treatment with mycolactone (>10 nM) [10, 32]. In contrast, the 
viability of human primary T cells and polymorphonuclear neutrophils treated 
under the same conditions was minimally affected [10], showing that certain cell 
types are more resistant than others against mycolactone toxicity. Notably, non-
cytotoxic treatment with mycolactone prevented the phenotypic and functional 
maturation of DCs, limiting their ability to activate T cells and produce inflamma-
tory chemokines in response to TLR stimulation [32]. It decreased DC expression 
of MHC class I and II, leading to impaired direct and indirect antigen presentation 
[60]. In monocytes and macrophages, mycolactone blocked the activation-induced 
production of cytokines and chemokines post-transcriptionally and irrespective of 
the activation stimulus [61, 62]. Mycolactone also downregulated the basal expres-
sion of TCR and homing receptor L-selectin (CD62L) by resting T cells, leading to 
altered responsiveness to TCR stimulation and impaired capacity to reach periph-
eral lymph nodes in vivo [10, 63, 64]. It also limited the T cell capacity to produce 
cytokines in response to activation stimuli that bypass the TCR, at the post-tran-
scriptional level. In mice, the systemic administration of mycolactone conferred 
protection against chronic skin inflammation and rheumatoid arthritis, demonstrat-
ing the anti-inflammatory potency of mycolactone in vivo [10]. Mycolactone also 
displayed potent anti- inflammatory activity on the nervous system, with nanomo-
lar concentrations of mycolactone preventing the activation-induced production of 
pro-inflammatory mediators by activated DRGs, Schwann cells and microglia in 
conditions that did not affect cell viability [47]. In intrathecally-injected rats, 
mycolactone decreased significantly the production of inflammatory cytokines in 
the spinal cord without inducing detectable cytotoxicity [47]. The overall conclu-
sion of these studies was that mycolactone represents a potent natural immunosup-
pressor operating by a novel molecular mechanism. They supported the view that 
M. ulcerans produces mycolactone to evade recognition and control by the host 
immune system.
2  Molecular Targets and Mechanisms of Action
In recent years, three distinct molecular targets have been proposed to explain the 
diverse biological effects of mycolactone. Proposed mechanisms of action are 
discussed below, starting from the most recently discovered, the Sec61 translo-
con, as we feel it is important to re-examine previous findings in the light of these 
new data.
2.1  Sec61 Blockade
Simmonds and co-workers made a breakthrough in 2014 by discovering that 
mycolactone blocks the production of TNF and other model secretory proteins by 
preventing protein translocation into the endoplasmic reticulum (ER), leading to 
their subsequent degradation in the cytosol by the ubiquitin:proteasome system 
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[62]. Using cell-free systems, High and co-workers then showed that mycolac-
tone causes selective defects in the cotranslational insertion of Sec61 secretory 
substrates [65]. Sec61 is a heterotrimeric complex which in eukaryotes mediates 
the transport of almost all secretory proteins (secreted proteins and most ER-, 
Golgi-, endosome- and lysosome-resident proteins, as well as proteins containing 
glycosylphosphatidylinositol- anchors) and integral transmembrane proteins (TMPs) 
into the ER [66]. We found that mycolactone operates by targeting the pore-forming 
subunit of the Sec61 translocon, and identified a single amino acid mutation con-
ferring resistance to mycolactone, localizing its interaction site near the lumenal 
plug of Sec61 [67]. Expression of this Sec61 mutant in mycolactone-treated T cells 
rescued their homing potential and effector functions, providing definitive genetic 
evidence that Sec61 is the host receptor mediating the immunomodulatory effects of 
mycolactone [67]. Compared to previously known Sec61 inhibitors (cotransin and 
derivatives, Apratoxin A), mycolactone was more effective at blocking the produc-
tion of cytokines and homing receptors by immune cells [46, 67]. Mycolactone is 
therefore the first Sec61 inhibitor that is produced by a human pathogen, and the 
most potent inhibitor to date.
TMPs can be divided into Type I, II or III, according to the presence of a signal 
peptide (SP) and the orientation of the protein’s N-terminus at the ER membrane 
[68]. Using in vitro assays of single-pass TMP translocation, High and co-workers 
observed that secretory proteins, Type I and Type II TMPs were generally suscep-
tible to mycolactone-mediated Sec61 blockade, while in contrast, mycolactone had 
no effect on Type III TMP integration [65, 69]. This led the authors to hypothesize 
that protein resistance to mycolactone essentially depends on how the protein ini-
tially engages the translocon. Our profiling of mycolactone’s signature in the pro-
teome of CD4+ T lymphocytes, DCs and DRG neurons broadly supported this 
mechanistic model for the effects of mycolactone on different classes of single- 
spanning TMPs, and extended its validity to multi-pass TMPs [46, 60, 67]. 
Importantly, these global analyses also highlighted proteomic alterations beyond 
Sec61 substrates, resulting from secondary effects of protein translocation block-
ade. For instance, by blocking the production of both IFN-γ and IFN-γ receptor in 
activated lymphocytes, mycolactone affected the autocrine activation of multiple 
IFN-responsive genes [67]. In macrophages, it resulted in altered IFN-γ-induced 
production of nitric oxide synthase (iNOS) [67], which is essential for the control of 
M. ulcerans infection. In addition to highlighting the critical importance of Sec61 
activity for immune cell function, migration and communication, these data thus 
provided a molecular explanation for the immunological defects of BU patients.
Mycolactone was recently shown to promote Bim-dependent cell apoptosis 
through the mTORC2-Akt-FoxO3 axis [36]. Using L929 fibroblasts as a model, Bieri 
et al. found that mycolactone inhibits the mechanistic Target of Rapamycin (mTOR) 
signaling pathway, leading to inactivation of the serine/threonine kinase Akt, subse-
quent activation of the transcription factor FoxO3, and up-regulation of pro-apoptotic 
Bim. The importance of Bim-dependent apoptosis in the pathogenesis was demon-
strated by M. ulcerans infection of Bim knock-out mice, which did not develop 
necrotic BU lesions and was able to contain the mycobacterial multiplication [36]. 
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How mycolactone interferes with mTORC2 signaling nevertheless remained elusive. 
Subsequent studies by our group showed that expression of mycolactone-resistant 
mutants of Sec61 in HEK293 cells protected them against the cytopathic effects of the 
toxin [67], establishing the critical role of Sec61 blockade in mycolactone-induced 
cell death. Recently, Simmonds and co-workers reported that inhibition of Sec61-
dependent translocation by mycolactone rapidly activates an integrated stress response 
(ISR) in RAW264.7 and HeLa cells without activating ER stress sensors, driving cyto-
toxicity via the ATF4/CHOP/Bcl-2/Bim route [70]. Our studies in DCs led to compa-
rable conclusions with regard to mycolactone stimulating ATF4/CHOP signaling, 
however we detected ER stress-specific activation signals within hours of treatment 
[46]. Mycolactone-driven ER stress nevertheless differed from conventional unfolded 
protein response (UPR) by the downregulation of GRP78/BIP, a master regulator of 
the UPR that is normally induced by canonical ER stress. Whether mycolactone-
driven ATF4 induction results primarily from ISR or UPR may thus depend on the cell 
type. Of note, there is convincing evidence that chronic UPR causes Akt inhibition 
through complex interactions with mTORC1/C2 signaling [71], providing a possible 
explanation for how Sec61 blockade activates the mTORC2-Akt-FoxO3 axis, leading 
to apoptosis by a parallel route downstream of the UPR [36]. Importantly, both studies 
support the view that mycolactone-mediated cytotoxicity is a late consequence of 
Sec61 blockade, resulting from the induction of chronic stress triggering apoptosis via 
the ATF4/CHOP/Bcl-2/Bim signaling pathway.
In summary, by blocking Sec61, mycolactone downregulates the production of a 
large array of secretory and membrane receptors. One major effect of this molecular 
blockade is that the host is unable to mount an effective immune response to the 
underlying mycobacterial infection. Prolonged cell exposure to mycolactone is 
however cytotoxic, since it triggers stress responses inducing apoptosis.
2.2  AT2R Stimulation
In 2014, Marsollier, Brodin and co-workers identified type 2 angiotensin II recep-
tors (AT2R) as additional targets of mycolactone, mediating its analgesic properties 
[50]. In primary hippocampal neurons, mycolactone (>7 nM) provoked cell hyper-
polarization within 20 min, through activation of KCN4 (TRAAK) potassium chan-
nels. The authors showed that mycolactone operates by activating AT2R, leading to 
phospholipase A2-mediated arachidonic acid (AA) liberation, and generation of 
prostaglandin E2 (PGE2) from AA by cyclooxygenase-1, which activates KCN4. 
Mycolactone also caused the hyperpolarization of primary DRGs, at concentrations 
superior to 1 μM [48]. The importance of the AT2R signaling cascade in mycolactone- 
driven hypoesthesia was demonstrated by use of an AT2R selective blocker in mice 
infected with M. ulcerans, or injected with mycolactone, and AT2R-KO animals as 
controls [50]. AT2R silencing in HeLa cells had no effect on mycolactone-driven 
defects in IFN-γ receptor expression nor MCP-1 chemokine production, indicating 
that AT2R is not involved in mycolactone-mediated immunomodulation [67]. Based 
on our current understanding of mycolactone-mediated Sec61 blockade, the 
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biogenesis of the multi-spanning membrane protein AT2R may resist its inhibitory 
effects on protein translocation [69]. Together with the recent evidences of Sec61-
dependent anti-inflammatory activity of mycolactone on the immune and nervous 
systems, and toxicity in neurons (see Sect. 2.1), these data suggest that mycolac-
tone-mediated activation of AT2R and inhibition of Sec61 are two independent 
mechanisms contributing to BU-associated analgesia.
2.3  N-WASP Activation
In 2013, we reported that mycolactone activates the Wiskott-Aldrich syndrome pro-
tein (WASP) family of actin-nucleating factors, leading to uncontrolled assembly of 
actin [18]. WASP and N-WASP belong to a family of scaffold proteins mediating 
the dynamic remodeling of the actin cytoskeleton, via interaction of their C-terminal 
verprolin-cofilin-acidic (VCA) domain with the ARP2/3 actin-nucleating complex. 
While WASP expression is restricted to hematopoietic cells, N-WASP is widely 
expressed. In basal conditions, WASP and N-WASP are auto-inhibited by intramo-
lecular interactions sequestering the VCA domain from ARP2/3. Binding of acti-
vated GTPases or phosphoinositide lipids to N-terminal target sequences triggers 
conformational changes resulting in release of the VCA, thereby enabling binding 
and activation of ARP2/3. Using in vitro assays of actin polymerization, we showed 
that mycolactone mimics endogenous GTPase CDC42 in disruption of WASP/N- -
WASP auto-inhibition. The possible contribution of WASP/N-WASP activation to 
mycolactone immunosuppressive effects was ruled out by silencing or inhibiting the 
proteins in cellular assays of cytokine production [18]. In contrast, N-WASP inhibi-
tion by wiskostatin in HeLa epithelial cells partly relieved mycolactone-induced 
alterations in actin polymerization and cell adhesion. A Sec61 blockade is unlikely 
to explain such early, wiskostatin-sensitive effects of mycolactone. We propose that 
a fraction of mycolactone may bind to cytosolic WASP/N-WASP following its dif-
fusion through the plasma membrane, leading to the uncontrolled assembly of actin 
and defective cell-matrix adhesion. In support of this model, a limited, yet signifi-
cant co-localization of mycolactone with active WASP was observed after 1 h of 
treatment in HeLa cells [18]. Mycolactone injection in mouse epidermis induced 
structural changes in the multilayered organization of this tissue that were sup-
pressed by wiskostatin, suggesting that mycolactone-driven activation of N-WASP 
and subsequent defects in cell adhesion occur in vivo. While this mechanism may 
not be central to BU pathogenesis, we speculate that it may synergize with Sec61 
blockade to impair skin integrity.
3  Conclusions
Recent years have witnessed tremendous progress in our understanding of the 
molecular mechanisms underpinning mycolactone biology (summarized in Fig. 4), 
and therefore BU pathogenesis. Notably, studies on mycolactone have revealed a 
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novel mechanism of immunomodulation based on protein translocation blockade, 
which may be exploited therapeutically to limit inflammation and pain. Meanwhile, 
attempts have been made to develop a live vaccine for BU based on immunization 
with mycolactone-negative M. ulcerans strains [8]. However, vaccination only tran-
siently delayed the onset of pathology induced by a highly virulent M. ulcerans 
strain [72]. While mycolactone is an obvious target antigen for a BU subunit vac-
cine, initial attempts by several groups to develop an immunogenic formulation of 
the toxoid failed [73]. Recent studies nevertheless indicated that toxin neutralizing 
antibodies can be elicited by protein-carrier conjugates of synthetic mycolactone 
[37], providing new prospects for the development of a BU vaccine.
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The Immunology of Buruli Ulcer
João Fevereiro, Alexandra G. Fraga, and Jorge Pedrosa
Buruli ulcer (BU) represents a unique human mycobacteriosis. Caused by 
Mycobacterium ulcerans, the disease spectrum is dominated by the activity of 
mycolactone, a dermanecrotic toxin that has shown the ability to interfere with the 
immune response. This poses an additional difficulty to the understanding of the 
immunological determinants for the outcome of infection, a fundamental step to 
develop better preventive or curative strategies. In this chapter, the immune response 
against M. ulcerans is reviewed, both with a series of clinical observations and 
experimental infection models and going through several other lines of evidence, 
including epidemiological and genetic studies. This holistic approach is expected to 
shed further light on the intriguing pathophysiology of this disease and help guide 
future research efforts.
1  Buruli Ulcer: The First Histological Observations 
of a Necrotic Track
Mycobacterium ulcerans has always been a distinct pathogen among mycobacteria. 
The classical clinical description of M. ulcerans infection, Buruli ulcer (BU), reports 
a lesion that usually begins as an indurated subcutaneous papule which slowly 
ulcerates, presenting as an ulcer with undermined edges [1–3]. Typical skin biopsies 
reveal epidermal destruction concurring with areas of hyperplasia and, in the deeper 
layers of the skin, a widespread panniculitis with many thrombotic capillaries and 
in some cases calcification of fat cells [1, 3–6]. In the necrotic core, a large number 
of bacteria are usually present in the extracellular space amidst apoptotic cell debris, 
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sometimes surrounded by a belt of scattered neutrophils and macrophages with 
intracellular bacilli, as well as T cells and foci of B cells [1, 4, 7–10]. As such, sus-
picions early arose of BU pathology being dominated by an exotoxin that would 
diffuse and destroy the surrounding tissues [4, 11].
Indeed, purified in 1999, a polyketide-derived macrolide named mycolactone was 
shown to reproduce many of the histopathological hallmarks of BU disease, inducing 
extensive tissue necrosis and microvascular thrombosis, in a dose- dependent way [12, 
13]. Specifically, mycolactone provokes apoptotic cell death by driving expression of 
pro-apoptotic proteins BCL2L11 (Bim) and Fas and inhibiting cell cycle progression 
[14–16]. Furthermore, this toxin has the remarkable ability to bind to the alpha sub-
unit of the Sec61 translocon in the endoplasmatic reticulum  (ER), impeding post-
translational modifications, such as glycosylation, and translocation  of newly 
synthesized membrane and secretory proteins into and across the ER membrane [17, 
18]. Eventually, cytokines interferon gamma (IFN-γ), tumor necrosis factor alpha 
(TNF-α), interleukin (IL) 6 and cyclooxygenase (Cox) 2, as well as a variety of other 
secreted proteins, end up in the cytosol, being marked for proteasome degradation 
[17, 18]. Lastly, mycolactone also disturbs several pathways related to stress response, 
collagen biosynthesis and cytoskeleton dynamics, the latter mainly achieved by 
hyperactivation of the Wiskott–Aldrich syndrome protein (WASP) [19, 20].
The pleiotropic effects of mycolactone make M. ulcerans infection a unique 
paradigm of successful manipulation of the host immune orchestra. By inducing 
cellular death and preventing the generation and processing of crucial signaling 
molecules, the ability of the host to cope with the pathogen becomes severely crip-
pled. Thus, what the actual role of the immune system is in BU, is a question of 
utmost importance to understand the disease.
2  Host Attempts to Control Mycobacterium ulcerans 
Infection
2.1  Local Immune Response
Due to its indolent course and various clinical presentations, characterizing the 
kinetics of the immune response against M. ulcerans in humans has always been a 
challenge. It is therefore not surprising that much of what is known about BU patho-
genesis today came from studies resorting to animal models, which seem to present 
several resemblances to the human findings [1, 21–23].
Although understanding the very early stages of the contact of M. ulcerans with 
the host is still of extreme difficulty, it is currently thought that the pathogen depends 
on skin surface injuries or transmission vectors to penetrate the epidermal layer of 
the skin, highly rich in keratinocytes [24–26]. The importance of these cells for BU 
pathogenesis became evident when it was discovered that upon recognition of M. 
ulcerans through dectin-1, toll-like receptor (TLR) 2 and to a lesser extent TLR4, 
keratinocytes produced bactericidal reactive oxygen species and cathelicidin, as 
well as chemokines IL-8 and the monocyte chemoattractant protein (MCP) 1 [27].
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Once mycolactone-producing strains of M. ulcerans reach the subcutaneous tis-
sue, there is an influx, within the first hours, of neutrophils to the center of the lesion 
and of major histocompatibility complex (MHC) class II+ cells to the periphery of 
the infection foci, followed by a sustained recruitment of macrophages for at least a 
week [22, 28]. During this stage, mycobacteria are phagocytosed and, with the con-
tribution of the activity of its superoxide dismustase and catalase enzymes, tran-
siently replicate within phagosomes [9, 29]. Upon replication, the pathogen is 
released to the extracellular space, accumulating in the newly formed necrotic areas 
where it perpetuates the cycle of mycolactone production, leading to the generation 
of acellular foci that continuously expand [9, 22]. Mycolactone further exacerbates 
this process by unbalancing the levels and activation state of thrombomodulin, pro-
tein C and other factors belonging to the coagulation cascade, favoring fibrin depo-
sition and subsequent vessel thrombosis [30, 31]. As a consequence, the central 
necrotic area shows a high number of extracellular bacilli, surrounded by an infil-
trate of neutrophils, macrophages and lymphocytes located in the interface between 
the necrotic area and healthy tissue [22]. With the inability of the immune system to 
reach the mycolactone producing-mycobacteria, the infection then progresses with 
the appearance of edema and ulceration of the epidermis, which can be potentiated 
by the coalescence of several foci of infection, if present [22].
Production of different congeners of mycolactone by different M. ulcerans lin-
eages may alter the aggressiveness of the disease or even lead to distinct pheno-
types, as it was initially observed in humans and later confirmed in mice [22, 23, 
32–34]. In fact, in a proteomics study comparing a wild type (WT) mycolactone- 
producing strain with a mycolactone-negative strain isolated from a transposon 
library, several proteins related to virulence and stress response factors were found 
to be upregulated in the mycolactone-negative strain [35]. In practice, in the absence 
of mycolactone, as in the case of the natural mutant Mexican isolate 5114, infection 
with M. ulcerans resembles other mycobacterial infections [22, 23, 36]. Indeed, 
after an initial influx of neutrophils, well-formed granuloma-like structures, mostly 
composed of macrophages with epithelioid transformation and of lymphocytes, 
organize in the following days to weeks and surround the proliferating mycobacte-
ria [12, 22, 23]. These inflammatory infiltrates eventually distribute homogeneously 
in the subcutaneous and muscle tissue, with no apparent necrosis or alterations 
occurring in the epidermal layer of the skin [12, 22, 23]. Surprisingly, the fact that 
mice are seemingly unable to eliminate the mycolactone-negative mutants for at 
least 12 months suggests that the bacteria use additional mycolactone-independent 
mechanisms to evade the immune system [22]. It should be noted that many of the 
classical mycobacterial virulence factors,  such as the 6 kDa early secretory anti-
genic target (ESAT-6), the  10 kDa culture filtrate antigen (CFP-10) or alpha- 
crystallin- like protein (HspX) present in the Mexican ancestral lineage strain, are 
also highly immunogenic, thus indicating that this M. ulcerans lineage has evolved 
to survive regardless of their presence [37, 38].
These studies are unveiling how mycolactone shapes the cellular landscape of 
BU, but dose-response analyses reveal in more detail the high degree of pleiotro-
pism presented by this toxin. Right from the inception of the immune response, 
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mycolactone is able to affect the phagocytic capacity of murine macrophages at 
high multiplicities of infection and to inhibit the production of a series of human 
and murine monocytic/macrophagic molecules, including the proinflammatory 
cytokine TNF-α [9, 12, 15, 28, 39, 40]. Moreover, it hinders the production of 
nitrous oxide species, assumed to be important to control the infection, according to 
in vitro experiments and a clinical trial with BU patients [41–43].
Mycolactone also possesses dose-dependent immunomodulatory effects on 
T cells and dendritic cells (DC). Besides suppressing DCs' maturation, migration 
and production of the chemokines macrophage inflammatory protein (MIP) 1α and 
MIP-1β, regulated on activation normal T cell expressed and secreted (RANTES), 
IFN-γ–inducible protein 10 kD and MCP-1, Sec61 blockade in DCs results in the 
suppression of direct and cross-presentation of synthetic peptides to CD8+ T cells by 
downregulation of MHC class I and β2 microglobulin [44, 45]. As for T cells, myco-
lactone represses TNF-α activity over factor nuclear kappa B (NF-κB) and tran-
scription and post translation of the T cell receptor, ultimately resulting in the 
blockage of IL-2 production, an essential cytokine for T cell proliferation [15, 46].
Although all of these mechanisms hinder cell-mediated immunity (CMI), none 
has been as extensively tested in in vivo models as IFN-γ, the hallmark cytokine of 
type 1 T helper (TH1) responses. Indeed, mice infected with M. ulcerans strains of 
low and intermediate virulence produce increased levels of IFN-γ, which induce 
phagosome maturation and acidification, as well as nitrite production [43]. Likewise, 
IFN-γ−/− mice display a severe impairment in the growth control of lower virulence 
strains when compared with WT mice [43, 47]. Importantly, none of these phenom-
ena are observed upon inoculation with highly virulent strains or high doses of 
mycolactone, which demonstrates the extent to which mycolactone can damage an 
otherwise protective immune response [43, 47].
Responses against M. ulcerans infection are therefore dependent on the amount/
variant of mycolactone produced by the pathogen. While many authors recognize 
the importance of CMI, the accumulation of mycolactone disturbing a wide array of 
CMI processes and the occupation by the mycobacteria of the extracellular space 
for most of the infection period places several question marks on what is or would 
be the ideal protective immune response. As such, other degrees of evidence are 
needed to develop a more accurate picture.
2.2  Regional and Systemic Responses
Viable M. ulcerans bacilli can be seen in the draining lymph node (DLN) of mice 
very early after subcutaneous infection, where cells initiate an immune response, as 
measured by their production of IFN-γ upon ex-vivo stimulation [28]. However 
histological analyses of the DLN also reveal the typical pattern of cell depletion 
and/or necrosis, affecting in this case both the T and the B cell compartments [48]. 
Remarkably, albeit T cells show an impairment in their proliferative capacity to 
expand upon antigenic stimuli, they are deemed to be relatively resistant to cell 
death by mycolactone [46, 49]. In contrast, mycolactone interferes with murine T 
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cell expression of L-selectin (CD62-L), a necessary molecule to home these cells to 
the peripheral lymph nodes [49]. Whilst these findings in animal models of infec-
tion were so far not validated in humans, the indication that mycolactone can target 
cell homing mechanisms warrants further investigation [31, 49].
Both in humans and mice, M. ulcerans is occasionally found in internal organs, 
but probably due to its restrictive growth temperature, its viability there decreases 
over time and infection does not effectively establish [50–54]. Relevantly, myco-
lactone also disseminates systemically and, in spite of not causing major cell death 
or compromising immunity against other intracellular pathogens, it does alter the 
cytokine production of circulating cells [52, 54, 55]. As a result, some authors 
scrutinized the cytokine production pattern of peripheral blood cells from 
BU-infected patients, which did not lead to consistent results. Understandably, this 
can be attributed to differences in the genetic background of the study populations, 
the virulence of endemic M. ulcerans strains, the cells or stimuli applied in the 
assays used or even the power of the studies. IFN-γ, the most thoroughly analyzed 
cytokine until now, is the paradigm of this aspect, with some studies reporting 
opposite outcomes [56–63]. Nonetheless, the most consensual view until now is 
that BU is associated with an impaired TH1 response, resulting in a lower prolifera-
tion of peripheral blood mononuclear cells (PBMCs) and production of IFN-γ 
upon stimulation [57, 60, 63, 64]. A deeper analysis of published studies further 
reveals that altough this response is not correlated with the stage of the lesion, it 
systematically returns in patients with healed lesions to the profile found in con-
trols from endemic regions [59, 63]. Moreover, reports indicate that there is a cor-
relation between the histological characteristics of a lesion and cytokine production, 
as patients who present well-formed granulomas stain more positively for IFN-γ, 
whereas patients without these structures tended to have more IL-10+ cells [61, 65]. 
Interestingly, ex  vivo IL-10 production by circulating leukocytes was found to 
increase during active disease in many of the studies, even if this was not statisti-
cally significant in some of them [56, 58–60, 62].
Consistent with some data in rodents, it was found that the production of chemo-
kines such as IL-8, MIP-1β and MCP-1 was suppressed in BU patients throughout 
the different stages of the disease, strongly supporting the notion that M. ulcerans 
infection leads to a defect in immune cell recruitment in advanced stages of the infec-
tious process [27, 44, 59]. A more recent analysis in humans with active BU con-
firmed the downregulation of MIP-1β and MCP-1 in the serum of patients, opening up 
a possibility to use certain chemokines as a molecular signature of the disease [31].
More extensive multi-analyte profiling of serum proteins in BU patients and 
endemic controls revealed that, although the disease does not influence significantly 
the leukocyte composition of the peripheral blood, it impacts an even wider array of 
circulating molecules [31, 66]. Indeed, several of these analytes contribute to acute 
phase reaction, metabolism, coagulation and tissue remodeling, with some of them 
already having been implicated in healing speed [31, 66]. Specifically regarding 
metabolic factors, M. ulcerans not only interferes with energy-generation, but also 
with peptide, lipid and nucleotide pathways [66]. Even though many of these altera-
tions seem to be in line with the expected response of the host to infectious 
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processes, others, as the proposed impairment of the tricarboxylic acid (TCA) cycle, 
could be the result of a direct effect of mycolactone [66, 67]. In reality, among TCA 
cycle intermediates, patients with BU have decreased citrate levels, whose relevance 
in other infectious diseases is associated with generating prostaglandins, nitric 
oxide and other antimicrobial peptides [66, 67].
All of these studies provide indications that the repercussions of M. ulcerans are 
more widespread than initially thought. While the disease focus is in the subcutane-
ous tissue, the ability of mycolactone to exert its actions beyond this local site most 
certainly contributes to the establishment of a permissive environment for the 
growth of the pathogen. This further hints on many other aspects of infection, such 
as immune cell metabolism, which are likely determinants for the way host cells 
interact with the pathogen.
3  Diagnostics Research Make it Evident: The Triggering 
of Cellular and Humoral Arms
Early attempts to find a better BU diagnostic method culminated in the develop-
ment of burulin, a whole cell lysate of M. ulcerans that induced a delayed-type 
hypersensitive response in individuals from BU-endemic regions, more noticeable 
in people with already healed lesions [68–70]. Unfortunately, patients presented an 
equally strong reaction to tuberculin, consequently making the test of little useful-
ness in regions where tuberculosis is also prevalent or where the majority of the 
population is vaccinated with Bacillus Calmette-Guérin (BCG) [69, 70]. 
Furthermore, PBMCs from BU patients were later shown to proliferate very little 
and produce only small amounts of IFN-γ upon stimulation with live or dead M. 
ulcerans when compared to healthy individuals with a positive tuberculin test [64]. 
In contrast, a significant proportion of the evaluated patients possessed M. ulcer-
ans-specific antibodies, which contrary to the cellular responses, can be detected in 
significant amounts throughout the different stages of the disease [64, 69]. 
Interestingly, incubation of serum from healthy endemic family controls with an 
M. ulcerans culture filtrate also revealed a notable amount of specific immuno-
globulin (Ig) G, but no IgM, implying that this latter class of Igs has more potential 
for the identification of new BU cases [71]. In accordance, most epidemiological 
studies managed to screen populations in contact with M. ulcerans with moderate 
success, by focusing on detecting IgG against the 18 kDa small heat shock protein 
(shsp), a constitutive M. ulcerans cell wall protein involved in biofilm production 
[72–75]. Screenings of M. ulcerans whole protein lysates also identified the 65 kDa 
heat shock protein (Hsp65) as a potential candidate for a serological approach to 
determine active BU disease [73]. However, this protein has homologs in other 
mycobacterial species, thus prompting further analysis on the specificity of such 
antibodies [77].
All in all, in addition to reinforcing a role for CMI in BU, the search for novel 
diagnostic methods has put some visibility on the presence of antibodies in the 
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context of M. ulcerans exposure and infection. Regarding each of these aspects, it 
remains to be established why not all exposed individuals develop the disease and 
how antibodies contribute to the control of M. ulcerans infections.
4  Antibiotic Treatment in the Aid of the Host Immune 
Response
Antibiotic regimens based on the conjoint use of rifampicin with another drug 
have been used with success in the treatment of BU, rapidly killing M. ulcerans 
and restoring a vast array of processes needed for tissue homeostasis [78, 79]. 
Probably the most critical achievement of these drugs is to break the chain of 
mycolactone production, which allows mycolactone to wane from the system 
[80]. Indeed, direct correlations between mycolactone concentration and the 
time needed to heal BU lesions were established, suggesting this is a crucial fac-
tor for the immune response to re-establish [80]. Following this idea, both in 
humans and experimentally infected mice, treatment is associated with restora-
tion of systemic levels of several inflammatory molecules, including IL-4, IL-7, 
granulocyte-macrophage colony- stimulating factor (GM-CSF), as well as 
the chemokines IL-8 and MCP-1 [59, 81]. Simultaneously, in contrast to the typi-
cal absence of local inflammatory infiltrates seen in the central area of active 
untreated BU lesions, patients undergoing chemotherapy display very diverse 
organizations of cellular immune infiltrates, including classical granulomas, dif-
fuse infiltrates or dense lymphocyte aggregations [79, 82, 83]. While this likely 
corresponds to different stages of the healing process, it is not clear if these 
might also represent inter-individual differences among BU patients [79, 83, 84]. 
Nevertheless, it is perceivable amidst the different histological observations in 
both humans and experimentally infected mice under treatment that phagocytes 
are needed throughout the process for uptaking bacteria and cellular debris, pav-
ing the way for wound healing [79, 83–85]. In mice, the regional preservation of 
DLN structures is noticeable, including germinal centers, a pattern not common 
to untreated groups, possibly due to the persistence of viable mycolactone- 
producing bacteria in the organ [85].
The immune break caused by mycolactone, in several reports described as para-
doxical reactions in BU patients, has frequently been mistaken for treatment failure 
[86–89]. In fact, patients under standard regimens of antibiotherapy may display 
temporary clinical deterioration with local signs of increasing inflammation, ulcer-
ation and even development of new lesions [86, 87, 90]. These reactions appear to 
be due to the presence of large amounts of antigens, that once mycolactone starts to 
wane from the system, elicit a potent inflammatory response [86, 87]. In accor-
dance, many of these paradoxical reactions appear to be related with age, duration 
of treatment, rapidly progressing forms of the disease such as edema, or even 
incomplete surgical lesion excisions that leave mycobacteria in surrounding tissues 
[86–88, 91, 92]. However, attempts to find biomarkers that could help to predict 
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paradoxical reactions, such as neopterin, a catabolic product released by macro-
phages upon IFN-γ stimulation, have so far failed [93]. While this makes it undeni-
ably more difficult to prevent such phenomena, patients’ symptoms have been 
successfully managed with corticosteroid adjunctive therapy [94, 95]. In a similar 
way, BU patients co-infected with human immunodeficiency virus (HIV) have ben-
efited from such an approach, since they develop a comparable immune reconstitu-
tion syndrome once treatment with antiretroviral therapy starts [96, 97]. Although 
evidence is still relatively limited, HIV infected patients tend to generally develop 
BU more frequently and with worse clinical outcomes when compared to the gen-
eral population, in spite of no direct correlation with the degree of immunosuppres-
sion having been established [96, 98–100]. On the other hand, immunomodulation 
with corticosteroids has been suggested to favor activation of latent M. ulcerans 
infection [101]. Moreover, these immunosuppressive drugs prolonged the time 
needed to completely resolve infection during antibiotherapy in mice, an effect 
attributed primarily  to the disturbance of immune cell recruitment to the site of 
infection [101, 102].
As a whole, this reinforces the notion that CMI is critical for the control of BU. In 
this line, innate effector cells emerge as one of the most, if not the main responsi-
ble determinant for containing bacterial proliferation at the site of lesion. Still, to what 
degree their interaction with mycolactone-compromised T and B cells influences their 
activity and consequently the outcome of BU treatment is yet to be clarified.
5  Epidemiological Clues and the Search for Novel 
Resistance and Susceptibility Markers
More than ever, there has been an effort in integrating epidemiological and patho-
physiological observations in a more comprehensive understanding of diseases 
[103]. The demography of BU has been however a source of debate, as efforts to 
identify risk populations have not always been conclusive [104]. Interestingly 
though, large observational studies appear to converge in some aspects: children 
under 15 years and the elderly are at a higher risk of contracting the disease, with 
the latter group also presenting more frequently severe phenotypes [92, 105–111]; 
and gender distribution of cases varies according to age group, with males tending 
to predominate in the younger ages and females in the adulthood [105, 107, 108, 
110–113]. While these differences could be a product of behavioral exposure, they 
could too indicate an underlying physiological basis, which would be in agreement 
with the ascertained roles of age and sex in numerous infectious diseases, including 
other mycobacterioses [114, 115].
The incidence of tuberculosis in humans is also  higher in children and older 
adults, albeit the clinical features tend to be distinct, probably as a consequence of 
the likewise distinct underlying immune response [116]. Nevertheless, in both these 
populations, Mycobacterium tuberculosis growth and active disease is predicted to 
be favored by an unbalance in the percentage of IFN-γ+ CD4+ T lymphocytes 
recruited to the infection site [117–120]. These findings were further replicated in 
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aged murine models of tuberculosis infection and ultimately match the postulated 
importance of IFN-γ in BU, which if not totally ablated by mycolactone, confers 
some degree of protection against M. ulcerans [43, 47, 115, 121]. Therefore, taken 
all of this into account, stratification by age of the cellular and molecular profile of 
BU patients could provide a critical avenue to obtain new information on the deter-
minants of susceptibility vs protective immune responses, both collectively as well 
as in different age groups.
Parallel to age, the influence of sex over biological processes such as the 
immune response can be observed in a broad range of conditions, from infectious 
diseases to vaccination [122]. Even though some differences in the immune sys-
tem of both genders are already established at birth, the effects become much 
more pronounced after puberty [122, 123]. This suggests that differences in expo-
sure to environmental reservoirs of M. ulcerans explain better the higher inci-
dence of BU among male pre-pubertal children than sex-related biological 
differences. After puberty however, sex hormones start to exert a powerful influ-
ence over several pathways of both the innate and acquired immune system arms 
resulting, for instance, in a bias towards TH2 cells in females and TH1 cells in 
males [122]. Strikingly, both male humans and mice appear to be more vulnerable 
to mycobacterial infections than their female counterparts, an observation that has 
been attributed to the effects of testosterone on, among others, macrophage motil-
ity [124, 125]. However, considering that BU pathogenesis and clinical features 
are mainly attributed to the activities of mycolactone, any effect of sex hormones 
in the immune response should pass unnoticeable unless it is in relationship with 
the mechanism of action of the toxin. In this line, estrogen has been shown to be 
able to activate neural WASP through a phosphorylation cascade induced by focal 
adhesion kinase, which could then render the cells more prone to the actions of 
mycolactone [20, 126]. In the end, this might be just one of several explanations 
for the seemingly increased susceptibility of adult women to the disease than men 
[127, 128].
Another debatable topic in BU is disease transmission. Although not the main 
focus of this chapter, some epidemiological records and experimental laboratory 
results point to environmental exposure as the main source for BU acquisition, 
namely through contact of injured skin with water bodies and through insect bites 
[25, 26, 113, 129–133]. However, some work in Africa, Asia and Australia addition-
ally raised the possibility of host genetics playing a major part in BU development 
[92, 134–137]. Even though no evidence apart from anecdotal reports supports 
human-to-human transmission, the odds ratio (OR) of acquiring BU was deter-
mined as five times higher in people with family history of BU [25, 137–139]. 
Curiously, when this relationship was explored more thoroughly, strong associa-
tions with grandparent BU history but not contemporaneous family members were 
found [137]. In parallel, BU WHO category III lesions were recently suggested to 
constitute distinct clinical entities from categories I and II. When compared to both 
milder categories, they showed no dependency on time to develop and take consid-
erably longer to heal [89, 109, 140]. Altogether, this strongly implies that additional 
host-intrinsic factors influence BU outcome, a lead followed by some studies 
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evaluating the role of single nucleotide polymorphisms (SNPs) in genes related to 
the immune function (Table 1). For instance, confirmation of the critical importance 
of nitric oxide (NO) and IFN-γ to BU pathogenesis was achieved, as SNPs leading 
to lower promoter activity of iNOS and IFNG were associated with higher suscepti-
bility to the disease [141].
However, genetic analyses are also helping to unravel the key function of other 
undisclosed molecular players of the immune system. Actually, the first ever 
human gene to be associated with BU was the solute carrier family 11, member 1 
(SLC11A1 or NRAMP1), whose main function is to transport divalent cations, 
including Zn2+, Fe2+ and Mn2+, to the late endosomal/lysosomal compartment [142, 
143]. Since lysosomes eventually fuse with the phagosomes, where M. ulcerans 
resides transiently, this provides an important clue for the importance of the intram-
acrophage phase for the containment of M. ulcerans infection [9, 44, 143]. 
Accordingly, in a Beninese cohort of 208 patients, SNPs in autophagy-related 
genes E3 ubiquitin- protein ligase (PARK2) and autophagy-related protein 16-1 
(ATG16L1) were associated with susceptibility to disease acquisition and pheno-
type aggressiveness [144]. In the same line, two different polymorphisms in the 
gene encoding the nucleotide- binding oligomerization domain-containing 2 
(NOD2) protein, which is involved in bacterial recognition, were also associated 
with disease phenotype [144]. In fact, in other infections with intracellular patho-
gens including some species of mycobacteria, NOD2, PARK2 and the autophagy 
process have been described to help to control bacterial load and to improve host 
survival [145, 146]. Overall, this underlines a prominent role for xenophagy, the 
recognition and targeting of bacteria to autophagosomes, in the control of M. ulcer-
ans infection, hence requiring further research (Table 1).
Table 1 Summary of genes significantly associated with BU disease susceptibility and or pheno-
type severity
First 
author 
and year
Country 
(Continent)
Population 
(n cases) Gene
SNP rs# 
number Association
Reported 
adjusted 
OR (95% 
CI)
Stienstra 
et al. 
(2006)
Ghana 
(Africa)
182 SLC11A1 
(NRAMP1)
rs17235409 Disease 
susceptibility
2.89 
(1.41–5.91)
Capela 
et al. 
(2016)
Benin 
(Africa)
208 PARK2 rs1333955 Disease 
susceptibility
1.43 
(1.00–2.06)
NOD2 rs9302752 WHO lesion 
category
2.23 
(1.14–4.37)
rs2066842 WHO lesion 
category
12.7 
(0.60–269)
ATG16L1 rs2241880 Lesion 
ulceration
0.35 
(0.13–0.90)
Bibert 
et al. 
(2017)
Ghana 
(Africa)
96 iNOS rs9282799 Disease 
susceptibility
1.99 
(1.22–3.26)
IFNG rs2069705 Disease 
susceptibility
1.56 
(1.14–1.99)
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Given the contribution of many genes to a clinical phenotype, gene association 
analyses can also present some interpretation challenges: single studies often lack 
the necessary power to control for all interactions, and genetic polymorphisms 
can not only vary in frequency, but additionally have different functional conse-
quences among different populations [147]. A good example is the lack of associa-
tion of PARK2 with susceptibility to BU, as  recently described in Ghana [141]. 
Although seemingly conflicting with previous results, the study populations were 
different and the tested polymorphisms were not the same, thus making direct data 
comparison difficult. Taken as a whole nonetheless, these population studies hold 
potential for a better understanding of host immune responses against BU, due to 
their ability to suggest, identify, or confirm potentially relevant targets for patient 
stratification or even disease treatment that could provide indispensable for future 
public health interventions.
6  (Un)successful Preventive Approaches
As of now, the only available vaccine targeting mycobacterial diseases is the BCG 
vaccine, a live attenuated bovine tuberculosis bacillus (Mycobacterium bovis) 
widely deployed against tuberculosis, but under an intense scrutiny for its unsatis-
factory results [148]. In the case of BU, even though BCG appears to decrease the 
incidence of osteomyelitis forms, the incidence of new BU cases remains mostly 
unaltered, reinforcing the urge for better alternatives [149–155].
Efforts to develop a specific vaccine against M. ulcerans started several 
decades ago. Initial immunization studies in mice with different live mycobacte-
rial species, including BCG and M. ulcerans, looked very promising in prevent-
ing the development of footpad swelling upon later challenge with M. ulcerans 
[156]. However, more recent experimental data clarified that even if a booster 
dose of the vaccine is administered or if the dose of M. ulcerans challenge is 
lowered, mice are only able to contain the infection for a short period of time, 
which is in accordance with observations in humans [48, 157, 158]. Nevertheless, 
these data provide important hints on the determinants of a protective immune 
response, some of which in agreement with what is seen during M. ulcerans 
clearance upon antibiotic treatment. Indeed, BCG-immunized mice display vis-
ible local cellular infiltrates together with a more rapid and sustained increase 
of IFN-γ and TNF-α levels and, in later time points, of the chemotactic MIP-2 
and of inducible nitric oxide synthase (iNOS)+ cells [48]. Concomitantly, a pro-
longed presence of CD4+ T cells producing IFN-γ is evident in murine DLN, 
indicating that the trafficking of the bacteria to the DLN and subsequent presen-
tation to the T cell compartment is temporarily being achieved [48]. Interestingly, 
immunization with a mycolactone-negative M. ulcerans strain appeared to be 
less effective than BCG in attracting cells to the site of the lesion and in induc-
ing iNOS+ cell accumulation [48]. On the other hand, in a study employing 
dewaxed M. ulcerans one month before infection, a strong generation of IgG 
against the bacilli was observed, with very little bacilli present in footpad 
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sections and no phenotype development [159]. However, this study only evalu-
ated protection for 28 days, and thus it remains to be investigated whether pro-
tection is long-lasting. Moreover, it is unclear if protective immunogens could 
have been removed during the dewaxing process, in spite of a general lack of 
protection detected in immunization interventions employing surface proteins, 
such as the 18 kDa shsp and the 27 kDa laminar binding protein [32, 160, 161]. 
Still, these results add to others confirming the extreme hydrophobicity of the 
M. ulcerans cell wall, which cumulatively with mycolactone represents a viru-
lence factor and aids in shielding the pathogen from immune surveillance mech-
anisms, consequently adding another layer of complexity to the development of 
preventive strategies [162].
Other immunization alternatives have thus been tested, such as vaccination with 
the mycolyl-transferase antigen 85A (Ag85A), a major secreted member of a family 
of proteins with important cell wall synthetic activity in several mycobacterial spe-
cies, including M. ulcerans [163, 164]. Whether in the form of a plasmid DNA vac-
cine or as a recombinant protein, vaccination strategies with Ag85A conferred some 
degree of protection by eliciting a cellular response with high levels of IFN-γ, IL-2 
and Ag85-specific IgGs, but, similarly to BCG, eventually failed to deter disease 
development [163–166]. Likewise, a vaccine employing DNA plasmids of 
polyketide synthase domains of Mycobacterium leprae Hsp65, previously tested in 
a murine model of tuberculosis, conferred protection against BU only  for a few 
months, despite the high homology of the amino acid sequence with the M. ulcerans 
orthologue [167, 168]. Therefore, better targets for immunization are still to be 
found and, to this end, a comparative genomics screening study identified several 
essential components of M. ulcerans that could provide important hints to direct 
future vaccination strategies [169]. 
So, why did not any of these immunization attempts succeed? Even if a tran-
sient protective response against M. ulcerans is generated, bacteria are consis-
tently able to overcome it at some point. This likely implies that, unless 
elimination of the replication of the bacilli is achieved at the very early stages 
post-infection, accumulation of mycolactone will eventually begin to signifi-
cantly damage the surrounding tissue including immune cells, thus defending the 
pathogen and downplaying any protective immune mechanism. Indeed, the 
administration of either antibiotics or bacteriophages in M. ulcerans infected 
mice corroborate this interpretation, since the killing of M. ulcerans is accompa-
nied by an increase in the cellular immune response associated with cytokines 
such as IFN-γ [85, 170, 171].
In this sense, neutralization of mycolactone itself seems to be an appealing target 
both for passive or active immunization strategies, as it would open the necessary 
opportunity for the immune response against M. ulcerans to develop and maintain 
effectively. This is not a novel concept, but has been for long hampered by the lipid- 
like nature of mycolactone, which makes it poorly immunogenic [168, 172]. 
However, recently, anti-mycolactone IgG antibodies were generated in mice through 
the administration of a protein conjugate of a truncated non-cytotoxic form of the 
toxin [173]. Although these antibodies were able to bind to mycolactone and to 
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neutralize its effect in in vitro assays with L929 fibroblast cell lines, it remains to be 
clarified if the antibodies are protective in vivo and if immunization with the trun-
cated form of mycolactone induces a long-lasting protective  humoral response 
[173]. Nevertheless, these are promising steps for future strategies targeting both 
active immunization efforts of endemic populations and passive immunization of 
BU patients.
7  Novel Models for Investigation and Future Perspectives
Research on BU includes a wide range of animal models, ranging from mammals 
and reptiles to birds, in an attempt to find one mimicking human disease best and 
allowing a detailed study of the pertaining cellular and molecular events [3, 174–
177]. Nonetheless, most of the evidence on BU pathophysiology and the host 
immune response has originated from experimentally infected mice, which, in 
spite of mimicking most of the clinical features of human BU, such as erythema, 
edema and ulcers, tend to progress very rapidly to necrosis [50]. In an attempt to 
directly tackle this issue, in vitro sub-culturing of a M. ulcerans Ghanaian isolate 
(NM20/02) resulted in an attenuated strain that allowed a more prolonged evalu-
ation of the cellular infiltrates [32]. Additionally, the extended kinetics facilitated 
the confirmation of other studies disclosing murine strain-specificities in the 
response against M. ulcerans infection, with overall evidence indicating  that 
BALB/c mice are able to delay bacterial growth and respond more effectively to 
BCG immunization than their C57BL/6 counterparts [21, 32, 157]. This critical 
point to be considered when extrapolating data to the human pathophysiology, 
can eventually be overcome by the addition of information from other animal 
models with more similarities with the human skin, such as pigs and guinea pigs 
[174, 175, 178, 179].
Intriguingly, whereas many of the above models have been very useful to learn 
about the disease pathogenesis, very little progress was made concerning the mech-
anisms behind natural resistance to the disease. In fact, for long it has been known 
that natural resistance to M. ulcerans infection occurs in some animal species and 
some studies also indicated the potential for spontaneous healing of BU lesions in 
humans [3, 86, 176, 180–183]. On the other hand, it is estimated that even with 
proper antibiotic and surgical treatment, more than 20% of patients develop perma-
nent sequelae [111]. What causes lie between these two extremes? Two recent stud-
iesaimed to shed some light on this question, by exploring the ability of the Hartley 
guinea pigs and the FVB/N mice to spontaneously heal BU [21, 184]. Strikingly, 
whereas the guinea pigs were able to achieve sterilizing immunity, FVB/N mice 
appear to halt the production of mycolactone by M. ulcerans without being able to 
completely eliminate the pathogen [21, 184]. Considering for instance, that changes 
in the sugar content of the growth medium of M. ulcerans can affect its production 
of mycolactone and antigens, this raises the hypothesis whether FVB/N mice deal 
with the infection by manipulating the local environment [185]. It is intriguing to 
observe that both models control the infection regardless of the initial inoculum, 
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which most likely suggests that there are key host factors that can effectively ham-
per the progression of the infection and that have never been so far considered as 
preventive or therapeutic approaches [21, 184]. Hence, it is highly likely that 
answers to this conundrum lie within the genetic makeup of BU patients that spon-
taneously recover from the disease, but with the current widespread use of antibiot-
ics, the task of identifying such cases is extremely difficult. Nevertheless, the 
existence of animal models of resistance already constitutes an exciting opportunity 
that should be seized to unravel what factors could be exploited in order to overturn 
a progressive disease into a state of full resolution.
8  Conclusions
For a long time, research on M. ulcerans infection has been  highly focused on 
experimental models. While these led to many important advances, integration of 
recent progress in epidemiological, clinical, cellular and molecular research consti-
tutes an opportunity to further our understanding of BU pathogenesis. In this con-
text, several lines of evidence point towards the importance of CMI in the local 
interaction with invading M. ulcerans bacilli, but the scope of this contact is still 
widely unknown. Likewise, bearing in mind that mycolactone can act beyond the 
site of infection, the consequences of its influence on the systemic production of 
cytokines or metabolic networks of the immune cells are yet to be understood. As 
such, it would be important to determine how immune recognition of M. ulcerans 
occurs at the molecular level, what host factors influence cytokine production upon 
this recognition and what the effect of this interaction is on CMI effector mecha-
nisms. As for the humoral immunity, it would also be paramount to understand what 
its importance  is and to what extent it prevents or delays the progression of the 
disease. It is only if answers for these fundamental questions are found, that the way 
to tailor more effective vaccination and prophylactic measures will become clear.
Acknowledgements This work was developed under the scope of the project NORTE-01-0145- 
FEDER-000013, supported by the Northern Portugal Regional Operational Programme (NORTE 
2020), under the Portugal 2020 Partnership Agreement, through the European Regional 
Development Fund (FEDER); FEDER, through the Competiveness Factors Operational 
Programme (COMPETE) and by National funds, through the Foundation for Science and 
Technology (FCT), under the scope of projects POCI-01-0145-FEDER-007038  and POCI-01- 
0145-FEDER-031312; Infect-ERA grant Infect-ERA/0002/2015; and FCT through the PhD grant 
PD/BD/113699/2015 to JF and the postdoctoral grant SFRH/BPD/112903/2015 to AGF.
References
 1. Dodge OG (1964) Mycobacterial skin ulcers in Uganda: histopathological and experimental 
aspects. J Pathol Bacteriol 88:169–174
 2. Hayman J (1993) Out of Africa: observations on the histopathology of Mycobacterium ulcer-
ans infection. J Clin Pathol 46:5–9
J. Fevereiro et al.
149
 3. MacCallum P, Tolhurst JC (1948) A new mycobacterial infection in man. J Pathol Bacteriol 
60:93–122
 4. Connor DH, Lunn HF (1965) Mycobacterium ulcerans infection (with comments on patho-
genesis). Int J Lepr 33(Suppl):698–709
 5. Guarner J, Bartlett J, Whitney EAS et al (2003) Histopathologic features of Mycobacterium 
ulcerans infection. Emerg Infect Dis 9:651–656
 6. Hayman J, McQueen A (1985) The pathology of Mycobacterium ulcerans infection. 
Pathology (Phila) 17:594–600
 7. Rondini S, Horsfield C, Mensah-Quainoo E et al (2006) Contiguous spread of Mycobacterium 
ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification 
of mycobacterial DNA. J Pathol 208:119–128. https://doi.org/10.1002/path.1864
 8. Ruf M-T, Steffen C, Bolz M et al (2017) Infiltrating leukocytes surround early Buruli ulcer 
lesions, but are unable to reach the mycolactone producing mycobacteria. Virulence 8:1918–
1926. https://doi.org/10.1080/21505594.2017.1370530
 9. Torrado E, Fraga AG, Castro AG et  al (2007) Evidence for an intramacrophage growth 
phase of Mycobacterium ulcerans. Infect Immun 75:977–987. https://doi.org/10.1128/
IAI.00889-06
 10. Walsh DS, Meyers WM, Portaels F et  al (2005) High rates of apoptosis in human 
Mycobacterium ulcerans culture-positive Buruli ulcer skin lesions. Am J Trop Med Hyg 
73:410–415
 11. Krieg RE, Hockmeyer WT, Connor DH (1974) Toxin of Mycobacterium ulcerans. Production 
and effects in Guinea pig skin. Arch Dermatol 110:783–788
 12. Adusumilli S, Mve-Obiang A, Sparer T et al (2005) Mycobacterium ulcerans toxic macrolide, 
mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro 
and in vivo. Cell Microbiol 7:1295–1304. https://doi.org/10.1111/j.1462-5822.2005.00557.x
 13. George KM, Chatterjee D, Gunawardana G et  al (1999) Mycolactone: a polyketide toxin 
from Mycobacterium ulcerans required for virulence. Science 283:854–857
 14. Bieri R, Scherr N, Ruf M-T et al (2017) The macrolide toxin mycolactone promotes bim- 
dependent apoptosis in Buruli ulcer through inhibition of mTOR. ACS Chem Biol 12:1297–
1307. https://doi.org/10.1021/acschembio.7b00053
 15. Pahlevan AA, Wright DJ, Andrews C et al (1999) The inhibitory action of Mycobacterium 
ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J 
Immunol 163:3928–3935
 16. Snyder DS, Small PLC (2003) Uptake and cellular actions of mycolactone, a virulence deter-
minant for Mycobacterium ulcerans. Microb Pathog 34:91–101
 17. Baron L, Paatero AO, Morel J-D et  al (2016) Mycolactone subverts immunity by selec-
tively blocking the Sec61 translocon. J Exp Med 213:2885–2896. https://doi.org/10.1084/
jem.20160662
 18. Hall BS, Hill K, McKenna M et al (2014) The pathogenic mechanism of the Mycobacterium 
ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the 
ER. PLoS Pathog 10:e1004061. https://doi.org/10.1371/journal.ppat.1004061
 19. Gama JB, Ohlmeier S, Martins TG et  al (2014) Proteomic analysis of the action of the 
Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen. 
PLoS Negl Trop Dis 8:e3066. https://doi.org/10.1371/journal.pntd.0003066
 20. Guenin-Macé L, Veyron-Churlet R, Thoulouze M-I et  al (2013) Mycolactone activa-
tion of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest 
123:1501–1512. https://doi.org/10.1172/JCI66576
 21. Marion E, Jarry U, Cano C et al (2016) FVB/N mice spontaneously heal ulcerative lesions 
induced by Mycobacterium ulcerans and switch M. ulcerans into a low mycolactone pro-
ducer. J Immunol 196:2690–2698. https://doi.org/10.4049/jimmunol.1502194
 22. Oliveira MS, Fraga AG, Torrado E et  al (2005) Infection with Mycobacterium ulcerans 
induces persistent inflammatory responses in mice. Infect Immun 73:6299–6310. https://doi.
org/10.1128/IAI.73.10.6299-6310.2005
The Immunology of Buruli Ulcer
150
 23. Ortiz RH, Leon DA, Estevez HO et al (2009) Differences in virulence and immune response 
induced in a murine model by isolates of Mycobacterium ulcerans from different geographic 
areas. Clin Exp Immunol 157:271–281. https://doi.org/10.1111/j.1365-2249.2009.03941.x
 24. Guenin-Macé L, Oldenburg R, Chrétien F, Demangel C (2014) Pathogenesis of skin ulcers: 
lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens. Cell Mol Life Sci 
71:2443–2450. https://doi.org/10.1007/s00018-014-1561-z
 25. Merritt RW, Walker ED, Small PLC et al (2010) Ecology and transmission of Buruli ulcer 
disease: a systematic review. PLoS Negl Trop Dis 4:e911. https://doi.org/10.1371/journal.
pntd.0000911
 26. Wallace JR, Mangas KM, Porter JL et al (2017) Mycobacterium ulcerans low infectious dose 
and mechanical transmission support insect bites and puncturing injuries in the spread of 
Buruli ulcer. PLoS Negl Trop Dis 11:e0005553. https://doi.org/10.1371/journal.pntd.0005553
 27. Lee H-M, Shin D-M, Choi D-K et al (2009) Innate immune responses to Mycobacterium 
ulcerans via toll-like receptors and dectin-1 in human keratinocytes. Cell Microbiol 11:678–
692. https://doi.org/10.1111/j.1462-5822.2009.01285.x
 28. Coutanceau E, Marsollier L, Brosch R et  al (2005) Modulation of the host immune 
response by a transient intracellular stage of Mycobacterium ulcerans: the contri-
bution of endogenous mycolactone toxin. Cell Microbiol 7:1187–1196. https://doi.
org/10.1111/j.1462-5822.2005.00546.x
 29. Roberts B, Hirst R (1996) Identification and characterisation of a superoxide dismutase 
and catalase from Mycobacterium ulcerans. J Med Microbiol 45:383–387. https://doi.
org/10.1099/00222615-45-5-383
 30. Ogbechi J, Ruf M-T, Hall BS et al (2015) Mycolactone-dependent depletion of endothelial 
cell thrombomodulin is strongly associated with fibrin deposition in Buruli ulcer lesions. 
PLoS Pathog 11:e1005011. https://doi.org/10.1371/journal.ppat.1005011
 31. Phillips RO, Sarfo FS, Landier J et al (2014) Combined inflammatory and metabolic defects 
reflected by reduced serum protein levels in patients with Buruli ulcer disease. PLoS Negl 
Trop Dis 8:e2786. https://doi.org/10.1371/journal.pntd.0002786
 32. Bénard A, Sala C, Pluschke G (2016) Mycobacterium ulcerans mouse model refinement for 
pre-clinical profiling of vaccine candidates. PLoS One 11:e0167059. https://doi.org/10.1371/
journal.pone.0167059
 33. Portaels F, Meyers WM, Ablordey A et  al (2008) First cultivation and characterization of 
Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2:e178. https://doi.
org/10.1371/journal.pntd.0000178
 34. Scherr N, Gersbach P, Dangy J-P et al (2013) Structure-activity relationship studies on the 
macrolide exotoxin mycolactone of Mycobacterium ulcerans. PLoS Negl Trop Dis 7:e2143. 
https://doi.org/10.1371/journal.pntd.0002143
 35. Tafelmeyer P, Laurent C, Lenormand P et  al (2008) Comprehensive proteome analy-
sis of Mycobacterium ulcerans and quantitative comparison of mycolactone biosynthesis. 
Proteomics 8:3124–3138. https://doi.org/10.1002/pmic.200701018
 36. Mve-Obiang A, Lee RE, Portaels F, Small PLC (2003) Heterogeneity of Mycolactones pro-
duced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect 
Immun 71:774–783. https://doi.org/10.1128/IAI.71.2.774-783.2003
 37. Huber CA, Ruf M-T, Pluschke G, Käser M (2008) Independent loss of immunogenic proteins 
in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol 15:598–606. 
https://doi.org/10.1128/CVI.00472-07
 38. Qi W, Käser M, Röltgen K et al (2009) Genomic diversity and evolution of Mycobacterium 
ulcerans revealed by next-generation sequencing. PLoS Pathog 5:e1000580. https://doi.
org/10.1371/journal.ppat.1000580
 39. Pimsler M, Sponsler TA, Meyers WM (1988) Immunosuppressive properties of the soluble 
toxin from Mycobacterium ulcerans. J Infect Dis 157:577–580
 40. Sarfo FS, Phillips RO, Rangers B et al (2010) Detection of Mycolactone A/B in Mycobacterium 
ulcerans-infected human tissue. PLoS Negl Trop Dis 4:e577. https://doi.org/10.1371/journal.
pntd.0000577
J. Fevereiro et al.
151
 41. Phillips R, Adjei O, Lucas S et al (2004) Pilot randomized double-blind trial of treatment 
of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob 
Agents Chemother 48:2866–2870. https://doi.org/10.1128/AAC.48.8.2866-2870.2004
 42. Phillips R, Kuijper S, Benjamin N et al (2004) In vitro killing of Mycobacterium ulcerans 
by acidified nitrite. Antimicrob Agents Chemother 48:3130–3132. https://doi.org/10.1128/
AAC.48.8.3130-3132.2004
 43. Torrado E, Fraga AG, Logarinho E et al (2010) IFN-gamma-dependent activation of macro-
phages during experimental infections by Mycobacterium ulcerans is impaired by the toxin 
mycolactone. J Immunol 184:947–955. https://doi.org/10.4049/jimmunol.0902717
 44. Coutanceau E, Decalf J, Martino A et al (2007) Selective suppression of dendritic cell func-
tions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204:1395–1403. https://doi.
org/10.1084/jem.20070234
 45. Grotzke JE, Kozik P, Morel J-D et al (2017) Sec61 blockade by mycolactone inhibits antigen 
cross-presentation independently of endosome-to-cytosol export. Proc Natl Acad Sci U S A 
114:E5910–E5919. https://doi.org/10.1073/pnas.1705242114
 46. Boulkroun S, Guenin-Macé L, Thoulouze M-I et al (2010) Mycolactone suppresses T cell 
responsiveness by altering both early signaling and posttranslational events. J Immunol 
184:1436–1444. https://doi.org/10.4049/jimmunol.0902854
 47. Bieri R, Bolz M, Ruf M-T, Pluschke G (2016) Interferon-γ is a crucial activator of early host 
immune defense against Mycobacterium ulcerans infection in mice. PLoS Negl Trop Dis 
10:e0004450. https://doi.org/10.1371/journal.pntd.0004450
 48. Fraga AG, Martins TG, Torrado E et al (2012) Cellular immunity confers transient protec-
tion in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium 
ulcerans vaccination. PLoS One 7:e33406. https://doi.org/10.1371/journal.pone.0033406
 49. Guenin-Macé L, Carrette F, Asperti-Boursin F et al (2011) Mycolactone impairs T cell hom-
ing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A 
108:12833–12838. https://doi.org/10.1073/pnas.1016496108
 50. Addo P, Owusu E, Adu-Addai B et  al (2005) Findings from a Buruli ulcer mouse model 
study. Ghana Med J 39:86–93
 51. Fenner F (1956) The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium 
balnei in the mouse and the developing chick embryo. Am Rev Tuberc 73:650–673
 52. Hong H, Coutanceau E, Leclerc M et al (2008) Mycolactone diffuses from Mycobacterium 
ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid 
organs. PLoS Negl Trop Dis 2:e325. https://doi.org/10.1371/journal.pntd.0000325
 53. Pattyn SR (1965) Bactériologie et pathologie humaine et expérimentale des ulcères à 
Mycobacterium ulcerans. Ann Soc Belges Méd Trop Parasitol Mycol 45:121–129
 54. Sarfo FS, Le Chevalier F, Aka N et al (2011) Mycolactone diffuses into the peripheral blood 
of Buruli ulcer patients—implications for diagnosis and disease monitoring. PLoS Negl Trop 
Dis 5:e1237. https://doi.org/10.1371/journal.pntd.0001237
 55. Fraga AG, Cruz A, Martins TG et al (2011) Mycobacterium ulcerans triggers T-cell immunity 
followed by local and regional but not systemic immunosuppression. Infect Immun 79:421–
430. https://doi.org/10.1128/IAI.00820-10
 56. Gooding TM, Johnson PDR, Smith M et al (2002) Cytokine profiles of patients infected with 
Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70:5562–5567
 57. Gooding TM, Kemp AS, Robins-Browne RM et al (2003) Acquired T-helper 1 lymphocyte 
anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36:1076–1077. 
https://doi.org/10.1086/368315
 58. Phillips R, Horsfield C, Kuijper S et  al (2006) Cytokine response to antigen stimulation 
of whole blood from patients with Mycobacterium ulcerans disease compared to that from 
patients with tuberculosis. Clin Vaccine Immunol 13:253–257. https://doi.org/10.1128/
CVI.13.2.253-257.2006
 59. Phillips R, Sarfo FS, Guenin-Macé L et al (2009) Immunosuppressive signature of cutane-
ous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer 
disease. J Infect Dis 200:1675–1684. https://doi.org/10.1086/646615
The Immunology of Buruli Ulcer
152
 60. Prévot G, Bourreau E, Pascalis H et al (2004) Differential production of systemic and intrale-
sional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. 
Infect Immun 72:958–965
 61. Schipper HS, Rutgers B, Huitema MG et  al (2007) Systemic and local interferon-gamma 
production following Mycobacterium ulcerans infection. Clin Exp Immunol 150:451–459. 
https://doi.org/10.1111/j.1365-2249.2007.03506.x
 62. Westenbrink BD, Stienstra Y, Huitema MG et al (2005) Cytokine responses to stimulation 
of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 
12:125–129. https://doi.org/10.1128/CDLI.12.1.125-129.2005
 63. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E et  al (2006) Systemic suppression of 
interferon- gamma responses in Buruli ulcer patients resolves after surgical excision of 
the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 
79:1150–1156. https://doi.org/10.1189/jlb.1005581
 64. Gooding TM, Johnson PD, Campbell DE et  al (2001) Immune response to infection 
with Mycobacterium ulcerans. Infect Immun 69:1704–1707. https://doi.org/10.1128/
IAI.69.3.1704-1707.2001
 65. Kiszewski AE, Becerril E, Aguilar LD et  al (2006) The local immune response in 
ulcerative lesions of Buruli disease. Clin Exp Immunol 143:445–451. https://doi.
org/10.1111/j.1365-2249.2006.03020.x
 66. Niang F, Sarfo FS, Frimpong M et al (2015) Metabolomic profiles delineate mycolactone 
signature in Buruli ulcer disease. Sci Rep 5:17693. https://doi.org/10.1038/srep17693
 67. O’Neill LAJ, Kishton RJ, Rathmell J (2016) A guide to immunometabolism for immunolo-
gists. Nat Rev Immunol 16:553–565. https://doi.org/10.1038/nri.2016.70
 68. Barker DJ (1973) Epidemiology of Mycobacterium ulcerans infection. Trans R Soc Trop 
Med Hyg 67:43–50
 69. Dobos KM, Spotts EA, Marston BJ et al (2000) Serologic response to culture filtrate antigens 
of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 6:158–164. https://
doi.org/10.3201/eid0602.000208
 70. Stanford JL, Revill WD, Gunthorpe WJ, Grange JM (1975) The production and preliminary 
investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg 
74:7–16
 71. Okenu DMN, Ofielu LO, Easley KA et al (2004) Immunoglobulin M antibody responses to 
Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease 
and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol 
11:387–391
 72. Diaz D, Döbeli H, Yeboah-Manu D et al (2006) Use of the immunodominant 18-kiloDalton 
small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. 
Clin Vaccine Immunol 13:1314–1321. https://doi.org/10.1128/CVI.00254-06
 73. Pidot SJ, Porter JL, Tobias NJ et al (2010) Regulation of the 18 kDa heat shock protein in 
Mycobacterium ulcerans: an alpha-crystallin orthologue that promotes biofilm formation. 
Mol Microbiol 78:1216–1231. https://doi.org/10.1111/j.1365-2958.2010.07401.x
 74. Röltgen K, Bratschi MW, Ross A et al (2014) Late onset of the serological response against 
the 18 kDa small heat shock protein of Mycobacterium ulcerans in children. PLoS Negl Trop 
Dis 8:e2904. https://doi.org/10.1371/journal.pntd.0002904
 75. Yeboah-Manu D, Röltgen K, Opare W et al (2012) Sero-epidemiology as a tool to screen 
populations for exposure to Mycobacterium ulcerans. PLoS Negl Trop Dis 6:e1460. https://
doi.org/10.1371/journal.pntd.0001460
 76. Dreyer A, Röltgen K, Dangy JP et al (2015) Identification of the Mycobacterium ulcerans 
protein MUL_3720 as a promising target for the development of a diagnostic test for Buruli 
ulcer. PLoS Negl Trop Dis 9:e0003477. https://doi.org/10.1371/journal.pntd.0003477
 77. Pidot SJ, Porter JL, Marsollier L et al (2010) Serological evaluation of Mycobacterium ulcer-
ans antigens identified by comparative genomics. PLoS Negl Trop Dis 4:e872. https://doi.
org/10.1371/journal.pntd.0000872
J. Fevereiro et al.
153
 78. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH (2011) Treating Mycobacterium 
ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? 
Future Microbiol 6:1185–1198. https://doi.org/10.2217/fmb.11.101
 79. Ruf M-T, Schütte D, Chauffour A et al (2012) Chemotherapy-associated changes of histo-
pathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. 
Antimicrob Agents Chemother 56:687–696. https://doi.org/10.1128/AAC.05543-11
 80. Sarfo FS, Phillips RO, Zhang J et al (2014) Kinetics of mycolactone in human subcutaneous 
tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis 14:202. 
https://doi.org/10.1186/1471-2334-14-202
 81. Sarfo FS, Converse PJ, Almeida DV et al (2013) Microbiological, histological, immunologi-
cal, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcer-
ans disease. PLoS Negl Trop Dis 7:e2101. https://doi.org/10.1371/journal.pntd.0002101
 82. Ruf M-T, Sopoh GE, Brun LV et al (2011) Histopathological changes and clinical responses 
of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic 
tissue? PLoS Negl Trop Dis 5:e1334. https://doi.org/10.1371/journal.pntd.0001334
 83. Schütte D, Um-Boock A, Mensah-Quainoo E et al (2007) Development of highly organized 
lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. 
PLoS Negl Trop Dis 1:e2. https://doi.org/10.1371/journal.pntd.0000002
 84. Schütte D, Umboock A, Pluschke G (2009) Phagocytosis of Mycobacterium ulcerans in the 
course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 
160:273–283. https://doi.org/10.1111/j.1365-2133.2008.08879.x
 85. Martins TG, Gama JB, Fraga AG et al (2012) Local and regional re-establishment of cellular 
immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS 
One 7:e32740. https://doi.org/10.1371/journal.pone.0032740
 86. Nienhuis WA, Stienstra Y, Abass KM et al (2012) Paradoxical responses after start of antimi-
crobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 54:519–526. https://
doi.org/10.1093/cid/cir856
 87. O’Brien DP, Robson M, Friedman ND et al (2013) Incidence, clinical spectrum, diagnostic features, 
treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium 
ulcerans infections. BMC Infect Dis 13:416. https://doi.org/10.1186/1471-2334-13-416
 88. O’Brien DP, Robson ME, Callan PP, McDonald AH (2009) “Paradoxical” immune-mediated 
reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment suc-
cess, not failure. Med J Aust 191:564–566
 89. Sarfo FS, Phillips R, Asiedu K et  al (2010) Clinical efficacy of combination of rifampin 
and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents 
Chemother 54:3678–3685. https://doi.org/10.1128/AAC.00299-10
 90. Ruf M-T, Chauty A, Adeye A et al (2011) Secondary Buruli ulcer skin lesions emerging sev-
eral months after completion of chemotherapy: paradoxical reaction or evidence for immune 
protection? PLoS Negl Trop Dis 5:e1252. https://doi.org/10.1371/journal.pntd.0001252
 91. Barogui YT, Klis S-A, Johnson RC et al (2016) Genetic susceptibility and predictors of para-
doxical reactions in Buruli ulcer. PLoS Negl Trop Dis 10:e0004594. https://doi.org/10.1371/
journal.pntd.0004594
 92. O’Brien DP, Friedman ND, Cowan R et al (2015) Mycobacterium ulcerans in the elderly: 
more severe disease and suboptimal outcomes. PLoS Negl Trop Dis 9:e0004253. https://doi.
org/10.1371/journal.pntd.0004253
 93. de Zeeuw J, Duggirala S, Nienhuis WA et al (2013) Serum levels of neopterin during antimi-
crobial treatment for Mycobacterium ulcerans infection. Am J Trop Med Hyg 89:498–500. 
https://doi.org/10.4269/ajtmh.12-0599
 94. Friedman ND, McDonald AH, Robson ME, O’Brien DP (2012) Corticosteroid use for para-
doxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Negl Trop 
Dis 6:e1767. https://doi.org/10.1371/journal.pntd.0001767
 95. Trevillyan JM, Johnson PDR (2013) Steroids control paradoxical worsening of Mycobacterium 
ulcerans infection following initiation of antibiotic therapy. Med J Aust 198:443–444
The Immunology of Buruli Ulcer
154
 96. Tuffour J, Owusu-Mireku E, Ruf M-T et al (2015) Challenges associated with management 
of Buruli ulcer/human immunodeficiency virus coinfection in a treatment center in Ghana: a 
case series study. Am J Trop Med Hyg 93:216–223. https://doi.org/10.4269/ajtmh.14-0571
 97. Wanda F, Nkemenang P, Ehounou G et  al (2014) Clinical features and management of a 
severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co- 
infection. BMC Infect Dis 14:423. https://doi.org/10.1186/1471-2334-14-423
 98. Johnson RC, Nackers F, Glynn JR et  al (2008) Association of HIV infection and 
Mycobacterium ulcerans disease in Benin. AIDS 22:901–903. https://doi.org/10.1097/
QAD.0b013e3282f7690a
 99. Toll A, Gallardo F, Ferran M et al (2005) Aggressive multifocal Buruli ulcer with associ-
ated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol 30:649–651. https://doi.
org/10.1111/j.1365-2230.2005.01892.x
 100. Vincent QB, Ardant M-F, Marsollier L et al (2014) HIV infection and Buruli ulcer in Africa. 
Lancet Infect Dis 14:796–797. https://doi.org/10.1016/S1473-3099(14)70882-5
 101. Prasad R (1993) Pulmonary sarcoidosis and chronic cutaneous atypical mycobacter ulcer. 
Aust Fam Physician 22:755–758
 102. Martins TG, Trigo G, Fraga AG et al (2012) Corticosteroid-induced immunosuppression ulti-
mately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcer-
ans infection. PLoS Negl Trop Dis 6:e1925. https://doi.org/10.1371/journal.pntd.0001925
 103. Ogino S, King EE, Beck AH et al (2012) Interdisciplinary education to integrate pathology 
and epidemiology: towards molecular and population-level health science. Am J Epidemiol 
176:659–667. https://doi.org/10.1093/aje/kws226
 104. Jacobsen KH, Padgett JJ (2010) Risk factors for Mycobacterium ulcerans infection. Int J 
Infect Dis 14:e677–e681. https://doi.org/10.1016/j.ijid.2009.11.013
 105. Amofah G, Bonsu F, Tetteh C et al (2002) Buruli ulcer in Ghana: results of a national case 
search. Emerg Infect Dis 8:167–170. https://doi.org/10.3201/eid0802.010119
 106. Debacker M, Aguiar J, Steunou C et  al (2004) Mycobacterium ulcerans disease: role of 
age and gender in incidence and morbidity. Trop Med Int Health 9:1297–1304. https://doi.
org/10.1111/j.1365-3156.2004.01339.x
 107. Debacker M, Portaels F, Aguiar J et al (2006) Risk factors for Buruli ulcer, Benin. Emerg 
Infect Dis 12:1325–1331. https://doi.org/10.3201/eid1209.050598
 108. Landier J, Fontanet A, Texier G (2014) Defining and targeting high-risk populations in Buruli 
ulcer. Lancet Glob Health 2:e629. https://doi.org/10.1016/S2214-109X(14)70311-0
 109. Tai AYC, Athan E, Friedman ND et al (2018) Increased severity and spread of Mycobacterium 
ulcerans, Southeastern Australia. Emerg Infect Dis 24:58. https://doi.org/10.3201/
eid2401.171070
 110. The Uganda Buruli Group (1971) Epidemiology of Mycobacterium ulcerans infection 
(Buruli ulcer) at Kinyara, Uganda. Trans R Soc Trop Med Hyg 65:763–775
 111. Vincent QB, Ardant M-F, Adeye A et  al (2014) Clinical epidemiology of laboratory- 
confirmed Buruli ulcer in Benin: a cohort study. Lancet Glob Health 2:e422–e430. https://
doi.org/10.1016/S2214-109X(14)70223-2
 112. Bratschi MW, Bolz M, Minyem JC et al (2013) Geographic distribution, age pattern and sites 
of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl 
Trop Dis 7:e2252. https://doi.org/10.1371/journal.pntd.0002252
 113. N’krumah RTAS, Koné B, Cissé G et al (2017) Characteristics and epidemiological profile of 
Buruli ulcer in the district of Tiassalé, south Côte d’Ivoire. Acta Trop 175:138–144. https://
doi.org/10.1016/j.actatropica.2016.12.023
 114. Nhamoyebonde S, Leslie A (2014) Biological differences between the sexes and suscepti-
bility to tuberculosis. J Infect Dis 209(Suppl 3):S100–S106. https://doi.org/10.1093/infdis/
jiu147
 115. Vesosky B, Turner J (2005) The influence of age on immunity to infection with Mycobacterium 
tuberculosis. Immunol Rev 205:229–243. https://doi.org/10.1111/j.0105-2896.2005.00257.x
 116. Alcaïs A, Fieschi C, Abel L, Casanova J-L (2005) Tuberculosis in children and adults: two 
distinct genetic diseases. J Exp Med 202:1617–1621. https://doi.org/10.1084/jem.20052302
J. Fevereiro et al.
155
 117. Dreesman A, Corbière V, Dirix V et  al (2017) Age-stratified T cell responses in children 
infected with Mycobacterium tuberculosis. Front Immunol 8:1059. https://doi.org/10.3389/
fimmu.2017.01059
 118. Guerra-Laso JM, González-García S, González-Cortés C et  al (2013) Macrophages from 
elders are more permissive to intracellular multiplication of Mycobacterium tuberculosis. 
Age (Dordr) 35:1235–1250. https://doi.org/10.1007/s11357-012-9451-5
 119. Guzzetta G, Kirschner D (2013) The roles of immune memory and aging in protective 
immunity and endogenous reactivation of tuberculosis. PLoS One 8:e60425. https://doi.
org/10.1371/journal.pone.0060425
 120. Harari A, Rozot V, Bellutti Enders F et  al (2011) Dominant TNF-α  +  Mycobacterium 
tuberculosis- specific CD4+ T cell responses discriminate between latent infection and active 
disease. Nat Med 17:372–376. https://doi.org/10.1038/nm.2299
 121. Orme IM (1987) Aging and immunity to tuberculosis: increased susceptibility of old mice 
reflects a decreased capacity to generate mediator T lymphocytes. J Immunol 138:4414–4418
 122. Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 
16:626–638. https://doi.org/10.1038/nri.2016.90
 123. Lamberts SW, van den Beld AW, van der Lely AJ (1997) The endocrinology of aging. Science 
278:419–424
 124. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B (2015) How sex and age 
affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 
14:309–321. https://doi.org/10.1111/acel.12326
 125. Yamamoto Y, Saito H, Setogawa T, Tomioka H (1991) Sex differences in host resistance to 
Mycobacterium marinum infection in mice. Infect Immun 59:4089–4096
 126. Sanchez AM, Flamini MI, Baldacci C et al (2010) Estrogen receptor-alpha promotes breast 
cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 
24:2114–2125. https://doi.org/10.1210/me.2010-0252
 127. Barker DJ (1972) The distribution of Buruli disease in Uganda. Trans R Soc Trop Med Hyg 
66:867–874
 128. Raghunathan PL, Whitney EAS, Asamoa K et al (2005) Risk factors for Buruli ulcer disease 
(Mycobacterium ulcerans infection): results from a case-control study in Ghana. Clin Infect 
Dis 40:1445–1453. https://doi.org/10.1086/429623
 129. Ampah KA, Asare P, Binnah DD-G et al (2016) Burden and historical trend of Buruli ulcer 
prevalence in selected communities along the Offin River of Ghana. PLoS Negl Trop Dis 
10:e0004603. https://doi.org/10.1371/journal.pntd.0004603
 130. Johnson PDR, Lavender CJ (2009) Correlation between Buruli ulcer and vector-borne noti-
fiable diseases, Victoria, Australia. Emerg Infect Dis 15:614–615. https://doi.org/10.3201/
eid1504.081162
 131. Marsollier L, Deniaux E, Brodin P et  al (2007) Protection against Mycobacterium ulcer-
ans lesion development by exposure to aquatic insect saliva. PLoS Med 4:e64. https://doi.
org/10.1371/journal.pmed.0040064
 132. Tian RDB, Lepidi H, Nappez C, Drancourt M (2016) Experimental survival of Mycobacterium 
ulcerans in watery soil, a potential source of Buruli ulcer. Am J Trop Med Hyg 94:89–92. 
https://doi.org/10.4269/ajtmh.15-0568
 133. Tomczyk S, Deribe K, Brooker SJ et  al (2014) Association between footwear use and 
neglected tropical diseases: a systematic review and meta-analysis. PLoS Negl Trop Dis 
8:e3285. https://doi.org/10.1371/journal.pntd.0003285
 134. Miyamoto Y, Komine M, Takatsuka Y et al (2014) Two cases of Buruli ulcer in Japanese 
brothers. J Dermatol 41:771–772. https://doi.org/10.1111/1346-8138.12540
 135. O’Brien DP, Wynne JW, Buultjens AH et al (2017) Exposure risk for infection and lack of 
human-to-human transmission of Mycobacterium ulcerans disease, Australia. Emerg Infect 
Dis 23:837–840. https://doi.org/10.3201/eid2305.160809
 136. Ohtsuka M, Kikuchi N, Yamamoto T et al (2014) Buruli ulcer caused by Mycobacterium ulcerans 
subsp shinshuense: a rare case of familial concurrent occurrence and detection of insertion sequence 
2404 in Japan. JAMA Dermatol 150:64–67. https://doi.org/10.1001/jamadermatol.2013.6816
The Immunology of Buruli Ulcer
156
 137. Sopoh GE, Barogui YT, Johnson RC et  al (2010) Family relationship, water contact and 
occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis 4:e746. https://doi.org/10.1371/
journal.pntd.0000746
 138. Debacker M, Zinsou C, Aguiar J et al (2002) Mycobacterium ulcerans disease (Buruli ulcer) 
following human bite. Lancet 360:1830. https://doi.org/10.1016/S0140-6736(02)11771-5
 139. Debacker M, Zinsou C, Aguiar J et  al (2003) First case of Mycobacterium ulcerans dis-
ease (Buruli ulcer) following a human bite. Clin Infect Dis 36:e67–e68. https://doi.
org/10.1086/367660
 140. Capela C, Sopoh GE, Houezo JG et al (2015) Clinical epidemiology of Buruli ulcer from 
Benin (2005-2013): effect of time-delay to diagnosis on clinical forms and severe pheno-
types. PLoS Negl Trop Dis 9:e0004005. https://doi.org/10.1371/journal.pntd.0004005
 141. Bibert S, Bratschi MW, Aboagye SY et  al (2017) Susceptibility to Mycobacterium ulcer-
ans disease (Buruli ulcer) is associated with IFNG and iNOS gene polymorphisms. Front 
Microbiol 8:1903. https://doi.org/10.3389/fmicb.2017.01903
 142. Goswami T, Bhattacharjee A, Babal P et al (2001) Natural-resistance-associated macrophage 
protein 1 is an H+/bivalent cation antiporter. Biochem J 354:511–519
 143. Stienstra Y, van der Werf TS, Oosterom E et al (2006) Susceptibility to Buruli ulcer is asso-
ciated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun 7:185–189. 
https://doi.org/10.1038/sj.gene.6364281
 144. Capela C, Dossou AD, Silva-Gomes R et al (2016) Genetic variation in autophagy-related 
genes influences the risk and phenotype of Buruli ulcer. PLoS Negl Trop Dis 10:e0004671. 
https://doi.org/10.1371/journal.pntd.0004671
 145. Juárez E, Carranza C, Hernández-Sánchez F et al (2012) NOD2 enhances the innate response 
of alveolar macrophages to Mycobacterium tuberculosis in humans. Eur J Immunol 42:880–
889. https://doi.org/10.1002/eji.201142105
 146. Manzanillo PS, Ayres JS, Watson RO et al (2013) The ubiquitin ligase parkin mediates resis-
tance to intracellular pathogens. Nature 501:512–516. https://doi.org/10.1038/nature12566
 147. Lewis CM (2002) Genetic association studies: design, analysis and interpretation. Brief 
Bioinform 3:146–153
 148. Fletcher HA (2016) Sleeping beauty and the story of the Bacille Calmette-Guérin vaccine. 
MBio 7:e01370–e01316. https://doi.org/10.1128/mBio.01370-16
 149. Nackers F, Dramaix M, Johnson RC et al (2006) BCG vaccine effectiveness against Buruli 
ulcer: a case-control study in Benin. Am J Trop Med Hyg 75:768–774
 150. Phillips RO, Phanzu DM, Beissner M et al (2015) Effectiveness of routine BCG vaccination 
on Buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana 
and Togo. PLoS Negl Trop Dis 9:e3457. https://doi.org/10.1371/journal.pntd.0003457
 151. Pommelet V, Vincent QB, Ardant M-F et  al (2014) Findings in patients from Benin with 
osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection. 
Clin Infect Dis 59:1256–1264. https://doi.org/10.1093/cid/ciu584
 152. Portaels F, Aguiar J, Debacker M et al (2002) Prophylactic effect of Mycobacterium bovis 
BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease 
(Buruli ulcer). Clin Diagn Lab Immunol 9:1389–1391
 153. Portaels F, Aguiar J, Debacker M et  al (2004) Mycobacterium bovis BCG vaccination as 
prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect 
Immun 72:62–65
 154. Smith PG, Revill WD, Lukwago E, Rykushin YP (1976) The protective effect of BCG against 
Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R 
Soc Trop Med Hyg 70:449–457
 155. The Uganda Buruli Group (1969) BCG vaccination against Mycobacterium ulcerans infec-
tion (Buruli ulcer). First results of a trial in Uganda. Lancet 1:111–115
 156. Fenner F (1957) Homologous and heterologous immunity in infections of mice with 
Mycobacterium ulcerans and Mycobacterium balnei. Am Rev Tuberc 76:76–89
 157. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH (2011) BCG-mediated protection 
against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis 5:e985. https://
doi.org/10.1371/journal.pntd.0000985
J. Fevereiro et al.
157
 158. Tanghe A, Adnet P-Y, Gartner T, Huygen K (2007) A booster vaccination with Mycobacterium 
bovis BCG does not increase the protective effect of the vaccine against experimen-
tal Mycobacterium ulcerans infection in mice. Infect Immun 75:2642–2644. https://doi.
org/10.1128/IAI.01622-06
 159. Watanabe M, Nakamura H, Nabekura R et al (2015) Protective effect of a dewaxed whole- 
cell vaccine against Mycobacterium ulcerans infection in mice. Vaccine 33:2232–2239. 
https://doi.org/10.1016/j.vaccine.2015.03.046
 160. Bolz M, Bénard A, Dreyer AM et al (2016) Vaccination with the surface proteins MUL_2232 
and MUL_3720 of Mycobacterium ulcerans induces antibodies but fails to provide protec-
tion against Buruli ulcer. PLoS Negl Trop Dis 10:e0004431. https://doi.org/10.1371/journal.
pntd.0004431
 161. Bolz M, Kerber S, Zimmer G, Pluschke G (2015) Use of recombinant virus replicon particles 
for vaccination against Mycobacterium ulcerans disease. PLoS Negl Trop Dis 9:e0004011. 
https://doi.org/10.1371/journal.pntd.0004011
 162. Geroult S, Phillips RO, Demangel C (2014) Adhesion of the ulcerative pathogen 
Mycobacterium ulcerans to DACC-coated dressings. J Wound Care 23:417–418, 422–424. 
https://doi.org/10.12968/jowc.2014.23.8.417
 163. Tanghe A, Content J, Van Vooren JP et  al (2001) Protective efficacy of a DNA vaccine 
encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 
69:5403–5411
 164. Tanghe A, Dangy J-P, Pluschke G, Huygen K (2008) Improved protective efficacy of a species- 
specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by 
homologous protein boosting. PLoS Negl Trop Dis 2:e199. https://doi.org/10.1371/journal.
pntd.0000199
 165. Hart BE, Hale LP, Lee S (2015) Recombinant BCG expressing Mycobacterium ulcerans 
Ag85A imparts enhanced protection against experimental Buruli ulcer. PLoS Negl Trop Dis 
9:e0004046. https://doi.org/10.1371/journal.pntd.0004046
 166. Hart BE, Lee S (2016) Overexpression of a Mycobacterium ulcerans Ag85B-EsxH fusion 
protein in recombinant BCG improves experimental Buruli ulcer vaccine efficacy. PLoS Negl 
Trop Dis 10:e0005229. https://doi.org/10.1371/journal.pntd.0005229
 167. Coutanceau E, Legras P, Marsollier L et al (2006) Immunogenicity of Mycobacterium ulcerans 
Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against 
Buruli ulcer. Microbes Infect 8:2075–2081. https://doi.org/10.1016/j.micinf.2006.03.009
 168. Roupie V, Pidot SJ, Einarsdottir T et al (2014) Analysis of the vaccine potential of plasmid 
DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans 
infected mice. PLoS Negl Trop Dis 8:e2604. https://doi.org/10.1371/journal.pntd.0002604
 169. Butt AM, Nasrullah I, Tahir S, Tong Y (2012) Comparative genomics analysis of 
Mycobacterium ulcerans for the identification of putative essential genes and therapeutic 
candidates. PLoS One 7:e43080. https://doi.org/10.1371/journal.pone.0043080
 170. Sarfo FS, Phillips RO, Ampadu E et  al (2009) Dynamics of the cytokine response to 
Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in 
humans. Clin Vaccine Immunol 16:61–65. https://doi.org/10.1128/CVI.00235-08
 171. Trigo G, Martins TG, Fraga AG et al (2013) Phage therapy is effective against infection by 
Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis 7:e2183. https://
doi.org/10.1371/journal.pntd.0002183
 172. Huygen K (2003) Prospects for vaccine development against Buruli disease. Expert Rev 
Vaccines 2:561–569. https://doi.org/10.1586/14760584.2.4.561
 173. Dangy J-P, Scherr N, Gersbach P et al (2016) Antibody-mediated neutralization of the exo-
toxin mycolactone, the main virulence factor produced by Mycobacterium ulcerans. PLoS 
Negl Trop Dis 10:e0004808. https://doi.org/10.1371/journal.pntd.0004808
 174. Bolz M, Ruggli N, Borel N et al (2016) Local cellular immune responses and pathogenesis of 
Buruli ulcer lesions in the experimental Mycobacterium ulcerans pig infection model. PLoS 
Negl Trop Dis 10:e0004678. https://doi.org/10.1371/journal.pntd.0004678
The Immunology of Buruli Ulcer
158
 175. Bolz M, Ruggli N, Ruf M-T et al (2014) Experimental infection of the pig with Mycobacterium 
ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease. PLoS Negl 
Trop Dis 8:e2968. https://doi.org/10.1371/journal.pntd.0002968
 176. Clancey JK (1964) Mycobacterial skin ulcers in Uganda: description of a new Mycobacterium 
(Mycobacterium Buruli). J Pathol Bacteriol 88:175–187
 177. Walsh DS, Cruz ECD, Abalos RM et al (2007) Clinical and histologic features of skin lesions 
in a cynomolgus monkey experimentally infected with Mycobacterium ulcerans (Buruli 
ulcer) by intradermal inoculation. Am J Trop Med Hyg 76:132–134
 178. Manna V, Bem J, Marks R (1982) An animal model for chronic ulceration. Br J Dermatol 
106:169–181
 179. Summerfield A, Meurens F, Ricklin ME (2015) The immunology of the porcine skin and 
its value as a model for human skin. Mol Immunol 66:14–21. https://doi.org/10.1016/j.
molimm.2014.10.023
 180. Beissner M, Piten E, Maman I et al (2012) Spontaneous clearance of a secondary Buruli ulcer 
lesion emerging ten months after completion of chemotherapy—a case report from Togo. 
PLoS Negl Trop Dis 6:e1747. https://doi.org/10.1371/journal.pntd.0001747
 181. Gordon CL, Buntine JA, Hayman JA et al (2011) Spontaneous clearance of Mycobacterium 
ulcerans in a case of Buruli ulcer. PLoS Negl Trop Dis 5:e1290. https://doi.org/10.1371/
journal.pntd.0001290
 182. Marion E, Chauty A, Kempf M et al (2016) Clinical features of spontaneous partial heal-
ing during Mycobacterium ulcerans infection. Open Forum Infect Dis 3:ofw013. https://doi.
org/10.1093/ofid/ofw013
 183. Revill WD, Morrow RH, Pike MC, Ateng J (1973) A controlled trial of the treatment of 
Mycobacterium ulcerans infection with clofazimine. Lancet 2:873–877
 184. Silva-Gomes R, Marcq E, Trigo G et  al (2015) Spontaneous healing of Mycobacterium 
ulcerans lesions in the Guinea Pig model. PLoS Negl Trop Dis 9:e0004265. https://doi.
org/10.1371/journal.pntd.0004265
 185. Deshayes C, Angala SK, Marion E et al (2013) Regulation of mycolactone, the Mycobacterium 
ulcerans toxin, depends on nutrient source. PLoS Negl Trop Dis 7:e2502. https://doi.
org/10.1371/journal.pntd.0002502
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter's Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
J. Fevereiro et al.
159© The Author(s) 2019
G. Pluschke, K. Röltgen (eds.), Buruli Ulcer, 
https://doi.org/10.1007/978-3-030-11114-4_9
M. Bolz (*) · M.-T. Ruf 
Swiss Tropical and Public Health Institute, Basel, Switzerland
Buruli Ulcer in Animals 
and Experimental Infection Models
Miriam Bolz and Marie-Thérèse Ruf
1  Naturally Infected Animals
Naturally infected animals presenting with typical BU lesions have so far only been 
described in Australia and there only in one major endemic focus, the central coastal 
Victoria close to Melbourne. Between 1980 and 1985, 11 M. ulcerans positive koa-
las (Phascolarctos cinereus) in a population of approximately 200 koalas on 
Raymond Island were described as having ulcers on the face, forearm, rump, groin 
or foot pad [1, 2]. More recently, examination of common ringtail (Pseudocheirus 
peregrinus) and common brushtail (Trichosurus vulpecula) possums from Point 
Lonesdale, a small BU endemic region with a recent human outbreak, revealed that 
38% of the analyzed ringtail possums and 24% of the brushtail possums had 
laboratory- confirmed M. ulcerans skin lesions and/or their feces tested positive for 
M. ulcerans DNA by PCR. Lesions were found on tails, toes, feet and noses with the 
majority occurring on the tail [3]. Another study by O’Brien et al. showed that M. 
ulcerans bacteria were present in possum lesions and from 90% of the animals with 
lesions, positive cultures could be obtained [4]. The high number of possums with 
skin lesions suggests that possums may represent an animal reservoir for M. ulcer-
ans in south-eastern Australia [3–5].
Sporadically, M. ulcerans positive lesions were also diagnosed in domesticated 
animals like dogs [6], a cat [7], horses [8] and alpacas [9]. In the dogs, lesions were 
found on the feet, legs and the rump and diagnosis was done by IS2404 real-time 
PCR (qPCR). Molecular typing in three animals confirmed that the infection was 
caused by disease-causing human strains [6]. The cat presented with a lesion on the 
nose and acid fast bacilli (AFB) staining as well as molecular methods confirmed 
the infection with M. ulcerans [7].
Despite considerable effort, several studies conducted in Africa were not able to 
corroborate the findings from Australia [10–12].
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2  The Mouse (Mus musculus) Model
2.1  History of the BU Mouse Model
Already with the first documentation of BU and its causative agent M. ulcerans, the 
description of potential animal models was published. Besides the report of the 
clinical picture and the cultivation of the new mycobacterial species, MacCallum 
et al. dedicated two separate chapters of their publication in 1957 to “Experimental 
investigations in laboratory animals” and the description of the “pathology of the 
experimental lesions in the rat” [13]. In their attempt to grow the unknown myco-
bacteria, the researchers conducted a series of experiments in guinea pigs, rats and 
mice, mostly injecting ground-up tissue of a patient lesion or exudate from a 
patient’s ulcer. As a next step they serially passaged a saline extract of lung tissue 
from infected animals that had died. None of the rats showed any signs of disease. 
Curiously, the rat of the fourth passage was forgotten and 16 months after intra- 
peritoneal (i.p.) injection developed edematous and ulcerated limbs and the tail 
sloughed off. Microscopic examination of ulcers revealed high numbers of AFB, 
thus the rat became the first animal to sustain M. ulcerans and characterize the bac-
teria while optimal in vitro growth conditions still had to be found [13]. Beside the 
rats, the scientists also reported the infection of 16 white mice, 12 guinea-pigs, two 
rabbits, one fowl and three lizards and made observations that would be re- confirmed 
in many more animal studies to follow: mice seemed more susceptible to infection 
than rats and guinea-pigs.
The actual development of the most commonly used animal model in BU 
research today, the mouse (Mus musculus), traces back to Fenner [14], who used it 
primarily for the evaluation of available antimicrobial compounds against the newly 
discovered M. ulcerans bacteria [14, 15]. In those early days of BU research, the 
mouse model was used to study all the major aspects of the disease that would later 
regain interest: chemotherapy testing [16], characterization of the immune response 
against M. ulcerans [17] and pathogenesis [18].
During the next 20 years, animal models in BU research were only occasion-
ally used, but importantly, the knowledge gained from previous studies served 
as a basis for the development of the mouse model for Mycobacterium leprae 
infection, the cause of leprosy [19]. A first grading system for assessing dis-
ease severity in the mouse model was described in 1972 in the context of drug 
testing [20] and further refinement of the mouse model to how it is mainly used 
today (foot pad injection) was then described in 1975 [21], a publication that 
reconfirmed the relative resistance of guinea pigs to M. ulcerans infection once 
more.
For another 20–30 years BU animal models were nearly forgotten again, before 
an increasing number of publications reflected the regained interest in the topic. The 
animal model that emerged as most commonly used was the mouse. Its applications 
can be roughly split into four different topics as further elaborated in this chapter: 
testing of antimicrobial compounds, vaccine development, study of the pathogene-
sis of BU and studies on the toxin mycolactone.
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2.2  Experimental Infection of the Mouse
2.2.1  Infection Sites
Very early in BU research and the use of the mouse model it was recognized that M. 
ulcerans needs a relatively cold location to grow in the mouse body [16, 18]. Even 
when animals were inoculated intracerebrally, the most vulnerable site of infection 
remained to be the tail [18]. Conveniently, low temperatures in mice are found in 
places that are not extensively covered with fur: the tail, the hind foot pads and the 
ears. Each of the three sites have their practical advantages and disadvantages; for 
example, the ears are very thin structures, which makes injection of bacteria chal-
lenging but on the other hand processing for histopathology is easy as there are no 
bones that have to be softened by decalcification, like it is the case in mouse foot 
pads. However, mouse ears do not contain a lot of fat tissue; hence they are very 
rarely used as site of infection, as M. ulcerans is mostly located close to fat cell 
areas in the human skin [22, 23]. It appears that nowadays, the few laboratories that 
use mice as animal models for BU have a preference for either infecting the tail 
[24–26] or the foot pads [27–33]. A recent study by Bénard et al. compared a new 
infection site, the hock, to the foot pad and the ear, concluding that in their hands the 
foot pad is the site of choice in the mouse for a well-defined, consistent and repro-
ducible infection [34].
2.2.2  Mouse Strains
The mouse strains used for infection with M. ulcerans in different laboratories are 
not overly diverse. While earlier studies had used outbred Swiss mice [28], the vast 
majority of newer studies used immunocompetent inbred strains that are very fre-
quently used in research in general: BALB/c [24, 28, 30, 35–37] and C57BL/6 mice 
[22, 32, 38] provided by different suppliers. Furthermore, a lot of studies did not use 
mixed sex mice but were only conducted in female animals. Again, depending on 
the laboratory, there seems to be a certain preference, rendering female BALB/c the 
most used mice for the BU mouse foot pad model by far. The first publication 
directly comparing the two most commonly used inbred strains, with each other and 
to infection in FVB/N mice was published in 2016 [25]. While infection led to 
ulceration of the tails and subsequent death of the animals in BALB/c and C57BL/6 
mice, FVB/N mice were able to spontaneously heal the developed ulcers and did not 
succumb to the infection, regardless of the different M. ulcerans strains used in the 
study [25]. The only other study published on the specific topic of mouse strain 
comparability reported that C57BL/6 might be slightly more susceptible to the 
infection, displaying increased leukocyte infiltration and bacterial growth compared 
to BALB/c mice [34].
Immunocompromised or transgenic mice were occasionally used to study the 
role of host factors in M. ulcerans infection. TNF receptor P55-deficient mice were 
shown to be equally susceptible to infection with highly virulent M. ulcerans strains 
as wild-type C57BL/6 mice, but showed increased susceptibility to non- and inter-
mediately virulent strains [39]. Bieri et al. documented the infection in interferon-γ 
(IFNγ)-deficient mice (B6.129S7-Ifngtm1Ts/J), identifying the cytokine as critical 
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regulator of early host defense mechanisms against M. ulcerans infection. Compared 
to wildtype mice, IFNγ-deficient mice displayed a faster progression of the infec-
tion with increased tissue necrosis, increased edema formation and a higher bacte-
rial burden [40]. These results were somewhat comparable with an earlier study that 
reported an increased susceptibility of IFNγ-deficient mice to an avirulent 
(mycolactone- negative) and an intermediately virulent M. ulcerans strain [41]. 
Studies in Rag2−/− mice and nude mice done in the same laboratory in Portugal 
showed a year later that lymphocytes are protective against infection with low- 
virulence strains but not against infection with highly virulent M. ulcerans [42].
Three more specialized transgenic mouse lines were used to study very specific 
questions in the mouse model for BU: Type 2 angiotensin II receptor knock-out 
mice (AT2R, [43]) were used for studying nerve damage caused by mycolactone but 
the infection in those mice was not further characterized [44]. Similarly, Fas- and 
Bim-knock out (KO) mice were used to establish the mode of action of the toxin 
mycolactone in vivo [45]. Mice lacking the proapoptotic Bcl-2 family member Bim 
did not develop necrotic BU lesions, but were able to control the mycobacterial 
multiplication. Recently a study used ICR mice, an outbred strain, for infection with 
M. ulcerans in order to study questions of BU transmission [46].
2.2.3  Mycobacterial Strains Used for Experimental Infection
Compared to the mouse strains used in the foot pad model of BU, the M. ulcerans 
strains used to infect the mice are much more diverse. Again, preferences appear to 
be present in different laboratories, probably mostly dependent on which strains 
were available to the laboratory at some point in time and which strains could be 
maintained without loss of virulence. As repeated passage by in  vitro culture 
prompts some of the M. ulcerans strains to lose their virulence plasmid [47, 48], 
some laboratories opted to passage their strains trough mouse foot pads in order to 
preserve their virulence [49–51]. Alternatively, low passage primary isolates have 
been used for productive infection of mice [52].
The most comprehensive study on how the use of M. ulcerans strains from dif-
ferent geographical origin and with different cultivation history influences virulence 
and immune responses induced in experimentally infected mice was published in 
2009 by Ortiz et al. Eleven different M. ulcerans strains isolated from different parts 
of the world over a time span of 47 years were used to infect 6–8 weeks old male 
BALB/c mice in the foot pad. Subsequently, their ability to cause a productive 
infection was reported as well as a detailed characterization of the inflammation 
induced by the different strains [53]. The bacterial strains used in these experiments 
partially overlap with the set of strains which was regularly used in the laboratory 
of Jorge Pedrosa, the only other research group that systematically characterized 
murine infection caused by different strains of M. ulcerans [30, 39, 41, 42, 48, 54]. 
The vast majority of BU mouse model studies were conducted with a single M. 
ulcerans strain. A few of those M. ulcerans isolates warrant mentioning as they are 
especially popular: Cu001 was originally isolated from a BU patient in Adzopé, 
Ivory Coast, in 1996 and has been successively passaged in foot pads of BALB/c 
mice ever since [28, 35]. It is probably the strain most often used for in  vivo 
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antibiotic treatment efficacy testing. Mu1615 is among the oldest isolates frequently 
used in mouse infection studies. It was originally obtained from a Malaysian BU 
patient in the 1960s and produces mycolactone A/B like the African isolates [55, 
56]. A spontaneous mycolactone negative mutant derived from this strain [47] has 
been used as avirulent M. ulcerans strain in the mouse model. S1013 was originally 
isolated in 2010 from a swab taken from the undermined edges of the ulcerative 
lesion of a Cameroonian BU patient [57]. Its passage number has been kept to an 
absolute minimum in order to preserve its virulence for studies in the mouse footpad 
model and the pig model of BU [40, 45, 52, 58–60].
2.2.4  Dose and Preparation of the Bacterial Inocula
Similarly to all the other experimental details of the BU mouse model described 
above, preparation of the inoculum, as well as how the number of bacteria in the 
inoculum is quantified varies from laboratory to laboratory. The waxy extracellular 
matrix of M. ulcerans together with the extreme slow growth of the bacteria are the 
two major factors that make preparation and dosing of an inoculum of M. ulcerans 
rather difficult. One strategy that some laboratories employ for dispersing clumps in 
their culture is to vortex the bacteria with glass beads prior to quantification of the 
inoculum [30, 32]. Sonication of the culture is another possible way of reducing 
clumps. However, both methods pose the risk of substantially altering the surface 
structure of the bacilli and with it potentially their interaction with the host after 
inoculation.
For estimating the number of bacteria in the inoculum, colony forming unit 
(CFU) counting or counting of AFB by microscopy are the most commonly used 
methods. The AFB counting method according to Shepard and McRae [61] offers 
the advantage that the actual dose is quantified at the time of injection, while 
2–3 months waiting time for colonies to grow is necessary after plating. On the 
other hand, CFU plating reveals the number of live M. ulcerans (or microclumps), 
which cannot be determined by microscopic enumeration. Hydrophobicity and the 
strong tendency of M. ulcerans to clump affect both methods, as well as dosing 
with the help of optical density (OD) or the so called McFarland standard [62]. 
Because an immediate estimate of how many bacteria are in a solution proved to be 
so difficult, some laboratories opted to produce cell banks of ready to go bacterial 
inocula that were frozen down for later use [63]. While this strategy allows to stan-
dardize inoculation, the freezing may affect to some extent relevant properties of 
the bacteria. In our hands, dosing the infection based on the wet weight of the 
bacterial pellet resulted in the most reproducible infection of mouse foot pads [34, 
40, 52, 58]. A wide range of inoculum sizes has been used. In some studies as few 
as a hundred or a thousand CFU [45, 50, 58] were injected, while others used up to 
105 or 106 CFU [54, 64].
2.2.5  Infection Outcomes and What to Measure
With an estimated generation time of 3–4 days in the mouse foot pad [14], animal 
experiments with M. ulcerans often last for a long time. Depending on the infection 
dose and the virulence of the strain injected, development of a visible pathology only 
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starts a few weeks after infection [14, 53], with a typical lag time of 3–4 weeks. 
When foot pads are inoculated, the first visible signs are usually edema on the top of 
the foot pad, followed by reddening of the foot and ankle and swelling to the point 
where foot pads appear to be “leaky”, so that cage bedding material starts to stick to 
the foot pad (Fig. 1). Infected mouse ears do not tolerate high bacterial inocula and 
infection often results in rapid loss of tissue [34]. Similarly, mouse tails do not com-
prise a lot of fat, hence the ulceration described in publications where mice were 
infected in the tail might have limited comparability to human BU lesions [24].
Several approaches to monitor progression of the infection exist. Measuring foot 
pad thickness with a caliper allows for repeated measurements while assessment of 
bacterial proliferation by CFU plating, AFB counting, or qRT-PCR require the 
euthanasia of the animal. For CFU determination the infected tissue is usually 
ground up, sometimes de-contaminated to avoid overgrowth with faster growing 
microorganisms and further processed [22, 52]. Very recently an optimized proce-
dure for extraction and quantification of bacterial RNA from infected mouse tissue 
was published, which provides a surrogate marker for viability of the bacteria [66, 
67]. Parallel to measuring foot pad thickness, a grading system can be applied to 
estimate the severity of the disease (Fig. 1). The grading system as it is used in many 
laboratories today was originally described in 1972 and has not substantially 
changed since then [20]. Both, grading system as well as foot pad thickness mea-
surements have mostly replaced the practice of measuring time to death of the ani-
mals. Instead, animals are monitored on a regular basis and animals are euthanized 
in compliance with laws for protection of experimental animals. If enumeration of 
AFB or quantification of bacterial DNA is not the primary objective of the analysis, 
all infected tissues can be processed for histopathology instead, and a description of 
inflammatory cellular infiltrates, tissue damage, etc. can be done.
For in  vivo monitoring of the infection, Zhang et  al. engineered recombinant 
bioluminescent M. ulcerans strains expressing luxAB from Vibrio harveyi [68]. The 
0 1
3 3+ 4 4
2+2
Fig. 1 Pathogenesis after subcutanous M. ulcerans injection in the mouse foot pad. Subcutaneous 
(s.c.) injection of acid fast bacilli into the healthy mouse foot pad (0) leads to progressive swelling 
and inflammation. (1) Grade 1, slight swelling; (2 and 2+) Grade 2, swelling with inflammation; (3 
and 3+) Grade 3, swelling with inflammation of the leg; (4) Grade 4, swelling with inflammation 
and possible ulceration, cage bedding sticking to the sole of the foot [65]
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relative light unit count measured for these strains in real-time correlated with the 
CFU counts [68]. The measured bioluminescence represents a suitable real-time 
surrogate marker for viable bacteria in mouse foot pads [33]. While these first con-
structs required exogenous substrate, limiting their utility in vivo, Zhang et al. went 
on engineering alternative bacterial strains that are autoluminescent and showed 
that they could reduce time, effort, animal numbers and costs of BU animal model 
experiments [69].
Another rather new approach proposed for monitoring antibiotic treatment suc-
cess is the detection of mycolactone by thin layer chromatography (TLC) or fluores-
cent TLC [70].
2.3  Research Applications for the Mouse Model
2.3.1  Antimicrobial Compound Testing
Antimicrobial compound testing is the application for which the BU mouse model 
was most frequently used since the discovery of the disease. Early on, researchers 
were interested in which antimicrobials would work against the newly described 
bacterium, which was the major incentive to have an animal model in the first place 
[15, 71, 72]. When the mouse model saw a revival in the early 2000s, testing new 
drugs in vivo was still its main use.
Systematic testing of different antimicrobial treatments in the mouse foot pad 
model with Rifampin, Rifabutin, Amikacin (AMK), Clarithromycin (CLR) and 
Streptomycin (STR) being the most intensively evaluated actives, showed that a 
combination therapy with Rifampicin (RIF) and AMK or STR might be effective for 
the treatment of human BU [28, 35] and led to the conduction of a human treatment 
trial using RIF and STR [73]. Mice were usually treated right away from the day of 
infection and only when a potential effective combination of drugs was found, later 
treatment starts were evaluated [29, 74]. When doses were administered in different 
time intervals, it became very clear, that the effect on M. ulcerans was significantly 
stronger when mice were treated daily [75]. Therapy durations varied between stud-
ies, but were mostly between 4 and 8 weeks [28, 29, 35, 36, 74, 76, 77]. Finally, 
Lefrançois et al. showed in 2007 that combination treatment with RIF and an ami-
noglycoside (STR or AMK) was able to prevent BU in mice with 8 weeks being the 
optimal duration of treatment [78]. Since the provisional guidelines of the World 
Health Organization (WHO) in 2004, BU patients were treated with a combination 
of RIF and STR [79]. This proved to be an effective treatment for the disease; how-
ever, the fact that STR had to be injected daily was less than optimal. Hence, 
researchers started to look for a cure that could be administered as a fully oral regi-
men and tested them in the mouse model [80–82]. As shown by Ji et al. in 2007 the 
combination of RIF and CLR has the highest potential of replacing the current stan-
dard treatment [82]. The WHO Technical Advisory Group on BU decided in 2017 
that the WHO recommendation for treatment of the disease should be changed to 
RIF and CLR, pending the availability of full results of a treatment trial with this 
drug combination.
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On a few occasions, treatment alternatives to drug administration were also 
tested in the BU mouse model: The effect of corticosteroid-induced immunosup-
pression on therapy with antibiotics was examined [83], phage therapy was shown 
to be effective in mice [54] and even the efficacy of hydrated clays on M. ulcerans 
growth was assessed in vivo on mouse tails [84]. However, as ideal the mouse model 
might be for drug testing and every therapy that can be applied by injection or 
orally, for the evaluation of topically applied therapies, including thermotherapy, 
the mouse model is highly impractical.
2.3.2  Vaccine Development
Including a vaccination phase prior to infection of mice with M. ulcerans further 
prolongs the overall time of the animal experiments, resulting in experiments that 
often last for several months. For example a single experiment including two immu-
nizations with an adjuvanted formulation of recombinant protein followed by infec-
tion with a low dose of bacteria results in almost five months of experiment time, 
not counting the time needed for specimen processing and follow up analyses [58]. 
An important factor determining the time span is the time researchers allow between 
the last immunization and the infection with M. ulcerans. Three weeks is generally 
agreed on as the minimum waiting time, although some research laboratories have 
published longer intervals, lasting up to 16 weeks [32, 85]. Mostly, protective effi-
cacy of the tested vaccines is assessed by comparing the speed and severity of the 
infection between mice receiving the candidate vaccine and a placebo group, very 
similarly to testing of antimicrobial compounds, where non- or mock-treated ani-
mals are used as negative controls.
After a first attempt of protecting rats and mice with Mycobacterium fortuitum 
against experimental M. ulcerans infections in 1985 [86], vaccination against BU 
was not experimentally addressed for another 15 years. Evidence in the literature of 
a partial protective effect of Bacillus Calmette-Guérin (BCG) vaccination in humans 
against BU prompted the research group of Kris Huygen to experimentally address 
this question in the mouse model and to become the major driver of the search for a 
BU vaccine in the following years [87, 88]. Tanghe et al. showed that intravenous 
vaccination with BCG (106 CFU) or intra-muscular vaccination with plasmid DNA 
encoding the BCG version of antigen 85A (Ag85A) both reduced the bacterial bur-
den in foot pads of infected mice [32]. Although BCG vaccination has been repeat-
edly shown to reduce CFU numbers in experimentally infected mice and/or slow 
down pathogenesis [24, 48, 51], the protection conferred by BCG was always only 
partial, of only relatively short duration and could not be prolonged by a booster 
vaccination [85]. Furthermore, a comparison between BALB/c mice and C57BL/6 
mice revealed that the efficacy of BCG vaccination against M. ulcerans may vary 
with both choice of host and pathogen strain [27]. A single sub-cutaneous vaccina-
tion with a mycolactone-negative M. ulcerans strain two months prior to foot pad 
infection with a virulent isolate was found to lead to a similar delay in foot pad 
swelling as a single BCG immunization [48], countering arguments that a homolo-
gous immunization would be more efficient than a heterologous with the M. bovis 
derived BCG.  Nevertheless, Hart et  al. further pursued this approach with some 
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success, as they were able to show that a prime vaccination with recombinant BCG 
expressing M. ulcerans Ag85A followed by a similar recombinant Mycobacterium 
smegmatis boost conferred superior protection against in vivo challenge than BCG 
alone [89]. While in this study immunizations were done intra- venously, the follow 
up study showed that a single sub-cutaneous injection with a BCG strain overex-
pressing two M. ulcerans antigens significantly prolonged survival times of mice 
compared to vaccination with the previously tested vaccination strains and applica-
tion routes [63]. Even though the observed differences in bacterial burden at some 
point during the experiment were correlated with longer survival of the mice, none 
of the vaccination strategies tested so far was able to completely protect against 
experimental infection with M. ulcerans.
Besides DNA-vaccines [24, 32, 51, 90] and immunization with live BCG and/or 
mycolactone negative M. ulcerans, a few other attempts have been made at develop-
ing a vaccine against BU: Mice were exposed to Naucoris aquatic insect bites or 
sensitized to Naucoris salivary gland homogenates [26], immunized with recombi-
nant virus replicon particles [52], adjuvanted recombinant proteins [58] or dewaxed 
whole-cell vaccines [64], all with limited protective efficacy at best.
2.3.3  Study of the Pathogenesis of Buruli Ulcer and the Immune 
Response to the Disease
While BU in humans results in different clinical presentations, pathogenesis in 
experimentally infected mice usually follows a defined pattern that is shaped by the 
virulence of the M. ulcerans strain used for infection. Two histopathological hall-
marks of the human disease are the presence of large extracellular clusters of AFB 
and the almost complete absence of inflammatory infiltrates in the center of the 
lesions [91, 92], but not necessarily in the periphery of lesions [93]. While acquir-
ing human tissue specimens from early BU cases is challenging due to practical 
and ethical reasons [93], the mouse model of M. ulcerans infection allowed to 
describe the early events in the pathogenesis of M. ulcerans infection in detail. In 
the mouse, at least some of the inoculated M. ulcerans bacteria are initially cap-
tured by phagocytes at the injection site and transported to the draining lymph 
node. The importance of initial intracellular stages prior to the emergence of extra-
cellular clusters [22] is not entirely clear. Infection with virulent strains in mice 
then leads to the fast influx of neutrophils and to some degree of monocytes/mac-
rophages, thus an early acute inflammatory response is induced [22, 30, 31]. Even 
though cellular responses are initiated in the draining lymph nodes, the progression 
from this initial acute to a more chronic inflammation with a predominance of 
mononuclear cells and/or lymphocytes is obstructed [30] because mycolactone is 
driving the cellular infiltrates into apoptosis. As a consequence AFB become extra-
cellular and proliferate in the developing necrotic and acellular subcutaneous 
lesion. At the boundary between the expanding necrotic areas and the surrounding 
healthy tissue, acute inflammatory infiltrates and intracellular bacteria are found 
[30]. This belt of immune cells remains a site of constant interaction between the 
pathogen and the immune system. As the infection progresses in infected mouse 
foot pads, edema becomes a prominent feature in histopathology, which is 
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macroscopically reflected by the onset of foot pad swelling [30, 31]. Swelling then 
extends to the ankle and the lower part of the leg, at which point mice are usually 
euthanized for ethical reasons [31]. Treatment of infected mice with RIF-STR rap-
idly leads to changes in the histopathological appearance of the infected tissue. The 
predominantly neutrophilic immune response changes to an infiltration dominated 
by lymphocytes and macrophages with prominent B-lymphocyte clusters and mac-
rophage accumulations surrounding the bacteria, which loose solid Ziehl-Neelsen 
staining and viability [31, 94, 95].
Both, immune response and pathogenesis observed in M. ulcerans mouse infec-
tions are strongly influenced by the toxin mycolactone. Mycolactone-negative bac-
teria are faster phagocytosed, no prominent necrosis is developing and the initial 
neutrophilic response becomes readily replaced by a predominantly lymphocytic 
and macrophagic infiltrate [22, 30]. Goto et al. examined whether nerve invasion 
occurred after infection of mouse foot pads with M. ulcerans and concluded, that 
the reported painlessness of BU might partially be attributed to intraneural invasion 
of bacilli [96]. Another study used injection of mycolactone rather than bacilli to 
study the effects of the toxin more directly in vivo [97].
3  Other Animal Models
3.1  Guinea Pig (Cavia porcellus)
Guinea pigs have been used as model for M. ulcerans infection as early as in 1974, 
when the presence of an exogenous diffusible toxin, nowadays known as mycolac-
tone, was proposed [98, 99]. Culture filtrate intradermally inoculated into guinea pig 
skin caused focal necrosis and inflammation, which closely resembled the skin 
lesions developing after injection of viable organisms as well as human BU skin 
lesions [98, 99]. In later experiments the effect of extracted mycolactone was com-
pared to the effects caused by infection of the skin with wild type and mycolactone- 
deficient M. ulcerans bacteria. It became clear that the histopathological effects 
observed were largely attributable to the polyketide toxin mycolactone, the main 
virulence factor of M. ulcerans, which induced apoptosis as demonstrated by TUNEL 
staining [100–102]. Macroscopic changes in the guinea pig after an intradermal 
injection of 106 and 107 M. ulcerans bacteria included the occurrence of a nodule 
after three days and the presence of ulcers after 8–12 days. Histopathological hall-
marks were described as the occurrence of central necrotic areas with extracellular 
AFB, which enlarged during the six weeks observation time and were surrounded by 
inflammatory infiltrates [100]. Recovery and re-growth of bacteria from the skin 
lesions was possible until week six after infection, but viability decreased substan-
tially during the observation period [100]. In a time-lapse study conducted by Silva-
Gomes et al. in which the ear and the back of the guinea pigs were subcutaneously 
inoculated, the early nodule-like structures progressed to ulcers with overlying scabs 
which healed between day 18–26 post-inoculation and were accompanied by bacte-
rial clearance regardless of the strain or the infectious dose used [103].
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One proposed potential way of contracting BU is the contamination of existing 
open wounds with M. ulcerans through exposure to a contaminated environment. In 
order to test this hypothesis, the skin of guinea pigs has been abraded and cultured 
M. ulcerans cells were applied on the open superficial wounds [104]. However, 
topical application failed to establish an infection during the 90 days of observation 
and all abrasion sites healed during the first week post exposure. In contrast, from 
all the sites intradermally injected with 106 M. ulcerans bacteria as positive control, 
re-cultivation was possible 90 days post infection [104].
Overall, guinea pigs seem to be quite resistant to M. ulcerans infections, and are 
far less frequently used as BU research model than mice.
3.2  Pig (Sus scrofa)
The pig has only recently been evaluated as a model to study BU [59, 60]. Pig and 
human skin share many similarities like thickness, general structure of the epider-
mis, dermis and the subcutaneous tissue, blood supply and the adnexal structures 
[105–109]. Moreover, the porcine immune system resembles the human immune 
system much more than the murine immune system [110]. This has made the por-
cine skin a preferred model for burn and wound healing studies [111–113]. In the 
studies conducted by Bolz et al. that represent the first description of the pig (Sus 
scrofa) as a model to study M. ulcerans infection, eight  week old piglets were 
infected subcutaneously with 100 μl of different numbers (2 × 103 to 2 × 107) of M. 
ulcerans bacteria [60]. For injections, both flanks [59, 60] as well as the upper and 
lower legs (unpublished results) were used to study up to 24 individual inoculation 
sites on a single pig, which greatly reduces the number of animals needed for indi-
vidual experiments. After 2.5 weeks macroscopic examinations revealed elevated, 
movable and firm nodular structures with the highest inoculation doses. After 
6.5  weeks these lesions presented either as indurated plaques or had ulcerated. 
Histopathological analysis showed that all key features typically found in early 
human BU lesions [93] were also present in the pig 2.5 weeks after inoculation 
(Fig.  2) [60]. At the inoculation site a necrotic core structure containing mainly 
extracellular clusters of AFB (Fig. 2a) and fat cell ghosts developed. The core as 
well as some infiltrating cells were strongly stained by the TUNEL method 
(Fig. 2b), indicating the presence of large numbers of apoptotic cells. The necrotic 
core was surrounded by a dense belt of infiltrating cells, which were mainly com-
posed of macrophages and CD3 positive T-cells (Fig. 2c) [59]. Inside the necrotic 
core debris of neutrophils was still detectable [59]. At week 6.5 the infiltration was 
even more organized, with the necrotic core being surrounded by a belt of neutro-
phils followed by a belt of macrophages and the outermost belt being mainly com-
posed of CD3 positive T-cells. Some of the pig lesions had ulcerated during this 
observation time. Although the majority of bacteria and necrotic slough were 
expelled during that process, small necrotic areas with AFB remained and under-
mined edges started to form. A slight epidermal hyperplasia was already observed 
after 2.5 weeks, however at later time points it was much more pronounced [60]. 
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Fig. 2 Histopathological appearance of a typical pig BU lesion two weeks after subcutaneous 
injection of 7 × 107 M. ulcerans bacteria. (a) Ziehl-Neelsen staining revealed the presence of large 
extracellular clusters, globi like structures and single intra- and extracellular AFB (pink rods). (b) 
The TUNEL staining method for apoptotic cells revealed a strong staining of the necrotic core as 
well as some TUNEL positive cells in the surrounding infiltration belt. (c) CD3 positive T-cells are 
only present in the outermost area of the infiltration and start to form a belt around the lesion core, 
which develops further until week 6
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Injection of synthetic mycolactone into pig skin induced a comparable dose depen-
dent effect in the tissue, with the formation of a necrotic core surrounded by inflam-
matory cells ([60] and unpublished results). In follow up studies cultivation of M. 
ulcerans bacteria re-isolated from infected pig skin was only possible up to 3 weeks 
after inoculation, and no chronic infection developed. The pig model thus seems to 
reproduce very well the early pathogenesis but not the chronic, necrotizing nature of 
human lesions.
3.3  Grasscutter (Thryonomys swinderianus)
Addo et al. [62] used the small hystricomorph rodent Thryonomys swinderianus, 
commonly called grasscutter, as a model for BU. The abundance of these animals in 
sub-Saharan Africa, the already existent establishment as laboratory animals and 
the substantially larger body size than mice (1.5–5  kg) were major reasons for 
choosing these animals. Grasscutters were subcutaneously inoculated into the 
shaved right thigh with 200 μl M. ulcerans suspension (1.0 and 5.0 McFarland stan-
dards) [62]. Progressive skin lesions (erythema, papule, nodule, edema, and under-
mined ulcer) developed in all inoculated animals with onset and severity of the 
lesions correlating with the infection dose. After the development of a nodule and a 
scab (40 to 154 days after inoculation), which was demonstrated to contain AFB, 
infection stalled and an inactive phase (265 to 371 days) occurred. Relapse occurred 
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in 90% of the animals and a fulminant progression of the disease with the formation 
of undermined ulcers was observed 441 to 540 days post inoculation. No systemic 
spread of bacteria was observed, with blood, urine and feces consistently being 
AFB-negative whilst the exudate and pus of the lesions was consistently AFB- 
positive. In histopathological analyses typical features of an M. ulcerans infection 
in the skin were observed together with rather untypically strong inflammation, 
neurogenic atrophy and osteomyelitis [62]. Re-cultivation of AFB from the infected 
animals however was not done and therefore viability of the AFB detected in exu-
date could not be determined.
3.4  Anole Lizard (Anolis carolinensis)
Based on the fact that M. ulcerans grows best at temperatures of 30–32 °C, and 
poikilothermic animals have a preferred body temperature of 32 °C, Marcus et al. 
tested the anole lizard, Anolis carolinensis, as a model to study BU [114, 115]. 
Lizards were inoculated with an M. ulcerans solution containing 103 CFU into the 
right lateral thorax, caudal to the edge of the right scapula. Five times a week lizards 
were incubated at 32 °C for 6–8 h. Six weeks post inoculation three different kind 
of lesions could be distinguished by histopathology [114]: a diffuse non- 
encapsulated, non-necrotizing granulomatous reaction with intracellular AFB (67% 
of the animals), a diffuse necrotizing granulomatous myositis of the thoracic wall 
with large numbers of extracellular AFB (24% of the animals) and the presence of 
several small, discrete, non-necrotizing encapsulated granulomas on the superficial 
surface of the supraspinatus nerve containing few intracellular AFB (4.8% of the 
animals). Lizards inoculated with dead M. ulcerans bacteria also developed non- 
necrotizing, non-encapsulated lesions, however, nearly all bacteria were found 
intracellularly. In contrast to the human disease, lesions did not develop inside the 
subcutaneous tissue but on the thoracic wall. Re-cultivated bacteria after single pas-
sage in the anole lizard showed a more rapid growth in vitro and were more virulent 
when introduced into mouse foot pads [114].
3.5  Nine-Banded Armadillo (Dasypus novemcinctus)
The nine-banded armadillo is a well-studied and characterized animal model in lep-
rosy research [116] with a body temperature of 30–35.8 °C. Walsh et al. showed that 
it can also be used to study BU in vivo [117]. In this study animals were intrader-
mally infected with 3 × 103 to 3 × 108 M. ulcerans into the lower abdominal and 
medial thigh regions. Injection sites were observed every 2–4  weeks for up to 
six months or death of the animal. 37% of the armadillos developed progressive 
cutaneous lesions, 15.5% developed evanescent papule-nodular lesions, 15.5% died 
within one week after inoculation and 32% of the animals developed no clinical 
signs [117]. Progressive cutaneous lesions presented with clinical signs comparable 
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to the human disease like undermined edges and extensive necrosis. All animals 
which developed ulcers died between four and six months after inoculation due to 
unidentified reasons. Histopathologically, lesions showed coagulating necrosis of 
the deep dermis, panniculitis, edema, sparse inflammation, fat cell ghosts and AFB, 
mainly present as extracellular clumps. Three months after inoculation, cultures of 
one animal on Loewenstein-Jensen media were negative, although AFB were still 
present [117].
3.6  Cynomologus Monkey (Maca fascicularis)
In a study with only one monkey it was shown that intradermal inoculation of M. 
ulcerans (2.2  ×  108) induced the formation of a papule which ulcerated within 
2–4 weeks after inoculation [118]. In biopsies, infiltration, edema, inflammatory 
infiltrates and extracellular bacteria were observed. Ulcers healed spontaneously 
between eight and 12 weeks post infection. At week six, cultures on Loewenstein- 
Jensen medium were negative, indicating that the cynomolgus monkey is only mod-
estly susceptible to M. ulcerans [118].
3.7  African Rat (Mastomys natalensis)
The common Africa rat was used by Singh and colleagues because of its abundance 
in sub-Saharan Africa. Inoculation of different doses into the tail vein led to ulcer-
ation and eventually the loss of the tail [119]. Supposedly due to the naturally sup-
pressed immune system, internal organs (lung, spleen, liver) as well as the footpads 
were involved in a small number of individuals [119].
3.8  Common Brushtail Possum (Trichosurus vulpecula)
Due to the lower body temperature and a high susceptibility of Trichosurus vulpec-
ula to M. tuberculosis and M. bovis, researchers infected these animals in two exper-
imental series with M. ulcerans. Inoculation with patient material into the hind leg 
of one possum led to the formation of a deep ulcer. Material from this lesion was 
used to inoculate four more animals, subcutaneously or intraperitoneally. Cutaneous 
ulcers and lesions at peripheral sites developed and AFB were recovered from them 
[120, 121]. In the second series it was shown that also non-inoculated T. vulpecula 
which were housed together with M. ulcerans inoculated animals developed ulcers 
from which AFB could be isolated [120]. Recent reports showed that wild possum 
species (Pseudocheirus peregrinus, Trichosurus vulpecula, Trichosurus cunning-
hami) in BU-endemic areas of Victoria, Australia are infected with M. ulcerans. 
Most clinically apparent cases were adults with ulcerative cutaneous lesions, gener-
ally confined to body areas without fur [4].
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4  Conclusions
Overall, none of the currently used animal models fully reflects the spectrum of 
human BU disease. The mouse model is the most widely used animal model for BU 
in research because it is cheaper than the other models, bacteria are multiplying well 
and the onset of the disease is relatively fast. Especially for drug and vaccine stud-
ies, that both require large numbers of animals, this model is most advantageous. 
However, due to the lack of subcutaneous fat tissue and limited tissue depth, the 
clinical and histopathological appearance of the lesions in mouse foot pads and 
mouse tails are quite different from human BU lesions. In contrast, in the pig and 
guinea pig models both clinical and histopathological appearances of BU resemble 
the human situation, making both species a good model for the characterization of 
the early pathogenesis of BU. However both species are only modestly susceptible 
to M. ulcerans infection and do not develop chronic infections. All other animal 
models described in this chapter have not been studied well enough to conclude for 
which purposes they would be more suitable than the well-established mouse foot-
pad model.
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1  Introduction
The clinical presentation of Buruli ulcer (BU) is manifold and includes relatively 
unspecific, non-ulcerative manifestations such as nodules, papules, plaques, and 
edema, which may eventually progress to necrotic ulcers [1]. Early case detection and 
adequate treatment are essential to prevent the formation of large cutaneous lesions that 
are often associated with serious morbidity and permanent disability. While surgical 
resection of BU lesions has long been the only treatment option, demonstration of the 
efficacy of rifampicin against M. ulcerans in a mouse footpad model [2, 3] and of a 
combined regimen of rifampicin and streptomycin in a clinical trial [4], have shifted 
first-line treatment recommendations to antibiotic therapy. Routine implementation of 
the drug regimen consisting of rifampicin and streptomycin administered daily for 
8 weeks, has greatly improved specific therapy and reduced the frequency of relapses 
[5–7]. However, considering the history of antibiotic resistance in other bacterial patho-
gens such as M. tuberculosis [8], concerns have arisen that inappropriate use of these 
antibiotics may lead to similar patterns of resistance in M. ulcerans. These concerns 
appear justified, as rifampicin, currently the only highly effective drug available for the 
treatment of BU, is also a major component in the treatment of other often co-prevalent 
mycobacterial infections such as tuberculosis and leprosy. Furthermore, streptomycin 
should be prescribed with caution, as long-term streptomycin toxicity in the form of a 
high incidence of persistent hearing loss has been documented in a follow up study of 
former BU patients who had received the combination therapy [9]. A new combination 
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therapy with rifampicin and clarithromycin is currently being evaluated as first-line 
treatment of BU.  Pre-treatment laboratory confirmation of clinically suspected BU 
cases has thus gained in importance; particularly because the differential diagnosis of 
skin conditions with similar manifestations is broad ([1, 10], http://www.who.int/
neglected_diseases/resources/9789241513531/en/) (Fig.  1) and misclassification of 
clinically suspected cases seems to be more common than previously assumed [11].
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Fig. 1 Differential diagnosis of BU. Infection with M. ulcerans can cause a variety of clinical 
manifestations, including both non-ulcerative and ulcerative forms. The differential diagnosis of 
BU thus comprises a wide spectrum of other skin conditions with a similar appearance. Shown are 
BU lesions (marked by a star) and non-BU lesions ((a) swollen lymph node; (b) lipoma; (c) gan-
glion; (d) cutaneous tuberculosis; (e) sickle cell necrosis; (f) burn; (g) snake bite). Pictures pro-
vided by Markus Schindler, Thomas Junghanss and Moritz Vogel are included
K. Röltgen et al.
185
For a detailed description of the currently available laboratory techniques and 
procedures for the detection of M. ulcerans the reader is referred to the WHO man-
ual “Laboratory Diagnosis of Buruli ulcer” edited by Françoise Portaels [12]. 
Laboratory tests routinely used for the detection of M. ulcerans infections include 
microscopic detection of acid fast bacilli (AFBs) in stained smears from clinical 
specimens and DNA detection by PCR targeting the M. ulcerans-specific insertion 
sequence (IS) element IS2404. Histopathological analysis of sections from the 
affected tissue and primary cultivation of the mycobacteria require sophisticated 
infrastructure and can only be performed by specifically trained personnel [12]. 
Furthermore, cultivation of the extremely slow growing mycobacteria takes several 
weeks to months and is thus impractical to aid pre-treatment diagnosis.
Of the established tests for the detection of M. ulcerans, IS2404 PCR has proven 
to be the most sensitive and specific, if performed according to demanding quality 
assurance schemes [13, 14]. Therefore, it is currently considered the diagnostic gold 
standard. However, data on the sensitivity and specificity of IS2404 PCR as well as 
of the other reconfirmatory tests are difficult to interpret from available comparative 
studies. Indeed, many studies reporting on the test performance of M. ulcerans detec-
tion evaluated sensitivity and specificity by comparing the respective tests to clinical 
diagnosis, which has limited accuracy, even when performed by experienced health 
staff. The sensitivity of microscopy—the only test that can be performed at district 
hospital level—has been reported to be relatively low. In BU endemic countries with 
resource-rich healthcare systems and good laboratory infrastructure, such as Australia 
and Japan, PCR-based diagnosis is routinely done, whereas in resource-poor set-
tings, logistical challenges and high costs often impede rapid PCR-based laboratory 
diagnosis at centralized reference laboratories. As a consequence, the diagnosis of 
BU at remote health facilities is often based on clinical judgment only. A simple and 
rapid point-of-care diagnostic test for BU is therefore of urgent need. Following rec-
ommendations of WHO, a diagnostic test suitable for application in developing 
countries should meet the so called ASSURED [15] criteria of being Affordable, 
Sensitive, Specific, User-friendly, Robust and rapid, Equipment free, and Deliverable 
to the end user. This chapter highlights current approaches as well as future prospects 
for the diagnosis of BU at district hospitals and the primary healthcare level, where 
the majority of BU patients are diagnosed to date.
2  Currently Available Laboratory Diagnostic Tests
2.1  Specimen Collection and Reference Standards
Before the introduction of antibiotic therapy in 2004 [16], the only treatment option 
for BU was surgical excision of the lesions, with or without subsequent skin graft-
ing. Laboratory reconfirmation was often done retrospectively by analyzing speci-
mens excised during surgery [17–19]. After 2004, when the importance of 
pre- treatment reconfirmatory laboratory diagnosis became more broadly recog-
nized, alternative sources for diagnostic specimens included punch biopsies obtained 
from non-ulcerative lesions and swab samples taken from the undermined edges of 
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ulcerative lesions, where the bacterial load is typically higher than in the core of a 
lesion. However, due to the invasiveness of punch biopsies, a consensus has been 
reached that in the interest of the patients, the method should be limited to special 
circumstances such as the establishment of differential diagnosis, investigations on 
paradoxical reactions or the reconfirmation of suspected treatment failure [12, 20]. 
Since 2007, a less invasive technique referred to as fine-needle aspiration (FNA), 
which can be performed at all healthcare levels and on both non-ulcerative lesions 
and ulcers with scarred edges that hinder the collection of swabs, has gradually 
replaced the use of punch biopsies for routine laboratory confirmation. The current 
recommendation for the collection of diagnostic specimens is thus to take swab and 
FNA samples from ulcers and non-ulcerative lesions, respectively. Recommendations 
for storage and transport conditions (e.g. media and optimal temperatures) for dif-
ferent types of samples are detailed in the aforementioned WHO manual “Laboratory 
diagnosis of Buruli ulcer” [12].
IS2404 PCR-based tests performed at reference centres have become a gold stan-
dard for the diagnosis of BU. While the accuracy of new diagnostic tests for M. 
ulcerans infection should therefore be assessed by a comparison to results obtained 
by PCR, the true accuracy of PCR assays is in turn difficult to evaluate, as it can 
only be compared to imperfect reference standards that have both limited specificity 
such as clinical diagnosis [10], or limited sensitivity, such as microscopy [21] and 
culture [22].
2.2  IS2404 PCR: The Current Gold Standard
In many mycobacterial species so called insertion sequence (IS) elements have been 
identified, representing suitable targets for PCR-based detection assays [23–26]. IS 
sequences are typically characterized by species-specificity and the presence of 
multiple copies within one genome, facilitating a highly specific and sensitive 
detection of the respective pathogens. In 1997, Ross et al. provided a milestone for 
the PCR-based diagnosis of BU by identifying an M. ulcerans-specific repetitive 
DNA fragment [27], which was later characterized in detail and designated IS2404 
[28]. The high copy number of IS2404 (between 150 and more than 200 copies per 
genome in M. ulcerans isolates from Australia and Africa) and of another IS, 
referred to as IS2606 (63 to 98 copies per genome in M. ulcerans isolates from 
Australia and Africa) [29], predestine their application as targets for sensitive PCR 
amplification tests for M. ulcerans. High specificity of developed PCR assays tar-
geting IS2404 was indicated by the lack of IS2404 PCR positivity among a wide 
range of other mycobacterial species [28, 30, 31]. The design of real-time quantita-
tive PCR (qPCR) assays targeting IS2404 [32, 33] has been another milestone in 
BU diagnostics development and has replaced conventional gel-based PCR as the 
routine method for laboratory confirmation of BU in many diagnostic and research 
laboratories [14]. Besides an increased sensitivity of M. ulcerans detection, major 
advantages of the qPCR assay are the reduced risk of contamination, and an 
improved turnaround time.
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Nevertheless, like any molecular test, the highly sensitive IS2404 PCR—whether 
performed as gel-based test or as a qPCR assay—is prone to contamination leading 
to false positive test results. Cross-contamination of samples with M. ulcerans 
genomic DNA may occur during sample collection or processing. However the 
most common problem is carryover of PCR product from previous amplification 
reactions. For instance, in a study describing histopathological features of BU, spec-
imens obtained from cases with filarial nodules and a keratin cyst without any his-
topathological indication for BU, tested positive in a nested IS2404 PCR [34]. To 
ensure accuracy of PCR assay results, it is thus essential to strictly adhere to the 
three-room principle necessitating one room for preparing the PCR mix, a second 
room for processing the samples and addition of template DNA in a PCR cabinet, 
and a third room for PCR amplification. Moreover, the accuracy of PCR is also 
endangered by false negative test results. In the study mentioned above, IS2404 
PCR was negative for a number of histology-confirmed BU patients [34]. If clinical 
diagnosis of BU appears convincing, but PCR results are negative, it is recom-
mended to collect and test a new set of samples to verify laboratory test results. 
False negative testing can result from a low concentration of M. ulcerans DNA in 
lesion specimens, a poor DNA extraction efficiency, low PCR sensitivity, and/or the 
presence of PCR inhibitors.
Thus strict adherence to good clinical laboratory practices and implementation 
of quality assurance protocols are necessary to generate reliable IS2404 PCR results. 
In 2008, the Technical Advisory Group of the WHO Global BU Initiative therefore 
recommended the establishment of an external quality assessment program (EQAP) 
for the PCR-based detection of M. ulcerans in clinical and also in environmental 
samples. This system was implemented and coordinated by WHO Collaborating 
Centres for BU (the Institute of Tropical Medicine (ITM) in Belgium for clinical 
samples and the Victorian Infectious Diseases Reference Laboratory in Australia for 
environmental samples) [14]. For the proficiency testing of clinical samples, coded 
specimens with known content were distributed by ITM to national reference and 
research laboratories that were asked to process the samples using DNA extraction 
and PCR procedures they usually apply for the detection of M. ulcerans DNA. Two 
rounds of clinical EQAP revealed a marked diversity in the quality of M. ulcerans 
DNA detection between laboratories. In the two assessment rounds, only 36% and 
31% of the participating reference laboratories had more than 90% concordant 
results with the proficiency panels. 64% and 38% reported false positive and 55% 
and 81% false negative results, respectively. These data demonstrate the need for 
continued internal and external quality assurance [14]. Transport of samples from 
remote endemic areas to central reference laboratories, ensuring sample integrity 
and timely return of results, represents another major challenge for the African BU 
control programs.
In summary, PCR targeting IS2404 is a sensitive and specific diagnostic labora-
tory test for M. ulcerans, but necessitates a well-equipped laboratory infrastructure, 
specifically trained laboratory staff and strict quality control. Recent advances in 
isothermal amplification and PCR product detection technologies have reduced 
equipment needs, but not staff requirements.
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2.3  Detection of AFBs by Microscopy: A Test for the Primary 
Healthcare Level with Limited Sensitivity
At the primary healthcare level, where most of the BU patients are diagnosed to 
date, microscopic detection of AFBs in direct smears from lesion specimens using 
a conventional light microscope is the only available confirmatory test for M. ulcer-
ans infection. This method relies on one of the characteristic properties of mycobac-
teria, namely their ability to form deeply coloured complexes with arylmethan dyes 
in phenol water such as carbol fuchsin, carbol crystal violet or carbol auramine O, 
that usually resist de-colorization by acidic ethanol (acid-fastness) [35]. For tuber-
culosis, sputum smear microscopy has for decades been the most widely used tool 
for the laboratory diagnosis in low- and middle-income countries. The most com-
monly used staining technique for the diagnosis of different mycobacterial infec-
tions is the so called Ziehl-Neelsen (ZN) method based on carbol fuchsin. When 
compared with IS2404 PCR, the reported sensitivity rates of direct smear micros-
copy for the detection of M. ulcerans ranged between 26% and 67%.1 The efficacy 
of the detection of small numbers of AFBs depends strongly on technical skills of 
the microscopist and on quality of the microscopic equipment. While being a simple 
and cost-effective first-line test for BU in resource-constrained settings, limited sen-
sitivity even in the hands of well-trained personnel is a serious drawback. 
Furthermore, misdiagnosis of cutaneous tuberculosis as BU based on microscopy 
may occur [40], as staining is not specific for M. ulcerans.
Although fluorescence microscopy based on auramine O staining has several 
advantages over light microscopy using ZN staining, its widespread use has long 
been hindered by the need for a more expensive fluorescence microscope. However, 
the recent advent of low-cost ultrabright light emitting diodes (LED) has enabled the 
development of simple and affordable fluorescence microscopes [41, 42]. Advantages 
of fluorescence microscopy include not only a simpler, quicker, and cheaper staining 
procedure, but also the possibility to screen slides with a lower power objective lens, 
which may improve sensitivity. For the diagnosis of tuberculosis, fluorescence 
microscopy seems to be as specific and more sensitive than light microscopy [43]. 
However, in a study on the detection of M. ulcerans, no significant difference in sen-
sitivity between the two microscopic detection methods was observed [38].
2.4  Considerations on the Accuracy of IS2404 qPCR and AFB 
Detection by Microscopy: Direct Comparison of the Two 
Techniques
A comparative analysis of IS2404 qPCR and smear microscopy conducted under 
optimal laboratory conditions using well-characterized lesion specimens from BU 
patients, showed that the amount of M. ulcerans DNA in extracts from the samples 
1  Twenty-six percent (11/43 punch biopsies) [36], 34% (344/1020 swab, FNA and tissue speci-
mens) [11], 56.1% (69/123 swabs) [21], 58.4% (45/77 swab and FNA specimens) [37], 59.4% 
(66/111 tissue specimens) [38], 64.6% (822/1273 tissue specimens) [39], 67% (83/124 swab and 
FNA specimens) [22].
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correlated well with the probability of finding AFBs [21]. While AFBs were detected 
in all IS2404 qPCR highly positive samples, the probability of microscopy- positivity 
decreased for specimens with lower DNA content. Samples with qPCR cycle thresh-
old (Ct) values above 34 were consistently negative (Fig. 2). A reasonable explana-
tion for these results is certainly the higher sensitivity of qPCR as compared to 
smear microscopy. However, failure to detect even a single AFB in 54 IS2404- 
positive swab smears after careful screening of entire microscopy slides using a 
high power objective lens [21], may also raise concerns about false positive qPCR 
results. Even if qPCR assays are performed under strict quality control, false posi-
tive results with high Ct values may emerge through cross-contamination of sam-
ples with minimal amounts of M. ulcerans DNA in the process of sample collection 
(such as healthcare workers or other personnel handling several patients and sam-
ples without changing their gloves). In this context, the number of qPCR cycles that 
should be performed and which Ct values should be considered meaningful may 
have to be reconsidered.
2.5  Histopathology and Cultivation of M. ulcerans: Research 
Tools Rather than Diagnostic Tests
The pathogenesis of BU is primarily driven by the unique polyketide-derived mac-
rolide exotoxin mycolactone of M. ulcerans, which causes apoptosis in mammalian 
cells [44]. In early non-ulcerative nodular stages of the infection the epidermis 
remains intact, but contiguous coagulative necrosis is found in the lower dermis. If 
mycolactone-mediated destruction of the subcutaneous tissue extends, the dermis 
and epidermis overlying foci of early M. ulcerans infection eventually degenerate. 
This leads to the formation of ulcers with undermined edges and a necrotic slough 
in the base. If mycolactone-mediated progression of tissue necrosis spreads mainly 
laterally, patients may develop extended non-ulcerative plaque or edematous forms 
of the disease [1].
Fig. 2 Correlation between IS2404 qPCR Ct values and microscopic AFB detection. A total of 
123 IS2404 qPCR-positive swab samples from BU lesions were analyzed by smear microscopy 
after ZN staining. While AFBs were detected in 69 (blue dots) of the 123 samples (56%), no 
AFBs were found in 54 (red dots) of the 123 samples (44%). AFBs were detected in all specimens 
having a qPCR Ct <27.8, whereas all specimens having a qPCR Ct >33.8 were microscopy- 
negative [21]
Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives
190
Macroscopic features are thus changing as BU lesions evolve, whereas the pro-
gressive contiguous coagulative necrosis of the dermal and subcutaneous adipose 
tissue with dead adipocytes appearing as characteristic “ghost” outlines [45, 46] are 
considered BU-specific histopathological hallmarks that can be found in both pre- 
ulcerative (nodules, plaques, edema) and ulcerative stages. Necrosis of the subcuta-
neous tissue and necrotic collagen in the dermis seem to be the best histopathological 
predictors of M. ulcerans disease [34], while other features, like epidermal hyper-
plasia, destruction of blood vessels and interstitial edema complete the picture. 
Vasculitis and mineral deposits have been observed mainly in specimens from 
African BU patients [46]. In active lesions, extracellular clusters of AFBs are typi-
cally located in deep layers of the necrotic subcutaneous fat tissue [21]. Due to an 
uneven distribution of the clusters [21], AFBs may not be found in all parts of an 
active BU lesion. While there is a remarkable lack of inflammatory leukocytes in the 
necrotic centre of the lesions, a belt of inflammatory cells surrounding the necrotic 
core can be observed already in early lesions [47].
For routine diagnosis of BU in the endemic African countries, histopathological 
analysis of tissue samples is impractical, as it necessitates sophisticated technology 
as well as specifically trained and highly experienced personnel. Moreover, ade-
quate tissue specimens obtained from the centre of a non-ulcerative lesion or from 
the edge of an ulcer by invasive sampling techniques are required. Therefore, histo-
pathological analyses are not routinely used for diagnosing BU in Africa, but rather 
for the establishment of a differential diagnosis such as for suspected cases of squa-
mous carcinoma secondary to BU [48, 49], or as a research tool to monitor treat-
ment success [50] or paradoxical reactions [51].
Culture of the causative organism of an infectious disease is a mainstay of bacte-
riological diagnosis, not least because it provides information on the viability of the 
pathogen and allows for drug susceptibility  testing. However, the extremely long 
generation time of M. ulcerans—colonies appear only after more than 2 months of 
incubation [18, 39]—excludes the application of cultivation for a pre-treatment con-
firmation of the clinical diagnosis. Moreover, successful cultivation of M. ulcerans 
depends on well-trained personnel and a complex laboratory infrastructure, only 
available at a few reference centres in the BU endemic African countries. Primary 
cultivation of M. ulcerans is thus performed mainly for research purposes, such as 
the monitoring of the efficacy of new treatment modalities [4, 6] as well as the dis-
tinction between paradoxical reactions and treatment failures [52, 53]. In addition, 
M. ulcerans isolates have been used for molecular epidemiological studies [29, 54, 
55] and are used for the surveillance of the potential emergence of drug resistance.
2.6  From Theory into Practice: Diagnosis of BU in Resource- 
Constrained Endemic Countries
BU mainly affects impoverished populations living in remote, rural areas of West 
and Central Africa with only limited access to health facilities. Patients often have 
to travel long distances to reach a BU treatment facility. Primary or district  level 
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health facilities, where the majority of BU patients present are usually not capable 
of performing PCR-based analyses. At best, direct microscopy of ZN-stained swab 
smears is performed, a test with limited sensitivity yielding a high proportion of 
false negative results. Specimens for PCR reconfirmation are usually stored and 
transported in bulk to reference laboratories, leading to delayed delivery of diagnos-
tic test results. Major delays in diagnosis and late initiation of treatment may on the 
other hand distract patients from returning to facilities of the formal health system. 
To avoid the dropout of patients, antibiotic therapy is often initiated upon the clini-
cal diagnosis.
As the routine use of IS2404 PCR in resource-constrained countries is also lim-
ited by high costs, more cost-effective stepwise approaches starting with the local 
microscopic analysis of swab smears for the presence of AFBs and—if this initial 
test is negative—subsequent testing by PCR at a reference laboratory have been 
proposed [37, 56]. However, the right balance between saving costs and taking the 
risk of false positive microscopy results has yet to be evaluated, as patients with 
cutaneous tuberculosis may receive the short 8 week course of antibiotics, if the 
treatment decision is made only on the grounds of a positive microscopy result [40].
Until the early 2000s clinical specimens from suspected BU patients were pri-
marily analyzed at international reference laboratories for retrospective confirma-
tion of the clinical diagnosis. Although several BU endemic African countries 
including Benin, Cameroon, Central African Republic, Côte d’Ivoire, Democratic 
Republic of the Congo, Ghana and Togo have installed their own reference labora-
tories for the diagnosis of BU [12], the situation has remained very challenging with 
respect to both timely sample transport and quality assurance. Therefore, the devel-
opment of a simple point-of-care diagnostic test for BU remains a major research 
priority [57].
3  Development of BU Diagnostics for District Hospital or 
Primary Healthcare Facility Level
In 2013, WHO together with the Foundation for Innovative New Diagnostics (FIND) 
convened a meeting of BU experts to review the need for BU diagnostics in the form 
of low-tech assays to be used in district hospitals and of simple, instrument- free rapid 
diagnostic tests (RDTs) that can be performed at the primary healthcare level. RDTs 
should be low-cost, simple to operate and read, stable, and yield results in a short 
period of time. They are expected to reduce the need for multiple healthcare visits, 
improve the chances that patients receive appropriate treatment, and can be highly 
cost-effective. Most available RDTs for neglected tropical diseases (NTDs) are based 
on immunoassays, including lateral flow, flow-through, agglutination, and dipstick 
test formats for antibody or antigen detection. Current strategies for the development 
of a BU RDT rely on antigen detection assays. For the diagnosis at district hospital 
level, options to detect M. ulcerans DNA by loop- mediated isothermal amplification 
(LAMP), antigens by enzyme-linked immunosorbent assay (ELISA) and mycolac-
tone by fluorescence-based thin layer chromatography (f-TLC) are being evaluated.
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3.1  LAMP: An Alternative for the Detection of M. ulcerans DNA
After its first description in 2000 [58], LAMP has gained attention as a rapid and 
cost-effective nucleic acid amplification method for the diagnosis of infectious 
diseases. Advantages of the LAMP technique over conventional PCR-based tests 
are lower technology requirements and simple read-out, as results can be read by 
the naked eye. However, this simple read-out does not allow for a distinction 
between the specific products and products of nonspecific amplification, posing a 
risk of false positive results [59], particularly when performed under suboptimal 
conditions [60]. Major improvements in LAMP test specificity have recently been 
reported by combining the technique with molecular beacons, targeting an inter-
nal sequence of the amplicon, thus allowing for a direct, specific detection of the 
expected product [61]. Nevertheless, significant training and infrastructure devel-
opment is required to achieve acceptable performance of LAMP assays [60], mak-
ing it suitable for district hospital settings, but not for the primary healthcare 
level.
In 2012, three different LAMP assays for the detection of M. ulcerans DNA 
were published. Sensitivity rates targeting either a sequence of the M. ulcerans 
virulence plasmid [62] or the multi-copy sequence IS2404 [63, 64] were deter-
mined to be close to those of conventional IS2404 PCR. No cross-reactivity was 
recorded with DNA of other closely related mycobacterial species [62–64]. 
However, the accuracy of these assays was assessed by testing only a very lim-
ited number of clinical specimens. As the potential occurrence of false positive 
results—compared to the conventional IS2404 PCR gold standard—was 
reported [63] even when performed in well-equipped specialized laboratories, 
LAMP assays will have to be evaluated in decentralized settings, where the 
technique is intended to be applied. Initial results have shown that the extraction 
and purification of M. ulcerans DNA and the generation of isothermal condi-
tions during the LAMP reaction remain major challenges for the application of 
LAMP assays under field conditions. Use of crude, non- purified DNA extracts 
and pocket warmers as heat source were shown to significantly decrease test 
sensitivity [64]. In order to overcome another shortcoming of the technique—
the requirement of cold-chains for transport and storage of reagents—a dry-
reagent LAMP assay targeting IS2404 was developed. Validation of this assay 
with a limited number of qPCR-confirmed lesion specimens in a laboratory 
environment indicated a sensitivity and specificity comparable to that of con-
ventional gel-based PCR [65].
Taken together, the LAMP method has the potential to be developed into a sensi-
tive and simple test for BU at district hospital level. As the technique requires basic 
laboratory infrastructure for template preparation and generation of isothermal con-
ditions, it is at its current stage of development not suitable for an application at the 
primary healthcare level.
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3.2  Detection of Mycolactone by f-TLC: Struggling 
with the Complexity of Lipid Extracts
As the production of mycolactone appears to be restricted to clinically relevant M. 
ulcerans lineages and some other closely related M. ulcerans ecovars [66], the toxin 
is considered an ideal target for the diagnosis of BU. In addition to their diagnostic 
application, mycolactone-based tests also have the potential to be used for the moni-
toring of treatment success by measuring mycolactone levels as an indicator for the 
presence of viable M. ulcerans bacteria in treated BU lesions [67].
One strategy to detect mycolactone is by staining of mycolactone bands after 
TLC-based separation of lipids extracted from clinical specimens. After demonstra-
tion by TLC and mass spectrometry that mycolactone can principally be detected in 
extracts from tissue samples of patients with ulcerative and non-ulcerative BU 
lesions [68], the TLC method has gradually been optimized to facilitate its applica-
tion in more peripheral laboratory settings. In order to overcome shortcomings of 
the technique such as low sensitivity and limited specificity due to the presence of 
other lipids with similar chromatographic behaviour in the lipid extracts, a boronate- 
assisted f-TLC was developed. Staining is based on the formation of cyclic boro-
nates with the 1,3-diols present in the mycolactone variants produced by the human 
pathogenic M. ulcerans lineages [69]. It has been reported that with this technique, 
mycolactone could selectively be visualized using an ultraviolet lamp with a detec-
tion limit of 2 ng [69]. In a preliminary study, f-TLC was applied to a panel of 
IS2404 PCR-positive samples from BU patients, returning 73.2% sensitivity and 
85.7% specificity [70]. Implementation of the f-TLC method in hospital laborato-
ries appears to be non-trivial and specific detection of mycolactone can be challeng-
ing due to background staining of co-extracted human lipids [71].
3.3  Serological Tests: Only Suitable for Seroepidemiological 
Studies
For serology-based diagnostic approaches, the identification of appropriate target 
antigens that are M. ulcerans-specific and at the same time capable of mounting 
strong immune responses in BU patients, but not in healthy individuals exposed to 
the pathogen is essential. Different strategies were used to find suitable antigens, but 
none of them led to the development of a diagnostic serological assay. While initial 
studies have reported that BU patients develop antibodies to antigens present in M. 
ulcerans culture filtrate, broad antigenic cross-reactivity among mycobacterial spe-
cies complicated the design of a serological test specific for M. ulcerans infections. 
Thus it is not surprising that the same studies have also shown that sera from healthy 
control individuals living in BU endemic areas, as well as from tuberculosis patients, 
contained antibodies that recognized the M. ulcerans target antigens [72, 73]. 
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Moreover, among M. ulcerans-specific antigens identified by comparative genom-
ics, none enabled a distinction between BU patients and healthy control subjects 
living in the same BU endemic area [74]. Furthermore, from a panel of monoclonal 
antibodies (mAbs) generated against immunodominant M. ulcerans proteins, only 
those specific for the 18 kDa small heat shock protein (shsp)—revealed sufficiently 
limited interspecies cross-reactivity. However, this antigen is not suitable as target 
for a BU-specific serological test, as anti-shsp antibodies are also frequently found 
in sera of healthy individuals living in BU endemic areas [75]. This circumstance 
however has opened up the opportunity for seroepidemiological studies assessing 
the exposure of populations to M. ulcerans [76–78].
3.4  Detection of Mycolactone and M. ulcerans Proteins by 
Antigen Detection Assays: Prospects for the Development 
of an RDT
As the development of sero-diagnostic tests for BU has failed, current strategies to 
develop RDTs for BU rely on the detection of M. ulcerans protein antigens or 
mycolactone. The main advantage of assays utilizing antigen-antibody interactions 
is their potential to be converted into test formats that can be deployed at the pri-
mary healthcare level. In fact, for numerous infectious diseases developed ELISAs 
in the form of antigen capture assays have been converted or have the potential to 
be converted into point-of-care (lateral flow) diagnostic assays [79–82].
In the case of mycolactone as a capture assay target antigen, the lipid-like nature 
of this macrolide toxin, as well as its cytotoxic and immunosuppressive properties 
have long hampered the generation of specific antibodies that can be used for its 
detection. Recently, a new strategy to immunize mice with a protein conjugate of a 
non-toxic synthetic truncated mycolactone derivative facilitated the generation of 
mAbs specific for the upper side chain and part of the core structure of mycolactone 
[83]. By using the generated mAbs, a first prototype competition assay was designed, 
in which a mycolactone-specific mAb is used in combination with a mycolactone 
derivative as signaling molecule, to quantify the amount of mycolactone in a sam-
ple. While the assay showed excellent specificity, its sensitivity must be optimized 
to allow for the detection of mycolactone in clinical specimens. If non-competing 
pairs of anti-mycolactone mAbs can be generated, development of an antigen cap-
ture assay may become possible.
An ideal protein target antigen for the development of a diagnostic test for BU 
should (1) be highly expressed by M. ulcerans, (2) have no orthologs in other preva-
lent pathogenic mycobacteria and (3) be easily accessible through a cell surface 
location. These predefined criteria were shown to be met by the M. ulcerans protein 
MUL_3720 [84]. Immunization of mice with the recombinantly expressed 
MUL_3720 facilitated the generation of a panel of high affinity mAbs against this 
antigen. Tandems of non-competing MUL_3720-specific mAbs recognizing differ-
ent epitopes were selected to enable the development of a highly specific MUL_3720 
detection assay in a sandwich-ELISA format [84]. Preliminary analyses comparing 
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qPCR and ELISA results indicate that the MUL_3720 capture assay is highly spe-
cific. Optimization of the ELISA format potentially suitable for district hospitals is 
on-going to reach a sufficiently high sensitivity of antigen detection. As a next step 
towards an RDT, the application of the generated mAbs in a lateral flow assay for-
mat is being evaluated.
4  Discussion
In spite of the availability of sensitive and specific IS2404 PCR assays routinely 
performed in resource-rich BU endemic countries and implemented in several 
national reference laboratories in BU endemic African countries, there is still an 
urgent need for simple and accurate point-of-care tests for the diagnosis of BU at 
district hospital and at primary healthcare level. In addition to logistical challenges 
and delays in the transport of clinical specimens to reference laboratories, outcomes 
of external quality assessment programs have demonstrated major shortcomings 
associated with the routine application of the PCR tests [14]. Ideally, the diagnosis 
of BU should furthermore not depend on the availability of laboratory infrastructure 
or of specifically trained laboratory personnel and should be performed directly at 
the point-of-care, so that treatment can be started without delay.
Immunochromatographic detection of antigens or antibodies in a dipstick or lat-
eral flow format constitute currently the core of commercially available point-of- 
care RDTs for infectious diseases [85]. Whereas attempts to design an antibody-based 
sero-diagnostic assay for BU have been equivocal [74–76], the recent identification 
of a target protein suitable for antigen-capture test formats, shows great promise 
[84]. In addition, mycolactone—the lipid-like molecule secreted by M. ulcerans—
may represent an optimal target molecule for the development of a sensitive and 
specific antigen detection test [83]. The advantage of antigen-based detection assays 
is that they can be converted to technically simple, robust test formats, easily appli-
cable even at the primary healthcare level. In contrast, prerequisites for most molec-
ular amplification techniques are incompatible with the ASSURED guidelines for 
point-of-care diagnostics [15].
In early 2011, WHO endorsed the first “sample in—answer out” qPCR platform 
with fully integrated sample processing for the diagnosis of tuberculosis in low- 
resource settings [86]. The GeneXpert MTB/RIF, a molecular test that can detect 
both M. tuberculosis DNA in sputum samples and rifampicin resistance mutations, 
has been developed for use at district and sub-district levels in tuberculosis endemic 
countries. However, in view of the limited resources available for the control of BU, 
costs for the production and broad introduction of a GeneXpert diagnostic test for 
M. ulcerans would be disproportionate. Several studies have reported attempts to 
develop nucleic acid-based point-of-care tests for the detection of M. ulcerans by 
the LAMP procedure [62–64]. While LAMP amplifies DNA with high sensitivity 
and specificity, its application under field conditions has so far been limited. This is 
mainly due to technology requirements associated with LAMP, such as template 
preparation  in field settings, production of kits with dried-down reagents, and 
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methods for unambiguous detection of amplification products [87]. If these prereq-
uisites are met, the LAMP platform can potentially be progressed into a format for 
the detection of M. ulcerans at district hospital level.
Point-of-care tests are key components to improve global health, but only if they 
are rigorously evaluated, and effectively regulated [88]. Careful pre-implementation 
evaluation of the accuracy of novel diagnostic tests for BU is absolutely essential 
and a consensus has to be reached on the reference standard to which the perfor-
mance of new diagnostic tests is compared. In view of the broad differential diagno-
sis of BU and reported misclassification of cases based on the clinical presentation 
of patients, a comparison to clinical diagnosis—as done in many previous studies—
is not satisfactory. Instead, test performance should be evaluated by a comparison to 
the current qPCR reference standard. However, strict quality assurance of the qPCR 
assay used for evaluation of the tests has to be ensured. Clearly, technological inno-
vation is not sufficient. After successful development and evaluation of a new point- 
of- care test for BU, decentralized implementation of the test will involve training 
programs and monitoring of the effectiveness of the new tests in decentralized set-
tings, to ensure the accuracy of test results.
5  Outlook
In the past years, the number of BU cases reported annually in many African 
endemic countries has declined. This may partly be attributed to the establishment 
of effective national BU control programs and a reduction in transmission inten-
sity. On the other hand, the intensity of disease surveillance and case search activi-
ties may have declined, resulting in an underestimation of the true disease burden. 
Limited funding for the control of BU can lead to a lack of awareness and a loss of 
local competencies among health workers. For instance, in a recent retrospective 
assessment of the diagnosis of BU in Ghana between 2008 and 2016, a gradual 
decline in the annual laboratory confirmation rate of clinically suspected cases 
from 52% in 2008 and 76% in 2009 to only 15% in 2016 was revealed, reflecting 
both the decline in BU incidence and the loss of clinical expertise [11]. Considering 
this scenario, as well as the broad differential diagnosis of BU, the availability of a 
reliable point-of-care test for the diagnosis of BU is crucially important. Apart 
from BU, several other NTDs present with skin manifestations, either as the pri-
mary or as an associated clinical condition. Many skin diseases have similarities in 
terms of their ability to cause long-term disabilities, reinforcement of poverty and 
geographical distribution. Collectively, these highly disabling and stigmatizing 
diseases constitute a great burden on the affected populations. Major deficiencies 
in our understanding of many of these diseases and a lack of tools to combat them 
necessitate further investment in research and development of control strategies. 
Integration provides an opportunity to leverage funding and to spearhead efforts 
for the development, optimization, and implementation of new diagnostic, thera-
peutic, and preventive tools for the simultaneous control of several co-endemic 
skin NTDs [89].
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1  Historical Aspects
MacCallum and coworkers described Buruli ulcer  (BU) as an infectious disease 
caused by Mycobacterium ulcerans in Victoria, Australia. They first considered the 
skin lesions in their patients to be caused by tuberculosis or leprosy, when they 
observed numerous acid-fast bacilli in the biopsy specimens [1]. The typical dura-
tion of illness was between 1 and 2 years; treatment was essentially surgical. With 
the advent of chemotherapy for tuberculosis [2–4], and later for leprosy, doctors 
made individual attempts to treat the lesions with anti-tuberculosis and anti-leprosy 
drugs. The anecdotal evidence suggested poor or no response to chemotherapy with 
rifampicin monotherapy [5], despite the fact that in vitro susceptibility of 33 strains 
of M. ulcerans was as good as for M. tuberculosis [6]. A randomized clinical trial by 
the British Medical Research Council in Buruli county (now called Nakasongola; 
Uganda) failed to show any benefit from clofazimine, a drug then first marketed for 
leprosy [7]. A small-sized trial with cotrimoxazole (18 participants; 12 evaluable) 
was inconclusive [8]. A small-sized randomized study in Côte d’Ivoire compared a 
204
combination of dapsone and rifampicin with placebo; the follow-up was limited; the 
ulcer size decreased slightly faster in the intervention group but the baseline charac-
teristics of both groups differed, and the study did not allow to draw any firm con-
clusions about the effectiveness of these drugs [9]. By the turn of the millennium, 
the discrepancy between in vitro efficacy of rifampicin [6] or clarithromycin [10] 
and lack of clinical response prompted to stressing the need for well-designed and 
well-powered drug trials, but in the meantime, to also improve early detection and 
surgical treatment [11].
One important question that comes to mind when looking back at earlier studies 
that failed to show effectiveness of antimicrobial treatment for BU is how the clini-
cal response was assessed. Even long before the chemical structure of the toxin 
mycolactone was discovered [12], it was realized that a toxin secreted by M. ulcer-
ans was responsible for the extensive tissue necrosis [13, 14] as well as for the 
immune suppression observed and replicated in experimental animals, using a cul-
ture filtrate of M. ulcerans [15]. Radical surgical excision was to some extent effec-
tive but at the cost of tissue loss, and the need for plastic surgery, e.g., split-skin or 
full-thickness skin grafting. Reported recurrence rates following surgical treatment 
were variable; one follow-up study from Benin reported 6.1% recurrence in a subset 
of patients (66/150; 44%) followed up to 7 years after surgery [16]. In a case series 
of 346 patients operated in three centers in Côte d’Ivoire, the recurrence rate was 
17.1% [17]. A large difference in recurrence rates was reported from two centers in 
Ghana; 21/45 (47%) of patients had a recurrence in one hospital, as compared to 
6/33 (18%) in the other hospital [18]. In a case series from the Bas Congo, DR 
Congo, of 51 patients seen over 2 consecutive years, 14 (39%) had recurrent disease 
after previous surgery [19]. Lesions at a pre-ulcerative stage can be excised success-
fully with primary closure, however a 1-year recurrence rate of 16% was observed 
in a cohort of 50 patients in Ghana [20].
With increased understanding of the dominant role of the secreted toxin myco-
lactone in the pathogenesis of Buruli ulcer, and realizing that perhaps the best mea-
sure of efficacy of antimicrobial treatment might be complete healing without 
recurrence, the effectiveness of antimicrobial treatment might have been underesti-
mated in the past. Indeed with killing of M. ulcerans in lesions, as exemplified by 
the beneficial effects of different classes of antimicrobials in vitro [6, 10, 21], myco-
lactone secretion might stop, but the impact on tissue damage including necrosis 
would conceivably take more time than in any other infectious disease. Likewise, 
there was increased understanding of the profound effects of mycolactone on the 
immune system, with little local [22] and systemic inflammation [15]. Yet another 
factor perhaps blurring the observation of response to antimicrobial therapy is a 
common paradoxical increase in lesion size, development of new lesions, and 
increased inflammation following antimicrobial therapy [23–25]. Apart from the 
in vitro studies [6, 10, 21], several studies in animal models had shown the efficacy 
of anti-mycobacterial drug combinations [26–28].
A formal proof-of-concept study to evaluate the potential of antimicrobial 
treatment without additional surgery was the landmark study conducted in Ghana, 
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under the umbrella of the WHO Global Buruli Ulcer Initiative [29]. Patients hav-
ing non-ulcerated lesions suspected to be M. ulcerans infection were randomly 
allocated to 0, 4, 8 or 12 weeks of antimicrobial treatment with a combination of 
streptomycin and rifampicin; later a 5th group receiving 2 weeks of treatment was 
added; the total number of study participants was 21. Lesions were subsequently 
surgically removed and submitted for culture, PCR and histopathology. As no 
bacteriological confirmation tests were carried out prior to the start of therapy, 
some of the lesions remained bacteriologically unconfirmed to be Buruli ulcer 
disease; none of the patients receiving at least 4 weeks of treatment had viable 
bacilli by culture of their excised lesion; none had recurrent disease 12 months 
after start of treatment. Although some questions remained unanswered, this study 
provided the first robust evidence that antimicrobial treatment alone was able to 
sterilize non-ulcerated lesions of M. ulcerans infection, with no recurrence or 
positive culture in patients treated for at least 4 weeks with the antimicrobial com-
bination [29].
With the introduction of antimicrobial treatment, a more conservative, less 
aggressive approach of surgery in addition to antimicrobial treatment was subse-
quently advocated [30–33].
For over 10 years now, the WHO has recommended antimicrobial treatment as 
the primary treatment modality. Below, we systematically discuss the literature on 
antimicrobial susceptibility of M. ulcerans in vitro and in animal models; and the 
accumulated evidence for effectiveness as well as safety (i.e., adverse reactions) of 
antimicrobial treatment regimens emerging from clinical studies.
2  Antimicrobial Susceptibility of M. ulcerans
For the review of in vitro activity of antimicrobial agents against M. ulcerans, we 
used a systematic approach searching the literature in PubMed. Using ‘(Buruli 
OR ulcerans) AND (antibiotic OR antimicrobial OR in-vitro OR susceptible)’, 
we retrieved 520 unique results that we further analyzed for duplicates and con-
sistent reporting. We cross-searched references obtained from articles we 
analyzed.
The most widely used antimicrobials for M. ulcerans infection have been 
rifampin, streptomycin and clarithromycin. M. ulcerans is a phylogenetically close 
relative of M. tuberculosis and M. leprae and has evolved from a common M. 
marinum- like ancestor [34]. Subsequently, many attempts to treat M. ulcerans infec-
tion have been undertaken seeking to use and repurpose antibiotics active against M. 
tuberculosis and M. leprae. To estimate efficacy in vitro, the usual way to screen 
these agents is by determining the minimal inhibitory concentration (MIC) of inocu-
lates of M. ulcerans in mycobacterial culture media. Next, inoculation of viable M. 
ulcerans in the mouse footpad is a well-established in vivo model to assess efficacy. 
The final test is eventually to test these agents in patients affected by Buruli ulcer 
disease. Such studies are extremely challenging, as the majority of potential study 
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participants are patients (many being children) that live in underprivileged circum-
stances with limited access to health care, and generally low educational background 
[35–37].
2.1  Ansamycins/Rifamycins
Ansamycins or rifamycins act on mycobacteria by inhibiting RNA synthesis through 
interfering with bacterial RNA-polymerase. Rifampin is the rifamycin most widely 
used in the treatment of Buruli ulcer. The drug has a strong bactericidal effect and 
an MIC of approximately 0.5 μg/ml [38–40]. Rifampin is administered orally at a 
dose of 10 mg/kg to humans to treat Buruli ulcer and is the backbone-drug of most 
regimens evaluated to date. Other rifamycins that have been shown to kill M. ulcer-
ans are the rifampin-analogues rifabutin [26] and rifapentine [41]. Rifapentine is 
highly active against M. ulcerans with an MIC of 0.125–0.5 μg/ml [41, 42]. Because 
of its longer half-life time compared to rifampin, an intermitted rifapentine-based 
regimen with only two or three times weekly administration of antibiotics has been 
tested in mice [41]. Such an intermittent regimen is suggested to allow outpatient 
management and to simplify clinical management. However intermittent regimens 
also bear the risk of confusion and low compliance and patients being subsequently 
lost during treatment. Even though antibiotic resistance is not a major concern in the 
slowly replicating organism M. ulcerans, rifampicin resistance has been detected in 
rare instances [43, 44]. In-vivo, resistant mutants were isolated after monotherapy 
with rifampin in mice, which should be avoided in the clinical setting. The resis-
tance was conferred by mutations in the rpoB gene of M. ulcerans [45]. Albeit 
uncommon and of unknown clinical significance, researchers in Ghana found 5.7–
11.4% of isolates from their study districts to be resistant to 40 μg/ml rifampin [40]. 
Yet another rifamycin tested in M. ulcerans is rifabutin. Rifabutin has an MIC of 
0.1–0.4 μg/ml against M. ulcerans [39].
2.2  Aminoglycosides: Streptomycin
Streptomycin is an injectable aminoglycoside with a strong bactericidal effect on M. 
ulcerans and one of the first agents ever shown to be effective against this organism 
[46, 47]. It is a protein synthesis inhibitor that hinders binding of formyl-methionyl- 
tRNA to the bacterial ribosomal 30S subunit. In the mouse model, streptomycin 
remains one of the most active agents against M. ulcerans and is used as intramus-
cular injection of 15 mg/kg in humans [48]. In single drug in vitro and in vivo stud-
ies, streptomycin was more active than amikacin and linezolid, but less active than 
rifampicin and moxifloxacin [49]. In preclinical studies, streptomycin-containing 
regimens outperform all other commonly used drug combinations both in terms of 
colony-forming units remaining in infected mouse footpads and recurrence rate. 
However, the need to inject streptomycin is very impracticable in the rural African 
setting where Buruli ulcer is most common. It bears the risk of parenteral 
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(needle- associated) infection and also threatens patient compliance due to fear of 
painful, daily injections, especially in children. Besides, streptomycin causes oto-
toxicity as well as nephrotoxicity as observed in patients followed after having been 
enrolled in the BURULICO trial [50].
2.3  Amikacin
Amikacin is another aminoglycoside that has been suggested for use in the treat-
ment of patients with Buruli ulcer. It is highly active against M. ulcerans with an 
MIC of 0.5–1 μg/ml [21] and was shown to be equally efficient in the mouse model 
[26]. In a study testing a series of isolates, the MIC ranged between 0.25–1 (mean, 
0.65) μg/ml [49]. Amikacin was as effective as streptomycin in the M. ulcerans 
mouse model [26].
2.4  Macrolides: Clarithromycin
Clarithromycin is a protein synthesis inhibitor of the macrolide family. It reversibly 
binds to the 23S rRNA on the 50s ribosomal subunit and subsequently prevents 
polypeptide synthesis. It acts mainly as a bacteriostatic drug in M. ulcerans therapy. 
The MIC of clarithromycin against M. ulcerans is approximately 0.12 μg/ml [10, 
26, 51, 52]. Clarithromycin is well tolerated, it can be taken orally and it is widely 
available. It has been shown to be non-inferior when replacing streptomycin after 
4 weeks in the 8 week rifampin-streptomycin regimen while treating small lesions 
[36]. Following preliminary results of a randomized controlled trial (ClinicalTrials.
gov identifier: NCT01659437) comparing 8  weeks rifampicin plus streptomycin 
with 8  weeks rifampicin plus clarithromycin, the latter regimen is now recom-
mended by WHO.1
2.5  Azithromycin
Azithromycin is a macrolide antimicrobial agent active against a variety of organ-
isms. The mean MIC against a collection of different strains was 0.39 μg/ml [40]. 
However when 100 mg of azithromycin was administered to mice infected with M. 
ulcerans, only a modest bacteriostatic activity was observed [53].
2.6  Fluoroquinolones
Various fluoroquinolones such as ciprofloxacin, ofloxacin and moxifloxacin have 
been shown to be active against M. ulcerans with MICs ranging from 0.25 to 1 μg/ml 
1 http://www.who.int/neglected_diseases/events/WHO_BU_TAG_2017_report.pdf?ua=1.
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[21]. Fluoroquinolones are bacterial DNA gyrase inhibitors. They impede DNA 
replication and transcription by hindering the DNA gyrase-catalyzed super-coiling 
of double-stranded DNA. In Australia, Buruli ulcer patients are frequently treated 
with rifampicin in combination with a fluoroquinolone, such as ciprofloxacin [54]. 
Such fluoroquinolones are administered orally and have favorable pharmacoki-
netic properties such as good tissue penetration. However, there is some concern 
about the use of fluoroquinolones in children; in Australia most Buruli ulcer 
patients are adults, most of them elderly, whereas in Africa where most of the cases 
are reported, the median age of patients is around 15 years. Fluoroquinolones may 
cause serious arthropathy in children and minors. However the evidence about 
increased toxicity in the young is incomplete. Although caution remains warranted, 
fluoroquinolones have increasingly been used in children without significantly 
increased adverse events or toxicity [55, 56]. The most potent fluoroquinolone 
against M. ulcerans is sparfloxacin, with an MIC at 0.25 μg/ml in most strains 
tested [21]. The MIC of ofloxacin in tested strains of M. ulcerans was 1.26 μg/ml 
[40]; in another study, ofloxacin was least active of all fluoroquinolones tested with 
an MIC of 2 μg/ml [21]. Moxifloxacin (MIC 0.14 μg/ml), sitafloxacin (MIC 0.125–
0.5 μg/ml) and prulifloxacin (MIC 1–3 μM) are also effective [49, 57, 58]. Of note, 
fluoroquinolones have increasingly been used in Ghana, one of the countries highly 
burdened with Buruli ulcer; an alarming rate of fluoroquinolone-resistant E. coli 
was noticed [59].
2.7  Clofazimine
Clofazimine is an anti-leprosy drug that has emerged as a critically important 
sterilizing drug in the treatment of multi-drug resistant tuberculosis. Its effect on 
mycobacteria is delayed but strongly bactericidal [60]. The mechanism of action 
is multifactorial, complex and not fully understood. As a prodrug, it is reduced by 
type 2 NADH-quinone oxidoreductase resulting in the release of bactericidal 
quantities of reactive oxygen species. It is then believed to competitively inhibit 
menaquinone, a crucial electron acceptor in the mycobacterial respiration chain 
[61]. Clofazimine possesses also some poorly understood anti-inflammatory 
activity for which it is used in conditions like severe acne or discoid lupus erythe-
matosus [62]. These anti- inflammatory properties might also be part of its mode 
of action in mycobacterial infections where tissue damage by inflammatory pro-
cesses is a hallmark. The MIC for various strains of M. ulcerans was 2.19 μg/ml 
on average [40]. As mentioned above, in an early trial clofazimine monotherapy 
was inefficacious in human Buruli ulcer patients [7]. In mice, clofazimine in com-
bination with rifampicin was very effective with relapse-free cure following a 
6-weeks oral regimen [63]. Clofazimine causes yellow-orange skin-discoloration 
as well as gastrointestinal disturbances as adverse effects [64]. Newer clofazimine 
analogs with reduced accumulation and thus less risk for skin discoloration are 
under development [58].
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2.8  Dapsone
Dapsone is an anti-leprosy drug that has widely been used. Activity against M. 
ulcerans is moderate—the MIC ranged between 2.0 and 4.0 μg/ml in one study [39] 
and the mean MIC was 0.94 μg/ml in another study [40].
2.9  Doxycycline
Doxycycline, a tetracycline, was inactive against M. ulcerans in one study [58].
2.10  Oxazolidinones
Linezolid showed only intermediate activity with an MIC ranging from 3 to 10 μM; 
as posizolid and sutezolid. This oxazolidinone is currently considered as a major 
component of second-line tuberculosis treatment [58, 65]. In another study with 29 
isolates of M. ulcerans tested, the mean MIC was 0.73 μg/ml [49].
2.11  Avermectins
Avermectins are a class of anti-helminth and anti-parasite drugs that are thought to 
have intermediate efficacy on M. tuberculosis [66]. Subsequent testing showed the 
MIC for ivermectin and moxidectin ranging from 4 to 8 μg/ml [67]. In another 
study, the MIC for selamectin was 2–4 μg/ml and ivermectin and moxidectin showed 
no activity >32 μg/ml [68].
2.12  Trimethoprim and Epiroprim
Trimethoprim was not effective against M. ulcerans. However, epiroprim, another 
dihydrofolate reductase inhibitor, showed an MIC of 0.5–1.0 μg/ml [69].
3  Experimental Drugs
A series of experimental compounds, mainly originating from TB drug research 
pipelines were tested for use in M. ulcerans chemotherapy.
Diarylthiazoles and 1,3-diaryltriazenes are compounds with high potency against 
mycobacteria, including M. ulcerans. Different experimental 1,3-diaryltriazene 
analogues showed sub-micro molar inhibitory activity against M. ulcerans 1615 lux 
[70]. Similarly, diarylthiazoles, like fatostatin, were found to have a significant effi-
cacy against M. ulcerans [58]. KRM-1648, a benzoxazinorifamycin with good effi-
cacy in the TB mouse model was equally tested for use in M. ulcerans and showed 
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good killing at an MIC of 12–25 μg/l [39]. The diarylquinoline bedaquiline, also a 
TB research drug had a mean MIC of 0.03 (0.015–0.12) μg/ml when tested against 
a set of 29 isolates [49].
GyrB is a common drug target in TB therapy and experimental GyrB inhibitors 
showed good to moderate activities (MIC 0.3–10 μM) against M. ulcerans [58]. In 
the same study, pyrrolamide and aminopyrazinamide exhibited activity with an 
MIC of 0.3–1.0 μM [58]. These investigators found one aminopyrazole, as well as 
pyrazolopyrimidine and one hydroxyquinolone to kill M. ulcerans with MICs from 
0.3 to 3.0 μM [58].
There is high genetic similarity between M. tuberculosis and M. ulcerans. Yet 
some of the compounds that are active against the first, failed to prove efficacy in the 
latter. SQ641, PA-824 a promising nitroimidazopyran for tuberculosis, semisyn-
thetic ketolides (HMR 3647 and HMR 3004), bisbenzaldehydes, as well as quinoli-
nyl pyrimidines and phenothiazines showed only moderate or no antimicrobial 
effect against M. ulcerans (Table 1) [21, 39, 49, 51, 52, 57, 58, 67, 70].
Table 1 Summary of compounds tested against M. ulcerans in vitro
Compound Class Mic in-vitro
Rifampin Rifamycin 0.1–0.81 μg/ml
Rifabutin Rifamycin 0.1–0.4 μg/ml
Rifapentine Rifamycin 0.125–0.5 μg/ml
Dapsone Sulfone 0.94–4.0 mg/l
Doxycycline Tetracycline Inactive
Streptomycin Aminoglycoside 0.33–1.10 μg/ml
Amikacin Aminoglycoside 0.5–0.65 μg/ml
Azithromycin Macrolide 0.39 μg/ml
Clarithromycin Macrolide 0.125–1.25 μg/ml
Ofloxacin Quinolone 1.26–2.0 μg/ml
Ciprofloxacin Quinolone 1.15 μg/ml; 1–3 uM
Sparfloxacin Quinolone 0.25 mg/l
Moxifloxacin Quinolone 0.14 μg/ml
Sitafloxacin Quinolone 0.125–0.5 μg/ml
Prulifloxacin Quinolone 1–3 μM
GyrA_NTBI-analog Topoisomerase II inhibitor Inactive
GYRA-NTBI PubChem_15983305 Topoisomerase II inhibitor Inactive
GyrB_Pyrollamide 
PubChem_25223515
Pyrrolamide 0.3–1.0 μM
GyrB_Aminopyrazinamide Aminopyrazinamide 0.3–1.0 μM
Oxazolidinone PubChem_10251911 Oxazolidinone 0.3–1.0 μM
Linezolid Oxazolidinone 3–10 μM; 0.73 μg/ml
Posizolid Oxazolidinone 3–10 μM
PubChem_10251911 Oxazolidinone 0.3–1.0 μM
Clofazimine Riminophenazine 2.19 μg/ml
Selamectin Avermectin 2–4 μg/ml
Ivermectin Avermectin 4–32 μg/ml
Moxidectin Avermectin 4–32 μg/ml
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Compound Class Mic in-vitro
HMR 3647 Ketolide 5–40 μg/ml
HMR 3004 Ketolide 5–40 μg/ml
1,3-diaryltriazenes
Diarylthiazoles
SQ641 8 μg/ml
KRM-1648 Benzoxazinorifamycin 0.012 and 0.025 μg/ml
R207910 Diarylquinoline 0.03 μg/ml
PA-824 Nitroimidazopyran 13.1 μg/ml
Aminopyrazoles 0.3–1.0 μM
Pyrazolopyrimidines 0.3–1.0 μM
hydroxyquinolones 1–3 μM
Quinolinyl pyrimidines Inactive
Phenothiazines Inactive
Diazene-1,2-dicarboxamides 5.67–7.25 μg/ml
4  Clinical Studies
As mentioned above, the shift to antimicrobial therapy was made following the 
landmark study by Etuaful et al. using 15 mg/kg body weight intramuscular strep-
tomycin and 10 mg/kg body weight oral rifampin [29]. The earlier mentioned ran-
domized placebo-controlled study from Côte d’Ivoire with 41 study participants 
testing a combination of rifampicin and dapsone lacked power and had too many 
dropouts with only 2 months follow-up [9].
During the past decade, case series and observational cohort studies of patients 
with BU were reported that we discuss here; case reports will not be discussed as 
BU patients may occasionally heal spontaneously [71, 72]. One observational 
cohort study in Benin reported on 224 patients, the majority with large (category III; 
>15 cm) lesions. 215 (96%) were categorized as treatment successes, and 9, includ-
ing 1 death and 8 losses to follow-up, were treatment failures. Of the 215 success-
fully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 
(53%) were treated with antibiotics plus surgical excision and skin grafting; 73% of 
patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% 
of patients with lesions of <5 cm had surgery [73]. Compliance with therapy was 
excellent; 208 of the 215 patients were actively retrieved 1 year after treatment and 
3 (1.44%) of the 208 retrieved patients had recurrence of M. ulcerans disease, 2 
among the 107 patients treated only with antibiotics and 1 among the 108 patients 
treated with antibiotics plus surgery. In a report from Australia, 40 patients received 
combined antimicrobial and surgical treatment. Failures occurred often but twice as 
often in the group that received surgery as the only treatment modality [74]. The 
Australian guidelines of 2006 (published in 2007) still proposed radical surgery 
including the removal of a rim of apparently healthy tissue for treatment [75]. 
Several other groups have reported on outcome of combined surgical and antimicro-
bial treatment—of 79 (61%) patients retrieved, 7 (9%) had a recurrence [76]. In a 
series of 92 patients treated in the Bas-Congo, DR Congo, patients received surgery 
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and antimicrobial (streptomycin/rifampicin) treatment sometimes more than 
8 weeks, with a high success rate (98.4% in PCR-confirmed patients) and low recur-
rence rate (1.1%).
With a substantial proportion of study participants receiving both surgery and anti-
microbial therapy it has been difficult to tease out the potential of antimicrobial treat-
ment alone. In larger lesions, the general assumption is that surgery as added therapy 
is essential to obtain wound closure; in smaller lesions, the hypothesis that antimicro-
bial treatment alone without extensive surgical debridement could heal BU with no 
recurrence, was tested in a controlled clinical trial including 151 study participants 
with small (<10 cm cross-sectional diameter) lesions, almost all being confirmed by 
PCR to have M. ulcerans infection. After 4 weeks of streptomycin/rifampicin combi-
nation therapy, patients were randomized to either continue for 4 more weeks or 
switch to oral treatment with rifampicin/clarithromycin combination therapy. A switch 
from streptomycin to clarithromycin after 4 weeks was non- inferior to 8 weeks strep-
tomycin and rifampicin in these early lesions; recurrence or failure was very low—
success rates were 96% in the group receiving 8 weeks of streptomycin/rifampicin, 
and 91% in the group that switched to oral treatment which was statistically non-
inferior [36]. In an observational cohort of 160 PCR- confirmed patients with BU, 
treated with streptomycin/rifampicin for 8 weeks, 152 healed without surgery; of 158 
patients seen 1 year later, no recurrences were noted [77]. In three centers in Ghana, 
43 patients—16 of them having category II/III lesions—received the streptomycin/
rifampicin combination regimen that was switched after 2 weeks to oral rifampicin/
clarithromycin. Ninety-three percent had successful outcome, only one had surgery, 
and none had recurrence at follow-up [37]. A recent report reflects perhaps better what 
happens under routine service conditions [78]. Patients (n = 50) with confirmed BU in 
two centers in the Brong- Ahafo Region of Ghana were followed over time; a majority 
had first used traditional treatment; the patient population consisted predominantly of 
peasant farmers with no formal education, or children. Only 40 completed treatment 
and of those, only 28 healed; in the others the lesions reduced in size [78].
In summary, based on the above evidence from various studies and reports—nota-
bly, the potential to achieve cure without relapse, at much higher rates than previously 
with surgery alone, the role of antimicrobial treatment in the management of BU has 
become standard of care [79]. All drugs used for BU have significant side effects, espe-
cially in the elderly [80]; but aminoglycoside drugs—streptomycin and amikacin—are 
notoriously the most toxic compounds [81], and although most of the evidence sup-
porting antimicrobial treatment for BU has been provided for the combination of 
rifampicin and streptomycin, there has been a search for an alternative, fully oral treat-
ment for over a decade now. The first report came from Australia where the patient 
population is typically elderly and more vulnerable for the ototoxicity of aminoglyco-
sides; the results of a small (n = 4) case series [82] was soon followed by larger series 
of 43 patients that had oral antimicrobials combined with surgery with only one patient 
that had a relapse [83]. Later, a series of 132 patients had oral therapy with less surgery 
than before and with excellent healing rates and only one relapse [84]. In Benin, all-
oral treatment was given for 8 weeks to 30 patients with BU with a slightly higher daily 
dose of clarithromycin (12 mg/kg once daily, combined with rifampicin 10 mg/kg); 
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they all healed without relapse [35]. The WHO initiated a randomized clinical trial in 
2012, that was recently completed (clinicaltrials.gov identifier: NCT01659437) com-
paring all-oral, 8-week rifampicin plus clarithromycin (in sustained release, once daily, 
15 mg/kg) with standard streptomycin/rifampicin treatment; interim analysis showed 
non-inferiority of the all-oral group compared to the streptomycin/rifampicin group, 
and in the bi-annual meeting on BU in Geneva in the Spring of 2017, it was decided 
that sufficient evidence had been provided to change the treatment recommendation to 
all-oral treatment, using rifampicin and clarithromycin.2 The Australian guidelines had 
already recommended all-oral antimicrobial treatment [85] earlier.
4.1  Secondary Infection
Wounds caused by M. ulcerans often harbor a multitude of secondary pathogens. 
Isolates of S. aureus, Aeromonas hydrophila, Pseudomonas aeruginosa and 
Klebsiella pneumoniae with a high degree of resistance to commonly used antibiot-
ics were found in BU lesions in Ghana and Nigeria [86, 87]. S. aureus isolated from 
M. ulcerans lesions were found to harbor a large array of virulence factors. In 
Ghana, an association between the presence of these organisms and delayed healing 
was observed. The question whether these secondary bacterial invading pathogens 
are merely bystanders of M. ulcerans infection or actual contributors has not been 
resolved [88]. Apart from the question whether these secondary invaders inhibit and 
delay wound healing or not, rational use of antimicrobials other than the combina-
tion recommended by WHO, should be discouraged, in order to prevent further 
antimicrobial selection pressure and the further emergence of resistance among 
these secondary organisms [89]. The skin microbiome was significantly changed, 
however it is not clear if and how this contributes to pathology [90]. The option to 
explore topical instead of systemic antimicrobial agents, e.g., nitric oxide needs 
perhaps further attention [91]. For more detailed information the reader is referred 
to chapter “Secondary Infection of Buruli Ulcer Lesions” of this book. 
4.2  HIV Co-infection
HIV co-infection complicates diagnosis and treatment of BU [92]. In 2015, a consen-
sus statement was published by WHO; HIV testing is recommended for all patients 
with BU. For more detailed information the reader is referred to chapter “Management 
of BU-HIV Co-infection” of this book. Combined antiretroviral treatment might be 
postponed 4 weeks after starting streptomycin/rifampicin treatment for BU, because 
of drug-drug interactions and adverse drug effects, and the importance to use the 
most effective bactericidal drug combination available for M. ulcerans infection.3
2 http://www.who.int/neglected_diseases/events/WHO_BU_TAG_2017_report.pdf?ua=1.
3 http://apps.who.int/iris/bitstream/10665/154241/1/WHO_HTM_NTD_IDM_2015.01_eng.
pdf?ua=1.
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5  Conclusions; Areas of Uncertainty; and Future 
Directions
There is no doubt that antimicrobial therapy—preferably, all-oral rifampicin-based 
treatment is essential for cure without relapse. Not all questions have been resolved, 
however. Despite the overwhelming evidence that the combination of clarithromy-
cin and rifampicin works well, with acceptable levels of toxicity especially in the 
relatively young patient population in West Africa, the dosage of these drugs has 
been different across different studies and regions. Drug-drug interactions of rifam-
picin and clarithromycin are complex—rifampicin induces the metabolism of clar-
ithromycin into its inactive metabolite 14-OH clarithromycin; and it induces its own 
hepatic elimination as well. Clarithromycin inhibits the elimination of rifampicin 
[93]. Increased drug exposure to rifampicin is much safer than previously 
thought [94].
An important next step could be to improve the dosage by extensive pharmaco-
kinetic modeling; a fixed dose combination drug might have considerable advantage 
for compliance, logistics and in order to prevent monotherapy; this approach has 
been shown to be highly successful in tuberculosis, malaria and HIV infection.
Further, duration of therapy has not been individualized; based on the initial 
observations in the small study by Etuaful et al. [29], where no viable M. ulcerans 
bacilli were recovered from lesions in patients treated for at least 4 weeks, an arbi-
trary safety margin of 4 more weeks was chosen. The question whether larger 
lesions need longer treatment, or smaller lesions perhaps less has not been addressed 
in well-designed studies. In a follow-up study among 56 patients in Ghana, who 
defaulted before the end of planned treatment, 92% of patients with category I 
lesions (<5 cm) were healed with treatment duration of 32 days or more [95], sug-
gesting that smaller lesions indeed might do well with much less than standard 
8-weeks treatment.
Next, the treatment of BU extends well beyond administration of antimicrobials 
alone. During the active phase of the disease adequate wound care is imperative to 
ensure healing and to prevent disabling scarring. Non-adhesive, absorbent dressing 
materials have been shown to improve the wound microenvironment and improve 
time to healing [96, 97], and might also play a role to prevent painful dressing 
changes. While M. ulcerans is generally thought to be a pain-free disease as the 
toxin mycolactone causes hypoalgesia [98–100], later on, as lesions start to heal and 
the mycolactone is washed out from the lesions and the system, patients report con-
siderable pain especially during wound dressing changes and during physiotherapy 
needed to prevent and treat contractures and disability [101]. For patient comfort 
and compliance, a sound wound-care program is essential, with adequate pain man-
agement [102].
During and after the completion of antimicrobial treatment, many patients still 
experience restrictions through either physical disability caused by wound contrac-
tures or joint involvement of lesions; or psycho-social participation restrictions 
caused by social stigmatization [103, 104]. Physical therapy and societal inclusion 
and de-stigmatization are therefore important components of BU control programs 
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[81, 105]. Community-based approaches with early case finding are essential to 
prevent the large disease burden in individuals and communities [106, 107].
Future research thus should focus on evaluating shorter treatment for limited 
lesions while supplementing standard treatment with clofazimine or fluoroquino-
lones to provide a treatment tailored to the lesion size and estimated bacterial bur-
den of individual patients.
Such attempts have so far been hampered by the fact that no good measurable 
surrogate parameter of treatment success, such as a blood marker, is available. 
However recent advances in the use of mass-spectrometry to carefully measure 
mycolactone in patient samples could aid in this regard.
Furthermore, there is dire need for the integration of control programs for tropi-
cal skin conditions such as BU, yaws, leprosy, etc. on a public health level [108]. 
Health officials should identify opportunities for systematic integration for the con-
trol of tropical neglected diseases depending on the prevalent diseases and available 
resources in any given setting.
Finally, BU treatment should be accompanied by surgery where needed, as well 
as good wound care, analgesia, physiotherapy and advocacy to reduce stigma.
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Thermotherapy of Buruli Ulcer
Thomas Junghanss
For decades surgical excision has been the standard therapy for Buruli ulcer (BU) 
with several drawbacks, however [1]. Surgery is traumatizing with extensive soft 
tissue excisions required to prevent relapse. Long hospitalisation is expensive for 
both health services and patient families. Since 2004 an antibiotic regimen consist-
ing of rifampicin and streptomycin for 8 weeks is recommended by WHO [2, 3]. Its 
efficacy has been demonstrated in various studies including a randomized controlled 
trial [4]. The parenteral application of streptomycin over 8 weeks is a substantial 
disadvantage in settings with limited resources and particularly in children who are 
mostly affected by BU in Africa. Ototoxicity has additionally been identified as a 
critical and prohibitive side effect [5]. In 2017 the WHO Technical Advisory Group 
on BU decided that the WHO recommendation for treatment should be changed to 
rifampicin and oral clarithromycin pending the publication of the full results of a 
recently completed clinical trial. On a national level, this combination has already 
been introduced in various countries.
The temperature sensitivity of Mycobacterium ulcerans has long been recog-
nized [6–9]. M. ulcerans differs from most other pathogenic mycobacteria in that it 
grows best at 30–33 °C and not above 37 °C [8]. Meyers et al. treated eight patients 
from Zaire maintaining a temperature of approximately 40 °C in the ulcerated area 
for a mean duration of 68 days [8]. There was no evidence of local recurrence dur-
ing follow-up periods of up to 22 months. Based on this impressive success rate, 
WHO guidelines listed the application of heat as a treatment option for BU [10]. 
However, the heat application devices initially employed were impractical in most 
endemic countries.
The phase change material (PCM) sodium acetate trihydrate, which is widely 
used in commercial pocket heat pads offers an ideal technical solution for 
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thermotherapy of BU. The unique feature of PCM is its thermal energy storing 
capacity combined with an almost constant temperature during the liquid-solid 
phase transition. Sodium acetate trihydrate appears ideal with its supercooling 
behaviour, since, once completely molten, the material will stay liquid even when 
the temperature falls far below its melting point. It can thus be stored at room tem-
perature without energy loss. With a starter, e.g. a piece of copper wire protected 
by a rubber tube placed within the PCM filled bag, the crystallization process is 
initiated when required. Once initiated, heat at constant temperature is emitted for 
around 6 h. Patients can be treated overnight. Further, the melting temperature of 
58 °C allows sterile gauze to be placed between the wound and the PCM bag to 
protect the wound and to still maintain temperatures of above 39 °C at the skin 
surface without the risk of burning (Fig. 1).
In summary, sodium acetate trihydrate heat packs:
• Are free from significant side effects
• Are easy to apply, rechargeable in boiling water and can be used many times
• Are non-toxic and non-hazardous to the environment
• Are sterilized between rounds of application during the recharging process
• Exert gentle pressure and thus reduce peri-lesional edema
• Protect wounds from trauma
• Urge patients and medical staff to pay attention to the wound when reapplied 
daily
The heat application device was tested in healthy volunteers and a mathematical 
model was developed and validated to predict its thermal behaviour. The thermal 
model allowed the prediction of skin surface temperatures and an optimization of 
the amount of PCM with respect to discharge time [11].
In a next step commercially available heat packs were tested in a prospective 
observational single centre proof-of-principle trial in Ayos/Cameroon. “Six laboratory 
Fig. 1 Heat packs, sterile 
gauze and elastic bandage 
are the ingredients needed 
for thermotherapy
T. Junghanss
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reconfirmed patients with ulcerative BU lesions received 28–31 (ulcers < 2 cm) or 
50–55 (ulcers > 2 cm) days of thermotherapy with the PCM sodium acetate trihydrate 
as heat application system. All patients enrolled in the trial completed the heat treat-
ment. Being completely mobile during the well- tolerated heat application, acceptabil-
ity of the PCM bandages was very high. In patients with smaller ulcers, wounds healed 
completely without further intervention. Patients with large defects had skin graft-
ing after successful heat treatment. Heat treatment was not associated with marked 
increases in local inflammation or the development of ectopic lymphoid tissue. One 
and a half years after completion of treatment, all patients were relapse-free” [12].
To confirm the findings of the pilot study a phase II open label single centre non- 
comparative clinical trial (ISRCTN 72102977) under GCP standards was carried 
out in Cameroon.
Laboratory confirmed BU patients received up to 8  weeks of heat treatment. 
The efficacy was assessed based on the endpoints ‘absence of clinical BU specific 
features’ or ‘wound closure’ within 6 months (“primary cure”), and ‘absence of 
clinical recurrence within 24 month’ (“definite cure”). Of 53 enrolled patients, 51 
(96%) had ulcerative disease. Sixty two percent were classified as World Health 
Organization category II, 19% each as category I and III. The average lesion size 
was 45 cm2. Within 6 months after completion of heat treatment, 92.4% (49 of 53, 
95% confidence interval (CI), 81.8–98.0%) achieved cure of their primary lesion. 
At 24 months follow-up 83.7% (41 of 49, 95% CI, 70.3–92.7%) of patients with 
primary cure remained free of recurrence (see Fig. 2). Heat treatment was well tol-
erated and the only adverse effects were occasional mild local skin reactions [13].
enrolment week 1 
week 8heat treatment end (40 d)
week 2 week 4
1 month FU
3 month FU 6 month FU 12 month FU 24 month FU (+4 days)
2 month FU
heat treatment ended
Fig. 2 Clinical evolution of patient 14 (laboratory confirmed ulcer of the right lateral ankle) exem-
plary for all patients. Images of all other patients are available as Supplemental Figures 1–65 of 
[13]. Pictures were taken within a range of ±2 days (heat treatment period), ±15 days (follow-up 
(FU) months 1–3), ±30 days (FU month 6) and ±60 days (FU months 12 + 24 months) from the 
designated time points (Source: [13])
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Interestingly, there is evidence from other studies and our own observations that 
after controlling the bulk of the mycobacterial burden remaining viable M. ulcerans 
may be eliminated by the immune system without additional specific treatment. 
Equally, confirmed BU nodules distant to heat treated primary lesions healed (see 
Fig. 3). Protective immune responses may be triggered by thermotherapy and che-
motherapy [4, 14, 15] but not surgery, where the mycobacterial antigens are largely 
removed [13].
Importantly, the skin lesions of ten patients, for which laboratory testing for M. 
ulcerans was negative, also healed under thermotherapy, indicating that heat might 
have a positive effect on the healing of wounds in general. This is encouraging for 
regions with limited access to laboratory confirmation and where quality assurance, 
in particular of PCR in reference labs, remains a problem [13]. With respect to reli-
ability of PCR-based laboratory diagnosis it has to be noted that in a multicentre 
Fig. 3 Distant healing in a patient with a BU lesion at the right wrist and a laboratory confirmed BU 
nodule at the left elbow. Both of the lesions healed after heat was applied to the right wrist only 
(Source: [13])
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external quality assessment for PCR detection of M. ulcerans only around one third 
of the participating laboratories had more than 90% concordant results [16].
Both, the proof-of-principle and the phase II trial showed that thermotherapy is 
well tolerated and effective. Daytime activities including schooling are not inter-
rupted. In addition to its specific effect, heat treatment appears to promote wound 
healing by increasing blood circulation, reducing edema through gentle compres-
sion and protecting the wound. Renewal of heat packs is inevitably connected to 
inspection and care for the wound.
The thermotherapy-specific cost of heat packs and recharging for 10 min in boil-
ing water are small. Nursing time mainly goes into wound management, which is 
not different from chemotherapy patients. Positioning of heat packs is straightfor-
ward and nurses are confident in heat pack application after few demonstrations.
In communities with limited resources treatment modalities which can be applied in 
early undifferentiated stages of diseases without causing harm and with the benefit of 
preventing advancement into severe complicated disease make a difference to peoples’ 
lives. All wounds “count” and the patient’s priority “I want to have my skin closed” 
(independent of the cause) is respected and promoted. This follows the broad under-
standing of universal health coverage [17]. The population impact lies in the rapid clo-
sure of a substantial proportion of wounds at the community level [18]. This avoids life 
threatening sequelae and disability and prevents the development of chronic wounds 
and the need for advanced treatment at the secondary or tertiary health services level. It 
saves costs both for the patient and the health care system. Patients with wounds prone 
to secondary bacterial infection benefit from treatment in the periphery because they 
are not exposed to nosocomial infections which are more frequent at higher levels of 
health services. This, again, saves people from sufferance and costs.
In summary, based on the results of the two studies with PCM heat packs, “ther-
motherapy can be considered an alternative to chemotherapy as primary treatment for 
BU for several reasons: it is highly effective, is easy to apply, cheap, well tolerated, 
free of relevant adverse effects, has nonspecific positive effects on wound healing 
and does not compromise wound healing in non-BU lesions in cases of misclassifi-
cation. This is an undisputable advantage in settings where treatment decisions need 
to rely primarily on clinical diagnosis. Changing of heat packs urges health staff and 
patients to take notice of the wound and thus increases the probability of regular 
wound care. Heat therapy has potential as home remedy for BU lesions suspected to 
be BU, ideally, combined with general wound management” [13].
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Secondary Infection of Buruli  
Ulcer Lesions
Grace Semabia Kpeli and Dorothy Yeboah-Manu
1  Background
Proper wound care is increasingly becoming a very crucial component of the man-
agement of Buruli ulcer (BU). The cytopathic activity of the main virulent factor 
of the causative pathogen, M. ulcerans, leads to the formation of extensive necrotic 
ulcerative lesions, which are a good medium for the growth of other bacteria. Data 
from a number of clinical studies showed that in up to 80% of cases presenting 
with limited (category I and II) lesions, healing occurs within 6 month after onset 
of antibiotic treatment without the need for surgery [1–7]. However, wound healing 
is delayed in a proportion of affected patients, in particular in those reporting with 
large lesions [4, 8, 9]. In particular, after completion of antimycobacterial therapy 
good monitoring and wound care is important to avoid massive secondary bacterial 
infections [10], potentially affecting the healing potential of wounds and increas-
ing the risk of more severe pathology and sepsis. The WHO recommends that sec-
ondary infection in BU should be suspected when a wound develops cellulitis or 
becomes painful [11]. Secondary infection in BU disease is not well characterized 
and recognized because it is assumed to be infrequent [11]. Thus, its occurrence 
has been documented only by few studies [10, 12–16]. Previously, it was specu-
lated that mycolactone secreted by M. ulcerans during active disease may sterilize 
BU wounds and prevent secondary infection by other bacteria, since a number of 
macrolides have broad spectrum activity against many bacterial species including 
streptococci, pneumococci, staphylococci, enterococci, mycoplasma, mycobacte-
ria, rickettsia, and chlamydia [17]. However, several studies [10, 14] have proven 
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that mycolactone does not prevent secondary bacterial infection of BU lesions. In 
these studies, the microbial flora of BU wounds was found to be very diverse and a 
broad range of bacteria species colonizing the lesions were identified. Furthermore, 
research by Scherr [18] using synthetic mycolactones also demonstrated the growth 
of the bacterial species Streptococcus pneumoniae, Neisseria meningitidis and 
Escherichia coli, as well as the yeast Saccharomyces cerevisae and the amoeba 
Dictyostelium discoideum in the presence of mycolactone. Thus, secondary infec-
tion in BU may be more common than formerly thought.
2  Bacterial Species Associated with Secondary Infections
2.1  Species Diversity
Extensive work on the microbial flora of BU wounds has been done by research 
groups in Ghana [10], Benin [14] and Nigeria [13]. Yeboah-Manu and Barogui 
studied the microbial flora of BU patients before, during and post antibiotic treat-
ment while the study by Anyim included pre-treatment patients only. In the study 
by Yeboah-Manu et al., many different bacterial species were isolated, including 
Staphylococcus aureus, Pseudomonas aeruginosa, Proteus mirabilis, Coagulase 
negative Staphylococcus, Chryseomonas luteola, Enterobacter cloacae, Klebsiella 
pneumonia, Escherichia coli, Streptococcus dysgalactia, Providencia stuar-
tii, Staphylococcus haemolyticus, Morganella morganii, Streptococcus agalac-
tia, Staphylococcus warneri, Proteus vulgaris and other Gram negative bacteria. 
S. aureus, P. aeruginosa and P. mirabilis were frequently isolated pre-treatment. 
During treatment, P. aeruginosa and P. mirabilis were the dominating isolates, 
while P. aeruginosa, P. mirabilis and S. aureus were the most frequently isolated 
bacteria post antibiotic treatment. The study by Barogui isolated Group A strepto-
cocci, Group B or C streptococci, S. aureus, S. epidermidis, Staphylococcus sp., P. 
aeruginosa and Enterobacteriaceae with S. aureus and P. aeruginosa dominating 
pre and post treatment and P. aeruginosa being the most frequently isolated bacteria 
during treatment. The study by Anyim et al. isolated S. aureus, A. hydrophila P. 
aeruginosa, K. pneumoniae, Enterobacter cloacae, Pseudomonas pseudomallei and 
Burkholderia cepacia.
The species diversity isolated from the wounds represent the spectrum of micro-
bial isolates commonly isolated from other wound types such as burn and infected 
diabetic foot ulcers. However, the main bacteria commonly cited as responsible for 
wound infection and healing delay are S. aureus, P. aeruginosa and β-hemolytic 
streptococci [19–21].
S. aureus and P. aeruginosa dominating among the isolates detected in the BU 
lesions, have been found to be associated with infection and healing delay in both 
chronic and acute wounds and are frequently implicated in healthcare-associated 
infections. The virulence of these bacterial species is based on their ability to pro-
duce a number of destructive enzymes and toxins. Through intrinsic and acquired 
mechanisms, they exhibit increased resistance to many antimicrobials. They also 
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have the ability to form biofilms which increase their persistence and antibiotic 
tolerance [21–23]. Interestingly, in the two studies which assessed the species 
diversity at different time points [10, 14], S. aureus was not isolated from patient 
lesions during antibiotic treatment. Further research will be needed to explain the 
absence of this bacterial species during treatment and its probable “re-emergence” 
post treatment.
3  Bacterial Burden
The role of microorganisms in wound healing and infection is diverse and related 
not only to the type of microbial species colonizing a wound but also to the number 
of microorganisms or the wound’s bioburden. Localized wound infection is a signif-
icant cause of impaired healing and wound chronicity [24]. The pathogenic effects 
of bacteria may be increased through the formation of biofilms and the release of 
toxic products [22]. Endotoxins released by Gram-negative bacteria in wounds lead 
to elevated levels of proinflammatory cytokines (IL-1 and tumour necrosis factor). 
In addition, factors including the release of free radicals, degradation of growth 
factors, production of metabolic products, consumption of local oxygen and inter-
ference with collagen formation may also result in a non-conducive wound environ-
ment. The effects of these mechanisms increase with high bacterial loads leading to 
impaired wound healing [20, 21].
Many studies have confirmed that, a wound’s bioburden is an important pre-
dictor of wound infection and wound healing. In decubitus ulcers, wound healing 
was found to progress only when the microbial load of wound fluid was below 106 
colony forming units (cfu) per ml of wound exudates (cfu/ml) or per gram of tissue 
(cfu/g) [25] with healing being inhibited above this value. The success of skin grafts 
has also been demonstrated to be associated with bacterial loads <5 × 104 cfu/cm2 
[26]. These studies and others on diabetic foot ulcers and pressure ulcers led to the 
conclusion that the determination of bacterial loads could be useful in the prediction 
of wound healing and infection [27–32]. Thus traditionally, bacterial levels above 
106  cfu/ml are used as predictors of wound infection and related wound healing 
delay. An exception to this is, where a wound is colonized by β-haemolytic strep-
tococci, which has been found to cause disease even at levels <105 cfu/g of tissue.
A recent study [33] assessing the bacterial load in the lesions of BU patients lon-
gitudinally to gain insight into the evolution of the bacterial load showed that levels 
of bacteria are not constant throughout the period of antibiotic treatment of BU 
patients. High bacterial loads were reported before and after treatment compared 
to decreased loads during treatment. A study by Gardner [34] reported a decrease 
in bacterial load in subjects on systemic antibiotics compared to those not on anti-
biotics. This could account for the decreased loads reported in BU patients during 
treatment with the 8-week regimen of streptomycin and rifampicin (SR8), which 
have broad spectrum activity. This result was also in agreement with clinical signs 
observed during the treatment period such as fewer lesions presenting with slough, 
necrosis and high wound exudate production. The increase in bacterial burden in 
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the BU lesions was found to be highest after the antibiotic treatment phase. The 
impact of an increased bacterial load on wound healing cannot be underestimated 
and the presence of bacteria in wounds even in the absence of obvious clinical signs 
can inhibit the normal wound healing process. BU wound management guidelines 
should therefore consider and include strategies for preventing secondary infection.
4  Diagnosing Secondary Infection in BU
Generally, for a wound to be considered as infected, bacterial multiplication should 
increase strong enough to induce immune reactions from the host. Clinically, such 
reactions will present with signs and symptoms such as pain, swelling, erythema 
(redness), increased temperature, malodour and discoloured granulation tissue etc. 
Diagnosing wound infection is challenging and ideally, a holistic analysis of lesions 
employing all available diagnostic methods is favourable [21].
Diagnosis should consider both the clinical presentation of the wound and the 
results of microbiological investigations through quantitative and qualitative inves-
tigations involving direct microscopy and cultures. In diagnosing BU secondary 
infection, where possible, histopathological analysis of suspected secondarily 
infected lesions gives an added advantage to the quality of results obtained. In the 
absence of specimen for histopathological analysis, bacterial loads above 105 cfu/g 
or cfu/ml are the accepted gold standard in diagnosing localized infection [32, 35, 
36] as research has shown that the bacterial burden of a wound has an inverse rela-
tionship with wound healing and wound healing is likely to progress only when 
bacterial counts are below 106 cfu/ml [25, 27–32].
Yeboah-Manu [10] combined clinical observations, histopathological analysis, 
qualitative and quantitative microbiological methods to identify secondary infection 
in BU wounds. Results revealed correlations between clinical signs and microbio-
logical and histopathological features (Fig. 1). Lesions of 28 patients with clinical 
indications of infection after SR8 treatment were analyzed and 75% of these lesions 
yielded quantitative cfu counts >106 cfu/ml with an average value of 1.2 × 109 cfu/
ml, clearly above the levels representing the lower limits of infection by quantitative 
microbiology (105 cfu/g or cfu/ml). Among these patients, clinical signs highly pre-
dictive for infection were pain and yellow discharge. Histopathology also confirmed 
the presence of infecting bacteria in 75% of the lesions microbiologically classified 
as infected.
5  Drug Susceptibility Patterns of Bacterial Isolates 
from BU Lesions
Countries with a high burden of infectious diseases rely on antibiotics as an impor-
tant part of their health-care. There are currently no guidelines for the management 
of secondarily infected BU lesions; however, it is common practice among health 
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personnel to prescribe additional antibiotics for BU patients suspected of having 
a secondary infection. Studies of the antibiotic susceptibility patterns of bacterial 
isolates from BU wounds has revealed a high level of resistance to the commonly 
prescribed first-line drugs against infectious diseases including the BU treatment 
drugs streptomycin and rifampicin [10, 14, 37].
The high level of streptomycin resistance reported in Ghana is not surprising as 
it is a widely used antibiotic in animal husbandry for treatment and disease preven-
tion. It was also until recently used as a first line treatment drug for tuberculosis 
in Ghana. Thus years of streptomycin use in both humans and animals appears to 
have resulted in selection pressure leading to high resistance rates. Lower levels 
of resistance were reported for amikacin, gentamicin and tobramycin (also ami-
noglycosides) as well as for the carbapenem imipenem [10]. Amikacin, genta-
micin and tobramycin are expensive injectable drugs only prescribed for serious 
and life- threatening infections. These factors discourage the abuse of these anti-
biotics and contribute to the low resistance levels reported. Carbapenems are the 
last choice of antibiotics used in treatment of infections due to extended spectrum 
β-lactamase (ESBL)-producing bacteria and are not widely used or easily acces-
sible. Meropenem is the only carbapenem approved for use in Ghana and has so far 
not recorded any resistance though it has been on the market since 2002.
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Fig. 1 Histopathological analysis of tissue from two patients excised 6 and 8 weeks respectively 
after SR8 treatment respectively. Histological sections were stained with Ziehl-Neelsen (acid fast 
bacteria) and methylene blue (DNA, secondary infection). (a) clinical presentation of a patient 
presenting with a large lesion on the right foot. (b) overview over excised tissue specimen (open 
ulcer surface) revealing the presence of an infection (blue band, box). (c/d) higher magnification 
confirming the presence of densely packed rods. (e) clinical presentation of a patient presenting 
with a large lesion covering the left leg. (f) overview over excised tissue specimen revealing an 
epidermal hyperplasia as well as a strong edema. (g/h): secondary infection of the dermal and 
subcutaneous tissue with rod shaped bacteria [10]
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Drug resistant bacteria including multi-drug resistant (MDR) P. aeruginosa, 
Methicillin resistant S. aureus (MRSA) and Extended Spectrum β-lactamase pro-
ducers were also detected in BU lesions [10, 14, 37–39]. Of increased concern is 
the high frequency of MRSA with prevalence rates of 33%, 38%, 13% and 22.8% 
reported [10, 14, 37, 38].
The resistome of whole genome sequenced S. aureus isolates from BU patients 
was investigated by Kpeli [37] and Amissah [12]. Kpeli’s study identified antibiotic 
resistance genes coding for resistance to β-lactams (blaZ), chloramphenicol (cat 
and catpC221), trimethoprim (dfrG), methicillin (mecA), quinolone (norA), strep-
tomycin (str) and tetracycline (tetK, tetL and tetM). The study also further investi-
gated the rpoB gene of rifampicin resistant strains and identified two known amino 
acid substitutions H481N and I527M implicated in rifampicin resistance. Amissah’s 
study identified resistance to penicillin characterized by the presence of various 
blaZ operons; resistance to chloramphenicol (catA and fexB), tetracycline (tetK, tetL 
and tetM), trimethoprim (drfG), streptomycin (str), and rifampicin (rpoB mutation 
encoding an amino acid substitution that changed Asp471 into Gly). Six methicil-
lin resistant isolates were also identified with five encoding the mecA gene and one 
identified as a borderline oxacillin resistant strain.
Based on the results from various studies on the antimicrobial susceptibilities of 
bacteria isolated from BU wounds, it is clear that the use of antibiotics needs to be 
minimized. The definition of secondary infection is subjective in many cases and 
clinicians are unsure of how to manage wounds, especially if they show no clini-
cal evidence of infection. Specific guidelines on the management of BU wounds 
secondarily infected by other bacterial species are urgently needed [14]. Guidelines 
on whether to use antibiotics for treating these wounds, the choice of antimicro-
bial agents to prescribe, the duration of treatment and whether topical antimicrobi-
als should be prescribed and prioritized over systemic antimicrobials need to be 
clarified.
6  Molecular Epidemiology
6.1  Sources of Infection
All wounds healing by secondary intention are prone to microbial contamination. 
Wounds can be infected from the environment, surrounding skin and also from 
endogenous sources such as the nasal mucosa, gastrointestinal tract and the geni-
tourinary tract. Sources of wound contamination in the health-center can be from 
health-care workers (HCW), other patients and the inanimate environment. Most 
of the bacterial pathogens recovered from the lesions of BU patients are known 
nosocomial pathogens. A study by Kpeli et al. [37] to identify the possible routes 
of infection of BU lesions identified three modes of infection of BU lesions in two 
health centers in Ghana; two health-care facility related sources, through a HCW 
and the environment, and a self-infection (Fig. 2). S. aureus was the main bacterial 
pathogen identified in many of the samples analyzed and these isolates were selected 
for further studies. The study employed molecular (S. aureus protein A, (spa) typ-
ing) and whole genome sequencing (WGS) methods to identify transmission events 
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ongoing within the health centers. Phylogenetic analysis of spa types found in S. 
aureus isolates from samples collected from the health center, from HCW’s and 
patients were analyzed. Different clusters were identified and comprised strains iso-
lated in both health centers (clusters A, C, D, H and J), strains found only in Facility 
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Fig. 2 Spa phylogeny 
showing clusters and 
relationships between 
isolates: Maximum 
likelihood phylogeny tree 
based on spa gene typing. 
The tree was rooted in the 
midpoint. Numbers in nodes 
indicate support values in 
the form of proportions of 
bootstrap pseudoreplicates. 
Branches with support 
values higher than 55% are 
collapsed. A–J = the clusters 
identified. The green 
colored strains are from 
Health center A, and the 
blue ones from Health 
center B. The yellow 
coloured circles represent 
MRSA and the violet circles 
show isolates from a HCW, 
patients and equipment in 
health center B. The red 
coloured strains in Cluster I 
were from three lesions of 
the same patient which had 
the same spa (t2500) and ST 
type (ST 3248) [37]
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A (clusters B, G, and I) and strains isolated only in Facility B (clusters E and F) 
(Fig. 2). Isolates within cluster F included isolates from samples taken from the 
hand of a health care worker and from patients dressed consecutively by this worker 
on the same day, isolates taken on another day from a forceps used to dress patients 
after it had been used on four different patients consecutively and two isolates from 
a patient who attended the health facility for treatment at two different time points 
(weeks 2 and 8) during treatment (Fig. 2). Isolates in cluster I were from three BU 
lesions of a patient. These isolates had the same spa type (t2500), and sequence type 
(ST 32489). They had SNP differences of 29 bp, 51 bp and 34 bp between them, 
and these small numbers of SNPs suggests that they could have been spread from 
a common source. Similar clusters were also predicted by the WGS analysis [37].
Using a WGS-based-gene-by-gene typing approach, Amissah et  al. [12] also 
identified transmission events between different patients at a health center. Results 
from this study showed that transmission events could have occurred during over-
lapping visits of the patients to the health center. Further analysis of the S. aureus 
isolates detected from the wounds showed that they belonged to lineages which 
have also been reported by other studies from the Ghanaian health-care setting 
strongly suggesting that these lineages could be associated with transmission within 
our health centers [12, 40].
7  Predisposing Socio-Economic Factors
Several factors could predispose BU patients to wound infection. Firstly, because 
of the painlessness of early lesions, most affected people do not report early to the 
formal health centers for treatment. They resort to home management of the wounds 
until they have deteriorated and lesions become clinically and microbiologically 
infected [33]. Secondly, BU is seen in many endemic areas as a spiritual disease. 
An unhealing wound is thought to be caused by spiritual forces, charms, witches, 
ancestral spirits or even the gods of the land [41]. These beliefs drive the affected to 
seek for help from traditional healers and witch doctors as their first point of call and 
not biomedical health facilities [41–44]. These witch doctors and traditional healers 
also apply various kinds of concoctions to manage the lesions and these concoctions 
may not have been prepared under hygienic conditions and may serve as conduits 
for the introduction of contaminants into the wounds.
Cases are only reported to the biomedical health centers after all efforts have 
been exhausted by these various approaches and no improvement has been seen. 
Therefore frequently large wounds are presented which may have been treated over 
long periods of time with various concoctions usually not prepared under aseptic 
conditions.
The socio-cultural beliefs and perceptions of the patients also affect their 
response to treatment even at the formal health centers. Some categories of people 
such as pregnant women, ‘promiscuous people’, breastfeeding mothers are con-
sidered unqualified to manage wounds in a community. Our research has shown 
that when patients encounter any of these categories of people in the formal health 
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center, they resort to re-dressing their wounds after they have been dressed by these 
people and thus end up introducing contaminants into their wounds [41].
Economic hardships have also been found to predispose BU patients to wound 
infection. In Ghana, treatment of the disease is free; however, affected patients have 
to bear the cost of wound management. This places a huge financial burden on 
patients and their families, which they are sometimes unable to bear. Thus instead 
of using fresh bandages anytime the wounds are dressed, patients resort to recycling 
of old bandages. Some of these bandages are not washed properly after use and 
analysis of some of the washed bandages by Yeboah-Manu et al. [10] showed that 
potential pathogens similar to those isolated from the wounds can be isolated from 
the recycled washed bandages.
8  Prevention of Secondary Infection
In order to prevent secondary infection, the cycle of events that lead to the con-
tamination of wounds by bacteria must be broken. This will entail dealing with 
the sources of potential pathogens in order to minimize their spread or transmis-
sibility. In BU wound management, observing aseptic techniques at every stage 
of wound management is critical to preventing super-infection by other bacteria. 
Thus education of both HCWs and patients is important and periodic monitoring to 
ensure compliance with laid down guidelines will also go a long way in reducing the 
occurrence of secondary infection in BU disease [45]. Decentralized treatment may 
reduce the risk of nosocomial wound infection compared to in-patient facilities [8]. 
Guidelines for the prevention and management of wound infection were released 
in 2010 by the WHO. These guidelines which can be accessed at www.who.int/
gpsc/SSI-outline.pdf?ua=1 provide core principles for the appropriate prevention 
and management of infected wounds as well as protocols to guide the management 
of the wound site, tetanus prone wounds and antibiotic prophylaxis and treatment. 
Separate guidelines for the prevention of surgical site infection  (www.who.int/hac/
techguide/tools/guidelines_prevention_and_management_wound_infection.pdf) 
have also been released by the WHO and these can also be used to strengthen infec-
tion prevention and control programmes in the health centers and applied in cases 
where infected patients require surgical interventions.
9  Wound Care
The median time to healing in early, limited BU lesions has been found to be 
18  weeks [1]. For large lesions, this can be more than 2  years. Therefore, after 
antibiotic therapy, wound care will form the core of BU wound management until 
wound closure is achieved and the procedure should be adequate to ensure wound 
healing by decreasing time to healing, pain and morbidity [46–48].
Basic principles of wound management seek to treat or manage relevant sys-
temic conditions, maintain a moist wound environment [49], protect the wound 
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from trauma, promote a clean wound base, prevent infection, and control edema 
and lymphoedema. Basic wound care depends on the type of wound being man-
aged; however fundamental wound management practices involve cleansing the 
wound, debriding and applying appropriate dressing materials. The correct type 
of dressing is essential in maintaining a moist wound environment and decreas-
ing rates of infection [45]. Traditional gauze dressings have been shown to have 
increased infection rates compared to moisture retaining dressings [47, 49], there-
fore selection of appropriate dressing is important. Personal observations show 
that different clinicians use varying dressing materials for BU patients to reduce 
edema, however none of the dressings have been evaluated in a controlled trial. 
Other practices that ensure timely wound healing are irrigation with physiologi-
cal saline solution during cleansing, pain management and working under asep-
tic conditions. The WHO has two guidelines on wound management that can be 
applied to BU [50, 51]. However, a study by Velding [45] accessing the wound 
care practices for BU in Ghana and Benin concluded that they differed from the 
recommended WHO guidelines [45]. It is important that health centers adhere 
to the available guidelines on wound care to ensure timely healing of wounds. 
Though some of the differences in wound management techniques were related to 
the economic conditions of the health centers, Velding recommends some simple 
and low cost solutions which can be implemented in the health centers to enhance 
the standard of wound care [45]. As such, health care workers need to be trained 
on the appropriate guidelines for wound management and a retraining and moni-
toring machinery should be put in place to ensure compliance with laid down 
guidelines.
Many lines of evidence indicate that good wound care practices can decrease 
the length of hospital stay and also increase the number of wounds healing without 
surgical intervention. Wound care is expensive and the burden usually falls on the 
affected patients and their families who are sometimes ill-equipped to handle the 
financial costs over a long period of time. Good wound care will therefore reduce 
this burden on the affected individuals by ensuring they do not stay for prolonged 
periods in the health centers.
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Management of BU-HIV Co-infection
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1  Epidemiology
In many Buruli ulcer (BU) endemic countries worldwide there is also a high HIV 
prevalence. This is especially the case in Africa with adult HIV prevalence rates 
between 1 and 5% in BU endemic countries. Evidence from Benin, Cameroon, 
Ghana and Gabon suggest that HIV may increase the risk of BU [1–5]. For example, 
in the Médecins Sans Frontières programme in Akonolinga, Cameroon, the preva-
lence of HIV was approximately 3–6 times higher in BU treated patients compared 
to the regional estimated HIV prevalence (37% vs 8% in women; 20% vs 5% in 
men; and 4% vs 0.7% in children) [2]. Likewise in Benin, in one region patients 
with BU were eight times more likely to have HIV infection than those without BU 
(2.6% vs 0.3%) [3], and in another region adults with BU were five times more 
likely to have HIV compared to the regional estimated HIV prevalence (5.0% vs 
1.1%) [4]. In Ghana HIV prevalence was 4–5 times higher in BU patients than those 
without BU (5% vs 0.9% in one study and 8.2% vs 2.5% in another study) [1, 6]. 
Therefore, there is a significant potential for the two infections to overlap in the 
same individual and HIV needs to be considered in all BU patients in settings with 
high background HIV prevalence.
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2  Clinical Effects of BU-HIV Co-Infection
HIV appears to affect the clinical presentation and severity of BU disease with a 
reported increased incidence of multiple, larger and ulcerated BU lesions in HIV- 
infected individuals (Fig. 1) [1, 2, 4, 5]. In Cameroon BU-HIV co-infected patients 
have a median lesion size of 5.5 cm (equivalent to WHO category 2) and up to 24% 
have multiple BU lesions (equivalent to WHO category 3) [2]. This results in 
increased patient morbidity as well as more time and resources required to treat 
lesions, and increased rates of long-term disability. Additionally it appears that the 
presence and severity of BU may reflect the level of underlying immune suppres-
sion in an HIV-infected person. In Akonolinga, Cameroon, 80% of patients with 
category 2 or 3 BU lesions had a CD4 count ≤500 cells/mm3 compared to 55% of 
those with category 1 lesions, and the main lesion size was significantly increased 
with decreasing CD4 cell counts [2].
BU-HIV co-infected patients often present with severe immunosuppression and 
thus in urgent need of antiretroviral therapy (ART). In Akonolinga, 22% of patients 
diagnosed with BU were classified as having advanced HIV disease (defined as CD4 
counts ≤200 cells/mm3) and 48% had CD4 counts between 200 and 500 cells/mm3 
[2]. In this programme, mortality in BU-HIV co-infected patients treated for BU with-
out ART was significantly higher than for HIV non-infected BU patients (11% vs 1%, 
p < 0.001). This is despite median CD4 cell counts at baseline among the 8 deceased 
HIV-infected patients being only moderately reduced at 229 cells/mm3, levels usually 
not associated with such a high mortality rate. Death occurred early with a median 
time to death post BU diagnosis of 41.5 days and none had received ART. This sug-
gests that a delay in ART initiation until after the completion of the recommended 
8 weeks BU antibiotic treatment may adversely affect mortality rates [2]. In Ghana, 
Fig. 1 Bilateral severe BU 
lesions on the lower limbs 
of an HIV co-infected 
patient
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during the management of BU lesions, two of four patients (50%) who did not start 
ART died compared with none of three (0%) who commenced ART [1]. In Gabon, all 
nine (100%) patients with known HIV infection died during the treatment of BU, 
although data regarding their ART status was not reported [5]. There are also several 
case reports describing deaths in BU-HIV patients not commenced on ART [7–9].
3  Diagnosis
It is not known whether co-infection with HIV affects the sensitivity or specificity 
of BU diagnostic tests, but it appears unlikely. Therefore recommended methods of 
BU diagnosis are the same as for HIV negative patients. This includes mainly 
IS2404 PCR testing of specimens, and microscopic detection of acid fast bacilli in 
stained smears from wound specimens [10]. As BU patients appear to represent a 
sentinel group with a higher prevalence of HIV, and knowing that HIV status will 
affect treatment options and may influence mortality and BU outcomes, it is recom-
mended that all BU patients presenting in settings with a high prevalence of HIV 
have their HIV status determined by offering quality provider-initiated HIV testing 
and counseling [11].
4  Management of BU-HIV Co-Infection
The management of BU-HIV co-infection presents a complex and challenging situ-
ation for clinicians involved in patient care. Effective management requires atten-
tion to the treatment of each infection, but also consideration of the potential 
interactions between the treatments.
4.1  BU Treatment
If the patient is not already on ART, BU treatment should be commenced first, with 
combination antibiotic treatment. This is recommended prior to commencing ART 
for HIV to minimize pill burden and avoid drug interactions and side effects in the 
early stages of BU treatment, to allow the time needed for patient preparation for 
ART, and to follow the usual principle of HIV care to treat and stabilize any co- 
infections prior to commencing ART [12].
In 2017 the WHO Technical Advisory Group on BU decided that the WHO rec-
ommendation for BU treatment in Africa should be changed to rifampicin 10 mg/kg 
daily up to a maximum of 600 mg/day plus clarithromycin 7.5 mg/kg twice daily 
(up to a maximum of 1000 mg daily). However, due to potential drug interactions 
this combination should be used with caution. An alternative is rifampicin 10 mg/kg 
daily up to a maximum of 600 mg/day plus moxifloxacin 400 mg daily. The use of 
the combination of rifampicin and streptomycin is no longer recommended due to 
unacceptable toxicity levels such as renal dysfunction and ototoxicity, drug 
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interactions with tenofovir, as well as the negative effects on adherence of daily 
painful injections. There is no evidence that the duration of BU antibiotic treatment 
needs to be prolonged beyond the standard recommended 8-week course for 
BU-HIV co- infected patients [13].
4.2  HIV Treatment
As currently recommended for all HIV-infected individuals, a CD4 cell count 
should be determined for all BU-HIV positive patients to assess the level of HIV- 
associated immune suppression. If the CD4 cell count is equal to or <350 cells/mm3 
then prophylactic cotrimoxazole (960 mg tablet daily) should be commenced imme-
diately to reduce mortality, morbidity and HIV disease progression [14]. If a CD4 
cell count is not available and the patients have advanced HIV disease (WHO clini-
cal stages 3 or 4) they should likewise receive cotrimoxazole prophylaxis. In areas 
with high prevalence of malaria and/or bacterial infections, cotrimoxazole should 
be commenced regardless of CD4 cell count in all BU-HIV-infected patients and 
continued for life. Patients with advanced HIV disease are at risk of a range of other 
opportunistic infections including cryptococcal meningitis, and it is recommended 
to screen with a cryptococcal antigen test if the CD4 cell count is <200 cells/mm3, 
and assess for danger signs of severe illness [14].
If patients are already receiving ART then this should be continued. All patients 
with active BU disease who are known or diagnosed as HIV positive but not on ART 
should initiate ART. This aims to reduce HIV associated mortality and morbidity, and 
HIV transmission [15]. Furthermore, as the immune system plays an important role in 
curing BU disease and in healing lesions, optimization of immunity with ART may be 
important to combat BU disease and potentially improve treatment outcomes (healing 
times, cure rates, long-term disability and recurrence rates). It has been found that in 
BU-HIV coinfected patients, a CD4 cell count >500 cells/mm3 was associated with a 
reduction in the time needed to heal BU lesions by more than 50% compared to those 
with a CD4 count ≤500 cells/mm3 [2]. This suggests that healing times are signifi-
cantly more prolonged among immune suppressed HIV positive individuals.
ART should begin as soon as possible after the start of BU treatment, preferably 
within 8 weeks, and as a priority in those with a CD4 cell count <350 cells/mm3 or 
WHO stage 3 or 4 disease. Patients with advanced HIV are at immediate risk of 
further life-threatening opportunistic infections and delay in ART initiation may 
result in significant HIV-associated morbidity and mortality. As described earlier, 
this risk appears to be significant in BU-HIV co-infected patients, perhaps related to 
an increased risk of bacterial sepsis from secondarily infected BU lesions. Therefore, 
early reconstitution of immunity with ART in advanced BU disease may be impor-
tant. Furthermore, this recommendation to start early also takes into account the fact 
that in routine programmes there may be delays in ART initiation whilst patients 
wait for assessment, training and availability of ART after completing their BU 
treatment. Also, as patients may receive BU treatment at a significant distance from 
ART centers, they may be lost to HIV care if ART initiation is delayed [16].
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It is possible that early initiation of ART will lead to an increased incidence of 
paradoxical reactions associated with immune reconstitution when combining BU 
antibiotic treatment and ART [1, 17, 18]. This may lead to significant tissue damage 
and undesired consequences, especially if lesions are in sensitive areas (e.g. the 
face) (Fig. 2). Thus care needs to be taken when initiating ART. If severe paradoxi-
cal reactions occur ART should be continued and the use of prednisolone to mini-
mize the severity of the effects should be considered [17, 19].
4.3  HIV and BU Treatment Interactions
There are a number of important issues regarding the use of antiretroviral drugs in 
patients receiving antibiotic treatment for BU. Firstly, as recommended for TB/HIV 
patients on ART using rifampicin containing regimens, the non-nucleoside reverse 
transcriptase inhibitor (NNRTI) component of the ART regimen should be efavirenz 
[20]. If this option is not available or appropriate then nevirapine can be used, but the 
lead-in dose of nevirapine should be omitted in the presence of rifampicin at the start 
of treatment. Additionally, caution should be exercised in the use of nevirapine par-
ticularly in patients with high or unknown CD4 cell-counts at initiation due to a 
potential increased risk of hypersensitivity and Stevens Johnson’s syndrome [21]. 
Close monitoring during the initial weeks of therapy is recommended when nevirap-
ine is initiated in these patients. Another alternative in adults and non-pregnant 
women is the integrase inhibitor dolutegravir which is preferred over efavirenz as a 
first-line antiretroviral in high-income settings and is being introduced in low- and 
middle-income settings. However, due to an interaction with rifampicin, it is cur-
rently recommended that the dose of dolutegravir should be doubled to 100 mg daily.
There are concerns about significantly reduced levels of protease inhibitor (PI) 
medications and increased toxicity when they are used with rifampicin and there-
fore they are ideally avoided during BU antibiotic treatment. If the patient is already 
receiving a PI-based regimen, and they are NNRTI-naïve and not infected with the 
Fig. 2 A severe paradoxical 
reaction associated with a 
severe BU lesion on the left 
ankle of an HIV co-infected 
patient 2 weeks after 
commencing antiretroviral 
treatment
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HIV-2 virus, the PI-based regimen should be changed to an NNRTI-based regimen 
using efavirenz. If they are not NNRTI-naïve or are infected with HIV-2 virus, then 
the recommended PI regimen to use is lopinavir/ritonavir (LPV/RTV) at either dou-
ble dose (800 mg/200 mg twice daily) or standard LPV dose with increased dose of 
RTV (400 mg/400 mg twice daily). However this combination in higher doses is 
frequently associated with high levels of toxicity and requires close clinical and 
laboratory monitoring. Again an alternative, if available, is for the integrase inhibi-
tor dolutegravir to replace the PI during the 8-week BU treatment.
Efavirenz can reduce clarithromycin levels by up to 39% [22] which likely fur-
ther compounds the known significant reduction of clarithromycin levels when co- 
administered with rifampicin [23]. Although the clinical consequences of these 
interactions are unknown, it could potentially lead to reduced effectiveness of the 
rifampicin/clarithromycin regimen for BU treatment, with secondary treatment fail-
ure and drug resistance. Increased toxicity is also reported when the two drugs are 
combined, with 46% of patients reported to develop a rash [24]. Therefore this 
combination should be used with caution. The alternative that avoids this interaction 
is rifampicin 10 mg/kg daily up to a maximum of 600 mg/day plus moxifloxacin 
400 mg daily. This regimen has the added benefit of reducing the risk of rifampicin 
resistant TB if BU treatment is used in patients also infected with undetected drug 
sensitive active tuberculosis [25].
4.4  Children
All children should be commenced on ART as soon as possible within 8 weeks of the 
start of BU treatment. Efavirenz is not approved for clinical use in children <3 years 
of age. Therefore in this age-group if initiating ART whilst on BU treatment with 
rifampicin, nevirapine should be used instead of efavirenz at a dose of 200 mg/m2. 
An alternative is to use a triple NRTI ART regimen (AZT/3TC/ABC or AZT/3TC/
TDF). If already on a PI-based ART regimen when commencing BU treatment with 
rifampicin, LPV/RTV can be continued but the dose of ritonavir should be increased 
to achieve a 1:1 ratio with LPV. Alternative options include either replacing the LPV/
RTV with nevirapine at a dose of 200 mg/m2 or using a triple NRTI regimen.
4.5  Tuberculosis
All patients should be actively screened for tuberculosis (TB) before commencing 
BU treatment and before starting ART [26]. As most BU-HIV co-infected patients 
live in highly endemic areas for TB, there is a significant risk of TB co-infection. As 
HIV-infected patients have a higher risk of TB reactivation, especially when severely 
immunosuppressed, there is a risk of co-existent active TB disease. Therefore it is 
important to exclude active TB disease prior to commencing BU treatment, as BU 
treatment regimens are not adequate to treat active TB, which may result in 
TB-related mortality and morbidity and the development of drug resistant TB. For 
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those with symptoms suggestive of TB, this includes the use of Xpert MTB/RIF on 
sputum, and if CD4 count ≤100 cells/mm3 or the patient is seriously ill (at any CD4 
cell count) the use of LF-LAM on urine. In those without symptoms of TB, TB 
preventative treatment should be started according to local guidelines [14].
4.6  Service Provision
BU patients found to be HIV-positive should be referred to clinicians trained in clini-
cal management of HIV infection. Ideally, management should be integrated within 
the BU treatment centres to facilitate timely initiation of ART and avoid loss of 
patients to follow up which may occur during an external referral process for HIV 
care. If HIV management capacity in BU treatment centres is not possible, then 
referral to the nearest HIV treatment centre for care is recommended. Good coopera-
tion between the BU and HIV treatment programmes at local, regional and national 
levels should be implemented to ensure the highest standard of care for BU-HIV 
co-infected patients. Approaches to support adherence to drug treatments for BU and 
HIV should be integrated, and programmes should implement a monitoring and 
reporting system to monitor and evaluate the outcomes of BU-HIV interventions.
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1  Introduction
Health social science (HSS) research has contributed in significant ways to our 
understanding of how rural communities in West Africa perceive and respond to 
Buruli ulcer (BU), and the challenges facing those involved with BU health service 
delivery. These challenges range from the need to mount more effective community 
outreach education programs leading to earlier BU detection to the need to identify 
and then address predisposing, enabling, and service delivery related factors [1] that 
result in treatment delay, drop out, and non-adherence. In this chapter, we briefly 
highlight HSS research that has broadened our knowledge of community response 
to BU and then consider HSS-inspired BU interventions. Most of the sources we 
draw upon involve research carried out in Benin, Cameroon, and Ghana. To date, 
few HSS studies have been conducted in other endemic countries such as Cote 
d’Ivoire, The Democratic Republic of the Congo, Nigeria and Uganda.1 We include 
in our overview a selection of studies conducted by both social scientists and medi-
cal researchers investigating social and cultural factors that influence health care 
decision-making.
Two things are important to bear in mind at the onset of this review. First, there 
is considerable cultural variability both within and between countries. It is therefore 
best not to overgeneralize the findings of one study to an entire country. While we 
do identify general patterns that emerge in the literature related to overarching 
themes, these patterns do not necessarily apply to all groups. Second, different stud-
ies have employed different research methodologies. These range from in-depth 
ethnographic research employing participant observation and detailed case studies 
1 Two recent studies conducted in Cote’ D’ivoire by Konan et al. [2] and Uganda by Pearson [3] are 
worthy of mention.
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to structured and semi-structured interviews, surveys, and focus groups. The find-
ings of one type of study may differ significantly from another study using different 
methods even when conducted in the same region. Each method has its own unique 
contribution. This is one reason social scientists often employ multiple methods and 
triangulate data to get at different aspects of any social phenomenon. The impor-
tance of doing so is demonstrated in a study of BU conducted by Grietens et al. [4], 
who speak to the value of establishing trust with research participants as a means of 
getting at sensitive issues related to health care seeking before attempting to con-
duct a survey.
2  Part One
We begin with research on factors that influence health care seeking beginning with 
predisposing factors. More attention is given to this topic than enabling and service 
related factors because they provide the most insight into how BU is perceived and 
experienced culturally.
2.1  Predisposing Factors: Cultural Perceptions of BU Causality, 
Social Stigma, and Preference for Traditional Healing
2.1.1  Cultural Perceptions of BU Causality
Cultural perceptions of illness causality are best assessed in terms of multiple levels 
of causality that encompass predisposing, efficient, instrumental, and ultimate 
causes of illness [5, 6]. Predisposing factors range from social transgressions to 
vulnerable traits and states. Efficient causes of illness involve agents whose actions 
reflect intention such as spirits or witchcraft. Instrumental causes of illness, such as 
insects, worms, or germs, have no intention. Ultimate causes of illness are associ-
ated with such things as God’s judgement or some notion of fate. Multiple ideas 
about the cause of an illness often coexist and it is common for efficient causes 
(agents) held responsible for causing serious or unusual illnesses to be viewed as 
working through or in concert with instrumental causes. This is particularly the case 
when the characteristics of an illness associate it with malevolent intent. In the case 
of BU, the unusual physical characteristics of BU—ulceration, long term suffering 
without death, and the negative social and economic hardship associated with the 
disease—lead many to consider it unnatural even when biomedical treatment is 
accepted.
Community members often maintain “what if” subjunctive reasoning [7, 8] when 
considering possible causes of an illness and may draw attention to one type or level 
of causality at a particular time for any of a variety of reasons. For example, drawing 
attention to mystical causes of a case of BU may entail rationalization for a course of 
action or involve the moral identity of the afflicted, a decision maker, the household, 
or even an entire community when illness etiology indexes cultural affiliation or 
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difference. Disease attribution may also be a means of “othering” a population. For 
example in Cote d’Ivoire, a country in which both physical and mystical causes of BU 
are thought to exist, a perceived rise in the number of BU cases has been attributed to 
an influx of migrant workers from other West African countries. These populations are 
thought to somehow harbor the causative agent of the disease. Notably, the impor-
tance of identifying an efficient cause of a “sent” illness (like witchcraft or sorcery) is 
generally not to seek retribution from a specific person or group. It is rather to give an 
unusual event some sense of coherence. What follows is a brief overview of how BU 
is perceived by members of the three index countries along with observations on the 
extent to which illness perceptions influence health care seeking behavior.
Benin
Mulder et al. [9] interviewed 153 former/active BU patients (107 treated at hospital, 
46 by healers) in Southern Benin about their perceptions of BU causality using a 
semi structured questionnaire. Fifty-eight percent of former patients reported attrib-
uting their illness to witchcraft, often for reasons associated with jealousy. However, 
only 13% reported that their perception of causality was an important factor in 
health care decision making when directly asked if such was the case.
Aujoulat et al. [10] carried out a more in-depth community based study of BU 
causality in the same region. Community members exposed to BU education as well 
as several health workers maintained the perception that BU-like symptoms could 
either be signs of a natural disease or an induced disease (sasa) caused by sorcery, 
witchcraft, or a curse only treatable by healers. Community members generally 
relied on diagnosis by treatment. The underlying cause of one’s illness was thought 
to become apparent based on the aliment’s response to different types of treatment 
and the trajectory of the illness over time. Notably, in this study, women were far 
more likely to ascribe BU-like symptoms to natural causes in part because children 
are often affected. Children are not seen as embroiled in problematic social relations 
associated with jealousy or any social infraction that might lead to witchcraft or 
sorcery.
One of the most common natural causes of BU recognized by women was 
worms. Informants described worms as a possible instrumental cause of BU linked 
to predisposing factors such as body weakness, fatigue, or environmental factors. 
However, they did not discount the idea that worm activity might be related to an 
efficient cause interfering with wound healing. The researchers also explored per-
ceptions of contagion. They found that contagion was commonly related to the foul 
smell of a necrotizing BU-related wound. Notably, while some community mem-
bers and health workers feared that BU might be contagious, most women who 
cared for a child with BU did not believe this to be the case because they had been 
in close proximity to an afflicted child and not gotten sick. Healers contributed to 
the perception that BU was contagious by insisting that a patient should remain in 
isolation during treatment. Notably, a major factor underlying why children having 
BU were kept out of school by some parents was fear others might consider the 
child contagious.
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A third study by Kpadonou et al. [11] further documented differences of opinion 
about causality among a sample of 244 former BU patients treated at Allada Hospital 
and residing within a 100 km radius of the hospital. This study found that while a 
majority of adults and teens attributed BU to witchcraft, a majority of children per-
ceived BU to have natural causes. The authors attributed this difference to children’s 
exposure to health education messages while being treated in hospital. Among teens 
and elders exposed to the same messages, cultural beliefs about efficient causes of 
disease remained salient. Regardless of what cause BU was attributed to, 90% of all 
informants stated they did not feel guilt associated with having the disease.
A fourth study by Boyer [12] carried out in Benin’s Ouémé River region investi-
gated stories and rumors circulating about BU and its treatment at a local Catholic 
mission hospital renown for BU lesion excision, and the social relations of BU causal 
attribution in the context of health care seeking. Boyer’s in-depth ethnography of BU 
included case studies of household decision making related to BU treatment. He 
found that in some instances mystical attribution of BU was employed by a male deci-
sion maker to justify treatment of a family member by traditional healers instead of 
treatment at a hospital for pragmatic reasons. In this region of Benin, decentralized 
care did not exist while Boyer was conducting his research, and going to a hospital 
resulted in a significant loss of revenue and/or labor on the part of the afflicted and/or 
a patient caretaker required by the hospital. Focusing on mystical causes of the illness 
and the need for traditional treatment upheld the moral identity of some decision mak-
ers opting for traditional treatment. Notably, Boyer documented cases where there 
was ambivalence about this decision on the part of other family members. Boyer 
draws attention to the fact that explanatory models of BU involving mystical causes 
can sometimes serve as post hoc rationalizations of action or inaction as well as being 
determinants of health care seeking. He further points to the folly of describing 
“beliefs” about BU as durable unquestioned ideas fixed in the mind of the afflicted 
instead of seeing them as ad hoc explanatory models subject to revision given the rich 
semantic illness network [13] of the Beninese. Ideas about BU, he argues, are hardly 
fixed and subject to the circulation of stories and rumors about the ailment and its 
treatment. All of this leads Boyer to caution against simplistically blaming “beliefs” 
for BU treatment delay and assuming that once beliefs (read superstitions) are 
addressed through education a preference for hospital care will follow.
A fifth study by Kennell [14, 15] conducted among the Aja ethnic group draws 
attention to why some ethnic groups wait before treating an ulcer to determine its 
cause and decide on a course of action, a process the Aja refer to as zohwiʒi. Among 
the Aja, there is a belief that skin eruptions/wounds may be a sign of Sakpata, the 
vodun deity of the earth long associated with small pox and measles. If deemed a 
sign of the spirit’s presence, it is believed the wound should not be treated by hos-
pital medicine for fear that the spirit might be angered and the patient face dire 
consequences. A watch and wait policy is deemed prudent to see if the wound erupts 
as a common abscess or is seen as unusual. If seen as a sign of Sakpata, the afflicted 
becomes an initiate in a spirit cult. Notably, while hospital medicines may not be 
used during the zohwiʒi process, herbal medicines may be applied to hasten the 
eruption process.
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Cameroon
Several ethnographic studies have looked at perceptions of BU causality in 
Cameroon. A detailed study of BU by Grietens et al. [4] in Cameroon highlights the 
importance of perceptions of multiple or “double causality.” This study found that 
in Southern Cameroon BU (referred to as atom) is commonly attributed to mystical 
causes associated with either some type of social infraction or witchcraft. Social 
infractions include such things as theft or trespassing (knowingly or unknowingly) 
on someone else’s agricultural plot protected by a powerful fetish. Guard fetishes 
are thought to have the power to inflict particular kinds of illnesses, including atom. 
Sorcery may also cause atom. Sorcery operates through antisocial malignant forces 
present in an invisible world (evu). These forces may be controlled and used by 
either a sorcerer or a healer. They may also be unconsciously present within some 
people and only become active at night when they are asleep. The characteristics of 
BU (a wound that does not heal, becomes more severe, and inflicts immense suffer-
ing) match the imagery of how people think sorcery operates. A common perception 
is that in order for a sorcerer to gain power to inflict suffering and in order for a 
healer to gain power to engage in “night battles” with malevolent forces, sacrifices 
must be made to strengthen the evu under their control. One way to do so is through 
the mystical eating of flesh, even the flesh of family members. Slow progressing BU 
wounds appearing on the limbs of children as well as adults are thought to be evi-
dence of such flesh eating.
Atom is also thought to have a natural origin related to insect bites, especially the 
bites of horseflies that fester and become more severe. Some community members 
exposed to outreach education programs have come to think of these wounds as 
being infected with microbes. Others perceive these insects to be sent by sorcerers 
to inflict harm and negatively influence disease progression. The possibility of 
“double causality” is shared by health staff who maintain an open mind when 
patients express a desire to seek the assistance of traditional healers while being 
treated at hospital. This is especially the case when the healing process is not going 
well. A point emphasized by Grietens et al. is that although perceptions of “double 
causality” are strong in the region, they are not necessarily the major reason for 
treatment delay at hospitals and health posts.
A study conducted by Awah et al. [16] in the Bankim region of Cameroon found 
perceptions of BU causality that are similar, yet distinct from those described in the 
Southern region of the country. BU like symptoms are seen as possibly having a 
natural cause, being the sign of a powerful spirit (mbouati), or being caused by 
witchcraft. Natural causes of the disease are associated with changes in ecology 
resulting from the building of a large dam in the region, and the introduction of rice 
cultivation. While residents recognize that the illness has become more common 
following these events, the instrumental cause of the disease is not understood. 
Mbouati is a spirit affliction that gives special powers to the afflicted, powers that 
some of the afflicted may not want to relinquish. Informants across several ethnic 
groups inhabiting the area voiced the opinion that both mbouati and BU co-existed, 
and that only traditional healers could determine the difference between the two as 
well as afflictions caused by witchcraft. Only the most powerful of healers, it is 
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thought, can transform a mystical ailment into a chronic physical ulcer (nbong) 
amenable to successful treatment by herbs or hospital medications. Furthermore, 
when a wound does not heal when treated it is conjectured that mbouati may be toy-
ing with healers or health staff and leading them to believe their treatment is suc-
cessful in early stages only to undermine their efforts latter.
Local observation that BU-related diseases have increased as a result of ecologi-
cal and social change is a subject investigated by Giles-Vernick et al. [17] in the 
central region of Cameroon. Adopting an ethno historical perspective and the use of 
multiple methodologies ranging from in-depth interviews to group discussions, 
these researchers investigated the circumstances that have led to a widely held per-
ception that the number of cases of atom have steadily increased during the last two 
to four decades. An increase in the number of atom cases is associated with ruptured 
social relations that took place at a time of heightened environmental degradation 
and ecological decline as well as rising economic hardship, competition, and jeal-
ousy. Atom is seen as a sign and symptom of diminished eding, a term that indexes 
both love and social cohesion leading to fruitful and productive ecological extrac-
tion by community members. The researchers note that social, environmental, and 
ecological disruption are perceived to have provoked and expanded the prevalence 
of atom through both natural and mystical causes. This study calls our attention to 
the necessity of studying NTDs in a broader “One world one health” context [18] 
attentive to both political ecology and those factors leading to structural vulnerabil-
ity. In the case of BU, this entails the need to document how changes in the environ-
ment and shifts in social relations associated with such factors as structural 
adjustment policies and changing cropping patterns, contribute to disease suscepti-
bility and increased exposure to the pathogen responsible for BU.
Ghana
The greatest number of social science studies of BU have been carried out in Ghana. 
A few studies of causality may be highlighted to illustrate the range of observations 
documented. A large community-based study of local perceptions of BU was car-
ried out by Renzaho et al. [19] in Ga district. Ten percent of the district was sur-
veyed and seven focus groups conducted. The survey found that 53% of informants 
had no idea of the cause of BU, 16% thought it might be caused by drinking non- 
potable water, 8% by poor hygiene and unclean surroundings, and 6% by swimming 
or wading in ponds. Only 5% of participants reported that BU might be caused by 
witchcraft. During focus groups, however, witchcraft surfaced as a common possi-
ble cause of BU and a major source of concern. The survey also suggested that 
children were far more likely to think BU was contagious than adults.
Ackumey et al. [20, 21] investigated perceptions of BU among those afflicted 
with BU in both the pre-ulcer and ulcer state in West and South Ga municipalities 
near Accra. They employed an explanatory model interview guide adapted for BU 
research. The patient-based data generated in this study was quite different from the 
community-based survey data generated by the aforementioned study. In the pre- 
ulcer state, respondents commonly reported behavior-based BU causality, espe-
cially swimming in ponds and rivers. However, informants who did not engage in 
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such behaviors questioned how this could be the cause of the illness. Still others 
questioned how this could be the major cause of BU when so many people who had 
contact with the same water sources did not become ill. Half of all informants 
believed their condition might be related to drinking unclean water, a general (not 
BU-specific) health message repeatedly heard from health workers. Many other 
informants attributed their ulcers to small wounds and insect bites that became 
aggravated as a result of their scratching them. About a third of all informants stated 
they had no idea of the cause of their condition. For those with large ulcers, witch-
craft was the most common cause reported followed by swimming in rivers, weak-
ness of blood, and drinking unclean water. Weak blood was reported to be a common 
cause of BU among children.
Notably, the authors found that 40% of informants with pre-ulcers and 50% of 
those with ulcers said their condition could not have been prevented because witch-
craft cannot be stopped. Nevertheless, approximately half of all informants stated 
that avoiding bathing in rivers or ponds prevented the disease. Many noted, how-
ever, that this was hardly feasible. The researchers concluded on the basis of their 
interviews that regardless of perception of causality, those afflicted with BU were 
willing to seek medical care if it was accessible. The afflicted maintained a prag-
matic attitude and were open to trying any treatment that might help them recover 
from their condition.
Another study of 86 BU patients in Ga district by Owusu and Adamba [22] reported 
data similar to Ackumey with a few notable differences. In this study, only 15% of 
informants attributed the cause of their disease to “enemies”(witchcraft), while 19% 
associated the disease with water use, walking through swampy areas while working 
in the fields (because BU commonly affects the lower limbs), and children swimming 
in the river. Thirteen percent thought the disease might come from insect bites, but 
informants could not specify which insect might be causing the disease. Of those who 
reported insect bite as a possible cause, many maintained dual casualty. They found it 
hard to believe that an insect bite could lead to such a serious illness unless witchcraft 
was involved. Of those who imagined dual diagnosis, it was deemed prudent to use 
herbal medicine before hospital medicine to deal with witches first.
A more recent study by Koka [23] in Ga district found that while 78% of infor-
mants (N = 300) thought BU had natural causes, 61% thought BU could be caused 
by supernatural agents as well. Notably, there was a statistically significant gender 
difference in perceptions of causality. Sixty nine percent of women reported natural 
causes of the disease while only 36% of men did so (p = 0.006). Education also 
proved to be a factor influencing perceptions of causality. Far more respondents 
with at least primary education (46%) were likely to report that Buruli ulcer can be 
caused by both natural and supernatural causes when compared to those with no 
education (29%) (p < 0.001). Moreover, those with at least primary education were 
far more likely to report only natural causes than those with no education.
Stienstra et al. [24] conducted a study of BU in three regions of Ghana (Agogo, 
Denkyira, and Amansie districts) and interviewed BU patients at hospitals as well as 
community members. More than half of all respondents associated poor personal 
hygiene with the disease, but many others thought this was not possible. They 
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observed that people with good hygiene suffered from the disease and that others 
with very poor hygiene living in the same village did not experience the disease. 
Nearly half of all respondents also identified the environment as a possible risk fac-
tor for BU, especially walking through swampy areas and being bitten by insects 
that lead one to scratch and open the skin to diseases. Only a few people mentioned 
drinking water or eating contaminated food as possible causes of BU. Twenty-three 
percent of all respondents feared BU might be contagious in some way (touch, 
clothing, flies, feeding, etc.) and a few thought the disease might be sexually trans-
mitted. Fifty-nine percent of respondents thought the disease might be caused by 
witchcraft, 47% by a curse, and a few mentioned God’s will as an ultimate cause. In 
the latter case, it was thought that God removed his protection against diseases 
because of some sin that one had committed. Notably, even though ancestors play 
an important role in Ghanaian life, they were not mentioned as a cause of BU.
Shifts in environmental landscapes have also been connected to a rise in BU cases 
in Ghana. Tschakert et al. [25] found that community members in an area of Ghana 
exposed to artisanal gold mining and illegal logging connected a rise in BU cases to 
ecological destruction, flooding, and increased bodies of stagnant and/or contami-
nated water. How these conditions led to increases in the disease was open to consid-
erable conjecture. Notably, community members identified having to cross disturbed 
spaces to engage in daily activities with increased risk of experiencing BU.
2.1.2  Stigma and Social Risk
It has been widely reported in all three index countries that BU is stigmatized. 
Stigma is a concept that covers a broad range of social responses to a condition or 
group that is negatively valued. Applied to an illness like BU, it encompasses both 
felt stigma and enacted stigma. Felt stigma entails a sense of shame, embarrass-
ment, inferiority, and fear of enacted stigma. Enacted stigma entails social exclu-
sion, discrimination, and isolation. Stienstra et al. [24] conducted what has become 
a landmark study of stigma related to BU attentive to both types of stigma. These 
researchers employed an eleven-question, pretested instrument to explore social 
exclusion in various areas of everyday life when one suffered from BU.  They 
administered the instrument to subsamples of both infected and non-infected com-
munity members. From their study of three regions of Ghana, they concluded that 
stigma for BU was pervasive. Half of all afflicted and non-afflicted informants, 
regardless of educational background, reported that those afflicted with BU were 
avoided by others, avoidance being slightly higher for men than women. Social 
avoidance was primarily reported for non-relatives and was particularly high in 
endemic areas.
Many of the afflicted reported feeling ashamed and stated that they tried to hide 
their wounds from others. Others, however, were concerned that their illness might 
be contagious. They displayed their wounds to let others know not to come near. 
Fear of transmitting BU was related to both natural causes and witchcraft. However, 
when witchcraft was associated with BU, stigma scores rose appreciably. The study 
found that not only was BU feared as contagious, but it was also thought to lead to 
infertility because the disease was perceived to render the blood of the afflicted 
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dirty. Having the disease made it more difficult for both the afflicted and family 
members to marry.
Notably, the study did not find that stigma scores correlated with any pattern of 
health-care seeking or treatment delay. However, it did find that stigma affected 
school attendance. Other studies in Ghana have likewise reported that stigma and 
fear of contamination is particularly strong among school children, leading the 
afflicted to drop out of school. Koka [23] found that in West Ga district it was not just 
students who feared that BU might be contagious, but also teachers. As a result, 
teachers did not intervene when students shunned those having the symptoms of BU.
In Benin, Mulder et  al. [9] employed the stigma questionnaire developed by 
Stienstra et al. and found that about half of all current BU patients interviewed expe-
rienced some degree of stigma. Patients treated at health posts and by traditional 
healers did not report statistically significant differences in levels of stigma. Stigma 
appeared to decrease post treatment with less than a third of former patients report-
ing stigma.2 Stigma was largely associated with the smell emanating from the 
wound. Patients often engaged in self-stigmatization, isolating themselves from 
others out of embarrassment. The actions of traditional healers also reinforced 
stigma. Many traditional healers demanded isolation while treating BU patients for 
months and in some cases years. Anthropologists working on a Stop Buruli research 
project in Benin documented another factor leading to self-isolation: a perception of 
vulnerability. They found that some patients with open wounds felt vulnerable to 
witchcraft and other malevolent forces. For this reason, they hid their wounds and 
when compelled to move through public spaces, would not display bandages.
Some social scientists have cautioned against overemphasizing the role of stigma 
as a factor causing BU treatment delay. Ribera et al. [27] found that social isolation 
was common among BU patients in Cameroon, but not a primary factor influencing 
health care seeking. Paying too much attention to stigma, they argue, deflects atten-
tion away from enabling and health service related factors causing delay. They also 
argue that while BU is commonly associated with social transgressions and witch-
craft in central Cameroon, stigma is not the main cause for patients abandoned at the 
hospitals. Their findings suggest that social isolation and abandonment are often 
part of a household coping strategy, an attempt to avoid plunging the household into 
a spiral of impoverishment.
Social risk has been identified as a factor influencing health seeking behavior for 
BU. Social risk refers to risk to one’s reputation that negatively affects present or 
future social relationships. When a woman is compelled to travel to a clinic for 
decentralized care or to remain in a hospital for long term BU care she may become 
the subject of rumors suggesting she is engaging in illicit sexual relations when 
travelling outside her community. Social risk associated with seeking health care 
was identified in each of the three index countries, but poorly documented in all but 
2 Some studies suggested some types of ongoing social exclusion. A study by de Zeeuw et al. [21] 
carried out in Benin and Ghana documented persisting social and work participation restrictions 
among former patients with BU. These restrictions remained long after treatment was completed 
and wounds had healed.
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Benin [28, 29]. Concern about social risk is one reason women travel to health posts 
with children or a chaperon, and that children serve as patient care takers at hospi-
tals. Notably, Amoussouhoui et al. [30] found that when outreach education about 
treatment and decentralized care was made available near one’s village in Benin, 
fear of social risk was reduced.
2.1.3  Traditional Healers
It has been widely reported that traditional healers are often a first resort for wound 
care in all three index countries [10, 16, 24, 31, 32], and that healers often treat BU 
related wounds for extended periods of time. It is beyond the scope of this chapter 
to provide a detailed account of the practices of traditional healers. These practices 
range from exorcism, the placating of spirits, and prayer to herbal treatment, and in 
many cases provision of both mystical and physical treatment. Researchers like 
Grietens et al. [4] and Johnson et al. [33] have aptly described some of the more 
common types of therapy offered by various kinds of healers in all three countries.3 
Traditional healers often engage in some form of divination to determine the etiol-
ogy of a wound and then decide whether they should treat the wound or refer the 
afflicted to another healer who specializes in another type of treatment. If a social 
infraction is suspected on the part of the afflicted, then a confession may be required 
and regret communicated in some way. Purification may be required in the form of 
ritual washing with magically infused water or the blood of a sacrificial animal. 
Stop Buruli Consortium researchers from all three index countries found that when 
herbal medicines are employed, medicines are commonly applied to dry a wound. 
Drying is seen as necessary for the healing process [34]. In some cases, burning or 
cutting a patient to remove bad blood may be undertaken. Interdictions may also be 
required in the form of prohibitions, which may involve various kinds of food, con-
tact with others during treatment, and/or suspension of sexual relations on the part 
of the patient. When witchcraft or a spirit’s presence is suspected, herbs and mysti-
cal protection offered by a traditional healer are commonly thought necessary even 
if biomedical treatment is eventually sought.
There has been heated discussion within the international Buruli research com-
munity about whether traditional healers should play a role in BU outreach and 
whether collaboration with health staff is feasible. Two factors that emerge from the 
literature as key to collaboration are an appreciation for dual illness causality, and 
mutual respect. Stated more succinctly, collaboration depends on whether the exper-
tise of healers is acknowledged when it comes to dealing with psychosocial and 
mystical aspects of patients’ BU experience as the “work of culture” [35]. The 
“work of culture” refers to the process whereby distressful states, perceived risk and 
motives, negative affects, and sensations are transformed into publicly accepted sets 
of meanings and symbols that can be manipulated or dealt with in some culturally 
salient manner. On the part of traditional healers, there has to be recognition of the 
expertise of clinical staff in treating BU wounds as a systemic health problem 
3 Also see Pearson for a detailed study of why herbalists are preferred for treatment of ulcers, boils, 
and BU in Uganda.
M. Nichter
259
requiring timely referral and treatment adherence. In short, collaboration requires 
task sharing.
Few rigorous studies have been carried out to date to test the conditions under 
which collaborative relations between hospital staff and healers might be estab-
lished toward the end of managing BU. One exception is a pilot project in Bankim, 
Cameroon [16]. The project is briefly summarized below in a section on social sci-
ence inspired interventions. The project was successful in establishing long-term 
collaborative relations between traditional healers, health staff, and community vol-
unteers. Findings of this study as well as observations made in Obom, Ghana sug-
gest that in regions where healer groups are supported by chiefs and well functioning, 
it is far easier to establish collaborative agreements and lines of referral than where 
such groups do not exist. In the case of Bankim, healer groups signed a contract 
specifying that they would treat suspected cases of BU for 10 days or less, and not 
treat a patient’s skin. Health staff in return granted traditional healers privileges to 
visit patients in health posts and offer spiritual protection and psychosocial 
support.
Three lessons learned in the Bankim case study may be highlighted. First, 
before introducing training courses for healers in general, it was found important 
to work with a select group of healers to establish best practices. These healers then 
served as role models for other healers. Second, it was necessary to insure that col-
laboration was a win-win proposition. Credit for healing a patient was shared 
between traditional healers and health staff, so that the reputation of both increased. 
Third, offering incentives to traditional healers to refer BU cases to hospital was 
found to be a culturally sensitive issue that needed to be handled carefully. In 
Bankim, traditional healer collaboration was not established by offering cash pay-
ments to healers for patient referrals. While an honorarium enabling a healer to 
bring a patient to a clinic was greatly appreciated, this had to be done in such a way 
that there was not a perception that healers gained from the sale of sick bodies to 
the hospital. This would render them morally suspect. One reason for this is that 
traditional healers are thought capable of engaging in witchcraft to generate more 
cases. Healers valued the symbolic capital they gained from collaborating with 
health staff more than the honorarium they received. This was documented in an 
impact evaluation conducted after funds for honorariums were no longer available. 
What traditional healers lost in terms of direct and indirect payments for treating 
BU cases was eclipsed by a rise in their status. The respect they received from 
health staff at outreach functions and in the hospital increased their status and was 
highly valued.
In Benin, Johnson et al. [33] supported collaboration with traditional healers in 
principle, but latter, some of the same authors urged caution when considering 
healer participation in BU programs based on their experience offering ad hoc train-
ing to a few independent healers. Following the training, a few of these healers 
represented themselves as BU treatment experts and kept instead of referring cases 
[36]. A more recent study in Benin, however, identified conditions under which 
healers were willing to refer cases and collaborate with health staff and commu-
nity volunteers. In a region of the country where decentralized care was recently 
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introduced for BU and other chronic ulcers, the popularity of clinic-based treatment 
soared due to the demonstration effect of good wound management and culturally 
sensitive outreach education [30]. Traditional healers responded by wanting to be 
associated with the community based BU outreach efforts being promoted. As in the 
case of Bankim, traditional healers did not see collaboration as a loss of status when 
invited to be part of outreach activities and offered respect.
Concern about cost and labor loss have been identified as major factors leading 
to the consultation of traditional healers who live near the afflicted, and are often 
relatives [37]. It is important to recognize the accessibility of healers as an impor-
tant factor influencing health seeking behavior, but it would be simplistic to con-
clude that accessibility is the only reason traditional healers are consulted at 
different stages of health problems. As noted by many medical anthropologists (cf. 
[38, 39]), traditional healers are consulted before or in conjunction with biomedi-
cal care for myriad reasons having social and cultural salience. Some social scien-
tists have argued that patient delay as a result of visiting traditional healers will 
cease to be a “problem” once adequate BU care is provided by the government [40] 
or educating the population [41] will lead them to give up superstitions. Based on 
a review of the BU literature to date, it would be premature if not erroneous to 
conclude that traditional healing remains popular only because of a lack of afford-
able biomedical care.
At the same time, it is important to recognize that healers are often chosen over 
poorly staffed and resourced health facilities. Hausermann [42] presents a compel-
ling case study of health care seeking for BU in a border region of Ghana-Cote 
d’Ivoire to make this case as well as to call attention to the impact of poorly imple-
mented BU health policy. Hausermann documents the disjunction between official 
policy narratives about BU and the lived experiences of people in endemic regions. 
Following the work of medical anthropologist Stacey Langwick [43] in Tanzania, 
her analysis shows that nurses refer patients to healers in part due to the inadequa-
cies of health posts under their charge. She raises an issue long debated in interna-
tional/global health. Is government support for the involvement of traditional healers 
(and community health volunteers) really about providing more holistic patient- 
centered care or deflecting attention from the shortcomings of the health system and 
those responsible for developing and implementing policy?
Enabling Factors
Studies of health care seeking in all three index countries have reported that enabling 
factors are a major reason for delays in seeking treatment at hospitals and health 
posts [9, 10, 16, 20, 24, 41, 44, 45]. Enabling factors include the seasonal availabil-
ity and cost of transportation, direct and indirect treatment costs, and opportunity 
costs in the form of labor loss, especially during peak agricultural seasons. Despite 
free antibiotic treatment for BU, these costs can be catastrophic [44–46].4 Another 
enabling factor is the identification of appropriate substitute caretakers for children 
4 Chukwuet al. [38] points out that the high costs of pre-diagnosis treatment for BU in Ghana can 
also put households in a precarious situation.
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left at home when a mother needs to travel to receive treatment for herself or a child 
[28]. For this reason it is important to look at the household as a unit of analysis [45, 
48] and to employ a household production of health [49, 50] lens when examining 
BU health care decisions and patient abandonment.5 Another useful lens employed 
by researcher Ines Agbo [28] is that of gender. A consideration of gender relations 
leads us to an appreciation of the impact BU treatment has on social networks 
beyond the immediate household of the afflicted given that assistance is commonly 
requested from extended kin during times of need. Agbo et al. draw attention to the 
ripple effect of BU beyond households as well as the impact that requests for assis-
tance on social relations over time [29].
Interventions offering patient support have been piloted in each of the three index 
countries (Benin: Ouinhi, Cameroon: Bankim, Ghana: Obom and Agogo). In each 
case, when free transportation to health posts and/or free food is offered to patients, 
clinic popularity increased and treatment delay and treatment drop-out decreased 
[16, 31, 40, 51].
2.2  Service Level Factors Affecting Health Care Seeking 
and Treatment Adherence
Several service related factors have been identified as leading to treatment delay, 
drop out, and perceptions of quality of care. Factors identified by social scientists 
beyond cost, waiting time, and lack of resources at health posts include poor staff- 
patient communication about the wound healing process, patient concern about pro-
longed hospital visits with little feedback on likely duration, and fear of amputation 
and skin grafts [52]. Other concerns reported related to bandaging and pain manage-
ment. In the case of bandaging, concerns were raised not only about the procedure 
itself, but the person doing the bandaging. If the intention of the person bandaging 
toward the patient was not positive, there was concern the healing process would be 
delayed. And in Ghana concern was raised if a pregnant nurse did a patient’s ban-
daging as her condition was thought to impede healing [34]. In the case of pain, a 
common perception was that pain was not appreciated or responded to by clinic 
staff, leading patients to often seek medicines for pain from the market or traditional 
healers. The most serious concern reported to researchers was lack of trust in clinic 
staff by patients in some clinical settings [19]. The positive impact of establishing 
trust through culturally sensitive education outreach, proactive CHWs, and psycho-
social as well as material support for patients has been demonstrated at NGO and 
mission-supported hospitals treating BU cases such as the Agogo Presbyterian 
Hospital and the Global Evangelical Mission Hospital serving the Ashanti region of 
5 The household production of health conceptual framework analyzes practices in which household 
members engage to maintain, protect, and promote health, as well as how household members 
respond to health related issues. The HHPH model situates health and illness within the larger 
environment of activities occurring in households and thus provides a valuable complementary 
component to the study of health care seeking.
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Ghana [51, 53], and the clinic and community-based interventions described below. 
An issue not adequately investigated is what kind of incentives might keep com-
munity stakeholders and clinic staff in different settings motivated [30, 36], and 
what factors might strengthen as well as weaken collaborative relationships. Social 
scientists tend to think of incentives in terms of different types of convertible capital 
(economic, cultural, social, symbolic; [54, 55]). In need of consideration are the 
ramifications of offering different types of capital as incentives in various ways in 
different cultural settings, and the impact of these incentives on both the identity of 
stake holders and teamwork.
3  Part Two: Social Science Inspired Interventions
Social scientists have worked closely with their public health/medical colleagues in 
developing, testing, and implementing health service interventions to raise the con-
sciousness of community members about BU in an effort to detect and treat cases 
earlier, reduce treatment no-show and drop-out, and increase treatment adherence. 
Interventions have been mounted in the areas of outreach education, patient support, 
community stakeholder collaboration, the formation of BU communities of prac-
tice, and the transforming of hospitals for long-term patients into therapeutic com-
munities. In this review I briefly highlight seven interventions that have gone beyond 
offering food and transport to outpatients as forms of support. All seven interven-
tions were sponsored by the Stop Buruli Consortium. For more information on the 
Stop Buruli Initiative the reader is referred to chapter “Transdisciplinary Research 
and Action to Stop Buruli Ulcer: A case Study from Philanthropy” of this book.
3.1  Outreach Education
An innovative form of outreach education was introduced in Benin, Cameroon, and 
Ghana based on a review of research documenting what community members did and 
did not know about BU, misconceptions about BU and its treatment, awareness of the 
availability of free treatment, and concerns about treatment. This intervention served 
as a foundation for building a new generation of community-based BU interventions, 
and the cornerstone for building BU communities of practice (described below).
The outreach program adopted a question–answer format and iterative process. 
In brief, the program employed an image-rich PowerPoint presentation on BU 
delivered by local teams equipped with portable generators and sound systems, lap-
top computers, and LCD projectors. Outreach meetings were interactive, not pas-
sive, and questions were invited from community members. Social scientists 
recorded and investigated how best to respond to questions posed in a way that was 
at the same time scientific and understandable to local audiences. Messages and 
visuals were tested and changed as needed. The following table summarizes the ten 
major sections of the outreach program (Table 1). Notably, specific sets of messages 
were designed to inform and educate the community about BU, reassure community 
members about the quality of care available at hospitals and health posts, offer hope 
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Table 1 Format of Stop Buruli Consortium outreach education
Ten sections of outreach 
education program Key messages conveyed Issues downplayed or emphasized
Signs and symptoms of 
BU, how to recognize 
the disease, and the 
need to treat it early
•  Visuals of physical signs of 
BU in different stages
•  Visual and tactile cues 
suggesting that a lesion, 
abscess ulcer, or edema 
may be BU
•  Progression of disease if 
not treated
Category I and II BU depicted, but 
not category III as this evoked 
great fear
High risk environments 
and modes of 
transmission
•  High risk environments 
where one is more likely to 
be exposed to 
Mycobacterium ulcerans
•  Focus was on addressing 
incorrect ideas about BU 
transmission and contagion
Less time and attention allotted to 
risk environments and possible 
modes of transmission as the 
science is inconclusive and 
behavior change related to 
exposure to water sources difficult 
given the local reality
What clinic staff do to 
determine if the 
affliction is BU or 
some other disease
Why health staff take swabs, 
what they look for under the 
microscope, why medicine for 
BU is specific and not the 
same as medications used for 
other ulcers
Step-by-step explanation of what 
staff is actually doing along with 
pictures to offset fears and rumors 
about what they are doing as a 
means to increase trust
Effective and 
ineffective treatments 
for BU
•  Why 56 days of pills and 
injections (or more) are 
needed
•  Why herbal medicine for 
this disease does not lead to 
a cure even if a wound is 
dried
•  Agricultural analogies used to 
convey the idea that medication 
is taken beyond treatment for the 
visible wound, as a means to get 
at the roots and seeds of BU as a 
systemic infection in the body
•  Pictures used to show 
inappropriate treatment, how 
drying wound is not curing, and 
effectiveness of medication 
after herbal medicine has failed 
to treat the wound
•  Traditional healers 
and rapid referral 
to hospitals and 
health posts
•  Emphasis on rapid 
referral
Positive messages about 
exemplar healers who 
recognize signs of BU and 
rapidly refer patients to clinic 
after spiritual protection is 
offered
• No message disrespecting local 
practices as superstitious
• Respect for traditional healers’ 
role in offering spiritual protection 
for those for whom this is a 
concern
Quality of care at the 
clinic
Quality of care offered by 
staff: pictures of what care in 
the clinic looks like, 
approachable staff, hygienic 
conditions, empathetic 
caretakers, etc.
To offset fear and evoke confidence
Care available free of 
charge or subsidized 
for BU patients 
at clinics
Types of support available 
ranging from free medications, 
to food, transport, and housing
(continued)
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Table 1 (continued)
Ten sections of outreach 
education program Key messages conveyed Issues downplayed or emphasized
Before and after 
pictures of BU related 
wounds successfully 
treated
•  Pictures of BU treatment, 
and the healing process at 
different stages
•  Depict the healing of ulcers 
on different parts of the 
body
Pictures depict children and male 
and female patients of different 
ages so members of the audience 
can personally relate
The presentation ends 
on a note of hope
Testimonials of patients who 
have been cured speak of their 
experiences and to the quality 
of care they have received at 
the clinic
Open microphone: some 
testimonials are planned and others 
are spontaneous
Questions from the 
audience
On any topic related to 
information presented or any 
other issue related to BU
•  Open microphone empowers 
people to speak
•  Questions are recorded and 
responses to questions assessed 
as part of iterative process of 
ongoing research
of a cure, display stakeholder collaboration, and inform community members about 
the kind of support available during treatment.
In each of the three countries, large-scale community outreach education meet-
ings were held in the evenings. Community health workers were responsible for 
organizing meetings and inviting chiefs, local healers, and former patients to attend. 
This increased their status in the community, enhanced lines of communication with 
health staff, and motivated them to become more actively involved in BU outreach. 
In contexts where multiple languages were spoken, CHWs were trained to act as 
translators from French or English into local dialects. Following community pro-
grams, BU screening took place, CHWs accompanied suspected cases to hospital 
and health posts, and followed up on confirmed cases. The outreach program was 
piloted in over 200 communities in the three countries and reached an estimated 
75,000 people [56]. Evaluations carried out in each country confirmed that the pro-
gram was effective in identifying significant numbers of BU cases and raising com-
munity confidence in clinic based care [16, 30].
3.2  Introducing Decentralized BU Care in Ouinhi, Benin
Although decentralized treatment of category I and II BU cases has been well estab-
lished in several regions of Benin, it has not been introduced into the Ouinhi region. 
In this endemic region, centralized hospital care and surgery was the norm. Despite 
outreach efforts by a very proactive Catholic mission hospital, few early category I 
BU cases were brought to the hospital due in large part to fear of surgery. In the inter-
vention, two local nurses were trained in the decentralized treatment of BU along 
with other types of chronic wounds. Outreach education programs were conducted 
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and a message delivered that outpatient care was now available at local health posts 
for BU, and that staff had been trained to treat chronic wounds and early stages of BU 
without surgery. The community responded well to the intervention [30]. Self-referral 
following outreach programs increased significantly and many category I cases were 
treated at the clinic. Notably, over 70% of all BU cases brought to the clinic and con-
firmed as BU could be treated by decentralized care with over a 90% success rate. 
Community volunteer groups were established by social scientists to ensure that 
patients finished a complete course of medications and followed wound care advice. 
A lesson learned was the importance of treating all chronic wounds in the community 
as a means of establishing broad based clinic credibility. This project inspired research 
currently underway to develop a pragmatic approach to clinic and community based 
wound care management in Benin and Cote d’Ivoire.
3.3  Establishing a BU Community of Practice: Cameroon
In Cameroon, previous efforts to identify BU through the mobilization of CHWs 
yielded poor results. A majority of BU cases were first treated by traditional practi-
tioners and few cases of category I BU were seen at hospital or health stations. 
Social scientists established a successful BU community of practice (BUCOP). A 
community of practice (COP) is an assemblage of stakeholders committed to a com-
mon objective, a common basic understanding of a focal problem, and mutual 
respect for what each stakeholder contributes to a process of problem-solving. In 
the case of BU, this entails health staff, CHWs, and traditional healers sharing a 
common understanding of the signs of BU, collaboration in encouraging the afflicted 
to seek and continue BU treatment, open lines of communication between stake-
holders, and mutual respect for what each contributes to the process of healing that 
includes, but extends beyond the management of BU as a disease.
The success of the BUCOP has been measured in terms of numbers of suspected 
BU cases referred and confirmed, decline in patient treatment drop-out, and sus-
tained collaboration among stakeholders both during and following the 3-year pilot 
project. The pilot project implemented the aforementioned BU outreach education 
program, increased levels of patient assistance beyond food and transport to include 
setting up halfway houses where patients could reside during treatment if they came 
from distant places, and established close working relations with traditional practi-
tioners groups. Traditional healers not only referred cases of suspected BU to health 
posts; they also participated in outreach programs, and at the invitation of health 
staff provided psychosocial support for hospital patients. Nearly all of the 50 tradi-
tional healers participating in the BUCOP adhered to a collaboration contract, and 
after 2 years were presented with identification badges by district health authorities 
based upon their performance.
The success of the pilot project is far beyond what researchers had thought pos-
sible to achieve [16]. During the project over 90% of suspected and confirmed cases 
of BU seen at the Bankim hospital were referred by community stakeholders. Many 
category I BU cases were identified and treated successfully, and ethnic groups like 
Social Science Contributions to BU Focused Health Service Research in West-Africa
266
the Fulani that previously had not sought treatment at the hospital began doing so. 
Notably, following 3 years of mass outreach education programs, the large majority 
of BU cases seen in Bankim Hospital were self-referred. Community members 
commonly checked with CHWs and healers if they suspected a case of BU before 
bringing the afflicted to a clinic. The status of healers, CHWs and the hospital all 
improved.
3.4  Yaws Cases Identified as a Result of BU Outreach 
in Cameroon: A Case for Integrated Skin Neglected 
Tropical Disease (NTD) Programs
One unanticipated outcome of BU outreach in Bankim, Cameroon was the identifi-
cation of cases of yaws. Up until a household survey identified 29 cases of yaws, a 
year before the intervention [57], yaws was thought to be rare, if not eliminated. It 
had not been seen at hospital or health posts in Bankim district for years. Mass BU 
outreach programs attracted community members with other chronic skin diseases. 
When yaws cases were recognized by health staff during wound screening, schools 
in the community were also screened. Over 850 cases of yaws were identified and 
treated [58]. This illustrates the effectiveness of mass outreach programs as well as 
the potential of integrated NTD programs. Notably, the demonstration effect of 
yaws treatment requiring only a single dose of azithromycin or penicillin, increased 
community confidence in clinic treatment for BU.
3.5  BU Children’s Support Group Ghana
In Ghana a children’s program was developed to accompany the community-based 
outreach program. The necessity for this intervention became clear when it was 
discovered that children having BU were stigmatized by classmates and often 
dropped out of school. Teachers did not intervene nor follow up on such children. 
Stop Buruli researcher Eric Koka realized that in addition to providing education 
about BU to students and teachers, the negative perception of BU needed to be 
transformed. An intervention was introduced that had three parts. First, students 
with category I–II BU were offered free transportation by motorcycle to a clinic, 
where they were treated and then returned to school. Motor cycle taxi rides are seen 
by children as an exciting adventure. Once at the clinic children were also given a 
nutritious snack, which they relished. A second component was establishing a peer 
mentorship program. Children who had been successfully treated mentored new 
patients and helped them deal with the fear of daily injections and informed them 
about the healing process, as well. Children found having a peer mentor reassuring. 
Third, an BU patients club was formed. T-shirts identifying patients and ex-patients 
were proudly worn and members were asked to be on the lookout for new cases as 
well as to give testimonials on the healing process at school.
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Eleven former patients’ clubs were formed between 2011 and 2014 involving 
132 school children. Most of the club members were between the ages of 6 and 
18 years with a median age of 12 years. A more positive and less stigmatized iden-
tity created by club activities contributed to more children willing to come for treat-
ment, and more parents willing to have their children screened and treated. In the 3 
years prior to the intervention (2007–2010) 18 of the 32 BU patients attending 
Obom health centre were school children. During the 3 years of the intervention 
(2011–2014) the number of BU cases increased to 273 of which 145 were children. 
Notably, out of the 145 school children receiving treatment, 138 were category one 
cases, and 42 (30%) were referred by members of the children’s BU club [59].
3.6  Mhealth as a Tool in Monitoring BU Healing in Ghana
Social scientist Mercy Ackumey teamed up with physician Nana Kotey to experi-
ment with using mobile phones to monitor wound and scar care in Ghana. Oral 
therapy has been on the horizon of BU care for some time and in 2017 the WHO 
Technical Advisory Group on BU provisionally recommended treatment with oral 
clarithromycin and rifampicin pending the full results of a clinical trial. Anticipating 
this therapeutic option, the researchers deemed it imperative to test how wound care 
might be monitored by mobile phone if patients were not visiting health posts daily 
for BU treatment. Mobile phones are widely available in the region of Ghana where 
the project took place. The team created a check list of possible signs of a wound 
that was not healing well. Using the check list, short, semi-structured phone calls 
were made to patients and questions asked about the status of their wound. If danger 
signs were indicated, the patient was asked to visit the clinic. Patients found the 
calls reassuring and the intervention enhanced the reputation of the clinic. The pilot 
project identified several issues that will need to be addressed in the future should 
the approach go to scale [60].
3.7  Transforming a BU Hospital into a Therapeutic Community 
for Inpatients
Reducing social distance between hospital staff and patients and establishing clear 
lines of communication is a major challenge when providing in-patient care for 
people afflicted by BU and other chronic ulcers. Research on hospitals as therapeu-
tic communities is virtually non-existent in Africa. An ethnography of Allada refer-
ence hospital in Benin responsible for treating BU and other chronic ulcers identified 
several sources of psychosocial distress and communication patterns compromising 
quality of care. Based on this research, an intervention was mounted to transform 
the hospital into a higher functioning therapeutic community. Question-answer edu-
cation sessions were introduced to provide patients the opportunity to inquire about 
their illness and its treatment and trajectory, weekly open- forums were established 
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to give patients and hospital staff a chance to air grievances, patient representatives 
met with hospital staff to resolve problems related to daily living in a non-confron-
tational manner, and psychosocial support for individual patients was provided 
through drop-in counseling sessions with social scientists in residence.
Patients reported positive changes in the quality of their care and interactions with 
care providers, care providers reported that the problem-solving process instituted 
was productive, and hospital administrators actively supported efforts to improve 
social relations and lines of communication [52]. Former patients were seen as a com-
munity outreach resource as both expert patients and ambassadors of the National BU 
control program were able to speak firsthand about the disease and the quality of care 
being offered. One systemic problem identified in both this and the Bankim project 
was community response to linear disease focused programs. Preferential treatment 
for BU patients in the form of subsidized treatment supported by the government and 
international funding agencies was deeply resented by patients being treated for other 
chronic wounds and who had to pay for their treatment out of their pocket. As far as 
patients and community members could see, all chronic wounds appear to warrant the 
same level of clinical attention, and special care for BU could not be defended on the 
basis of being contagious and therefore a community wide risk like TB.
4  Conclusion
Social science has contributed in important ways to health service research related to 
BU and to the development and testing of innovative community and clinic based 
interventions. This brief overview of research illustrates the importance of using 
mixed methods to investigate predisposing, enabling, and service related factors 
influencing health care seeking, treatment adherence, and subjective perceptions of 
quality of care. It also draws attention to the importance of community outreach and 
the active participation of community stakeholders in BU programs. This entails giv-
ing community health volunteers, former patients, and traditional healers a proactive 
and not just a passive role in outreach and patient support, learning how to establish 
respectful partnerships and effective lines of communication, and assessing how to 
keep all stakeholders motivated. Lessons learned from the BU interventions high-
lighted in this chapter have broad relevance to other NTD and (re)emerging disease 
preparedness programs. They also illustrate why integrated skin NTD and wound 
care programs are needed and ways in which linear programs, privileging the care of 
one kind of chronic wound over another, undermine community trust.
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1  Introduction
Over the past decades, advances in Buruli ulcer (BU) research and control have 
been substantially shaped by philanthropic and civil society engagement. It has 
been a long journey for advocates to attract public attention and funding for BU. In 
1998, the World Health Organization (WHO) established the Global Buruli Ulcer 
Initiative, supported by the Nippon Foundation. A first international conference on 
BU, organized by WHO, led to the 1999 Yamoussoukro Declaration, which brought 
greater public awareness to the disease, for the first time [1].
Intensified research and control activities started thereafter. In 2004, the World 
Health Assembly adopted a resolution on BU, which called upon the international 
community, organizations and bodies of the United Nations system, donors, non- 
governmental organizations, foundations and research institutions to cooperate 
directly with disease-endemic countries in order to strengthen control and research 
activities; and to develop partnerships and to foster collaboration with organizations 
and programs involved in health-system development, in order to ensure that effec-
tive interventions can reach all those in need [2].
Despite increased attention and the coordinated efforts by the WHO-Global 
Buruli Ulcer Initiative, research and control activities remained highly underfunded, 
with advances limited. In 2007, the UBS Optimus Foundation (UBS-OF) identified 
BU as a disease where a relatively small investment had the potential to make a big 
difference. With the goal to catalyse a transdisciplinary consortium bundling BU 
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research into a concerted effort, the UBS-OF engaged researchers from different 
disciplines and countries, with a prominent role of endemic countries and good 
links to national BU control programs.
Philanthropic engagement aspires for innovation and impact. This chapter takes 
a critical look back at the whys, hows, and major results of the Stop Buruli Initiative 
initiated by the UBS-OF and partially co-funded by the Medicor Foundation. It 
discusses the long-term and comprehensive approach of the UBS-OF in research 
and control of BU, and the lessons learned for achieving the aspiration of innovation 
and impact.
2  The Beginnings: Six Reasons Why
2.1  Reason #1: Lack of Funding Incentives
BU is one of the Neglected Tropical Diseases (NTDs) listed under the WHO clas-
sification system. These disease conditions disproportionately affect populations 
living in tropical and sub-tropical areas and people living in poverty.
Research and development efforts for BU were marginal. Like for many other 
NTDs, industry has no incentive to invest in products such as diagnostics, medi-
cines, vaccines and other control tools defined by global health needs or public 
priorities and targeting populations and governments with low purchasing power. 
According to G-Finder data, total investment in BU research by the private sector 
between 2007 and 2016 was merely around USD 300,000.
Furthermore, philanthropic and public research funding for BU has been far 
lower than for other tropical diseases. Between 2007 and 2016, BU research fund-
ing amounted to as little as 38 million USD in total. Slightly more than one third (14 
million USD) originated from philanthropic sources, with the remaining (24 million 
USD) from the public sector, which majorly invested in basic or vaccine research. 
The biggest single commitment was the 2010–2013, EU-supported project to 
develop a vaccine protecting against BU (BuruliVac).
The lack of interest and funding for BU also affects the academic world. BU 
remains one of the least studied diseases because this is not where researchers can 
make a great academic career. Little attention means small academic impact, diffi-
culties to publish in high-ranking journals and to acquire research funding. For a 
foundation with relatively small grant-making resources, this ‘niche’ situation was 
a compelling argument to invest in BU.
2.2  Reason #2: A Disease of Social Justice
The second compelling argument was based on social justice and a desire for global 
health equity. The neglect of the disease goes along with the neglect of the affected 
populations. BU affects the most vulnerable and voiceless people. Children living in 
remote and poverty-stricken areas of Africa are suffering the most.
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Findings from epidemiological studies indicated that the BU burden in Africa 
was underestimated [3] and solid world-wide prevalence data were not available. 
BU was reported in 33 countries, but not all endemic countries regularly reported 
case numbers to the WHO and in some countries, endemic regions still have to be 
mapped. Assessment of the global disease burden was impeded by the remoteness 
and poverty of the most affected populations and countries. The Global Burden of 
disease study 2016, the most comprehensive worldwide observational epidemio-
logical study, did not include estimates on BU burden.
Organizations working on BU were confronted with a spiral of neglect: lack of 
epidemiological data veiled the evidence of the real dimensions of the disease. This, 
in turn, compromised attention and support, which hindered the collection of more 
robust and comprehensive evidence. This, characteristic for most neglected dis-
eases, is a matter of social justice, exacerbating the shadowy existence of the vic-
tims of the disease.
2.3  Reason #3: A Disease with Devastating Consequences
The poorest populations, lacking access to health care, were the least served. Even 
though case fatality may be low, the severity and chronic nature of the disease often 
leads to devastating consequences of BU for the individual, their families and the 
affected communities. When diagnosed and treated early, BU can be a well- 
manageable disease. However, at the time, the majority of patients did not seek 
biomedical treatment until the condition was in later stages. Massive extension of 
BU lesions and delayed wound healing often causes irreversible physical disability 
due to deformities on arms, legs, trunks and in the face. Alone the painful changing 
of wound dressings already makes the disease a human tragedy for all affected. 
Stigma, discrimination, and the need for long-term hospital stays far away from 
home aggravated the social and economic conditions for affected households. The 
cost burden due to long-term treatments far from home and productivity loss of BU 
patients, and of parents accompanying children during hospital stays, can amount to 
catastrophic levels for the household economy, not seldom leading to abandonment 
of patients by the family [4].
A human-rights based perspective justified a global response to BU, but attention 
failed to increase.
2.4  Reason #4: The Pioneer Effect
While the needs-driven perspective to reduce inequity, social injustice and human 
suffering was convincing for philanthropic support, there was also the argument of 
likelihood for success. Philanthropic support tends to be open to taking risks, but 
only if these are calculated. Investment into BU research was likely to show a posi-
tive benefit/risk balance.
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BU, coined the mysterious disease, was characterized by a great vacuum of 
knowledge and little understanding by researchers, implementers, and affected per-
sons themselves. It was a disease where nearly nothing was known regarding trans-
mission and epidemiology, where clinical presentation was difficult to interpret 
even by experts, where diagnostic procedures were complicated, costly and often 
leading to false results, where wide surgical excision of the affected tissue was the 
only recommended treatment option, where efficacy of antibiotic therapies was 
debated, where patients often had no access to treatment and where it was not clear 
how to reduce the risk of acquiring the disease.
To start to bring light into such nearly total darkness is a way to become a pioneer 
in an area where very few others are engaged but may join the bandwagon after they 
see success. The opportunity to be at the forefront of research and disease control, 
and to act as a catalyst by convening a variety of stakeholders and partners, was one 
of the most convincing arguments for the UBS-OF to engage in a multi-disciplinary 
BU initiative.
This pioneering effect in combination with the prospect that relatively small 
investments can make a real difference for many patients and their families was a 
powerful argument. The reason why little money could lead to big impact was also 
related to the fact that there was no need for big investments into new infrastructure, 
since much of the activities could piggyback on existing and well-established 
research and health care structures.
2.5  Reason #5: Existing Critical Mass of Researchers 
and Implementing Agencies
Research groups working on BU already existed, although the primary foci of 
researchers in the field were usually other mycobacterial diseases, like tuberculosis 
and leprosy, and not BU. Researchers with suitable expertise were therefore avail-
able and at the time when the Stop Buruli Initiative was launched, it was not the 
absence of scientific know-how or interest, but the lack of funding and coordination 
that impeded scientific progress.
A network analysis of institutions active in BU research at the time showed how 
small yet fragmented the scientific community was. Organizations active in BU 
research spanned all over the world, over four continents, with very diverse disci-
plines, expertise and experience.
The existence and diversity of this critical mass of researchers and institutions 
willing to engage in BU research was essential for rapid progress and potential for 
impact.
2.6  Reason #6: Scalability and Uptake
Despite fragmentation, a network of collaborations between institutions from dif-
ferent affected countries and national disease control programs already existed. The 
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network analysis of institutions and publications concluded that most BU research 
was quite recent, mainly starting in the 1990s, but fast-growing especially in the 
early years of 2000 when the WHO Global Buruli Disease Initiative was estab-
lished. By the year 2007, nearly a dozen experts had published more than 50 arti-
cles, and roughly 20 institutions worldwide were involved in research, with a high 
density of inter-institutional collaborations. Research activities were on-going pri-
marily in four countries with BU case reports: Australia, Benin, Cameroon and 
Ghana.
Existing longstanding institutional partnerships between these four countries and 
researchers in the USA, Belgium, and Switzerland were a key element for setting up 
the new consortium. The organizational anchoring and partnership-based collabora-
tions with national Ministries of Health and National BU control programmes were 
crucial. This permitted scientists to connect with practitioners and to consolidate 
and translate research efforts into action. From the beginning, favourable conditions 
existed for access to patients and specimens, as well as a high likelihood of integrat-
ing new findings into policy guidelines and practice. The WHO Global Buruli Ulcer 
Initiative, with its annual meetings that brought together all relevant stakeholders 
from across the globe and the Technical Advisory Group that included many of the 
researchers, enabled translation of key findings into normative guidelines at the 
global level.
2.7  Stop Buruli Initiative
In sum, the decision to invest in BU research and control followed a set of principles 
and reflections. An initiative was defined by the UBS-OF as “a relevant and neglected 
field, with a potential for change, where the foundation can take a leading role.” BU 
matched the four elements contained in the definition. It is a relevant disease, as 
emphasized by international declarations and a World Health Assembly adopted 
resolution in 2004; it is neglected, i.e. not in the spotlight and receiving scarce 
resources due to both market and policy failures; there is a potential for change by 
helping to develop standard know-how and tools for diagnostics and therapies that 
are being implemented throughout African and other affected areas; and the 
UBS-OF can take a leading role through convening key stakeholders, creating cohe-
sion among them, and attracting new funders to get aligned in a common effort to 
address the problem.
3  The Model: Transdisciplinary Research 
and Implementation
In 2007, the UBS-OF invited a core group of institutions to develop a consortium 
proposal with an overall research agenda, under the guiding principle to lead from 
innovation over validation of the findings and interventions to public health applica-
tion. The invitation specified the major lines by mentioning transmission, 
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ecological, social and economic, as well as clinical aspects, and by considering a 
focus on developing applicable and affordable tools; an integrated multidisciplinary 
approach; research capacity strengthening, including technology transfer and train-
ing of researchers from BU endemic countries; strengthening of North-South and 
South-South partnerships.
The consortium partners initially included seven institutions, with key expertise 
in different fields, including the Swiss Tropical and Public Health Institute 
(SwissTPH), Switzerland (research coordinator); Fairmed (former Aide Aux 
Lépreux Emmaüs-Suisse (ALES)), Cameroon; Institute of Tropical Medicine 
(ITM), Belgium; Noguchi Memorial Institute for Medical Research (NMIMR), 
Ghana; Programme national de lutte contre l’ulcère de Buruli et la lèpre, Benin; 
University of Melbourne, Australia; and University of Tennessee, USA.
This was the start of a model for a transdisciplinary approach, linking research to 
implementation, building local capacity across disciplines and through co-creating 
knowledge leading to action and, ultimately, impact for patients, their families, and 
countries. The role of the UBS-OF was to bring the diverse stakeholders together 
and to point the way to generate the tools and solutions that were needed, but also 
to advocate for and to ensure the taking up of those tools under real life 
conditions.
4  Key Elements for Advancing Transdisciplinarity
4.1  Transdisciplinarity Does Not ‘Just Happen’
Transdisciplinary research agendas are often specified as a goal in the context of 
research for development promoted by development agencies or philanthropic 
grants. But experience shows how difficult it is to work across disciplines, and to 
consider policy and practice as an integral part of the research agenda. This requires 
patience, persistence and willingness to adapt the course based on factors internal 
and external to the initiative.
One key element is to convene the right disciplines and partners, and to jointly 
discuss and develop the aims and actions. But multi-disciplinary consortia are, by 
definition, complex constructs embracing not only different disciplines, but also 
different institutional cultures. Such a research consortium is of paramount com-
plexity, since the element of North-South partnerships with all its socio-politically 
rooted facets adds to the already complex nature of a multi-stakeholder collabora-
tion. A research consortium does not develop in a neutral space. Wanted or not, 
explicit or implicit, power relations among different partners may lead to unequal 
decision-making and imbalanced resource allocations.
To bring all disciplines and different partners into alignment and to foster an 
effective and efficient collaboration requires an active orchestration of the partner-
ship. Beyond the financial resources, it is the convening power and the agile man-
agement of an engaged, unbiased donor that brings added value to the functioning 
of a complex consortium.
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The development of the social sciences within the Stop Buruli consortium pro-
vides an illustrative example for the relevance of such an active and agile manage-
ment approach. The consortium embraced research and action along four axes: 
disease transmission, diagnosis, treatment, and socio-economic and cultural aspects. 
The UBS-OF convened representatives from all different disciplines right from the 
beginning, and all partners showed great willingness to develop a joint effort along 
the four axes. But the social science axis started to lag behind, unable to integrate 
their research questions into the overall consortium agenda. The first social science 
proposal suggested a classic information, education, and communication approach 
with the aim to educate the population about signs and symptoms of BU, but ignored 
to consider the research priorities of the other axes. The misalignment of the social 
science research risked developing into a parallel direction, leading to a fragmenta-
tion of workstreams instead of the concerted action that had been envisioned.
4.2  Governance Model
The key to redirecting the social sciences towards a path of convergence with the 
other disciplines was not to request the researchers to rephrase and resubmit propos-
als, but to adapt the consortium’s governance structure. The consortium had consti-
tuted a steering committee with representatives from the seven different partner 
organizations, but lacked a representative from a strong social science partner. In 
other words, the social scientists were within the research teams but lacked a voice 
at the higher level of decision-making, i.e. at the level of the steering committee.
The solution to the problem was to seek and include an eighth partner, and to add 
a senior-level social science representative to the steering committee. This is how, 
upon request of the UBS-OF, the Anthropology Unit of the University of Arizona 
joined the consortium. That way, the research directions discussed and decided by 
the steering committee gained in quality concerning transdisciplinarity.
The governance model of the Stop Buruli Consortium then consisted of eight 
members of the steering committee and for reasons of agility, a day to day manage-
ment team of three rotating members, overseeing the different work packages along 
the four axes. The close relation of the steering committee with the national BU 
control programs in the three BU endemic African countries involved (Ghana, 
Benin, Cameroon) and with the WHO Technical Advisory Group for BU permitted 
flexibility for the consortium activities, but at the same time close interaction with 
the Ministries of Health for collecting data and developing recommendations and 
guidelines, nationally and globally. The regular WHO Meetings on BU control and 
research served as an important platform for exchange with other stakeholders, 
which enabled results from the research activities to be brought into the broader 
context and influence policy discussions.
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5  Results
The three funding cycles (2007–2018) powered by the UBS-OF brought important 
advancements to research and control of BU as well as educating a future genera-
tion of African scientists. The broad transdisciplinary focus of the consortium with 
the integrated action not only secured an efficient and effective use of the funds, but 
it also leveraged funding from other donors, which continue with relevant, con-
certed research and action to this day. As the planning for the third cycle began, it 
was recognized by the UBS-OF and the consortium members that important chan-
nels had been built across disciplines and new partnerships formed, including a 
product development partnership with the Foundation for Innovative New 
Diagnostics (FIND), but that a formal structure to facilitate that cross-talk was no 
longer needed.
The research output of the consortium led to more than 60 publications, training 
of 25 African graduate students, more than 9000 BU sufferers having received 
improved treatment and education, as well as three hands-on, field workshops in 
Africa that allowed for professional and practical training of young scientists by 
senior experts in laboratory-based and field research. The consolidated approach 
achieved considerable success along the four axes. The following sections outline 
some of the major achievements and future perspectives:
5.1  Diagnosis
Diagnosis is a major challenge in BU control. District hospitals often rely on clini-
cal diagnosis only, which is very often inaccurate and complicated by other disease 
conditions with similar presentation as BU. There is over/under treatment as a result 
of misdiagnosis and poor surveillance of the disease due to absence of effective 
diagnostic services. It is therefore important that clinical diagnosis is supported by 
laboratory confirmation.
The diagnostic field recorded impressive progress. The consortium optimized the 
method of fine needle aspiration for improved collection of specimens from closed 
lesions [5]. An illustrative and open access video-guide of how-to-do-it and WHO 
supported teaching and training activities improved the accuracy of diagnosis 
undertaken by qualified health staff in BU affected countries. In addition, optimiza-
tion of PCR-based diagnosis by ITM improved laboratory confirmation of clinical 
cases [6, 7].
However, PCR technology based diagnosis is expensive, requires time and expe-
rienced health staff and technology, which are only available at specialized BU ref-
erence laboratories, which are far away from the affected patients and communities. 
Therefore, high priority was given to the development of rapid, low-tech, sensitive 
and specific diagnostic tests for use at district hospital and at community levels.
The identification of a M. ulcerans protein suitable for the development of an 
antigen capture assay [8] allowed to develop a simple ELISA executable at district 
hospital level. In collaboration with the FIND and Abbott/Standard Diagnostics 
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(SD), the monoclonal antibodies generated by SwissTPH are now used in further 
research aimed at the development of a point-of-care test. First prototypes of rapid 
diagnostic tests (RDTs) are under laboratory validation; if successful, these will 
pave the way for surveillance and early diagnosis of BU at the community and pri-
mary health care levels.
Another promising avenue for diagnostic test development is a technology 
known as loop-mediated isothermal amplification (LAMP) of pathogen DNA. This 
approach has recently been exploited in development of simple molecular tests for 
many infectious diseases, among them tuberculosis, sleeping sickness, leishmania-
sis, malaria and Chagas disease. The Noguchi Memorial Institute for Medical 
Research (NMIMR) in Ghana and the Department for Infectious Diseases and 
Tropical Medicine (DITM) in Germany, in collaboration with FIND and other part-
ners, are advancing the development of a Buruli LAMP test, which is highly accu-
rate, and does require less specialised training or equipment than PCR.
The macrolide exotoxin mycolactone of M. ulcerans plays a crucial role in the 
pathogenesis of BU. Therefore major efforts have been made to raise mycolactone- 
specific antibodies. However, in spite of numerous attempts by several expert labo-
ratories, generation of antibodies against mycolactone had failed for a long time. 
Based on quantitative structure-activity relationship analysis with synthetic myco-
lactones [9] SwissTPH has successfully developed a new immunization strategy, 
using a protein carrier conjugate of a synthetic truncated non-toxic mycolactone 
derivative. It has turned out that this formulation elicits mycolactone specific anti-
bodies that neutralize the toxin [10]. This provides the basis for a new approach for 
BU vaccine design supported by the Medicor Foundation (see below). Furthermore, 
the M. ulcerans specific mycolactone may represent an ideal target for the develop-
ment of a specific diagnostic test and the successful generation of mycolactone- 
specific antibodies has opened new options for diagnostic test development, an 
approach followed by SwissTPH in collaboration with FIND.
5.2  Treatment
The Stop Buruli consortium has also achieved highly relevant findings for BU treat-
ment. Concerns that secondary lesions after streptomycin/rifampicin combination 
therapy given for 8 weeks were linked to relapses or failures of treatments could be 
discarded, supporting the WHO recommendations in the treatment guidelines for 
health workers.
A specific focus was given to wound care and healing. One of the findings 
showed that delay in wound healing may be related either to clinical deterioration, 
known as paradoxical reactions, or to secondary bacterial infections. It could also be 
shown by the NMIMR in collaboration with SwissTPH and the University of 
Melbourne that BU wounds are frequently super-infected with hospital-acquired 
multi-resistant bacteria [11–13].
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The early pathogenesis of BU and the molecular mechanism of tissue necrosis 
caused by the toxin mycolactone produced by M. ulcerans were investigated [14–
16] providing important insights relevant for diagnosis and treatment.
Wound management practices at primary and secondary health care facilities in 
Ghana were investigated and recommendations for improvements made [17]. In 
Benin a decentralized community-based treatment program for BU was imple-
mented and assessed by the national control program supported by the University of 
Arizona [18]. The impact evaluation found that community confidence in decentral-
ized BU care was greatly enhanced by clinic staff who came to be seen as having 
expertise in the care of most chronic wounds. The pilot program further demon-
strates the added value of integrated wound management for skin NTD control. The 
model developed in this pilot study may serve as a foundation and proof of concept 
for a larger community-based decentralized wound care agenda.
A major conclusion of the consortium was that BU control should be integrated 
into horizontal programs for the integrated diagnosis and treatment of tropical skin 
diseases. WHO advocates for this approach and the UBS-OF continues to support a 
pilot project in Benin and Ivory Coast that includes several Stop Buruli members as 
well as the NGO Anesvad.
5.3  Transmission
Despite intensive environmental studies carried out by the consortium, the exact 
mode of transmission of M. ulcerans still remains unknown. However, studies 
brought new insights which contribute to the better understanding of the puzzle of 
transmission. For example, certain correlations between environmental factors and 
BU incidence could be shown by researchers from the NMIMR, which confirmed 
behavioural risk factors for contracting the disease, such as farming in swampy 
areas or application of leaves on wounds [19]. Sero-epidemiological studies showed 
that exposure to M. ulcerans increases at an age of about 4 years. However, many 
exposed individuals do not develop clinical disease [20]. Findings in M. ulcerans 
infected possums in Australia led researchers from the Melbourne University to 
propose that humans might harbour M. ulcerans in their gastrointestinal tract and 
shed the bacterium in their faeces. A study with faecal samples of BU patients from 
Ghana concluded however, that the human gastrointestinal tract is unlikely to be a 
significant reservoir of M. ulcerans.
M. ulcerans DNA has been detected in many environmental, in particular aquatic 
sources, but how bacteria enter the skin tissue is not clear. The hypothesis of bacte-
ria entering through open wounds was tested using a guinea pig model by research-
ers of the University of Tennessee. While injection of M. ulcerans into the skin led 
to the development of lesions, the researchers were unable to produce infection via 
topical application of M. ulcerans on open abrasions. These results suggest that BU 
is not likely to be due to passive entry of bacteria into deeper skin tissue via super-
ficial skin abrasions [21].
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Evidence also showed that M. ulcerans is growing in amoeba, but this does not 
seem to represent an important environmental reservoir. In Australia, possums were 
found to develop clinical BU, and to serve as an animal reservoir in the Buruli 
endemic region of Victoria, but no comparable reservoir was found in Africa. While 
M. ulcerans DNA was found in the faeces of BU-affected possums in Australia, no 
such DNA could be demonstrated in faecal samples of human patients in Ghana 
[22].
A breakthrough was achieved through whole genome sequencing analyses which 
provided insights into the diversity, population structure and evolutionary history of 
M. ulcerans. The identification of local clonal complexes revealed that transmission 
over large distances is rare [23–26].
All in all, transmission of BU remains an enigma despite many insights into 
details relevant for transmission.
5.4  Socio-Cultural Aspects
The social science axis of the consortium investigated the cultural perceptions of 
BU and socio-economic factors influencing BU health-seeking and decision mak-
ing. Using a formative research approach, interventions to improve early access of 
BU patients to diagnosis and treatment were designed and validated. In Cameroon, 
a BU community of practice involving multiple community stakeholders from clinic 
staff and former patients to community health workers and traditional healers 
resulted in improvement of case identification, reduction in health care seeking 
delay and an increase in treatment adherence [23, 27]. The process of social science 
intervention and major lessons learned from the Bankim case study in Cameroon 
are described in detail in  chapter “Social Science Contributions to BU Focused 
Health Service Research in West-Africa” of this book. In Benin, establishing a ther-
apeutic community in an in-patient ward resulted in positive impact on health staff 
and patient relations [28]. In Ghana, enhanced capacity of health staff in antibiotic 
treatment and wound care and community-based surveillance, patients screening 
and referrals to medical treatment improved early detection of disease [29]. In all 
three countries, pilot studies showed how patient support, such as transport or food 
offers improved treatment-seeking and adherence. The active engagement of differ-
ent stakeholders from the communities, including former patients and traditional 
healers, addressing real life problems of the affected and their families contributed 
to improved early treatment and management of BU cases. The social science con-
tributions and outcomes of the community-based studies and interventions are 
described in detail in the aforementioned “Social Science” chapter of this book.
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6  Lessons Learnt and Conclusions
Transdisciplinary research and action approaches are promising and currently much 
promoted by many institutions. The scope is multidimensional, and the aim is to 
create impact based on research and evidence that is directly applicable to real-life 
conditions. The first important lesson to learn from the Stop Buruli Initiative is the 
key role of the funder as a convening partner of a diverse group of partners, bringing 
the right expertise to the table and facilitating co-development of research and 
intervention.
The second lesson, related to the complexity of multidimensionality, is the rele-
vance of time. Collaborating across disciplines is challenging, and requires suffi-
cient space and time for exchange and mutual learning. From the beginning, the 
Stop Buruli Initiative had a time horizon for support of 9–10 years, with 3-year 
cycles, and regular meetings. The long-term commitment permitted the consortium 
to adapt its priorities and approaches based on interim findings as well as to 
strengthen research capacity and to pave the way for sustainable solutions.
The organization of the overall activities into different work packages certainly 
helped to structure the research along clear topics, with defined milestones and 
deliverables for all work streams. However, the third important lesson that can be 
drawn from the consortium is the importance of good governance and an agile man-
agement of the donor. To develop, test and validate research results in the field, 
considering the political, social and economic conditions, is not a direct input- 
output- outcome equation, but requires dialogue and continuous adjustments. Such 
dialogue requires an institutionally neutral agency, which has the legitimacy, is able 
and sufficiently flexible to enable shared learning and to change course of action if 
needed. The experience of the social sciences’ initial lack of integration illustrates 
how important the governance model with equal representation of different disci-
plines and partners is, and how flexible, responsive and patient a donor needs to be.
The fourth lesson to learn from the model is the weight of communication and 
advocacy for leverage. By actively reaching out to other potential donors, offering 
well-established and reliable platforms for collaboration, lines of research and 
action could be further expanded. Support by additional donors allowed to peruse 
promising outcomes and partnerships from the consortium leading to further trans-
disciplinary research projects.
The Medicor Foundation, a philanthropic foundation based in Triesen, 
Liechtenstein, supported over a period of 10 years multidisciplinary research on 
BU. In a first phase, biomedical and field research activities in Cameroon and Benin, 
aiming at the improvement of diagnosis and treatment of BU were facilitated. 
Motivated by promising results, Medicor supported in a second phase diagnostics 
and vaccine research focussed on the key virulence factor of M. ulcerans, the mac-
rolide toxin mycolactone. Within a 6-year cooperation, early product development 
activities have generated concept validation and candidate products. These lead can-
didates are now handed over to other funders, such as FIND (see below), for full 
product development. In a third phase, the Medicor Foundation is currently 
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supporting a project aiming at the demonstration that thermotherapy of BU can be 
successfully implemented at health post level.
To consider funding, it was important for the Medicor Foundation, (1) to work 
with committed, professional, trusted and experienced partners and (2) that specific 
research projects were defined that were expected to generate with limited funding 
results within a period of 2–3 years. An important conclusion of the 10-year experi-
ence with research support for BU is that on the other hand only a long-term com-
mitment covering several project phases can generate tangible results.
The Foundation for Innovative New Diagnostics (FIND) has supported develop-
ment of diagnostics for BU since 2014, with funding from various sources, includ-
ing UBS-OF, the Swiss Agency for Development Cooperation (SDC), the German 
Federal Ministry of Education and Research through KfW, and recently Anesvad.
The network of partnerships established through the Stop Buruli Consortium 
contributed immensely in identification of the unmet diagnostic needs for BU, 
development of the FIND strategy for the disease, and access to clinical samples for 
use in test validation.
In conclusion, the coordinated effort advanced through the model of the Stop 
Buruli consortium led to a substantial push in BU research and control. While the 
big philanthropic organizations are more prone to address big societal problems, 
smaller foundations are well positioned to address ‘niche’ problems that remain 
otherwise unaddressed, but where they can have a big impact, if well-managed and 
with the right partners in place, both in their niche and also serving as a model.
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